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1.1 Duchenne and Becker Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a genetic, X-chromosome recessive, severe and 
progressive muscle wasting disorder, affecting around one in 5 000 new-born boys.1,2 The 
onset of the disease is in early childhood and, nowadays, most children are diagnosed before 
the age of fi ve. The fi rst signs of muscular weakness become apparent around the age of two 
or three years. In most patients the age at which the child starts to walk is delayed (retarded 
motor development). The children have less endurance and diffi culties with running and 
climbing stairs.3 Gower’s sign is a refl ection of the weakness of the muscles of the lower 
extremities (knee and hip extensors): the child helps himself to get upright from sitting posi-
tion by using his upper extremities: fi rst by rising to stand on his arms and knees, and then 
“walking” his hands up his legs to stand upright.4 Muscle wasting is often symmetrical, how-
ever not all muscles are affected to the same extent. A prominent feature of the early stage of 
the disease is enlargement of the calve muscles (pseudohypertrophy), which are eventually 
replaced by connective and adipose tissue. Furthermore, the pelvic girdle, trunk and abdo-
men are severely affected and to a lesser extent the shoulder girdle and proximal muscles 
of the upper extremities. Progressive weakness and contractures of the leg muscles lead to 
wheelchair-dependency around the age of ten. Thereafter the muscle contractions increase 
rapidly leading to spinal deformities and scoliosis, often with an asymmetric distribution 
pattern. Involvement of the intercostal muscles and distortion of the thorax lead to respiratory 
failure and patients often require assisted ventilation in the mid to late teens. Next dilated 
cardiomyopathy becomes apparent and most patients die before the age of thirty, most often 
due to respiratory or cardiac failure. Another common feature is mental retardation (IQ less 
than 70) in around 20-30% of the patients.5
At present there is no cure for DMD. However, during the past decades pharmacological 
interventions and improved care have led to increased function and quality of life and a pro-
longed life expectancy. Whereas for patients born in the 1960s the mean age of death was 
around 15, this has increased till 25 for those born between 1980 and 1990.6 Pharmacological 
treatment involves mainly corticosteroids (predniso(lo)ne or defl azacort). It is not exactly 
known in which way steroids act. They are anti-infl ammatory/immunosuppressive drugs, 
which may reduce muscle necrosis and infl ammation. Furthermore, they might reduce mus-
cle degeneration by enhancing proliferation of myogenic precursor stem cells and increase 
muscle regeneration due to their anabolic effects.7,8 They have shown to improve muscle 
function, to prolong ambulation for about three years, to reduce the need for scoliosis surgery 
and to have a positive effect on cardiac function. However, they also induce considerable 
side effects, like weight gain, a decline in growth rate and delayed puberty.9-13 Treatment 
with angiotensin-converting enzyme (ACE)-inhibitors, e.g. captopril and enalapril, has a 
positive effect on preventing/delaying of cardiomyopathy.8,14,15 Importantly, the introduction 
of assisted ventilation has resulted in a major improvement in the survival during the last 
decades. The average age of death for non-ventilated patients is around 19 years, whereas for 
ventilated patients it increases till 25-30 years. Whilst till the 1980s respiratory failure was 
the main cause of death, this has now shifted towards cardiac failure.6,16-19
Becker muscular dystrophy (BMD) is a related, but much milder, form of muscular weak-
ness, affecting around one in 20 000 men. The phenotype varies between individual patients, 
from very mild to moderately severe, but the course of the disease is more benign compared 
to DMD. On average, the age of onset is around 12 years; however some patients remain 
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asymptomatic until much higher ages. The age of wheelchair-dependency also shows more 
variability, but in general is in their second or third decade of life, although some patients 
remain ambulant for much longer. The most severely affected patients die between 40 and 50 
years of age, whereas patients with a mild phenotype have (nearly) normal life expectancies. 
The majority of patients eventually develops subclinical cardiomyopathy, which becomes 
symptomatic in over 70% of patients.5,20,21
Since DMD is an X-linked, recessive disease, females can be carriers. The majority of female 
carriers shows no signs of disease. The proportion of carriers displaying symptoms varies 
among different surveys between 2.5 to 22%.22-24 These symptoms mainly comprise skeletal 
muscle weakness and enlarged calves, but this is generally very mild and often does not affect 
daily activities. A small part of these carriers (around 10%) develops symptomatic cardiomy-
opathy later in life; however cardiac abnormalities on echocardiogram or electrocardiogram 
(left ventricular dilatation and decreased shortening fraction) can be found in around 40% of 
the women. There is no relation between the presence of skeletal muscle weakness and the 
development of cardiomyopathy.22,25 Cognitive impairment is also observed in some symp-
tomatic carriers and is associated with mutations in the distal part of the gene, affecting the 
Dp140 and/or Dp71 isoforms involved in the development of cognitive function (see para-
graph 1.2.2).26
Several mechanisms may be responsible for the symptoms in these carriers. First, and 
most reported, skewed (non-random) X-chromosome inactivation (XCI) can lead to higher 
expression of the mutated allele. The degree of skewed XCI might also correlate with the 
severity and age of onset of the symptoms, i.e. females with manifestations at muscle level 
show a higher degree of skewed XCI than manifesting carriers at cardiac level.26,27 Secondly, 
the DMD gene can be disrupted by X-autosomal translocations. Due to non-random inac-
tivation of the intact gene, which is commonly observed with X-autosomal translocations, 
this can lead to clinical symptoms.28 Furthermore, rarely it is caused by co-occurrence with 
other genetic abnormalities, like X-chromosome monosomy, uniparental disomy and male 
pseudohermaphroditism.22,29
1.2 DMD gene and dystrophin protein
1.2.1 Genetic defects in DMD and BMD
The X-linked, recessive inheritance pattern of DMD indicated that the gene responsible for 
the disease was located on the X-chromosome. Case reports of X/autosomal translocations 
in rare female DMD patients and genetic linkage studies narrowed the location of the gene to 
Xp21, which resulted in cloning of this region in the 1980s.30-35 Unexpectedly, a linkage study 
in BMD patients revealed that the gene responsible for BMD was located in the same region.36 
Shortly thereafter the 14 kb cDNA corresponding to the complete transcript was cloned.37 
Deletions in the DMD gene were found in around 50% of DMD patients.38 Furthermore the 
protein product of approximately 400 kDa was identifi ed.39 This protein could not or only 
in very low levels (<3%) be detected in DMD patients. In BMD patients on the other hands, 
dystrophin of reduced length and/or abundance was observed.40,41 These observations led to 
the postulation of the reading frame hypothesis.42,43 In DMD, mutations in the gene causing 
a disruption of the open reading frame or introducing a premature stop codon lead to a com-
11
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plete absence of dystrophin. In BMD, the open reading frame stays intact (i.e. the size of the 
deletion in base pairs is divisible by three) thereby translation can continue and a shorter, but 
partly functional, dystrophin protein is present (fi g. 1.1). This reading frame rule holds for 
over 90% of cases.42,44 Only in-frame deletions that are very large (≥36 exons) or deleting 
essential parts of the protein (the complete actin-binding domain or (part of) the cysteine-rich 
domain; see paragraph 1.2.2) lead to DMD. Furthermore, a small number of mutations that 
do disrupt the reading frame, lead to BMD instead of DMD (2%). This is probably due to 
correction of the reading frame at RNA level, since if only mutations that are confi rmed at 
RNA level are taken into account, 99.5% fi ts within the reading frame theory.44
The DMD gene is the largest gene in the human genome consisting of around 2.4 mil-
lion base pairs, which is approximately 0.1% of the total human genome.45,46 The coding 
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Fig. 1.1: The reading frame rule
a) In the normal situation pre-mRNA is spliced to produce mRNA, which in turn is translated into the dystrophin 
protein. This fully functional protein forms a bridge between the actin cytoskeleton and the extracellular matrix. b) 
In DMD mutations lead to a disruption of the open reading frame and translation into protein stops prematurely. 
A truncated, non-functional dystrophin protein, which is degraded, is formed and the bridge function is lost. c) In 
BMD mutations do not disrupt the open reading frame and translation into a shorter, but largely functional protein 
can occur. The bridge function is maintained.
12
CHAPTER 1
sequence spans around 0.5% (14 kb) of the gene, dispersed over 79 exons.45 The gene has 
a relatively high spontaneous mutation rate, as around one third of the mutations found in 
DMD and BMD are de novo.47
Two hotspot regions exist: a major spanning exon 45-53 and a minor spanning exon 
2-20.48 Intragenic deletions make up the largest part (65-70%) of all mutations. Most of them 
are found in the major hotspot. Duplications of one or multiple exons account for 7% of all 
mutations and are mainly found in the minor hotspot. Point mutations and small deletions or 
insertions account for around 20% of the mutations.44,49
The clinical phenotype is partly related to the amount of dystrophin detected in muscle 
biopsies. No or very low levels (≤3% of normal levels) are found in DMD patients, leading 
to a quite uniform severe phenotype. The severity of symptoms in BMD is highly variable. 
Studies about the relation between dystrophin quantity and disease severity show mixed 
results. Whereas some found higher levels in mildly affected patients compared to severely 
affected patients having <10% of dystrophin, others found less or no correlation.40,41,50-53 
Furthermore, the severity of the BMD phenotype is partly correlated to the location of the 
in-frame mutation. Mild BMD is often associated with deletions involving the central rod 
domain (see paragraph 1.2.2). A moderate (typical) phenotype is generally found in patients 
carrying deletions in the major hotspot (exon 45-53) and most severe phenotypes are often 
associated with deletions affecting the actin-binding domain (exon 2-8) of the protein.54
1.2.2 Dystrophin protein
The dystrophin protein consists of 3 685 amino acids and has a molecular weight of 
427 kDa.49 The protein is located inside the muscle fi bres and forms a bridge between the 
actin cytoskeleton and the extracellular matrix (ECM). Thereby it provides mechanical sta-
bility to the muscle fi bres during each contraction. The protein consists of four domains: 
fi rst an N-terminus, containing two actin-binding domains (ABDs), both consisting of 
a CH1- and a CH2-domain, which are bound to contractile structures (F-actin) inside the 
muscle cells. This is followed by a central domain, the so-called central rod domain, con-
sisting of 24 spectrin-like triple helical coiled repeat units, interrupted by four proline-rich 
hinge regions. A third ABD is present in repeat 11 to 17, while repeats 16-17 contain a 
binding site for neuronal nitric oxide synthase (nNOS).55,56 Subsequently the protein con-
tains a cysteine-rich part and fi nally a C-terminal domain. The cysteine-rich domain binds 
to β-dystroglycan, which is part of a membrane bound dystrophin-associated glycoprotein 
complex (DGC) (fi g. 1.2). B-dystroglycan is a transmembrane protein that is bound to the 
extracellular α-dystroglycan, which in turn is bound to laminin-2, a part of the ECM. The 
central rod domain can absorb mechanical force. Hereby the protein transmits energy pro-
duced by the actin-myosin contraction machinery via the cell membranes to the connective 
tissue and tendons surrounding the muscles, to maintain the energy balance and prevent 
overstressing of the muscle fi bres.57
In addition to its mechanical linker function, dystrophin is involved in the organisation 
of the DGC as well as many other proteins and the control of the growth of the muscle 
cells.39,58 The DGC is important in the maintenance of calcium homeostasis, both by main-
taining membrane integrity, thereby preventing ‘leakiness’, and by proper localization of 
receptors (e.g. ryanodine receptors (RyRs)) involved in the functioning of Ca2+-channels.59 In 
the DGC, β-dystroglycan is connected to a complex of α-, β-, γ- and δ-sarcoglycans and sar-
cospan. This complex functions in maintaining membrane stability.60 B-dystroglycan is also 
13
GENERAL INTRODUCTION
bound to caveolin-3, a structural protein of skeletal muscle caveolae, small invaginations of 
the plasma membrane playing a role in, among others, signal transduction. Caveolins act as 
scaffolding proteins to compartmentalize and functionally regulate signalling molecules.61 
Furthermore, the C-terminal domain of dystrophin is connected to α-dystrobrevin and syntro-
phin. nNOS is recruited to the membrane by binding to dystrophin and syntrophin. Especially 
the spectrin-like repeat 16 and 17 of dystrophin turned out to be important for targeting 
nNOS to the sarcolemma.56 In contracting muscles, nNOS produces NO to induce vasodila-
tation in order to increase the local blood fl ow necessary for the increased mechanical load. 
The absence of nNOS in DMD causes abnormal vasoconstriction and ischemic stress, which 
contributes to the muscle degeneration.62 Syntrophin is also connected to sodium channels, 
which are involved in regulating the Na+-distribution. In DMD, defects in cardiac conduction 
systems are thought to be caused by disturbances in Na+-distribution.63 A-dystrobrevin is 
linked to syncoilin too; thereby forming a bridge between the DGC and the desmin interme-
























Fig. 1.2: The dystrophin-associated glycoprotein complex
The dystrophin-associated glycoprotein complex (DGC) is composed of α- and β-dystroglycan, a sarcoglycan- 
sarcospan complex and the dystrophin containing cytoplasmic complex. Dystrophin (purple) forms the link between 
the actin cytoskeleton with its N-terminal domain and extracellular matrix component laminin-2 (lilac) via α- and 
β-dystroglycan (dark blue) with its C-terminal domain. B-dystroglycan is also bound to the sarcoglycan-sarcospan 
complex (light blue/black) and to caveolin-3 (orange), a scaffolding protein of skeletal muscle caveolae. Furthermore, 
the C-terminal domain of dystrophin is connected to α-dystrobrevin (green) and syntrophin (salmon pink), which 
recruits nNOS (yellow), a vasodilator, to the membrane. Α-dystrobrevin, in turn, is linked to syncoilin (brown), 
forming a bridge between the DGC and the desmin intermediate fi lament protein network (brown).
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Next, in addition to the most common form of the dystrophin protein (called Dp427m) found 
in skeletal muscles, cardiomyocytes and in low amounts in glial cells, additional full-length 
and shorter isoforms of dystrophin exist. This is due to the presence of at least seven different 
promoters and alternative splicing events.49,65 Three full-length variants exist (including the 
muscle isoform Dp427m), which only differ in their fi rst exon. Dp427c (sometimes referred 
to as Dp427b) is expressed in the brain (in the cortical neurons and hippocampus) and the 
retina. Dp427p is expressed in cerebellar Purkinje cells and to a small extent in skeletal 
muscle.66,67 Four internal promoters lead to the production of shorter dystrophin proteins, 
expressed in specifi c tissues, which are named after their molecular weight. These isoforms 
lack the actin-binding terminus but have retained the cysteine-rich part, associated with the 
DGC, and the C-terminal domain. Dp260, transcription starting in intron 29, is expressed in 
the retina.68 In the brain, retina and kidney Dp140 is found, which has its promoter in intron 44 
and ATG start site in exon 51. The promoter of Dp116 is located in intron 55, producing an 
isoform expressed in Schwann cells in adult peripheral nerves.69 Finally, the two shortest 
isoforms are starting from a unique fi rst exon in intron 62, which is spliced to exon 63. Dp71 
is ubiquitously expressed in non-muscle tissues (most notably brain, retina, kidney, liver and 
lung) and in cardiomyocytes, but not in skeletal muscle.70 Different Dp71 isoforms exist, due 
to the exclusion of exon 78 in some isoforms, resulting in a frame-shift, thereby inducing a 
unique, hydrophilic C-terminus in contrast to the hydrophobic C-terminus of the other dys-
trophin isoforms. Dp71 also interacts with the DGC in numerous cell types and plays a role in 
several cellular processes and during embryonic development. Its absence is associated with 
cognitive impairment and retinal dysfunction; two commonly observed non-muscular DMD 
phenotypes.71 However this cannot account for all patients with cognitive dysfunction, since 
most mutations do not affect the Dp71 isoform or Dp140 isoform, which is also expressed in 
the brain. This is probably due to more general changes in the central nervous system (CNS), 
since full-length dystrophin and the DGC play a role in the development and functioning 
of the CNS.72,73 Nevertheless, mutations affecting the distal part of the gene are more often 
associated with mental impairment, suggesting an additive negative effect when all dystro-
phin isoforms are deleted.72,74 Dp40 lacks the normal C-terminal end due to an alternative 
polyadenylation site in intron 70. It is widely expressed in non-muscle tissues, most notably 
the brain.75,76 In addition, alternative splicing facilitates the expression of many more dystro-
phin protein isoforms of which has been hypothesized to have a tissue-specifi c function. All 
these different isoforms might partly explain the variation in symptoms and involvement of 
specifi c tissues among DMD and BMD patients, depending on the specifi c location of the 
mutation. For example, mutations in the distal part of the gene, e.g. distal to exon 63, are 
associated with (severe) mental retardation and often also affect the transcription of the Dp71 
isoform,49,77 whereas retinal involvement is associated with mutations that affect Dp260.78
1.2.3 Animal models for DMD
The most widely used model for DMD is the mdx mouse model (C57Bl/10ScSn-DMDmdx/J). 
These mice have a single base mutation within exon 23 (a C to T substitution at position 
3185), leading to a premature stop codon, so a truncated, non-functional dystrophin protein is 
formed.79 Despite the absence of dystrophin, the phenotype of the mdx mice is relatively mild 
compared to human DMD patients. However, compared to wild type mice, mdx muscles are 
clearly dystrophic and functionally impaired. Furthermore mdx mice show an impaired ven-
tricular heart function, most prominently in the right ventricle, compared to wild type mice 
15
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as assessed by magnetic resonance imaging (MRI).80 Nevertheless, their life span is only 
slightly reduced and the muscular weakness is mild. This is probably due to an improved 
regeneration, upregulation of muscle transcriptional factors (e.g. MyoD) and compensa-
tory mechanisms, like the upregulation of utrophin, a dystrophin homologue, which can 
partly take over its function.81 The gene encoding for utrophin (UTRN) is smaller than the 
DMD gene (1 Mb versus 2.4 Mb), contains 72 exons and is widely expressed. Like dystro-
phin, utrophin forms a link between the cytoskeleton and the ECM. Structurally utrophin 
is very similar to dystrophin: the N-terminal, cysteine-rich and C-terminal domains show 
~80% similarity and the spectrin-like repeat domain ~35%. Utrophin is ubiquitously present 
in muscle in early foetal stages, but levels decrease during development and in adult muscle 
it is solely found at neuromuscular junctions, to retain their structural integrity. In developing 
and regenerating fi bres it its present along the entire sarcolemma, where it is later replaced by 
dystrophin. In the absence of dystrophin, utrophin can be found along the entire muscle fi bre 
membrane where it recruits most of the proteins normally associated with dystrophin.82-84 In 
both DMD patients and mdx mice, utrophin is upregulated, albeit to a larger extent in mdx 
mice.85 Mice that lack both dystrophin and utrophin (mdx/Utrn-/-; double knockout mice) 
show a very severe, progressive muscular dystrophy. Their muscles display severe signs of 
damage and are rapidly replaced by fi brotic and adipose tissue. Ventricular dysfunction is 
already prominent at two month of age. Furthermore, these mice are functionally impaired, 
have an arched spine (kyphosis) and a life span of 20 weeks at maximum.80,86 Due to the 
very severe phenotype and short life span, mdx/Utrn-/- mice are not practical as an experi-
mental model. An intermediate model is the mdx mouse with haploinsuffi ciency for utrophin 
(mdx/Utrn+/-). Their life span is signifi cantly longer than that of mdx/Utrn-/- mice. However, 
infl ammation and fi brosis in both skeletal muscle and diaphragm are more severe than in 
the mdx mouse.87 The functional performance of mdx/Utrn+/- mice is also signifi cantly worse 
compared to mdx mice with two Utrn copies.88
In addition, many more double mutants have been created to study the role of other factors 
involved in muscle functioning and during development of dystrophic pathology.89,90 Several 
double knockouts have been generated lacking components of or proteins associated with 
the DGC. MyoD is a myogenic regulatory factor that plays an important role during muscle 
differentiation and regeneration. Mdx/MyoD-/- mice exhibit marked muscle dystrophy and 
develop severe cardiomyopathy during ageing.91 Additional knockout of myocyte nuclear 
factor (MNF), a transcription factor selectively expressed in satellite cells, (mdx/Mnf-/-) 
causes a severe phenotype and death within a few weeks as a result of satellite cell dys-
function.92 In the absence of the DGC component α-dystrobrevin, the DGC stays largely 
intact, but DGC-dependent signalling is impaired, resulting in a moderately more severe 
pathology compared to mdx mice in mice also lacking the DGC-component α-dystrobrevin 
(mdx/Adbn-/-) mice, i.e. life expectancy of eight to ten months and increased fi brosis/necrosis. 
Triple mutants lacking utrophin and α-dystrobrevin (mdx/Utrn-/-/Adbn-/-) display a phenotype 
comparable to mdx/Utrn-/- mice.93 In addition to the DGC, α7β1-integrin connects the ECM 
to the cytoskeleton and mdx/Itga7-/- animals are born normally, but die within one month.94 
Calcium-buffer parvalbumin (PV) is present in high concentrations in skeletal muscles of 
rodents compared to humans. Mdx/Pv-/- mice were generated to test whether this explains 
the relatively mild phenotype of mdx mice. However, these mice were only slightly more 
affected than mdx mice, indicating this factor might contribute to the mild pathology but is 
certainly not the only cause.95 The additional loss of the vasodilator NO producing nNOS in 
mdx mice (mdx/nNOS-/-) does not alter the mdx phenotype, indicating that relocalization of 
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nNOS to the cytosol does not contribute signifi cantly to mdx pathogenesis.96
To show the effect of genetic background on the severity of the dystrophic phenotype the 
DBA/2-mdx mouse has been generated by crossing mdx mice (C57Bl/10 background) with 
mice with a DBA/2 background. DBA/2 mice exhibited a lower self-renewal effi ciency of 
satellite cells than C57Bl/6 mice. Skeletal muscles of DBA/2-mdx mice exhibited lower mus-
cle weight, fewer myofi bres, and increased fat and fi brosis. This results in a more severe 
phenotype, showing severe muscular weakness.97
Next to the naturally occurring mutation in the mdx mouse, several DMD mutations have 
been induced in mice. For example, treatment of mice with the chemical N-ethylnitrosourea, 
a powerful mutagen, resulted in several new mdx-like mouse models on a C57Bl/6 back-
ground (B6Ros.Cg-Dmdmdx-cv/J).98 In mdx mice only the full-length Dp427 dystrophin isoform 
is affected, while in some of these mdxcv mice one or more additional isoforms are also 
affected. Mdx2cv mice have an A to T single base substitution in a splice acceptor sequence 
in intron 42, causing disrupted splicing, resulting in out-of-frame transcripts, which also 
affects the Dp260 isoform.99 Mdx3cv mice have a mutation (T>A) in intron 65, which induces 
a new splice site, resulting in a frame-shift. In these mice all isoforms, including the brain 
Dp71 isoform are affected.100 Mdx4cv mice have a C to T mutation at position 7 916 in exon 
53, introducing a premature stop codon and affecting the Dp260 and Dp140 isoform. Mdx5cv 
mice have a 53 base pair deletion in exon ten due to an A tot T substitution at position 1 324, 
which introduces a cryptic splice donor site causing a frame-shifting deletion.99 All these 
mice have a phenotype roughly comparable to the mdx mouse, although some minor differ-
ences exist. Compared to mdx mice, mdx3cv mice display a relatively high number of revertant 
fi bres, whereas very low levels are present in mdx4cv and mdx5cv mice.101 Probably due to the 
low level of near full-length dystrophin expression (~5%), the mdx3cv mice show higher fore-
limb grip strength than mdx4cv mice, although muscle pathology is comparable.102 Additional 
knockout of utrophin in mdx3cv mice (mdx3cv/Utrn-/-), rendering them defi cient in all dystro-
phin isoforms and utrophin, are even much milder affected compared to mdx/Utrn-/- mice, 
refl ected by increased survival and stronger specifi c muscle force. Furthermore the mdx5cv 
model exhibits a slightly more severe phenotype, refl ected by variances in gene expression, 
and histological differences and worse functional performance.103
Immunodefi cient mdx or mdx-like transgenic mice have been developed to allow testing 
of transplantation of healthy donor cells (see paragraph 1.4.4). Mdx nu/nu mice are mdx mice 
bred onto a nude background (Foxn1-/-), lack functional T-cells and display other skin defects. 
Their pathology is largely comparable to mdx mice, but the collagen content and fi brogenesis 
is affected by the nude mutation in skeletal limb muscle.104,105 Scid mice are defi cient in both 
T and B lymphocytes, due to a mutation in the Scid gene.106 They were crossed with mdx mice 
(Scid/mdx), combining the Scid mutation with the Dmd mutation.107 A disadvantage of this 
model is that the mice still have functional NK cells, limiting their use. Therefore recently 
the NSG-mdx4cv model has been generated, whose disease severity is comparable to mdx 
mice. This model contains both the Scid mutation and an IL2Rg mutation, which depletes NK 
cells and suppresses thymic lymphomas at the same time, in an mdx background.108
Additionally, several mouse models or cell lines have been generated often affecting only 
one or a few of the different dystrophin isoforms. mdx52 mice have been generated by delet-
ing exon 52 of the murine Dmd gene using a homologous recombination technique. In these 
mice the Dp140 and the retinal Dp260 isoform are absent, resulting in retinal abnormalities. 
Furthermore the muscle pathology is comparable to mdx mice, showing muscle hypertrophy 
and severe degeneration in the diaphragm.109 In Dp71-/- mice the expression of the Dp71 iso-
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form is specifi cally inactivated by deleting its fi rst unique exon and replacing it by a reporter 
gene, which revealed differential activity of the Dp71 promoter during various stages of 
development and cell differentiation and between cell types.110
Transgenic mdx mouse models expressing dystrophin transgenes have been generated 
to reveal which parts of dystrophin are essential for functionality. In mdx mice in which 
full-length dystrophin was overexpressed under a muscle-specifi c promoter, pathology 
was completely prevented,111 whereas mdx mice carrying a transgene with the non-muscle 
Dp71 isoform expressed in muscle, only showed restoration of the DGC, but no ameliora-
tion of muscle pathology. This indicates that the N-terminal actin-binding and/or central 
spectrin-like repeat domains are required for the functionality of the dystrophin protein.112,113 
Furthermore expression of a minigene missing exons 71 to 74, mimicking a dystrophin iso-
form normally only present in brain and not in muscle, in transgenic mdx animals resulted 
in normal muscle morphology and physiology, suggesting these exons are not crucial for 
dystrophin function.114 Myofi bres from mdx mice expressing a microdystrophin transgene 
(ΔR4-R23) showed less damage after lengthening contractions than mdx and even wild type 
muscles. This is probably due to molecular and cellular adaptations in these mice. Compared 
with wild type myofi bres an increase in α7-integrin and utrophin expression was seen due to 
chronic myotendinous strain (e.g. partial tears) caused by over-stretching of muscle to which 
they are more susceptible.115
Next to the mdx mice models, expressing (almost) no dystrophin and transgenic mdx 
mice expressing normal or higher levels of (truncated) dystrophins, several models exist 
expressing different levels of dystrophin. Transgenic mice expressing low levels of full-
length dystrophin or minidystrophins of murine or human origin have been generated.116 First 
of all, these mice are useful to determine which part(s) of the protein are crucial for its func-
tion. Mice expressing around 50% of the aforementioned truncated dystrophin lacking exons 
71-74 in skeletal muscle and 10-20% in diaphragm displayed a markedly milder phenotype 
compared to mdx mice.114 In another transgenic mdx model, expression of minidystrophins by 
a muscle-specifi c promoter resulted in around 50% of dystrophin in fast-twitch skeletal mus-
cle, but almost no expression in slow-twitch muscle, heart and diaphragm, which ameliorated 
the dystrophy in muscles in which it was expressed.117 Secondly, they provide an indication 
which quantity of dystrophin protein restoration is required to (partly) prevent pathology. 
Injection of wild type embryonic stem cells (ESCs) into mdx blastocysts generated chimeric 
mice expressing more variable levels, which resulted in a dose-dependent amelioration of the 
muscle pathology and function; i.e. no improvement is seen in mice with >5% dystrophin, 
whereas chimeric mice with 10-30% appeared almost indistinguishable from wild type.118 A 
more sophisticated model expressing various levels of dystrophin is the mdx-Xist∆hs mouse, 
generated in our own group, where dystrophin levels range from 3-47%. These mice have 
been generated by crossing non-dystrophic female mice with skewed X-inactivation, due to 
mutations in the Xist promoter resulting in preferential inactivation of the mutated Xist allele, 
with mdx males. This leads to female offspring in which the X-chromosome containing the 
wild type Dmd gene is preferentially inactivated. In these mice the level of dystrophin needed 
to improve the phenotype is dose-dependent, but varies between different aspects of the 
disease phenotype. Low levels (3-14%) are already suffi cient to ameliorate some dystrophic 
symptoms, including cardiomyopathy, but levels >30% are needed for full recovery, espe-
cially when mice are subjected to forced exercise.119 When these mice were crossed with mice 
also lacking utrophin (mdx/Utrn-/-/Xist∆hs) low dystrophin levels (<4%) greatly improved sur-




Finally, a mouse line carrying an intact and functional copy of the complete human dys-
trophin gene (hDMD) integrated on mouse chromosome fi ve has been made. These mice 
have been generated by fusion of yeast spheroplasts containing an artifi cial chromosome 
carrying this hDMD gene with murine ESCs and injecting these into mouse blastocysts. 
Dystrophin expression of the different isoforms in a tissue-specifi c manner is maintained in 
these hDMD mice. Crossing of these mice with mdx or mdx/Utrn-/- mice prevented muscular 
dystrophy completely, indicating the functionality of the transgene.121 These mice are very 
useful for testing of therapies specifi c for the human DMD gene. However these mice carry 
an intact version of the human DMD gene; therefore studies on the effect of therapies on 
muscular dystrophy are not possible. Attempts to generate dystrophic mouse models carrying 
hDMD genes with specifi c mutations have not been successful so far [Veltrop et al., personal 
communication].
Several spontaneously occurring canine X-chromosome linked muscular dystrophy with dys-
trophin defi ciency (CXMD) models similar to DMD in humans have also been described. The 
golden retriever muscular dystrophy (GRMD) dog is most well described. These dogs have 
a single base substitution in the 3’ consensus splice site of exon seven, resulting in skipping 
of exon seven, thereby introducing a premature stop codon in exon eight. The course of the 
disease is more comparable to human patients than that of the mdx mouse. The dogs display 
rapid and fatal muscular dystrophy, characterised by muscle atrophy, myofi bre degeneration, 
replacement by fi brotic and adipose tissue and cardiomyopathy.122 Most affected animals 
die within a few years, mainly due to degeneration of the cardiac muscle.123 Although phe-
notypically the GRMD dog seems a better model for DMD, it shows a lot of interindividual 
variation in the severity of the pathology: some animals die within days after birth, whereas 
others appear almost normal and live for years.124,125 This makes the dogs less suitable for 
experimental use, due to standardisation problems. Furthermore, experiments with dogs are 
very costly: dogs have a long breeding time and the availability is low (a heterozygous breed-
ing program is needed, due to the severity of the phenotype). Furthermore, for therapeutic 
studies the size of the dogs requires large amounts of compound. Because of the large size of 
the golden retriever, the GRMD dog has been bred with a much smaller beagle to generate 
the canine X-linked muscular dystrophy (CXMDJ) model. The phenotype of this dog is less 
severe compared to GRMD; cardiac involvement is milder and survival rate increased.126-128
Next to the GRMD and CXMDJ dystrophin defi ciency has been described in several 
other dog strains, carrying various mutations in the DMD gene. For some of these the exact 
mutation has been characterized. Rottweilers carrying a substitution in exon 58 creating a 
premature stop codon and German short-haired pointers with a large deletion encompassing 
the entire DMD gene have been described.129 Cavalier King Charles Spaniels with dys-
trophin-defi cient muscular dystrophy have a point mutation in the 5’ donor splice site of 
exon 50 that results in deletion of exon 50 on RNA level, thereby causing a frame-shift.130 
Furthermore the absence of dystrophin is reported in several other strains, such as Belgian 
Shepherd Brittany Spaniel, Irish Terrier, Labrador Retriever, Miniature Schnauzer and Rat 
Terrier.131-136 In Japanese Spitz dogs full-length dystrophin is absent, but a 70-80 kDa protein 
is present on immunoblotting with antibodies against the C-terminal domain of dystrophin. 
These dogs display clinical signs comparable to other CXMD models, indicating that the 
protein of this size is not large enough to protect against dystrophy.137
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Another natural animal model occurs in cats: hypertrophic feline muscular dystrophy 
(HFMD). This is caused by a deletion of around 200 kb in the DMD gene, involving the 
muscle (Dp427m) and Purkinje (Dp427p) promoter. Dp427c is present in low levels in the 
muscles.138,139 Unlike humans, canine and murine models, these cats exhibit little fi brosis, 
but display extensive muscle hypertrophy and Ca2+-deposits in the muscle fi bres, becoming 
apparent from an age of around 10-14 weeks. Eventually these animals die of compression 
of the oesophagus by hypertrophic diaphragm muscles or renal failure, due to impaired water 
uptake caused by hypertrophy of the tongue.140 Although hypertrophy is also present in the 
heart, these cats only occasionally display heart failure.141
Since the dystrophin protein is highly conserved during evolution, homologues are also found 
in invertebrates, like the worm Caenorhabditis elegans, zebra fi sh Danio rerio and fruit fl y 
Drosophila melanogaster.142 In C. elegans null mutations of the dystrophin-like gene dys-1 
cause only subtle changes like hyperactive locomotion, but muscle histology appears normal 
and shows no signs of degeneration, probably due to the short life-span of these worms. 
However if dys-1 mutated worms are crossed into an hlh-1 background, carrying a weak 
mutation in the hlh-1 gene (the C. elegans homologue of MyoD; also called CeMyoD) exten-
sive muscle degeneration is observed.143,144 Several dystrophin null mutations, called Sapje or 
Sapje-like, have also been identifi ed in D. rerio. These zebra fi sh display progressive muscle 
degeneration due to failure of somatic muscle attachment, causing ‘tearing’ of muscle.145,146
The most recently developed animal model is the DMD pig, carrying a deletion of exon 
52.147 The rationale behind choosing a pig is that pigs closely resemble human size, anatomy 
and physiology.148 These pigs display a severe, progressive muscular dystrophy, impaired 
mobility and death within three months. Three months-old pigs show similarities with DMD 
patients in gene expression profi les refl ecting infl ammation, de- and regeneration and fi bro-
sis. However some pigs die shortly after birth and their profi les are more like those seen 
after acute muscle injury. At the moment male DMD pigs are generated by nuclear transfer 
of male pigs cells with a deletion of exon 52, but the generation of female DMD+/Δexon52 cells 
will be used to produce heterozygous females for future breeding.147
1.3 Antisense oligonucleotide-mediated exon skipping
Antisense oligonucleotides (AONs) are typically small synthetic pieces of DNA or RNA 
(15-30 base pairs), which are complementary to their target mRNA. Initially, DNA AONs 
were used for the specifi c knockdown of gene expression. These DNA AONs bind to the 
(pre-)mRNA to form DNA-RNA hybrids, which are recognized by RNase H. This enzyme 
cleaves the RNA at the location of the bound AON, thereby preventing the translation into 
protein, thus decreasing protein expression. DNA AONs are degraded quickly by endonu-
cleases. Therefore AONs with a phosphorothioate (PS) instead of a phosphodiester (PO) 
backbone were developed, which are more endonuclease-resistant. These led to very effi -
cient expression knockdown (85-95%) of, for example, genes (UL36 or IL2) involved in 
cytomegalo virus (CMV) induced retinitis.149 In addition to activation of RNase H, AONs can 
also downregulate gene expression by inducing translational arrest through steric hindrance 
of ribosomal activity, interference with mRNA maturation by inhibiting splicing or destabi-
lisation of pre-mRNA in the nucleus.150 Later, 2’-O-modifi ed RNA oligos were developed, 
which have a higher affi nity for mRNA and turned out not to induce RNase H-dependent 
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cleavage.151 The activation of RNase H is useful when downregulation of gene expression is 
required, but not when AONs are used for modulation of pre-mRNA splicing.
For DMD, AON-mediated exon skipping is based on the reading frame rule (fi g. 1.1), 
which underlies the phenotypic differences between DMD and BMD. Furthermore, in some 
DMD patients rare, dystrophin-positive (so-called “revertant” fi bres) are found, which are 
the result of spontaneous exon skipping or secondary mutations restoring the reading frame 
in these fi bres and allowing dystrophin production. It was hypothesised that using AONs 
to induces skipping of specifi c exons could lead to the restoration of the reading frame and 
thereby production of slightly shorter dystrophin proteins (fi g. 1.3), as found in BMD and 
revertant fi bres.152 This approach is mutation-specifi c and a large variety in mutations exists 
among DMD patients. Fortunately the aforementioned two hotspots comprise a large propor-
tion of the mutations.44
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Fig. 1.3: The exon skipping approach
In Duchenne muscular dystrophy (DMD), mutations in the DMD gene cause a disruption of the open reading frame, 
causing translation into protein to stop prematurely and loss of functional dystrophin. The exon skipping approach 
aims to restore the open reading frame by using an antisense oligonucleotide (AON) to bind to the pre-mRNA, 
thereby hiding one (or multiple) exons for the splicing machinery, which causes the exon(s) to be ‘skipped’ and not 
being incorporated in the mRNA. This enables the translation into a shorter, but largely functional ‘BMD-like’ dys-
trophin protein. Since this approach is mutation-specifi c, different mutations require the skipping of different exons.
a) Example of a deletion of exon 48–50, where the reading frame can be restored by the skipping of exon 51. 




Knowing that RNA/RNA duplexes are more stable than DNA/RNA duplexes led to the use of 
RNA in AONs. As RNA is even less stable in biological systems than DNA, the 2’-OH posi-
tion of the ribose was modifi ed (2’-O-methyl (2OMe) or 2’-O-(2-methoxy)ethyl (2OMOE)). 
During the last decades, various chemical modifi cations (fi g. 1.4) have been developed for 
use in antisense technology, differing in sugar and backbone chemistry and having differ-
ent biophysical, biochemical and biological properties. One of the earliest, and one of the 
most common, of these modifi cations, the 2’-O-methyl phosphorothioate (2OMePS) chem-
istry, has an increased affi nity for RNA and improved cellular uptake. Disadvantages of the 
PS backbone are that the safety profi le could be improved and some sequences elicit an 
immune response, although the latter is also observed with other backbone chemistries.150 
The tendency to induce an immune response is partly counteracted by the 2OMe modifi ca-
tion. Furthermore 2OMePS AONs bind to serum proteins, which prevents renal clearance 
and thus improves bioavailability.153
Peptide nucleic acids (PNA) contain a fl exible, uncharged, achiral N-(2-aminoethyl)gly-
cine backbone to which nucleobases are attached via methylenecarbonyl linkages instead 
of the PO backbone and riboses of DNA oligos. PNAs have a high affi nity for RNA, are 
nontoxic even at high concentrations, are peptidase- and nuclease-resistant and have a high 
sequence-specifi city. PNAs are very diffi cult to transfect due to their uncharged nature and 
their insolubility caused by their hydrophobic nature. This can be solved by the attachment 
of carrier groups, which can easily be linked to the peptide backbone, or addition of cationic 
lysine residues. Another disadvantage is the rapid clearance of PNAs in vivo. Their mecha-
nism of action is by steric hindrance.154
Locked nucleic acid (LNA) DNA oligos contain a 2’-O, 4’-C-methylene bridge in 
the β-D-ribofuranosyl confi guration. They have a high hybridisation affi nity towards tar-































































Fig. 1.4: Chemical structure of different backbones of antisense oligonucleotides
Phosphorothioate (PS) DNA; 2’-O-methyl phosphorothioate (2OMePS) RNA; 2’-O-(2-methoxy)ethyl phosphoro-
thioate (2OMOEPS) RNA; peptide nucleic acid (PNA); locked nucleic acid (LNA); ethylene bridged nucleic acid 
(ENA); phosphorodiamidate morpholino (PMO) and dendrimeric octaguanidine conjugated phosphorodiamidate 
morpholino (Vivo-PMO).
Picture kindly provided by Peter de Visser.
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get mRNA or DNA, thereby forming stable duplexes. This is an advantage, but also a 
disadvantage, since LNAs longer than 15 base pairs tend to self-anneal and are not very 
sequence-specifi c, which increases the chance of unwanted side effects.155 However, cur-
rently mainly LNA/2’-O-methyl oligonucleotide mixmers are used, which show much more 
sequence-specifi city.156 LNAs have a good nuclear uptake and are nuclease-resistant.
Ethylene bridged nucleic acids (ENA) contain an ethylene bridge between the 2’-O and 
the 4’-C of the ribose. They have similar properties to LNAs, but have a higher affi nity for 
RNA, are very stable and more nuclease-resistant.157,158
Phosphorodiamidate morpholino oligomers (PMO/morpholino) have a six-membered 
morpholino ring instead of the ribose and the PO bond is replaced by a phosphorodiamidate 
linkage. They do not activate RNase H, are very resistant to nucleases and are non-toxic. The 
fact that they are uncharged prevents undesired binding to proteins, limiting circulation time. 
However, this also results in limited nuclear uptake, where pre-mRNA splicing takes place. 
Their uncharged nature makes them hard to transfect in cell cultures, but in vivo PMOs were 
found to be taken up by tissues after local injection. This is probably due to the fact that the 
uncharged nature does not interact with other cellular components. In contrast to 2OMePS 
AONs, which bind serum proteins and are thus protected from renal clearance,159 PMOs are 
effi ciently fi ltered out by the kidney within minutes after injection.160 In general, for use in 
DMD PMOs are often a bit longer than 2OMePS AONs (25 nucleotides or more compared to 
around 20 nucleotides for 2OMePS AONs). They primarily act by steric prevention of ribo-
somal assembly.150,155,161 PMOs have been linked to arginine-rich cell-penetrating peptides 
(pPMOs) to increase uptake and effi ciency. These conjugates indeed have higher effi cacy, 
but there are toxicity concerns and the peptide might evoke an immune response, though the 
latter has not yet been observed.162 Conjugation of PMOs with an octaguanidine dendrimer 
(vivo-morpholino) improves the delivery of the compound in vivo. Since this polymer is not 
a peptide, the risk of an immune response is small and has not been observed so far,163 though 
the polymer is toxic at higher concentrations as well.
1.3.2 AON design and targets
Target sites for exon skipping AONs are splice sites, exonic splicing enhancer (ESE) sites 
or exon inclusion sequences (EIS). Splice sites are required for the correct identifi cation 
of exons by the spliceosome, a catalytic complex that coordinates the splicing process and 
consists of fi ve small nuclear ribonucleoproteins (snRNPs) and hundreds of other splicing 
factors. The 5’ (donor) splice site (beginning of an intron), the branch point (just upstream 
of the acceptor splice site) and the 3’ (acceptor) splice site (end of an intron) contain consen-
sus sequences that are bound by snRNPs and splicing factors to bring about the removal of 
introns and ligation of exons. Blockage of splice sites or the branch point prevents incorpo-
ration of the exon in the mRNA. Exon recognition is further facilitated by ESE sites, which 
are exonic sequence motives to which certain splicing factors (serine- and arginine-rich (SR) 
proteins) can bind. AONs targeting ESEs have been proposed to sterically hinder the binding 
of SR proteins and thus prevent exon recognition.164-167
1.3.3 Antisense-mediated exon skipping in vitro
First proofs-of-principle for the feasibility of restoring the reading frame by exon skipping 
have been shown in vitro in cultured primary human myoblasts, derived from DMD patients 
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and in mdx cell cultures.
In the early nineties, a DMD patient (named “DMD Kobe”) was identifi ed carrying a 
deletion of 52 base pairs within exon 19, which led to the skipping of the whole exon.168,169 
The authors hypothesised that this sequence might be important for splicing. An AON target-
ing part of this exon induced exon skipping in human control lymphoblastoid cells.170,171 In 
cells derived from a patient with a deletion of exon 20, PS AONs (able to activate RNase H) 
against the aforementioned sequence, resulted in exon 19 skipping and the restoration of 
dystrophin in ~20% of treated cells.172
By that time, exon skipping with 2OMePS AONs, unable to activate RNase H, had also 
been explored, both in DMD patient derived cells173 and mdx myoblasts.174,175 In two patients 
with an out-of-frame exon 45 deletion treatment with AONs resulted in exon 46 skipping, 
which should restore the open reading frame. Exon skipping levels were ~15%, which 
restored the synthesis of functional dystrophin in more than 75% of the cells.173 Subsequently, 
2OMePS AONs against other exons were developed, which showed specifi c skipping of the 
particular exon in healthy control cells167,176 or DMD patient-derived cells for a variety of 
exons and mutations.177-180 In DMD patient-derived cells restoration of dystrophin synthesis 
was detectable at the membrane and the (at least partial) functionality of these BMD-like 
proteins was suggested by the reformation of the DGC, as shown by increased membrane 
expression of DGC-associated proteins. Another interesting fi nding was the higher exon 
skipping levels observed in these patient cell lines, than previously seen in control cell lines. 
A possible explanation is that nonsense-mediated decay (NMD) reduces levels of the origi-
nal out-of-frame transcripts, which are therefore less stable than the newly formed in-frame 
transcripts.177
2OMOE AONs containing a PO bond (2OMOEPO) were also able to induce exon skip-
ping in mdx derived cell cultures. When the PO bond was replaced by a PS bond (2OMOEPS), 
increasing its stability and sequence-specifi city, effectiveness was increased. Furthermore, 
whereas for 2OMePS AONs targeting mouse exon 23, 20 oligonucleotides appears to be the 
optimal length,161 for 2OMOEPS AONs 25-mers were more effi cient than 20-mers. When 
compared to 20-mer 2OMePS AONs, these 25-mer 2OMOEPS AONs induced higher exon 
skipping levels in vitro for skipping of exon 23, probably due to improved cellular uptake.181
In vitro testing of PMOs, the other chemistry currently mainly used for exon skipping in 
DMD, is far more diffi cult, since the neutral PMOs are, in contrast to the negatively charged 
2OMePS AONs, not easily taken up by cells. However annealing of the PMOs to various 
complementary DNA/RNA molecules (‘leashes’) in combination with lipofectamine as a 
transfection reagent could overcome this problem and exon skipping and dystrophin res-
torations was shown in mdx-derived cell cultures after PMO transfection.182 Effi ciency of 
PMOs has also been shown in control cells and cells derived from DMD patients or animal 
models.130,183,184
AONs with a RNA/ENA chimeric backbone (a fusion of 2OMe RNA and ENA) have 
been used to induce exon skipping in DMD patient-derived cells requiring exon 19 skipping 
far more effi ciently than the aforementioned PS AON against this exon.158 These chimeras 
were also able to induce exon 45 or 46 skipping and restore dystrophin restoration in patient 
cells requiring exon 45 skipping.The same was shown for an RNA/ENA chimera targeting 
exon 41 in patient-derived cells with a nonsense mutation in this exon.185
Finally, 20-mer PNA AONs have been tested in mdx-derived myoblasts. PNAs against 
exon 23 were able to induce specifi c skipping of this particular exon.186
Comparison of AON analogues with different backbone chemistries against exon 46 in 
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cells from a patient with an exon 45 deletion showed highest skipping levels for LNAs, 
followed by 2OMePS, whereas PMOs induced low skipping effi ciency and PNAs were inef-
fective. However, as mentioned before, LNAs were far less sequence-specifi c as 2OMePS 
AONs.155 Sequence-specifi city of 2OMePS AONs has further been tested by comparing exon 
skipping levels in cultured cells from patients with small mutations in in-frame exons versus 
control cells. Some AONs were equally effi cient in both types of cells, whereas for others 
effi ciency was largely reduced in the cells carrying small mutations, which indicates that for 
this kind of mutations mutation-specifi c AONs may be required.180
In theory, skipping of a single exon would be benefi cial for approximately 64% of the known 
mutations in DMD patients. However, there still is a large population which requires the 
skipping of two or more exons for reading frame restoration.187 The theoretic applicability 
of exon skipping could be extended to 79% by double exon skipping and around 90% of 
patients by multiple exon skipping. Feasibility of double exon skipping was fi rst shown in 
two different patient cell lines. One patient had a nonsense mutation in exon 43, for which 
dystrophin synthesis could be restored by skipping of exon 43 and 44. The second, carrying 
an exon 46-50 deletion, was successfully treated with a combination of AONs against exon 
45 and 51. Dystrophin synthesis was found in 70% of the myotubes, which is almost as high 
as after single exon skipping (75-80%).188 Subsequently, successful double exon skipping 
was tested in the GRMD and CXMDJ canine models for DMD which need double skipping 
to bypass the mutation. Cells derived from these dogs have also been used to show double 
exon skipping in vitro (see paragraph 1.3.4.2).189,190
A surprising fi nding in control myotubes was that combinational treatment with 45AON 
and 51AON caused the skipping of the entire stretch of exons from 45 through 51. This would 
largely increase its therapeutic applicability for a number of different mutations. Indeed the 
same result could be induced in patient cells with an exon 48-50 deletion.188 Furthermore 
multi-exon skipping has been shown for exon 19-25 using 2OMePS AON cocktails in 
mdx-derived cell cultures.191 Skipping of other larger stretches of exons however turned out 
to be technically challenging and has had limited success so far.192 The use of several ratios 
of 45AON and 55AON in both control and patient cell lines resulted in undetectable to very 
low exon 45-55 skipping frequencies.193 Recently Aoki et al. showed successful multiple 
skipping of exons 45-55 in vivo in the mdx52 mouse, although these results raise some ques-
tions (see paragraph 1.3.4.1).194
Exon skipping is in theory useful for the majority of patients. Exceptions are mutations that 
involve regions in the gene that are essential for the function of the dystrophin protein: the 
actin-binding parts, the cysteine-rich C-terminal part (binding to the DGC), the promoter 
region or the fi rst exon. Furthermore it is not applicable to translocations. Fortunately these 
kind of mutations make up only a small part (~8%) of all known mutations.187 The largest 
part of mutations is made up by deletions and small mutations. A minor part consists of exon 
duplications (double or multiple). In the case of single duplications, skipping of one of these 
exons would in theory generate wild type dystrophin transcripts. However, this turned out to 
be challenging. In cells with an exon 45 duplication, skipping a single exon 45 was indeed 
possible, but in other cases the skipping was so effi cient that both exons were skipped, lead-
ing to an out-of-frame transcript.178 Skipping of an additional exon could restore the reading 
frame again. For example for an exon 18 duplication, successful skipping of exon 17 and 
both exon 18s resulted in restoration of the reading frame.195 Successful skipping of multiple 
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exon duplications has not yet been achieved.178 In total 6% of patients could benefi t from 
single or multiple skipping of exon duplications.
1.3.4 Antisense-mediated exon skipping in vivo in animal models
1.3.4.1 AONs in murine models for DMD
After the promising in vitro results, AONs have been tested in vivo in animal models. As 
mentioned before, the mdx mouse is most widely used. The target site for exon 23 was fi rst 
optimised in mdx myotube cell cultures. This resulted in a 25-mer 5’ splice site targeting 
AON with a 2OMePS backbone (called 5’SS-25; later renamed to M23D(+12-13)), which 
was tested locally in the mdx mouse. This showed the fi rst proof-of-concept for inducing 
exon 23 skipping in vivo with a 2OMePS AON. After two and four weeks, intramuscu-
lar treatment (weekly 1 μg of AON complexed with 2 μg of lipofectamine) induced low 
levels of dystrophin expression and restoration of γ-sarcoglycan at the cell membrane, sug-
gesting at least partial functionality of the newly formed dystrophin protein. However this 
AON also induced skipping of additional exons (21 and/or 22), which resulted in in-frame 
∆21-23 transcripts and out-of-frame ∆22-23 transcripts.196 Thereafter the sequence and tar-
get site for this AON was further optimised in vitro in mdx myotube cultures, resulting in a 
20-mer, named M23D(+02-18), which was effective in inducing exon skipping and dystro-
phin protein expression for concentrations as low as 5 nM.197 A single intramuscular injection 
of 5 μg of this compound in combination with a copolymer F127 in the tibialis anterior of 
both young (two or four weeks old) and aged (six months old) mice resulted in marked dys-
trophin expression two weeks after injection, persisting up to three months after injection. 
The functionality of the dystrophin protein was suggested by the re-expression of dystro-
glycans, sarcoglycans and nNOS at the membrane. It also resulted in partial restoration of 
physiological function, maximum isometric tetanic force, of the treated muscles. Importantly 
no auto-immune response against the newly formed dystrophin protein was observed.198
Also a 25-mer 2OMOEPS induced exon skipping after intramuscular injections (5 μg) 
in the tibialis anterior of mdx mice. This was more effective than 20-mer 2OMePS AONs, 
whereas no differences between 25-mer 2OMOEPO, 20-mer MOE20PS and 20-mer 
2OMePS AONs were observed.181 However, direct comparison has only been tested for exon 
23 skipping in the mdx mouse, so could also be a sequence-depended effect, as is seen with 
2OMePS versus PMO AONs.161
PMO AONs have shown to be effective in vivo as well. Whereas transfection was diffi cult 
in cultured cells due to their neutral backbone, this is no problem in vivo were no transfec-
tion reagent is needed. Also for PMOs the AON design was fi rst optimised in cultured mdx 
cells by complexing it to leashes and lipofectamine as described above. This resulted in a 
ψM23D(+07–18):leash 3 lipoplex, which elicited a dose-dependent increase in dystrophin 
expression in the majority of muscle fi bres and dystrophin protein levels up to 60% of lev-
els found in healthy muscle two weeks after a single intramuscular injection of 1 μg in the 
tibialis anterior. Effi ciency was comparable in both young (three weeks old) and aged (six 
months old) mdx mice.182
Local injection of 5, 10 or 20 μg of PNAs or several PNA-peptide conjugates in the 
tibialis anterior of mdx mice resulted in dystrophin positive fi bres two weeks after a single 




Of course, since DMD affects body-wide musculature, including heart and diaphragm, 
injection of every muscle separately is not feasible and systemic treatment is required. 
For M23D(+02-18) AONs with the 2OMePS backbone, three intravenous injections with 
2 mg of AON combined with copolymer F127 at weekly intervals resulted in dystrophin 
expression, highest in gastrocnemius, intercostal muscles and the diaphragm, without signs 
of toxicity or damage to other organs. However dystrophin could not be detected in the car-
diac muscle.199
To optimise delivery and effi ciency, different administration routes have been compared. 
Intravenous injection resulted rapidly in high plasma levels, which were quickly cleared. 
Peak plasma levels were twofold lower after subcutaneous and intraperitoneal injection, but 
clearance was much slower. Furthermore, intravenous injection resulted in very high AON 
levels in the kidney and liver, which might induce toxicity after long term treatment. Skipping 
levels were highest after intravenous injection and slightly lower for both subcutaneous and 
intraperitoneal injection. Dystrophin expression followed a similar pattern. Importantly, 
all three routes resulted in exon skipping and dystrophin expression in the heart, albeit at 
low levels. Due to the better pharmacokinetic profi le of subcutaneous versus intravenous 
injection and slightly higher exon skipping compared to intraperitoneal administration, sub-
cutaneous injection seemed to be the delivery method of choice. After repeated subcutaneous 
treatment (two weekly injections of 100 mg/kg for eight weeks) also a decrease in serum 
creatine kinase (CK) levels was observed. CK is an enzyme that leaks out of the muscles 
into the blood stream when muscles are damaged, so a decrease indicates an improvement 
of muscle integrity.200
Long term treatment for six months of mdx mice with 200 mg/kg/week of these AONs 
was well tolerated and the benefi cial effect was maintained. Furthermore the same study 
showed that this treatment had higher therapeutic effects in the more severely affected 
mdx/Utrn+/- model.201
For PMOs repeated systemic (intravenous) injections with 2 mg of AON per week induced 
exon skipping and expression of dystrophin protein body-wide, albeit with large variations 
between individual muscles. Highest levels were found in the quadriceps, abdominal and 
intercostal muscles; lower levels were found in the tibialis anterior and diaphragm. CK levels 
were decreased and muscle function was improved as well. As with 2OMePS AONs, target-
ing of the cardiac muscle appeared diffi cult, since exon skipping and dystrophin expression 
were undetectable.202 Wu et al. showed that dystrophin restoration in cardiac muscle could 
be achieved (up to 30% of healthy levels) by systemic PMO treatment, although extremely 
high doses (up to 3 g/kg body weight) were required.203
In the mdx mouse model PMOs appeared more effective and at lower doses compared to 
2OMePS AONs. A direct comparison revealed that this was indeed the case for AONs target-
ing mouse exon 23. Intramuscular injection of both AONs in the gastrocnemius, resulted in 
much higher skipping levels for PMOs than for 2OMePS AONs at the same molar amount 
(2.9 nmol AON on two consecutive days). Systemic (intravenous) comparison in the mdx 
mouse (three times 14.52 μmol/kg/week) showed, as had been noticed before, that most of 
the 2OMePS AONs are taken up by the liver and kidney. However the PMOs were almost 
exclusively taken up by the kidney. 2OMePS AONs bind to serum proteins while PMOs 
do not, probably explaining the high renal clearance of PMOs versus 2OMePS AONs (see 
paragraph 1.3.1). 2OMePS AON uptake was higher for all skeletal muscles, diaphragm and 
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heart. In contrast to the biodistribution, exon skipping effi ciency was much higher for the 
PMO AONs in skeletal muscle and diaphragm (approximately 40% versus 10%). Skipping 
levels in the heart were much lower and almost comparable between both compounds (2.5% 
for the PMOs versus 1.5% for the 2OMePS AONs). Protein levels showed higher levels in 
skeletal muscle compared to cardiac muscle too.161
To further optimise exon skipping effi ciency multiple strategies can be used (see also 
paragraph 1.3.6). One approach is to conjugate the AON to a cell-penetrating and/or 
muscle-targeting peptide. A PMO conjugated to an arginine-rich cell-penetrating peptide 
(pPMO) showed to be more effective than the naked PMO AON. Systemic (intravenous) 
treatment of mdx mice was very potent in both skeletal muscle, diaphragm and, importantly, 
heart. pPMOs led to a decrease in CK levels.204 Another study confi rmed that the long term 
(12 weeks) systemic treatment with 30 mg/kg/biweekly of pPMOs was effective in restoring 
dystrophin expression in skeletal muscle, improving muscle function and preventing heart 
failure.205 Therapeutically relevant effects were still observed after one year of treatment 
with 1.5 mg/kg/biweekly in mdx mice without serious adverse events.206 These pPMOs were 
also able to rescue the severe mdx/Utrn-/- mouse model by systemic (intraperitoneal) treat-
ment with 25 mg/kg/week for six weeks. Considerable improvement of survival and muscle 
function was observed, combined with dystrophin expression in almost all muscles, except 
for the heart.207 Peptides might elicit an immune response, but no signs of such a response 
or toxicity were found in the murine models so far. The study of Wu et al. indicated that 
pPMOs have a high acute toxicity (an LD50 of approximately 85 mg/kg). Nonetheless, effec-
tive doses for inducing exon skipping and dystrophin restoration in mice are much lower.206 
Unfortunately, when a pPMO compound was tested in primates, there were safety issues. In 
cynomolgus monkeys pPMO doses equivalent to the ones used in mice, were not toxic, but 
also induced only very limited exon skipping. Higher doses were effective, but also caused 
tubular degeneration in the kidneys, a sign of renal toxicity. By contrast naked PMO did not 
cause toxicological effects at much higher doses.162,208
Yin et al. generated a chimeric fusion peptide consisting of a muscle-targeting hepta-
peptide (MSP) fused to an arginine-rich cell penetrating-peptide (B-peptide), which they 
conjugated to a PMO oligomer (B-MSP-PMO). These B-MSP-PMOs were already effi cient 
at very low doses (3 mg/kg/week for six weeks) in restoring high levels of dystrophin expres-
sion body-wide without obvious signs of toxicity.209
Novel cell-penetrating peptides have been discovered by inducing modifi cations to a 
D. melanogaster-derived R6-Penetratin peptide. These peptides are called PNA or PMO 
internalisation peptides (Pips). A conjugate of Pip2b and a PNA AON (Pip2b-PNA) resulted 
in approximately threefold higher dystrophin-positive fi bres compared to the naked AON 
after local injection of 5 μg in the tibialis anterior of mdx mice.210 More and improved Pips 
have been developed. Pip5e fused with a PMO (Pip5e-PMO) showed high exon skipping 
effi ciency after a single intravenous injection of 5 μg in the mdx mouse. Most importantly 
it also effi ciently targeted the heart, leading to dystrophin levels of more than 50% of wild 
type levels.211 Further characterisation of this Pip-peptide by using different derivatives of 
Pip5e-PMO (Pip6-PMOs) revealed that the central hydrophobic core and the hydrophobic/
cationic balance is imperative for effi cient targeting of the heart.212 These results will be used 
to further optimise the Pip-PMO for testing in a clinical trial.
Another modifi cation of the PMO is conjugation to a dendrimeric octaguanidine polymer 
(vivo-morpholino). This modifi cation also signifi cantly improved the delivery and dystro-
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phin production in mdx mice after intravenous injection. Repeated treatment (fi ve times 
6 mg/kg/biweekly) resulted in dystrophin expression in almost 100% of the skeletal muscle 
fi bres and levels of protein up to 50% of wild type levels. Importantly, levels of ~10% of 
those found in healthy hearts were found in the cardiac muscle. In these mice no signs of an 
immune response or toxicity were observed.163
A third method to reduce the dose is through the use of biodegradable nanoparticles. 
Intraperitoneal injection of cationic polymethylmethacrylate (PMMA) nanoparticles (NP) 
loaded with a low dose of 2OMePS AON were able to induce body-wide exon skipping 
and dystrophin restoration in the mdx mouse far more effi ciently than naked 2OMePS 
AONs at the same dose (0.9 mg/kg/week).213 Further optimisation of the NPs resulted in 
PMMA/N-isopropilacrylamide+ NPs, called ZM2, which were, after seven weeks of injec-
tions with 7.5 mg/kg/week, able to restore dystrophin protein in both skeletal and cardiac 
muscle in up to 40% of the fi bres albeit at very low levels.214 They also demonstrated its 
longer term effi cacy, since this effect was, in contrast to naked 2OMePS AONs, still detect-
able 90 days after the last injection, although the amount of dystrophin positive fi bres had 
decreased till 7% at maximum.215
Both 2OMePS and PMO AONs have also been tested in the mdx4cv mouse. These mice 
require skipping of both exon 52 and 53 to remove the mutation and maintain the reading 
frame. Immortalised myoblast cell cultures from these mice were used to design the most 
effective AONs against exon 52 and 53, which were then tested in vivo in the mdx4cv mice. 
2OMePS AONs induced exon skipping in these cell cultures, but no dystrophin protein was 
observed. Intramuscular injection of 100 μg of the AON cocktail complexed with F127 in 
the tibialis anterior resulted in sporadic exon skipping in this muscle, but no detection of dys-
trophin protein. A combination of PMO AONs against both exons resulted both in vitro and 
in vivo (after injection of 40 μg of cocktail tested in different ratios in the tibialis anterior) in 
exon skipping and restoration of dystrophin expression.216
The mdx52 mouse has been used to test the feasibility of multi-exon skipping targeting 
the human mutation hotspot (exon 45-55) with vivo-morpholinos. First in vitro in cultured 
myotubes from these mice and after intramuscular injection with a mixture of ten AONs, 
skipping of all target exons could be demonstrated. Furthermore systemic injections of this 
AON cocktail resulted in dystrophin expression up to 15% of wild type levels, accompanied 
by improved functional performance and histopathology.194 This is the fi rst successful appli-
cation of multi-exon skipping, which was shown to be diffi cult in vitro (see paragraph 1.3.3). 
However these results are controversial, since they needed a cocktail containing a large num-
ber of AONs to achieve skipping of this stretch of exons, while none of the anticipated 
intermediate products showing skipping of only one or a few exons were observed.
AONs are sequence-, and therefore species-, specifi c. So, to be able to test human-specifi c 
AONs hDMD mice can be used. Intramuscular injection (gastrocnemius) of 2OMePS AONs 
against exon 44, 46 or 49 induced specifi c skipping of the targeted human exons. It also high-
lighted the sequence-specifi city of the AONs, since in the corresponding mouse sequences, 
with only two or three mismatches, no detectable skipping was observed.217 As described 
before, PMOs were more effi cient in the mdx mouse than 2OMePS AONs. However in the 
hDMD mouse, AONs targeting human exon 44, 45, 46 or 51 were comparably effective or 
only marginally different between both chemistries after intramuscular injection. This indi-
cated that the differences between PMO and 2OMePS observed for exon 23 targeting AONs 
are probably more due to sequence differences than to chemistry differences. Furthermore, 
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this paper also suggested important differences in sequence-specifi city. 2OMePS AONs with 
two mismatches had a greatly reduced effi ciency, whereas PMO AONs remained equally 
effective. This can increase the risk of off-target side effects.161
Studies in these hDMD mice revealed that the uptake of AON by the healthy hDMD 
muscle fi bres is much lower than by dystrophic mdx fi bres. This can probably be explained 
by the dystrophic nature of the mdx fi bres: the lack of dystrophin results in damage to the 
muscle fi bres, leading to leakage of CK into the bloodstream. It has been proposed that the 
AONs migrate into the muscle fi bres through these same holes.218 In this way the disease is 
facilitating delivery of the potential therapeutic compound. Indeed AON uptake and skipping 
in the hDMD mouse is more diffi cult. The exon skipping levels observed after intramuscular 
injection with either 2OMePS or PMO AONs were lower than previously observed in the 
mdx mouse and in cell cultures. A pilot experiment with systemic (intravenous) injection 
of nine times 100 mg/kg 2OMePS AONs targeting exon 51 in the hDMD mouse resulted 
in very low or undetectable exon skipping in the muscles.219 An alternative hypothesis is 
that the uptake of AONs depends on myotube formation, e.g. during development or active 
regeneration, and that AONs are therefore more easily taken up by immature myotubes than 
by mature myofi bres. PMO uptake and PMO-induced exon skipping was greatly enhanced 
after cardiotoxin-induced injury in wild type mice.220 Any or both hypotheses might also 
provide an explanation why targeting of the heart is so diffi cult. The heart muscle is struc-
turally and pathologically different from skeletal muscle, since it is made up of individual 
cardiomyocytes, which do not become ‘leaky’. Furthermore in heart, in contrast to skeletal 
muscle, hardly any regeneration takes plays. Recently, vivo-morpholinos against exon 50 
were shown to be able to achieve high levels of exon skipping after systemic (intravenous) 
injection (15 mg/kg) in the healthy skeletal muscles of the hDMD mouse and even low levels 
in the cardiac muscle. There were no overt signs of toxicity or adverse effects, only a small 
increase in serum CK levels, which could refl ect a bit of membrane integrity disturbance.221
1.3.4.2 AONs in other animal models
First AON experiments with the canine model have been performed in vitro in myoblast cell 
cultures of the GRMD dog. The nature of the mutation requires the skipping of two exons 
(exon six and exon eight) to restore the reading frame, thereby making it more challenging. 
In vitro, 2OMePS AONs induced higher exon skipping levels than the PMOs, but only for a 
short term and without induction of detectable dystrophin protein. PMOs could restore a low 
level of dystrophin production, but only at very high concentrations. pPMOs could induce 
slightly higher exon skipping levels and restored dystrophin expression.189 Further testing of 
these AON cocktails in vivo by intramuscular injections, revealed that the AONs targeting 
exon eight were effective, but the AONs targeting exon six, which had shown effectiveness 
in vitro, were not.222 Another small experiment (in a six months old and a fi ve year old dog) 
with cocktails of 2OMePS AONs or PMOs, resulted in high skipping levels of the desired 
exons and restoration of dystrophin protein to near normal levels after a single injection in 
the tibialis anterior with the highest test dose of 1.2 mg. The structure of the dystrophin-pos-
itive cells was reported to be improved.223
Systemic (intravenous) treatment of CXMDJ dogs with a cocktail of three PMO AONs 
targeting exon six (two PMOs) and exon eight (one PMO), generated body-wide production 
of functional dystrophin. In the heart there was, as observed in mice, only modest production 
of dystrophin. Furthermore, an interindividual variation between dogs and intra-individual 
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variation between different muscles of the same dog was seen. Functional improvement 
could be shown too and no signs of toxicity were observed with doses up to 200 mg/kg/injec-
tion for fi ve to 11 times.190 Further optimisation of the cocktail and using a vivo-morpholino 
backbone resulted in a four AON cocktail (two against exon six and two against exon eight), 
inducing more effi cient exon skipping and higher dystrophin expression after intramuscular 
injection with 30 μg of each AON in the cocktail.224
1.3.5 AONs in clinical trials
After the promising preclinical results in vitro and in vivo, the fi rst clinical trials were initi-
ated. An overview of all clinical trials, completed and currently ongoing, is given in table 1.1. 
Normally, the fi rst human trials are done in healthy volunteers (phase I). However, this is not 
possible in this case, since exon skipping in healthy persons would result in disruption of 
the reading frame. Therefore this phase was skipped and AONs were tested immediately in 
DMD patients (phase I).
1.3.5.1 Local treatment with AONs
The fi rst trials used local (intramuscular) injections to obtain proof-of-principle in humans 
and examine possible adverse effects. These fi rst trials focused on skipping of exon 51 for 
both 2OMePS (in 2006) and PMO AONs (in 2008), since this would be applicable to the 
relatively largest group of known mutations (13%).187
A single injection in the tibialis anterior with 0.8 mg of a 2OMePS AON (called PRO051) 
in four patients resulted in specifi c exon 51 skipping without adverse effects. It restored dys-
trophin expression at the sarcolemma in 64-97% of the myofi bres and restored protein levels 
till 17-35% of control levels. However, it also clearly indicated the importance of muscle 
quality since the target of AONs, the dystrophin transcript, is only expressed in muscle fi bres 
and not in adipose and fi brotic tissue, which replaces the muscle tissue when the disease 
progresses. The patient with the lowest dystrophin levels had the most advanced disease state 
and relatively little muscle tissue left.225
For PMO AONs a placebo-controlled, single-blinded study was performed. Seven 
patients received an injection with a PMO AON (called AVI-4658) into their extensor digito-
rum brevis and saline into the contralateral muscle. In two patients receiving the lowest dose 
(0.09 mg) this resulted in low levels of exon 51 skipping, but no detectable increase in dys-
trophin expression. However, a clear dystrophin restoration was observed in the higher dose 
(0.9 mg) group. As for the PRO051 study no adverse events, like an infl ammatory response, 
were observed. Immunofl uorescent staining for dystrophin indicated 11-21% higher intensity 
levels in the AON-treated muscle compared to the contralateral saline-treated muscle, and 
levels of 22-32% of control dystrophin levels.226 Since both studies studied different mus-
cles and used different techniques for quantifying immunocytochemistry the results are not 
directly comparable.227 However both studies showed unequivocal effectiveness of the used 
compound in the absence of side effects.
1.3.5.2 Systemic treatment with AONs
The next step towards clinical application of exon skipping are systemic clinical trials. The 
fi rst pilot experiment has been conducted in Japan. Takeshima et al. treated one DMD patient 
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intravenously with a weekly dose of 0.5 mg/kg body weight of a PS AON against exon 19 for 
four weeks. Only very low levels of exon skipping and dystrophin protein were observed in a 
muscle biopsy.228 This is not surprising, as the dose used was very low and the PS backbone 
chemistry is not ideal for exon skipping purposes (see paragraph 1.3). Furthermore, this was 
only one single patient, so no real, reliable conclusions can be drawn from this experiment.
More extensive, open-label, dose-escalation, phase I/IIa studies have been completed for 
both 2OMePS and PMO AONs. The fi rst was a study with abdominal subcutaneous injec-
tions of PRO051 (2OMePS AON; now called GSK2402968 or drisapersen) in 12 patients 
testing fi ve weekly doses (0.5, 2, 4 and 6 mg/kg body weight) in groups of three patients. 
Doses of 2 mg/kg body weight or higher resulted in specifi c exon 51 skipping. In ten out of 
12 patients dystrophin expression in a tibialis anterior biopsy could be observed in 60-100% 
of the muscle fi bres at levels up to 15.6% of healthy levels in a dose-dependent manner. After 
analysis of this fi rst phase (six to 15 months later), all patients entered an open-label exten-
sion study in which they received weekly injections of the highest dose. After 12 weeks, this 
resulted in functional improvement as measured by the six minute walk test. Since a placebo 
group is lacking, interpretation of this improvement must be done with caution. Nevertheless, 
the overall results were encouraging and only mild adverse events, like irritation at the injec-
tion side and mild proteinuria, were observed.229 Furthermore the extension trial has been 
continued. Patients have now been treated for over three years. In the fi rst 72 weeks they 
received weekly injections, followed by an intermittent dosing scheme (eight weeks on, four 
weeks off). Except from two patients who lost ambulation in between the initial trial and the 
extension trial and two patients who were already in decline, the remaining eight showed sta-
bilisation of six minute walking distance [presented at the 18th international conference of the 
World Muscle Society, Asilomar, CA, USA, Oct 2013]. Considering the age of the patients 
and the natural history data, this is unlikely to be solely to be attributed to a placebo effect.
To determine the safety, tolerability and pharmacokinetics of drisapersen a study in 
non-ambulant patients with different AON doses has been performed. Patients received a 
single dose of drisapersen (or placebo) by subcutaneous administration. Initially doses of 3, 
6, 9 and 12 mg/kg were planned, but since the study objectives were met with the 9 mg/kg 
dose, it was decided not to proceed with the 12 mg/kg dose. Only between the 3 and 6 mg/kg 
some dose proportionality was seen, but not in the whole range from 3 to 9 mg/kg. The two 
lowest doses did not raise large safety concerns, but in the 9 mg/kg group fever and transient 
elevation of infl ammatory parameters was observed. It was concluded that 6 mg/kg is the 
maximum tolerated dose for drisapersen in non-ambulant DMD patients.230
AVI-4658 (PMO AON; also called eteplirsen) was tested by 12 weekly intravenous infu-
sions of different doses (0.5, 1, 2, 4, 10 and 20 mg/kg body weight) in a total of 19 patients, 
without serious adverse events. In a biceps biopsy, exon 51 skipping and restoration of pro-
tein expression was observed starting at a dose of 2 mg/kg body weight, albeit variable 
between individual patients. The responding patients showed dystrophin levels of 8-16% 
of healthy controls by immunofl uorescent staining. Notably, there were three patients who 
responded very well, with up to 55% of dystrophin-positive fi bres by immunofl uorescent 
staining and dystrophin levels up to 18% by western blot. In four other patients a more mod-
est improvement in dystrophin levels was observed. The functionality of the newly formed 
proteins was confi rmed by the restoration of DGC-associated proteins at the sarcolemma. 
In addition, a reduction of infl ammatory infi ltrates was observed in the highest dose group, 
which probably indicates a reduction in necrosis and an increased resistance to mechanical 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































half-life of PMOs. Since PMOs do not bind to plasma proteins (see paragraph 1.3.1), they are 
rapidly fi ltered out by the kidney (accounting for 40-60% of total plasma clearance). Thus, 
the amount available for uptake by other tissues (e.g. muscles) is low. Therefore further opti-
misation (e.g. higher doses) is needed.
The next steps are larger randomised, placebo-controlled studies and targeting of other 
exons. For drisapersen a study in ambulant patients where different treatment regimens are 
compared (NCT01153932*), is conducted. Recently a press statement was released, stating 
that patients treated continuously with 6 mg/kg/wk showed increased walking distance in six 
minutes compared to placebo after 24 and 48 weeks of treatment and patients receiving inter-
mittent dosing (10-week cycles of 9 doses at 6 mg/kg over 6 weeks and 4 weeks off drug) 
only after 48 weeks. Dystrophin analysis was performed on muscle biopsies obtained before 
and after 24 weeks of treatment. Dystrophin restoration was reported for 72% of patients on 
the continuous dose, 59% of the intermittent dose and 5% of placebo-treated patients.233 In 
parallel, a large phase III study (pivotal study) was initiated in January 2011 (NCT01254019). 
Hundred and eighty ambulant patients received 6 mg/kg body weight AON once weekly for 
one year or placebo. This study was done to show whether long term treatment is safe and 
leads to functional improvement or slowing down of disease progression. Unfortunately the 
primary endpoint, i.e. a signifi cant increase in six minute walk distance compared to placebo 
was not met.232 The study was conducted in a broader patient group compared to previous 
studies (e.g. wider age range and less strict requirements in time rising up from the fl oor), 
which might explain the lack of differences between the treatment group and the placebo 
group. For example, if patients below and above the age of seven were analysed separately, 
walking distances compared to placebo of respectively 22 meter and 6 meter were observed 
[presented at the 18th international conference of the World Muscle Society, Asilomar, CA, 
USA, Oct 2013]. More detailed analysis on subsets and dystrophin restoration will be per-
formed. Most ongoing and completed trials for drisapersen also have an open-label extension 
study (see table 1.1). However, due to the disappointing results of the phase III study dosing 
in those studies has been suspended, pending further analysis, but patients are still monitored.
In addition a placebo-controlled clinical trial for AVI-4658 with higher doses (30 mg/kg 
and 50 mg/kg body weight) for 24 weeks (four patients per group) has been completed (but 
not yet published) to assess its effi cacy and safety. Thereafter these patients were enrolled 
in an open-label extension study. In this extension phase the placebo-treated patients were 
equally, i.e. 2:2, divided over the 30 and 50 mg/kg group (placebo/delayed). During the initial 
study signifi cant increases in dystrophin positive fi bres (as measured by immunofl uorescent 
staining) were seen after 24 weeks in biopsies of the 30 mg/kg group compared to placebo, 
but not in the 50 mg/kg group after 12 weeks. Dystrophin restoration was also seen in the pla-
cebo/delayed group after 48 weeks (24 weeks after start treatment). This was accompanied 
by restoration of compounds of the DGC at the sarcolemma. Functionally, a stabilization in 
walking distance during the six minute walk test was observed in the groups treated from 
the start (combined), whereas the delayed treatment group (both combined) declined rapidly 
till 36 weeks (12 weeks after start treatment) and then also stabilised. However these results 
must be interpreted with caution, since two patients in the 30 mg/kg group, who lost ambu-
lation during the trial are not included in the analysis. Furthermore, to explain the observed 
patterns the investigators suggest that it takes around 12 weeks before clinically meaning-
fully dystrophin levels are produced, accounting for the large drop in walking distance in the 
delayed treatment group until after ~12 weeks of treatment. However, this drop was not seen 
* Registration on www.clinicaltrials.gov
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in the fi rst 12 weeks of the trial in the other two groups (when excluding the two patients 
who lost ambulation). Furthermore, dystrophin staining was not yet observed in the 12-week 
biopsies of the 50 mg/kg treated patients. Nonetheless, encouraging is that overall treatment 
was well tolerated in all groups for this long period.234 Patients are currently still treated in 
the extension study (NCT01540409), showing continued stabilisation of both groups in func-
tional performance as measured by the 6MWD up till 84 weeks, without adverse events.235
These trials focus on skipping of exon 51, applicable to the relative largest group of 
patients. Skipping of exon 44 would be useful for another large group of patients (6.2%).44 A 
phase I/IIa study with PRO044 (2OMePS AON against exon 44) with a similar set-up as the 
phase I/IIa study for PRO051, but also comparing subcutaneous and intravenous injection 
routes, is currently ongoing (NCT01037309). Also, a phase IIb trial with PRO045 (2OMePS 
AON against exon 45), fi rst comparing different doses (0.15-9.0 mg/kg/week) by subcuta-
neous injection and thereafter 48 weeks of treatment with the selected, most optimal dose, 
has recently started (NCT01826474). Furthermore an open-label phase I/II trial for PRO053 
(2OMePS AON against exon 53), assessing escalating doses of PRO053 via intravenous or 
subcutaneous injection (NCT01957059).
Furthermore, preclinical studies with other 2OMePS AONs (targeting exon 52 and 55) 
are performed by Prosensa Therapeutics and for PMOs targeting exon 45, 50 and 53 are per-
formed by Sarepta. In addition to this, preclinical tests with AVI-5038 (pPMO AON against 
exon 50) are ongoing, although toxicity issues with this pPMO have been reported.
Next to all (pre-)clinical trials with AONs also a large trial (NCT01539772) is ongoing 
studying the natural history of disease in BMD patients. The phenotype will be characterised 
and specifi c abnormal dystrophin proteins will be correlated with the range of clinical out-
comes in order to predict the clinical effect of therapeutic exon skipping for different AONs/
mutations. In the Netherlands a similar study has been conducted. This revealed that BMD 
patients with out-of-frame mutations that could theoretically be corrected by the skipping of 
one exon (exons 22, 44, 45, 51, 53 or 55) had a relatively milder course of disease pathol-
ogy, as refl ected by age of wheelchair dependency, than BMD patients with other mutations 
and, most importantly, a milder phenotype compared to DMD patients. Compared to DMD 
patients, ambulation, respiratory and cardiac function was better. Although this might be 
an overestimation of possible therapeutic effects of AON treatment, since in BMD patients 
these in-frame-mutations are present from birth, this is encouraging for possible outcomes of 
the exon skipping therapy.236
For DMD the natural history and progression of the disease will be studied in two large 
clinical trials. A prospective study (NCT01753804) will also search for biomarkers that 
correlate with disease progression and could potentially be used as a surrogate outcome 
measure in future clinical trials. Another prospective study (NCT00468832) looks at the 
natural history by studying the preservation of functional capabilities, respiratory function 
and the progressive loss of muscle strength. It focuses mainly on the effect of glucocorticoids 
on these parameters and the fi rst part (consisting of 340 participants) has recently been pub-
lished.237,238 Patients were divided in three groups: glucocorticoid naïve, past glucocorticoid 
users and current glucocorticoid users. Higher preservation of muscle function in glucocor-
ticoid users was seen and this effect remains when treatment continues throughout teenage 
and adolescent years, although effects are largest when treatment starts early. Furthermore, 
outcome measures currently used in clinical trials show variation (either increasing, stable or 
decreasing) depending on the age of the patient and the disease stage.
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1.3.6 Improvement of AON delivery and effi ciency
Next to the backbone-modifi cation methods or choosing the most effi cient delivery route 
described above (see paragraph 1.3.4) several other strategies can be applied to increase 
AON delivery and/or effi ciency. First of all the dosing regimen can infl uence the exon skip-
ping and dystrophin levels. For PMOs it has been shown that a dosing regimen of multiple 
low doses (four times per week 50 mg/kg) seems to be preferable above a few high doses 
(once 200 mg/kg/week) to reduce the risk of toxicity and increase the effi ciency, since both 
AONs and dystrophin protein show an accumulation over time.239 In this thesis this is also 
shown for 2OMePS AONs (chapter 3), where a clear increase in AON levels was seen after 
dividing the total dose of AONs per week in daily injections compared to administering it 
all at once or in two times, which was followed by increased exon skipping in some muscles. 
However, this effect on AON levels was also observed in non-target organs as the liver and 
the kidney, which can increase the risk of unwanted side effects.240
The effi cacy of AONs depends partly on the amount of AON that reaches its target, i.e. 
the muscle fi bre nuclei. Several strategies to improve muscle-specifi c uptake are under inves-
tigation, like muscle-homing peptides and cell-penetrating peptides (see paragraph 1.3.4). 
For specifi cally enhancing nuclear uptake Moreno et al. synthesized a 5’-cap containing a 
nuclear localization signal (2,2,7-trimethylguanosine cap; m3G-CAP) that is naturally found 
in snRNAs. Attaching this cap to 2OmePS AONs increased their effi cacy, possibly due to 
improved nuclear delivery.241
Due to AON clearance and turnover, the effect of AONs is only temporarily, thus repeated, 
life-long, injections are required, should this approach prove to be effi cacious. The fi rst clin-
ical trials showed that the average serum half-life was 29 days for 2OMePS AONs and less 
than 2.5 hours for PMOs. A way to allow a more prolonged effect is the use of viral vectors 
stably expressing modifi ed snRNP genes. SnRNPs are small protein-RNA hybrids that are 
amongst others involved in pre-mRNA splicing and histone processing. The natural anti-
sense sequence can be replaced by antisense sequences targeting dystrophin exons.242-245 The 
U1 and U7 snRNPs have been used most in splicing modulation experiments.246 Exon 51 tar-
geting U1 snRNPs induced effective skipping of exon 51 and rescue of dystrophin synthesis 
in a patient-derived cell line.242,247 SnRNPs are expressed under their own promoter, so there 
is less likelihood of eliciting an immune response, due to the presence of viral promoters. 
Since snRNPs are very small they easily fi t within an adeno-associated viral (AAV) vector. 
AAVs are very effi cient at transferring genes into skeletal muscles. Injection of AAV vectors 
expressing U1 or U7 snRNPs targeting mouse exon 23 resulted in sustained production of 
functional dystrophin in the mdx mouse after intramuscular injection and body-wide dys-
trophin expression and reduced muscle wasting after systemic treatment.244,245 They could 
even rescue the severe phenotype of the mdx/Utrn-/- mouse.248 However a serious problem 
with the use of AAV vectors is the possibility of an immune response against the viral capsid. 
Therefore maximising the effi ciency of snRNP delivered per AAV vector is necessary to 
reduce the vector dose. Modifying an U7 snRNP with a muscle- and heart specifi c enhancer 
increased antisense delivery and exon skipping. However, it revealed that, although the 
amount of transcripts was increased, many of them were not appropriately processed, which 
is necessary for their functionality, and many non-functional by-products were formed. This 
indicates that the exon skipping capacity of these U7 snRNPs is limited by saturation of the 
processing capacity of the host cell.249 Other problems are the diffi culty to produce AAV 
particles on a large scale under good manufacturing practice, necessary for implementation 
in the clinic, and the translation from mice to larger animals or humans. In mice it is feasible 
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to treat a whole muscle, but transfection of whole muscles body-wide is more challenging in 
larger animals and humans. U1 and U7 snRNP antisense constructs targeting multiple human 
exons are presently developed for use in clinical trials.250 Furthermore there are concerns for 
an immune response against AAV vectors, as has been observed in dogs with AAVs used for 
gene replacement therapy (see paragraph 1.4.3). In a fi ve year follow-up study in GRMD 
dogs, notably no immune response was observed. However, still a large decline in dystrophin 
positive fi bres was observed.251 Therefore repeated would be required, which would largely 
increase the chance of immune rejection. A study in mdx mice showed that the speed of 
decrease in AAV vectors correlated with loss of dystrophin restoration and was mainly due 
to regeneration. Therefore optimal dosing would be required to induce suffi cient dystrophin 
levels to arrest the dystrophic process and maintain therapeutic value on the long term.252 
This will be challenging in DMD patients.
Another approach to induce or enhance exon skipping is the use of small chemical com-
pounds. Several compounds that infl uence splicing have been reported for DMD and other 
diseases caused by incorrect splicing events. For example the cytokine kinetin to specifi cally 
correct the splice defect in familial dysautonomia and several compounds have been iden-
tifi ed to enhance exon seven inclusion in spinal muscular atrophy.253,254 For DMD, TG003 
has been reported to induce exon 31 skipping and dystrophin restoration in patient cells 
harbouring a point mutation in this exon. TG003 is a specifi c inhibitor for Cdc-like kinases, 
proteins involved in the activation of splice regulator proteins, binding to ESEs. TG003 spe-
cifi cally inhibited exon 31 inclusion in mutated, but not in wild type cells.255 However this 
compound is specifi c for this mutation and, since this mutation is very rare, its application 
is rather limited. Also one cannot exclude that the compound will disrupt splicing of regular 
exons in other genes.
In order to identify more general exon skipping enhancing compounds, large drug 
screening systems have been used. Thereby a guanine analogue, 6-thioguanine (6TG) was 
identifi ed that increased PMO-induced exon 23 skipping levels in vitro in cultured mdx cells. 
Furthermore it enhanced exon skipping after local intramuscular injection in the tibialis ante-
rior of both AONs and 6TG in mdx mice.256 However repetition of these experiments in 
vitro and in vivo with both 2OMePS and PMO AONs, resulted in numerous splicing events 
induced by 6TG alone in vitro, only enhancement of exon skipping levels by suboptimal AON 
sequences/doses in vitro and no effect on treatment with AONs of either chemistry after local 
injection in vivo (this thesis; chapter 5).257 Additionally, compounds should enhance AON-
induced exon skipping rather than inducing skipping by themselves, as the latter involves the 
risk of aspecifi c exon skipping events.
Recently, dantrolene has been described as a sequence- or backbone-independent 
enhancer of AON-mediated exon skipping. It increased 2OMePS-mediated exon skipping 
for different exons in vitro and PMO-mediated exon skipping both locally and systemically 
in vivo in mdx mice, but did not induce exon skipping by itself. Dantrolene targets the RyR, 
regulating Ca2+-signalling in the nucleus, which is infl uencing splicing.258
Rather than increasing AON delivery and/or activity itself, a strategy could be to increase the 
possible targets for these AONs. These targets are the DMD pre-mRNA, which is expressed 
only by muscle tissue. Since more and more muscle tissue gets replaced by fi brotic and adi-
pose tissue over time in DMD patients, fewer targets remain for the AONs and the therapeutic 
effect will be lower in older patients. Improving muscle quality or mass can be attempted 
by various pharmacological approaches targeting different parts of the DMD pathology (see 
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chapter 2). Increasing muscle mass by myostatin inhibition, i.e. by inhibitory compounds or 
AON-mediated exon skipping, has been tested in combination with dystrophin AONs (see 
paragraph 2.7.1). Furthermore, in this thesis some pharmacological compounds have been 
investigated in combination with AONs. First of all, the corticosteroid prednisolone, the cur-
rent standard of care for DMD patients has been tested (see paragraph 2.2). This had no effect 
on the exon skipping levels induced by AONs itself, but might result in a moderate increase 
in dystrophin protein expression in vivo after systemic AON-treatment of mdx mice (this the-
sis chapter 6).260 Secondly, the angiotensin II type 1 receptor (AT1) antagonist losartan (see 
paragraph 2.8), described to improve pathology in mdx mice,259 was tested. However these 
experiments were discontinued since no effect of losartan itself was seen in our hands (see 
chapter 7) and new literature could not or only partially reproduce published results.261-264
1.4 Other approaches targeting the underlying genetic defect
Next to antisense-mediated exon skipping several other potential therapies aim to (partially) 
correct the mutation in the DMD gene or replace the dysfunctional gene. An overview of the 
current trials for these therapies is given in table 1.2.
1.4.1 Stop codon readthrough
A small subset of patients (around 14%) carries nonsense mutations due to single nucle-
otide substitutions.187 It has long been known that certain antibiotics can force the cell to 
ignore premature stop codons, allowing the production of full-length proteins. Gentamicin 
was tested in clinical trials for stop codon readthrough decades ago. In vitro studies in cells 
derived from DMD/BMD patients variable readthrough effi ciencies (from 1 to 10%) were 
observed and showed that this is dependent on the type of stop codon mutation (UGA, UAA 
or UAG) and the nucleotides fl anking the stop codon.265 Early studies with gentamicin in the 
mdx mouse resulted in dystrophin levels of up to 20%.266
While results in mice were very promising, initial results in humans were disappoint-
ing.267,268 This turned out to be due to different gentamicin isomers. Only one isomer has 
high readthrough activity, and gentamicin batches contain a mix of different isomers of 
which the ratio varies between different batches.269 After identifying the most effi cient gen-
tamicin isomer, a new clinical trial was performed. This indeed revealed that short term 
gentamicin treatment reduced serum CK levels in patients with premature stop codons, but 
not frame-shifting mutations. Treatment for six months resulted in a signifi cant increase in 
dystrophin levels of ~15% in three out of 12 patients.270 However, due to the risk of renal and 
ototoxicity, long term treatment with gentamicin is not a viable option.
High throughput screening using a cell line containing a luciferase gene with a prema-
ture stop codon identifi ed PTC124 (ataluren), a compound with a much better safety profi le. 
This compound restored dystrophin in the mdx mouse up to levels of 25%, was well toler-
ated by healthy volunteers and DMD patients in short dose-escalation studies were in the 
latter a modest increase in dystrophin levels was seen.271-273 The fi nal results of the trial in 
DMD patients or its extension study have not yet been published. These trials were followed 
by a large, multicentre double-blinded placebo-controlled Phase II/III trial, where patients 
received high or low doses of ataluren or placebo for 48 weeks and then all were treated with 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































improvement in the six minute walk test) was not reached and the extension study was put 
on hold. Interestingly, patients receiving the low dose showed an increase in the distance 
walked in six minutes compared to the placebo group, although this was not signifi cant. 
This counterintuitive result (low dose patients doing better than high dose patients) is due to 
the apparent bell shaped dose-response curve for ataluren.274,275 The fi nal results of this trial 
(NCT00592553) and its extension study (NCT00847379) have not yet been published. Due 
to these results, ongoing (extension) clinical trials have been suspended/terminated to fi rst 
investigate the results in more depth and optimise dosing. Recently the extension study open 
for all patients treated in previous trials has been reopened (NCT01247207/NCT01557400). 
In addition, a new phase III double-blinded, placebo-controlled study comparing different 
lower doses of PTC-124 has recently started (NCT01826487). Furthermore, it turned out that 
the results of the luciferase screening assay may have been biased due to stabilisation of the 
luciferase enzyme by PTC124 derivatives resulting in enhanced luciferase effi ciency.276,277 
Nevertheless, additional assays showed that PTC124 has at least some readthrough poten-
tial.273,278
The mixed results with PTC124 and the discovery of the luciferase assay bias, led to 
new luciferase independent high-throughput screening of possible, more potent readthrough 
compounds. Hereby RTC13 was identifi ed, which resulted in partial dystrophin restoration 
in several skeletal muscles, diaphragm and heart, leading to improvement of muscle strength 
after four weeks of systemic (intraperitoneal) in mdx mice, without signs of toxicity.279
Another factor that can infl uence the outcome of stop codon readthrough is the aforemen-
tioned NMD, resulting in fewer targets for the readthrough compounds. Its effi ciency varies 
between individuals, for different stop codons, location within the mRNA and sequence con-
text. Studies in vitro, in cystic fi brosis patient-derived cells, carrying a premature stop codon 
in their CTGF gene, revealed that the response to gentamicin treatment was dependent on 
the activity of NMD in these cells. Indeed, blocking of NMD in cells from non-responders 
enhanced responsiveness to gentamicin treatment.280
1.4.2 Trans-splicing
Another approach to repair the mutated gene at mRNA level is trans-splicing by which a 
mutated exon can be replaced with its normal version, missing exons can be introduced 
or duplications corrected. It is based on a naturally observed mechanism mainly in lower 
eukaryotes called trans-splicing, i.e. the splicing between two independently transcribed 
pre-mRNAs. For mRNA repair purposes trans-splicing means the splicing in trans of the 
endogenous mutated pre-mRNA and an exogenous engineered pre-trans-splicing mole-
cule (PTM). In addition to the sequence to be introduced, this PTM contains also antisense 
sequences for intron-specifi c annealing and sequences to be recognized by the splicing 
machinery. Trans-splicing will only take place when the target pre-mRNA is expressed, 
rendering it tissue-specifi c and preserving expression level of the repaired transcript.281 Its 
feasibility has mainly been shown for 3’ replacement, but 5’ replacement and exon replace-
ment by double trans-splicing in vitro using minigenes has been reported as well.282-284 
For DMD proof-of-principle has been shown in vitro in patient cells and in vivo in animal 
models. In cultured cells derived from a DMD patient with a nonsense mutation in exon 71 
lentiviral transfection with PTMs containing human dystrophin cDNA from exon 59 to 79 
induced correctly trans-spliced transcripts. A single intramuscular injection of AAV2/1 vec-
tors expressing the PTM with the murine wild type exon 23 linked to exon 59-70 in mdx or 
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mdx4cv mice resulted in the expression of trans-spliced transcripts harbouring the exogenous 
sequence, showing one PTM can be used for multiple mutations. However in both cases, 
despite effi cient viral transfection, repair mRNA levels were low (up to 30% in vitro and ~1% 
in vitro), resulting in undetectable levels of (micro)dystrophin by western blot. By immuno-
fl uorescent staining sarcolemmal localization of microdystrophin was observed in vivo. A 
risk of this trans-splicing approaches with PTMs is that translation of the PTM itself could 
resulted in a truncated protein acting as a dominant negative form or eliciting an immune 
response.285
1.4.3 Gene replacement
In contrast to exon skipping or stop codon readthrough, replacing the mutated gene (gene 
replacement) is not mutation-specifi c. However, gene delivery to muscle is challenging due 
to its abundance (30-40% of the body) and accessibility (post-mitotic fi bres surrounded by 
layers of connective tissue). This reduces the effi ciency of gene delivery by plasmids.286 Also, 
most viral vectors do not effi ciently transduce muscle, except for AAV. However, AAV has a 
cloning capacity of ~4.5 kb, while the dystrophin cDNA is 14 kb.287 Therefore the attention 
has verged to the use of shortened dystrophin constructs.
As described above, dystrophin contains repetitive, partly redundant domains. This 
allowed the generation of mini- and microdystrophins containing only domains minimally 
required for functionality (fi g. 1.5).287-289 The 6.3 kb minidystrophin gene is based on a very 
mild BMD patient with a deletion of exon 17 to 48, thereby lacking 46% of the coding 
region.290 This minidystrophin was able to almost completely prevent dystrophic symptoms 
when expressed in transgenic mdx mice.116 Promising results with microdystrophins were fi rst 
shown in the mdx mouse model. Local administration of several of these microdystrophins, 
delivered by AAV under a muscle-specifi c promoter, resulted in high and stable recovery of 
dystrophin expression and improvement of myofi bre morphology.115,288,291-294 Results on the 
effect of skeletal-specifi c expression of microdystrophin on cardiomyopathy are inconsistent. 
Whereas in young mdx4cv mice (4-5 months old) skeletal muscle repair by specifi c transgenic 
expression of a minidystrophin aggravates dilated cardiomyopathy due to increased exer-
cise,295 in six to nine months old mdx/Utrn-/- mice diaphragm rescue by pPMO treatment 
prevented heart failure296 and in aged mdx mice skeletal-specifi c microdystrophin expression 
had no effect (neither positive nor negative) on cardiomyopathy.297 Systemic (intravenous) 
treatment of mdx mice with ∆R4-23/∆CT in an rAAV6 vector resulted in body-wide expres-
sion of these microdystrophins in skeletal muscle and heart after a single injection in both 
young and old mdx mice.298,299
Subsequent studies in dogs raised the issue of a cytotoxic immune response against viral 
capsid proteins and/or transgene product.300 Intramuscular injection of AAV1, AAV2 and 
AAV6 serotypes in wild type dogs induced a robust cellular immune response to the viral 
capsid proteins itself.301,302 The same response was observed after local injection of AAV9 in 
adult, but not in neonatal dogs.303 Ohshima et al. demonstrated that immune responses were 
less for AAV8 compared to AAV2, however still present and rAAV8-mediated microdystro-
phin expression in dystrophic dogs lasted for eight weeks, but showed a decline over time.304 
Systemic (intravenous) administration of rAAV6 in healthy dogs also resulted in an immune 
response; however gene expression could be ameliorated with transient immunosuppres-
sion.305 Furthermore in neonatal dogs AAV9 carrying a microdystrophin (Δ3990) eluted a 
marked early infl ammatory response too, although widespread dystrophin expression was 
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detectable after 16 weeks in the two surviving dogs.306
In non-human primates immune responses were observed to AAV1 and AAV8 vectors 
after intramuscular, but not after regional intravenous injection.307 Rodino-Klapac et al. did 
not observe a T-cell response after systemic injection AAV8-microdystrophin (∆R4-23/∆CT) 
in non-human primates and observed microdystrophin expression levels up to 80%. However 
this percentage dropped to 40% in macaques in which antibodies were present before injec-
tion.308
This work culminated in a clinical trial where patients were injected intramuscularly with 
different doses of AAVs expressing microdystrophins ∆3990 under a CMV promoter.309,310 
Unfortunately, only a few dystrophin positive fi bres were observed in some patients, while 
viral genomes were detected in all muscle biopsies. Unexpectedly, T-cells targeting dystro-
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Fig. 1.5: Schematic overview of the dystrophin protein, the minidystrophin protein and var-
ious microdystrophin proteins
The dystrophin protein consists of four domains: fi rst, an N-terminal actin-binding domain (ABD1); second, a 
central rod domain, consisting of 24 spectrin-like repeats, interrupted by four proline-rich hinge regions (H1–H4). 
A second actin-binding domain is present between repeat 11 and 17 (ABD2); third, a cysteine-rich domain, contain-
ing a β-dystroglycan-binding domain (Dg-BD), which is part of the dystrophin-associated glycoprotein complex; 
and fi nally, a C-terminal domain, containing an α-sarcoglycan and an α-dystrobrevin binding domain (S-BD and 
Db-BD). The 6.3 kb minidystrophin based on a very mild BMD patient with a deletion of exon 17-48 contains the 
N-terminal ABD1, nine of the 24 central rod repeats (1-3 and 19-24), three of the hinge regions (H1, H3 and H4) 
and the cysteine-rich Dg-BD. Several microdystrophins, as described in the text, are based on this minidystrophin 
by deleting extra parts of the protein to fi t in AAV vectors.
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phin epitopes were detected in blood of several patients using the ELISPOT assay.310 In one 
patient the epitope was present in the microdystrophin, while it was deleted in the patient. 
This is likely a true “auto-immune” response to a foreign epitope. However, for other patients, 
T-cells specifi c for epitopes expressed in dystrophin-positive revertant fi bres in patients’ 
muscle were found also before AAV-microdystrophin injection. It is unclear whether the 
“immunisation” with microdystrophin exacerbated the anti-dystrophin immune response and 
what the consequences will be for approaches aiming to restore dystrophin. It is reassuring 
that dystrophin was expressed in the revertant fi bres, despite anti-dystrophin T-cells in the 
circulation, and that in exon skipping trials the number of T-cells infi ltrated into the muscle 
appeared to go down rather than up after dystrophin restoration.231
To allow delivery of larger, more functional minidystrophins it has been attempted to 
split the dystrophin cDNA over two AAV cassettes, relying on homologous recombination 
or trans-splicing to join the 5’ and 3’ ends.311-313 This has been successful in animal models, 
albeit at lower effi ciencies than when delivering a single transgene. Alternatively, intraperi-
toneal delivery of helper-dependent adenoviral vectors allowed delivery of the complete 
dystrophin cDNA to diaphragms of mdx/Utrn-/- mice, which improved respiratory function 
and diaphragm histology.314
The two main hurdles for AAV-mediated gene therapy are overcoming immunity and 
delivery. As described above an immune response can occur both to AAV and the trans-
gene. However, long term transgene expression could be achieved in dogs without 
immunosuppression using AAV2/8-mediated delivery of a species-specifi c microdystrophin 
(∆R4-23/∆CT) in combination with a tissue-specifi c promoter.315 Furthermore, transient 
immunosuppression was suffi cient to allow long term transgene expression in dog after 
AAV6-mediated ΔR2-15/ΔR18-19/H3/ΔR20-23/ΔCT microdystrophin delivery.316 The 
same immunosuppression scheme was also used in a larger study in eight normal and 
14 dystrophic dogs in which in total six dystrophic dogs were injected in eight muscles 
with AAV9-ΔR2-15/ΔR18-19/H3/ΔR20-23/ΔCT. This resulted in robust dystrophin expres-
sion two months later, despite large T-cell infi ltration, and restoration of DGC-components. 
Also some parts of muscle physiology were improved (protection against eccentric contrac-
tion-induced force decline), however others were not changed (specifi c tetanic muscle force), 
indicating that microdystrophin treatment in dogs still needs optimisation.317
Muscle and heart delivery can be improved by choosing optimal AAV serotypes, 
e.g. AAV6, AAV8 and AAV9.318-320 Alternatively, AAV2 transduction could be improved up 
to tenfold in heart and diaphragm by pre-treatment with synthetic polylysines.321 Suggested 
mechanisms for this are an altered AAV surface charge and/or a reduced humeral response 
against AAVs. Polylysine pre-treatment would allow using lower doses of viral particles. 
However, it did result in death of some of the mice,321 so the clinical applicability of this 
approach remains to be seen.
Improved delivery of viral vectors and plasmids can also be achieved by hydrodynamic 
delivery to individual muscles or muscle groups. This has been reported for rodents and pri-
mates322-325 and high pressure transvenous delivery using saline has been tested in the lower 
legs of adult muscular dystrophy patients.326 Delivery of saline up to 20% of limb volume 
is feasible and tolerable. However, patients receiving 20% showed elevations in compart-
ment pressure, suggesting that this might be the maximum tolerable volume. Currently only 
regional delivery is feasible, implying that multiple treatments are needed for whole body 
treatment. This poses obvious challenges due to the immunogenicity issues described above. 
Nevertheless, AAV gene delivery to heart is effi cient and resulted in improved heart quality 
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and function in mouse and dog models.327-330
1.4.4 Cell therapy
Cell therapy for DMD is in fact a form of gene therapy, as cells from a healthy donor will 
contain the functional DMD gene. The added benefi t is that these cells will also contribute 
to the regeneration of damaged muscle in patients. In theory cell therapy thus seems very 
appealing. However, again the abundance and accessibility of muscle tissue is impeding 
this approach. Furthermore, muscle tissue is primarily post-mitotic. Upon muscle damage, 
satellite cells are activated and proliferate and repair the damage. These satellite cells can be 
isolated from healthy donors and expanded ex vivo and the resulting cells (myoblasts) can 
be transplanted into patients. Unfortunately, early clinical trials using this approach revealed 
that the majority of myoblasts died quickly and that none of them was able to leave the blood 
stream to migrate into muscle tissue.331 Even upon direct injection into muscle the migration 
of myoblasts was poor. To overcome this, multiple injections have been used and dystrophin 
restoration has been obtained by high-density injections of many (25-250) injections per 
cubic centimetre.332,333 While this may be feasible for some small superfi cial muscles, it is not 
for larger and/or more diffi cult to reach muscles such as the diaphragm and for whole body 
treatment.
It has become clear that there are other stem cells that are able to migrate from the blood 
stream into muscle tissue and participate in muscle fi bre regeneration. These include cells 
from the immune system, from blood vessel walls (mesangioblasts), fat stem cells (pericytes) 
and bone cells.331 For most of these cells the effi ciency is very low and often dystrophin-pos-
itive fi bres in treated animal models are below 5%.
Satellite cells are skeletal muscle progenitor cells that are normally in a quiescent state, 
but can be activated upon muscle damage to form new muscle fi bres or fuse with exist-
ing fi bres for repair. These Pax3- and Pax7-expressing cells could be isolated from wild 
type mice and contribute both to fi bre repair and the muscle satellite cell compartment after 
injection into muscles of mdx nu/nu mice (immunodefi cient mdx mice). Unfortunately it 
turned out that the myogenic capacity and proliferation potential of satellite cells, which is 
normally great, are rapidly reduced after expansion in vitro.334 Myoblast transplantation was 
less successful in immunocompetent mdx mice. Although both short and long term dystro-
phin expression was observed in injected muscle, the number of dystrophin-positive fi bres 
rapidly decreased over time. This turned out to be due to limited migration of the myoblasts, 
poor survival of the cells and immune rejection. In NSG-mdx4cv mice a low number (900) of 
Pax7-ZsGreen donor cells (satellite cells) could regenerate into functional muscle cells and 
increase maximal force generation capacity of transplanted muscle.108
Muscle-derived stem cells (MDSCs) were found to show better engraftment. MDSCs 
are isolated from skeletal muscle and have in vitro shown the ability to generate multiple 
cell lineages and to generate for example myofi bres when transplanted into skeletal muscle 
or osteoblasts when transplanted into bone.335 Wild type MDSCs implanted into the injured 
gastrocnemius of aged mdx mice resulted in improved myofi bre repair and reduced fat dep-
osition and fi brosis.336
Mesangioblasts are the most promising cell type so far. These cells express early, epi-
thelial markers and can migrate from blood vessels into tissues. Furthermore they have 
the potential to differentiate into muscle. In the GRMD model, mesangioblast transplan-
tation of donor or autologous corrected stem cells by intra-arterial injection resulted in up 
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to 10% of dystrophin-positive fi bres and functional improvement in these dogs. However 
some dogs died of pneumonia, which could be the result of accumulation of the cells in the 
lungs.337 The fi rst clinical trials with mesenchymal stem cell transplantation either autologous 
(NCT01834040) or derived from healthy HLA-matched family members into DMD patients 
are currently ongoing (NCT01610440).
Pericytes have various similarities to mesangioblasts (and may in fact be the same cells) 
and can be derived from skeletal muscle, but also from other tissues, e.g. blood vessels. In 
vitro and in vivo these cells have shown to be able to differentiate into myoblasts and injec-
tion in SCID/mdx mice contributed to muscle repair.338
Next to the diffi culty to achieve high effi ciency necessary due to the abundance of muscle, 
another hurdle is the need for constant immunosuppression if donor stem cells are used to 
avoid an immune response against the newly formed myofi bres. However a recent article 
describes the use of human adipose-derived stromal cells (hASCs) in four GRMD dogs with-
out immunosuppression, although these results (no immune reaction to human cells in dogs) 
are controversial. These cells are able to differentiate into muscle cells after engraftment. 
Local injections did not result in engraftment of the hASCs, but was seen after systemic (in 
the cephalic vein) and dystrophin expression lasted until six months after the last injection.339 
Another alternative is to use autologous cells, which are corrected in vitro. However, as 
described above, it is diffi cult to maintain the myogenic potential during expansion in vitro 
and furthermore this may change the behaviour of the cells upon re-injection.
The effect of knockout of myostatin (see paragraph 2.7.1) on the success of myoblast trans-
plantation has also been tested, with opposing results. In vitro myostatin knockout in MDSCs 
resulted in silencing of genes critical for early myogenesis and led to poor myotube forma-
tion. However after transplantation in vivo in aged mdx mice their myogenic capacity was 
restored upon myostatin knockout, probably due to myostatin in the host environment. These 
cells did have repair capacity after injection in injured mdx muscle, although they were not 
more effective than wild type MDSCs and were, in contrast to the wild type MDSCs, not 
able to reduce lipofi brotic degeneration.336 On the contrary, another study using myoblasts 
in which myostatin signalling was blocked with a dominant negative Acvr2b using a lenti-
viral vector (see paragraph 2.7.1), resulted in vitro in increased proliferation and fusion. In 
vivo it improved transplantation success in immunodefi cient mdx mice after intramuscular 
injection compared to control myoblast transplantation, by increasing myoblast proliferation 
and fusion and acting on the expression of myogenic regulatory factors.340 This discrepancy 
could be due to the different ways, and thereby timing, of achieving myostatin blocking, 
which in the fi rst study was achieved by genetic inactivation and in the second study by 
blocking signalling in expanded myoblast cultures.
1.4.5 Genome editing
Direct modifi cation of the gene itself at the DNA level (genome editing or genome sur-
gery) has shown promising results for a number of other genetic diseases and is the newest 
therapeutic approach currently explored for DMD. For this purpose endonucleases (mega-
nucleases, zinc fi nger nucleases, transcription activator-like effector nucleases (TALENs) or 
RNA-guided nucleases) can be used. These cut the DNA at specifi c places, causing double 
strand breaks that are subsequently repaired either by homologous recombination with a pro-
vided donor DNA template, which has the ability to correct point mutations and other small 
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mutations, or non-homologous end joining, resulting in the insertion or deletions of a few base 
pairs (indels).341 Proof-of-principle was shown in vitro by co-transfection of a microdystro-
phin plasmid containing a premature stopcodon and a meganuclease plasmid. Meganuclease 
activity resulted in small deletions or insertions via non-homologous end joining resulting in 
in frame transcripts in some cells, thereby restoring microdystrophin expression. The same 
was shown in vivo intramuscularly in immunodefi cient mdx mice.342 A disadvantage of mega-
nucleases is that they are too large to enter myoblasts; therefore electroporation is required, 
limiting the feasibility of the technique for systemic treatment. Furthermore, although these 
endonucleases are able to cut at a specifi c spot, in vitro experiments showed that the size of 
the deletions was not uniformly distributed throughout the gene.343 First proof-of-principle 
for correcting human dystrophin mutations with meganucleases was shown using a lentiviral 
packed repair matrix carrying exons 45-52. Co-transfection in immortalized patients cells 
carrying a deletion of exons 45-52 with lentiviral vector packed meganucleases targeting 
exon 44 and a donor sequence containing exon 45-52, resulted in insertion of exons 45 to 52 
by homologous recombination and full-length dystrophin expression.344 The more recently 
developed endonucleases TALENs are more effi cient and have shown a higher success rate 
for other diseases. Transfection via electroporation with TALENs specifi cally inducing indels 
in exon 51 via non-homologous end joining in DMD patient-derived myoblasts, resulted in 
reading frame restoration and in re-expression of dystrophin protein.345 These are promising 
fi rst steps, but many hurdles have to be overcome will this approach prove to be successful. 
The main challenge at the moment is that the correction effi ciency is very low (~1 in 100 000 
to 1 000 000).
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Outline of this thesis
In chapter 2 a broad overview of secondary defects in DMD caused by the absence of a 
functional dystrophin protein is given and different pathways involved in pathogenesis are 
described. Furthermore therapeutic approaches targeting disease symptoms and disturbed 
signalling pathways are discussed.
In chapter 3 and 4 more detailed studies into the pharmacokinetic and pharmacody-
namic properties of AONs in mdx mice are described. Chapter 3 discusses the effects of 
different dosage and maintenance schemes in mdx mice, while chapter 4 provides a more 
detailed analysis of the pharmacokinetic and pharmacodynamic profi le of AONs in mdx mice, 
by studying the turnover of the compound, skipped transcripts and newly formed dystrophin 
protein.
In the next three chapters the use of different compounds in combination with AONs to 
enhance the therapeutic effects of the AONs, is tested. In chapter 5 a compound described 
in the literature to enhance antisense-mediated exon skipping itself, 6-thioguanine (6TG), is 
tested in cultured cells and locally in the mdx mouse. In chapter 6 and 7 pharmaceutical 
compounds are used that could improve muscle quality, thereby potentially increasing the 
targets, i.e. dystrophin transcripts, for the AONs and indirectly enhancing exon skipping 
effects. In chapter 6 prednisolone, a corticosteroid used by the majority of DMD patients, is 
used, and in chapter 7 the angiotensin II type 1 receptor blocker losartan, which targets the 
renin-angiotensin system, known to be upregulated in DMD.
This is followed by a short summary in chapter 8 of the results obtained in the preceding 











TARGETING THE SECONDARY DEFECTS IN DMD
2 Other therapeutic approaches
Since at present there is no cure for DMD, there are other, mainly pharmacological, approaches 
that attempt to combat the symptoms caused by the underlying genetic defect. In this chapter 
an overview of the different players, and thereby targets, in the DMD pathology is given, 
together with compounds/approaches that act on those targets and have been used/tested in 
DMD patients or dystrophic animal models. A schematic overview of the pathways involved 
in the pathology and the main approaches acting on these parts is given in fi g. 2.1. Table 2.1 
gives an overview of all compounds, except from those discussed in chapter 1, currently in 
clinical trials for DMD and/or BMD. The overview in this chapter is certainly not an exhaus-
tive list of all compounds ever tested in context of DMD or related diseases, which might 
relevant for DMD too, but aims to give a broad overview of possible approaches and their 
current status/results. In particular it aims to provide insight in which groups of compounds, 
with most promising outcome or mechanism of action, could be tested   to try to enhance the 






















































Fig. 2.1: Schematic overview of DMD pathology and therapeutic strategies
In DMD the primary defect, the absence of a functional dystrophin protein due to reading frame disruption or stop 
codon introducing mutations in the DMD gene, causes a cascade of downstream effects, including disturbance of 
calcium homeostasis, chronic infl ammation and increase of reactive oxygen species (ROS). This in turn eventually 
leads to a loss of muscle fi bres, which are replaced by fi brotic and adipose tissue, resulting in a loss of muscle 
function.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Instead of trying to bring back dystrophin into muscle, an alternative strategy is to increase 
the expression of the dystrophin homologue utrophin. In the mdx mouse model it has been 
shown that transgenic overexpression of truncated utrophin ameliorates the dystrophic phe-
notype.346 Full-length utrophin is even more effi cient and could prevent pathology in mdx 
mice and improve the phenotype in CXMD dogs.347-349 This started off high-throughput 
screens for drugs that can increase utrophin expression. Expression of utrophin is controlled 
by two isoforms of the utrophin promoter. The utrophin A is active in skeletal muscle and 
the utrophin B promoter in heart, lungs and endothelial cells. Most research focuses on the 
utrophin A isoform.350 A cell model stably expressing the utrophin A promoter linked to lucif-
erase has been used to assess the potential of thousands of drugs. One of these drugs, SMT 
C1100 was one of the most effi cient hits. Its effect has been validated in the mdx mouse 
model, where oral treatment with this compound increased utrophin expression up to twofold, 
resulting into improved muscle histology and function. Unfortunately, a phase I clinical trial 
in healthy volunteers revealed that the drug plasma levels needed to induce an effect could 
not be obtained in humans.351 Current research focuses on reformulation of this compound. 
A new trial in healthy volunteers with SMT C1100 in a nanoparticle aqueous suspension 
formulation resulted in higher plasma levels that were suffi cient to increase utrophin levels 
in animal models. There are plans for a dose-fi nding phase Ib study in DMD patients.352 A 
concern with utrophin upregulation approaches is that utrophin, in contrast to dystrophin, 
turned out not to be able to bind nNOS and restore its expression at the sarcolemma, whereas 
disturbances in nNOS function are important in DMD pathology.353
Biglycan is an endogenous protein that is present during development outside skeletal 
muscle fi bres and cardiac muscle. It plays an important role in the regulation of signalling 
pathways and structural proteins, among which proteins (e.g. sarcoglycans, dystrobrevins, 
syntrophins and nNOS) that are part of the DGC.354 Biglycan injection (local and systemic) 
in mdx mice resulted in upregulation of utrophin, recruitment of nNOS and improved muscle 
function and resistance to exercise-induced damage.355 A possibility why biglycan, in contrast 
to utrophin alone,353 could restore nNOS expression at the sarcolemma, is that biglycan also 
restores other compounds of the DGC, creating a more complete utrophin-associated com-
plex, including nNOS.
The expression levels of utrophin in skeletal muscle are  also controlled by post-tran-
scriptional mechanisms, e.g. the activation of p38, which enhances the stability of utrophin 
mRNA. An activator of p38, heparin, was able to increase utrophin A expression in the dia-
phragm of mdx mice (ten days treatment with 500 UI/kg).356
2.2 Corticosteroids and other anti-infl ammatory compounds
In healthy persons infl ammation and activation of immune cells are benefi cial for removing 
necrotic or damaged tissue after minor muscle damage and actually enhance muscle repair. 
However in DMD patients muscle damage is continuous.357 Therefore, chronic infl ammation 
is a prominent feature in DMD pathology. It was fi rst thought to be mainly a non-specifi c 
secondary feature: the continuous damage to muscle fi bres in the absence of dystrophin, the 
increased Ca2+-infl ux and production of reactive oxygen species (ROS) were thought to lead 
to immune cells infi ltration and the production of pro-infl ammatory cytokines and chemok-
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ines. However, it has become more and more clear that infl ammation also plays an important 
specifi c role in the onset and progression of the disease pathology. Many different types 
of infl ammatory cells (e.g. lymphocytes, macrophages, neutrophils, eosinophils and mast 
cells) have shown to play a role in the increased infl ammation in DMD and mdx muscles. 
Large infi ltrates of immune cells (mainly macrophages and CD4+ T-cells) in muscle fi bres are 
already observed before onset and in early stages of the disease. The characterization of this 
population is also distinct from that of non-specifi c infl ammation following muscle injury, 
indicating an auto-immune component in the disease pathology. Furthermore muscle fi bres 
from DMD patients have a large increase in major histocompatibility complex (MHC) I 
expression, which is normally lowly expressed by skeletal muscle cells, suggesting they can 
serve as potential antigen presenting cells.357,358
Both CD4+ (helper) and CD8+ (cytotoxic) T-lymphocytes levels are elevated in DMD. 
This T-cell activation is probably muscle-specifi c, since the frequency of activated T-cells 
was not elevated in mdx lymph nodes. Their role in aggravating pathology is shown by in 
vivo antibody-mediated depletion of T-cells, which reduced muscle pathology by around 60% 
(CD4+ cells) to 75% (CD8+ cells) in mdx mice.359 In early stages CD4+ T helper cells, which 
can activate other immune cells, are present. CD4+ T-cells consist of two subpopulations: 
TH1 CD4
+ T-cells and TH2 CD4
+ T-cells. TH1 CD4
+ T-cells produce IFN-γ and IL-12, which 
promote infl ammation, but may have an attenuating effect on fi brosis. TH2 CD4
+ T-cells are 
associated with IL-4, IL-5 and IL-13 cytokines and are strongly linked to fi brogenesis.360 In 
addition, T-lymphocytes are an important source of TGF-β1 (see paragraph 2.7).
Macrophages are also a large source of TGF-β1 and platelet-derived growth factor (PDGF), 
a fi brogenic cytokine.361 Depletion of macrophages in neonatal mdx mice resulted in a large 
decrease in muscle necrosis, suggesting they play a role in the early stages of the disease.362 
Macrophages can have phenotypically and functionally distinct subtypes. Classically acti-
vated M1 macrophages are activated by TH1 cytokines IFN-γ and IL-12, express high levels 
of inducible NOS (iNOS) and promote tissue infl ammation. Those are found fi rst after acute 
muscle injury, cleaning up necrotic tissue and presenting antigens. Alternatively-activated 
M2 macrophages are activated by TH2 cytokines IL-4 and IL-13, express high levels of 
arginase and suppress the TH1 response.
363 Different M2 subtypes exist, of which M2c mac-
rophages are seen in early phases and de-activate M1 macrophages. M2b macrophages have 
been observed in regenerating muscle after injury and M2a macrophages are abundant in 
fi nal phases of tissue repair.357
Eosinophils are increased in DMD biopsies and can secrete IL-4 and IL-10, which pro-
mote TH2 CD4
+ T-cell responses and thereby fi brogenesis. They also produce MBP-1, which 
attenuates the cellular immune response and promotes fi brosis. Knockout of MBP-1 in 
mdx mice (mdx/Mbp-1-/-) results in a reduction in diaphragm fi brosis, without changes in 
macrophage content or infl ammatory cytokines as tumour necrosis factor-α (TNF-α) and 
interferon-γ (IFN-γ).364
In addition mast cells and dendritic cells have been suggested to play a role in the patho-
physiology of DMD, since the mast cell content is elevated in dystrophic humans, dogs 
and mice and activated dendritic cell infi ltration is increased in dystrophic myofi bres.365,366 
Furthermore mdx myofi bres have been shown to be vulnerable to purifi ed mast cell gran-
ule-induced necrosis.367
Considering the signifi cance of infl ammation in DMD pathology, several therapeutic 
strategies are based upon immune interventions.
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Since at the moment no cure or therapy targeting the underlying genetic effect is availa-
ble, most patients are treated with corticosteroids, most used are prednisone, prednisolone 
(prednisone is converted in the liver to its active form prednisolone) and defl azacort (an oxa-
zolidine derivative of prednisone). Corticosteroids are 21 carbon steroid hormones, which 
have a wide range of actions, e.g. on carbohydrate and protein metabolism, lipid metabolism, 
electrolyte and water balance, the cardiovascular system, the neuromuscular system, lym-
phoid tissue and immune response.368 Their exact mechanism of action in DMD is not known, 
but they probably reduce muscle necrosis and infl ammation.10,13,369 They might work partly 
via increasing α7β1-integrin and laminin-2, thereby stabilising the DGC.
370 Prednisolone had 
a positive effect on muscle strength and histology (decrease in centrally located nuclei) in 
mdx mice.371 Furthermore, in mdx mice it could reverse alterations in the brain. Mdx mouse 
brains show increased vascular permeability (impaired blood-brain barrier functionality) and 
reduced levels of several DGC-associated proteins and the Dp71isoform. These levels and 
the function of the blood-brain barrier were restored by prednisolone treatment.372 In a dys-
trophin- and MyoD-defi cient C. elegans model a reduction in the number of degenerating 
fi bres was seen after prednisolone treatment.369 As C. elegans only has a simple immune 
system, other mechanisms seem to be involved as well. One study in mdx mice suggests that 
defl azacort increases the calcineurin/NF-AT pathway. JNK1 activation in dystrophic muscle 
leads to an increased interaction and thereby nuclear restriction of the nuclear transcription 
factors of activated T-cells (NF-AT), which are regulatory proteins for hypertrophic growth 
of both cardiac and skeletal muscle. Defl azacort treatment leads to an increase of NF-AT 
target genes, among which the dystrophin homologue utrophin, thereby it decreases the 
dystrophic muscle fi bre pathology.373,374 An alternative possibility is that the anabolic effect 
of corticosteroids increases muscle regeneration and growth by enhancing proliferation of 
myogenic precursor stem cells or myoblasts.10 Furthermore corticosteroids have a positive 
effect on Ca2+-homeostasis, which is deregulated in DMD patients (see paragraph 2.12).368 
Unfortunately, corticosteroids also have deleterious side effects like osteoporosis, weight 
gain, growth inhibition, delayed puberty, mood swings and cataracts.13,375-377 In unaffected 
individuals they have a catabolic effect on muscle, but in DMD this is generally abrogated 
by the positive effects.378 Whilst in mdx mice prednisolone treatment is initially benefi cial, it 
induces fi brosis and is detrimental to muscle function on the long term.379,380 Notably, pred-
nisolone induced fi brosis in the heart in mice, but this is not observed in DMD patients, 
where corticosteroid use prevents/delays ventricular dysfunction.11,381-383 A comparative trial 
suggests that prednisone and defl azacort are equally effective at slowing disease progres-
sion, but that defl azacort causes less side effects than prednisone (less weight gain).384 On 
average corticosteroids have shown to prolong ambulation for around three years, but, since 
they do not target the underlying cause, they cannot prevent the eventual loss of muscle 
fi bres and function.10 Therefore early start of treatment might be appropriate, since it cannot 
recover lost function.385 In addition, not all patients tolerate long term use of corticoster-
oids, due to the numerous side effects. Several trials with prednisone have been conducted 
with altering treatment regimens, e.g. alternate day, weekend only or continuous low dose, 
to try to keep the positive effects, but reduce the side effects. However mostly less func-
tional benefi t was observed compared to the most widely recommended daily dose of 
0.75 mg/kg/day or no reduction in side effects.386-390 As there are many different dosing regi-
mens for both prednisone and defl azacort, recently a large trial has been initiated comparing 
0.75 mg/kg prednisolone daily and on an intermittent (ten days on, ten days off) dosing regi-
men and 0.9 mg/kg/day defl azacort (the dose equivalent to 0.75 mg/kg/day prednisolone) in 
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order to determine the most optimal balance between increasing effi cacy and decreasing side 
effects and toxicity (FOR-DMD study, NCT01603407).7
Due to the side effects of corticosteroids after prolonged treatment, research has been 
conducted to fi nd compounds with similar therapeutic actions, but fewer side effects. Serra 
et al. compared the effi ciency of several non-steroidal anti-infl ammatory drugs (NSAIDs) to 
methylprednisolone in mdx mice: two non-specifi c COX-inhibitors (aspirin and ibuprofen) 
and a selective COX-2-inhibitor (parecoxib). The anti-infl ammatory effects of all drugs were 
largely comparable and resulted in amelioration of muscle morphology, with aspirin being 
slightly less effective and parecoxib slightly more.391 In contrast, in another study, another 
specifi c COX-2-inhibitor (meloxicam) had little or no effect on exercise-induced muscle 
pathology in mdx mice.392
Another compound, HCT 1026, a NO-donating derivative of the NSAID fl urbiprofen, 
was more potent than prednisolone in preventing muscle damage after one year treatment 
in mdx mice. Importantly HCT 1026 does not induce the side effects of corticosteroids.393 It 
normalizes blood fl ow and thereby alleviated functional muscle ischemia.394 
Doxycyline is an antibiotic member of the tetracycline family that, next to antimicrobial 
properties, also inhibits matrix metalloproteinases (MMPs; see paragraph 2.13) and reduces 
infl ammation. Administration to mdx mice resulted in less infl ammation, thereby protecting 
against the onset of myonecrosis on short term and reduction of pathology in both skeletal and 
cardiac muscle and improved muscle function in aged mice in the long run (nine months).395 
However, it must be noted that the dosage used was far higher than the human equivalent 
dosage used for its antimicrobial properties. Therefore additional studies are needed to test 
whether this dosage is applicable in humans.
Resveratol is a compound that can be found in food like grapes and red wine and has 
shown to have anti-infl ammatory and oxidative metabolic enhancing properties. It acts 
through the Sirt1-PGC-1α pathway. A study treating nine weeks old mdx mice for eight 
months showed, via Sirt1 activation, a reduction of oxidative stress, loss of muscle mass 
and fi brotic tissue, but no reduction of infl ammation.396 The same treatment also resulted in 
amelioration of cardiomyopathy by Sirt1-mediated downregulation of p300, a pro-hyper-
trophic co-activator which is critical for cardiac development, but induces cardiomyocyte 
hypertrophy after overexpression.397 Eight weeks treatment of younger (four weeks old) mice 
improved specifi c muscle force and short term (ten days) treatment of fi ve weeks old mdx 
mice resulted in a decreased expression of infl ammatory genes.398,399 Utrophin is a down-
stream target of PGC-1α, but no increase in utrophin protein expression was observed in 
either study, although the last study did see a positive effect on utrophin mRNA levels.
Oxatomide (Tinset®), a histamine H1 antagonist used for the treatment of allergies, has 
anti-infl ammatory effects by inhibiting the release of pro-infl ammatory mediators from 
among others mast cells.400 Furthermore, oxatomide has suppressive effects on antigen-pre-
senting cells such as macrophages and dendritic cells.365 In young, exercised mdx mice 
oxatomide improved whole body strength.401 However in a pilot open-label trial in ster-
oid-naïve DMD patients no improvement in muscle strength or function was observed after 
three or six months of treatment.402
2.3 NO-cGMP signalling pathway
NO is synthesized by nNOS and is an important regulator of contractile function and muscle 
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integrity in both skeletal and cardiac muscle.403,404 In DMD and many other neuromuscular 
diseases the NO-cGMP signalling pathways are disturbed. Contracting muscle normally pro-
duces NO to ensure vasodilation and increased blood fl ow to fulfi l the increased need of the 
working muscle for oxygen and nutrients. Lacking nNOS, contraction leads to a decrease in 
blood supply during contraction, sometimes resulting in micro-infarctions and thus increas-
ing the amount of muscle damage. Hence a therapeutic strategy is to amplify NO-cGMP 
signalling by phosphodiesterase (PDE) inhibitors, mainly PDE5. These compounds are well 
known for their vasodilative properties in among others treatment of erectile dysfunction and 
heart failure.405,406 A large drug screening in the dystrophin-defi cient zebra fi sh Sapje identi-
fi ed the non-selective PDE-inhibitor aminophylline as a potential candidate to restore normal 
muscle histology. Aminophylline is known for its anti-infl ammatory effects by inhibiting 
several infl ammatory mediators. Thereafter also the PDE4-inhibitor rolipram and espe-
cially the PDE5-inhibitor sildenafi l citrate (Viagra®/Revatio®) showed a positive effect.407 
Sildenafi l citrate also improved respiratory and cardiac function in mdx mice.408,409 The exact 
mechanism of the cytoprotective effects of sildenafi l citrate is not known. Mitochondria are 
dysfunctional in mdx mice and DMD patients, resulting in reduced ATP production, thereby 
not meeting the energy demand of the muscle cells. Since the NO-cGMP pathway plays a 
regulatory role in mitochondria, it was thought sildenafi l citrate-mediated PDE5 inhibition 
might have its benefi cial effects by improving mitochondrial function. However, detailed 
analysis showed no effect of sildenafi l citrate on mitochondrial function in mdx mice.410 It 
probably exerts its effects by inhibiting Ca2+-entry via transient receptor potential canonical 
channels (mainly TRPC6) and pro-infl ammatory cytokines, like NF-κB and MAPKs.411,412 An 
alternative hypothesis is that it has its positive effects by improving the blood supply to the 
muscles. Other PDE5-inhibitors were shown to be effective as well. The PDE5A-inhibitor 
tadalafi l resulted in amelioration of muscle damage in mdx mice.413 A subsequent clinical 
trial in BMD patients showed alleviation of muscle ischemia.414 Several clinical trials with 
both compounds are currently ongoing: trials to determine if tadalafi l and/or sildenafi l citrate 
can improve muscle blood fl ow during exercise in DMD or BMD patients (NCT01359670, 
NCT01580501 and NCT01070511) and the effect of Revatio® (sildenafi l citrate) on cardiac, 
muscular and cognitive function in BMD (NCT01350154). However a six months trial in 
DMD/BMD patients has recently been suspended (NCT01168908), due to negative results 
during an interim analysis. No benefi t of Revatio was observed and, although group sizes 
were small, more subjects in the Revatio-treated group showed a worsening of cardiac func-
tion than in the control group, indicating it may even have adverse effects on cardiac function 
[presented at the Annual Connect Conference of the Parent Project Muscular Dystrophy, 
Baltimore, MA, USA, June 2013]. Tadalafi l acts more specifi c, since it only stimulates cGMP, 
while sildenafi l stimulates cGMP but also cAMP, which can result in putting too much stress 
on the heart. Furthermore, tadalafi l has a better pharmacokinetical profi le (longer acting) and 
a good safety profi le. Pilot studies in DMD, mainly single dose-escalation studies, did not 
show serious adverse events and showed indications of protective effects to exercise induced 
damage. Therefore, a large phase III randomized, double-blind, placebo-controlled study 
in 306 DMD boys will start soon, examining the effi cacy of 48 weeks of tadalafi l treatment 
(NCT01865084).
Isosorbide dinitrate and MyoNovin (guaifenesin dinitrate) are NO-donating drugs. Short 
term treatment (18 days) of mdx mice had a positive effect on the stem cell population and 
resulted in accelerated fi bre regeneration, especially in combination with prednisolone treat-
ment.415 A clinical trial in healthy volunteers to compare the pharmacokinetics of isosorbide 
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dinitrate and the NSAID ibuprofen and mainly to defi ne possible drug interactions of a com-
bined administration of both compounds is currently ongoing, in preparation for a trial in 
DMD patients (NCT01478022).
2.4 Anti-oxidants
As mentioned above oxidative stress plays a role in DMD pathology. One of the pathways 
mediating this response is via nNOS. nNOS produces NO, an important modulator involved 
in the regulation of numerous processes, e.g. muscle contractility, glucose uptake and repair. 
Normally nNOS interacts with the DGC, but it is dislocated in DMD (see paragraph 1.2.2). 
In itself the absence of nNOS does not lead to muscular dystrophy, but in dystrophin-defi -
cient muscles it may aggravate the damage via, among others, increasing NAD(P)H oxidase 
activity and increasing infl ammation and decreased blood fl ow to muscle due to impaired 
vasodilation. However oxidative stress itself probably also contributes to the dislocation of 
nNOS and the disruption of the DGC, by activating the NF-κB pathway and caveolin-3 sig-
nalling pathway.416
In mdx mice pathology differs between limb muscles and the diaphragm. Limb muscles 
undergo various cycles of necrosis, infl ammation and degeneration around the age of two 
to eight weeks and show massive regeneration, which compensates for the loss of necrotic 
fi bres, from three to 12 months, after which it starts to decline.417,418 In contrast the diaphragm 
displays continuous and progressive degeneration throughout the life-span, combined with 
ineffective regeneration leading to muscle fi bre loss, more resembling the human DMD 
pathology.419 This difference in degeneration/regeneration in combination with the increase 
oxidant production observed in the mdx diaphragm compared to skeletal muscle, makes the 
diaphragm extra vulnerable for oxidative stress.416
Considering its role in DMD pathology, several strategies aim to target the oxidative 
stress. One class of compounds targets the NF-κB pathway (see paragraph 2.5). Furthermore 
several other anti-oxidants have been tested at various levels in DMD.
Coenzyme Q10 is essential for several enzymatic steps in the production of energy and 
functions as an anti-oxidant. In a pilot clinical trial addition of coenzyme Q10 to predniso-
lone treatment improved muscle strength.420 A clinical trial with coenzyme Q10 alone or in 
combination with the ACE-inhibitor lisinopril is currently ongoing (NCT01126697; see par-
agraph 2.8). Another clinical trial comparing coenzyme Q10, prednisone or a combination in 
non-ambulant patients has been terminated, since the American Academy of Neurology now 
recommends that all patients with DMD should be offered treatment with corticosteroids.
Idebenone (2-(10-hydroxy-decyl)-5,6-dimethoxy-3-methyl-[1,4] benzoquinone; 
Catena®), a synthetic analogue of coenzyme Q10, is a compound that reduces oxidative stress 
by acting as a free radical scavenger and it improves mitochondrial function by increasing 
ATP-production and protecting the mitochondria against lipid peroxidation.421 In the mdx 
mouse model idebenone treatment resulted in a reduction of infl ammation and lower levels 
of fi brosis in heart, thereby normalizing heart function and improving voluntary running.422 
In a small phase I/II clinical trial in DMD patients no signifi cant difference in heart function 
was observed. However, this study was not ideal due to the small number of patients and 
the fact that the idebenone-treated group was signifi cantly older than the placebo-treated 
group. Nevertheless, the forced vital capacity of treated patients was better than those of 
60
CHAPTER 2
control patients, suggesting a protective effect on respiratory function.423 In addition more in 
depth analysis of the results on respiratory function showed that effectiveness on respiratory 
parameters was only seen in the glucocorticosteroid-naïve patients receiving idebenone ver-
sus placebo and not in the patients receiving concomitant steroids. Importantly, respiratory 
parameters were higher at baseline in the steroid users compared to non-users, indicating 
positive effects on respiratory function by steroids itself. These analyses may indicate that 
the maximal treatment effect is already reached by steroids alone or that steroids suppress the 
effects of idebenone, although the latter seems unlikely, since there is no mechanistic expla-
nation for this.424 These patients have been followed for an additional two years to assess the 
long term safety and tolerability and the effi cacy on skeletal muscle, respiratory and cardiac 
function, but no results have been published yet (NCT00758225). Idebenone is currently also 
tested in a larger group of DMD patients in two stages: fi rst, in patients that have never been 
treated with corticosteroids and then in combination with corticosteroids (NCT01027884).
2.5 TNF-α and the IKK-NF-κB signalling pathway
Another hallmark of the chronic infl ammation is a large increase in cytokine expression, 
i.e. TNF-α and IFN-γ.358,425-427 TNF-α activates the IKK/NF-κB signalling pathway (fi g. 2.2). 
NF-κB is present in all cells and is kept in an inactive form in the cytoplasm by the inhibitory 
protein IκB. When IκB is degraded by IκB kinase (IKK), NF-κB migrates to the nucleus 
where it can activate a cascade of infl ammatory factors: activating pro-infl ammatory mac-
rophages and inhibiting myogenesis, thereby increasing necrosis and infl ammation and 
reducing regeneration in muscle fi bres.428-430 Normally, anti-infl ammatory factors deactivate 
NF-κB to reduce the infl ammation. However, when NF-κB is not inactivated this can lead 
to chronic infl ammation. In mdx mice NF-κB is not deactivated, but initiates a cascade of 
infl ammatory molecules, which in turn further activate NF-κB (positive feedback loop).431
Since the TNF-α/NF-κB pathway is highly elevated in DMD, drugs that inhibit activation 
of this pathway may possibly prevent the muscle degeneration in DMD.
Blocking TNF-α with a specifi c antibody (infl iximab/Remicade® or etanercept/Enbrel®) has 
an anti-infl ammatory effect and thereby reduces the breakdown of dystrophic muscle in mdx 
mice, without impairing the formation of new myotubes. This drug is already being used in 
other infl ammatory diseases, such as rheumatoid arthritis and Crohn’s disease.392,432,433
Pyrrolidine dithiocarbamate (PDTC) stabilises cytosolic IκB-α, thereby reducing NF-κB 








Fig. 2.2: Simplifi ed scheme of the TNF-α/
NF-κB signalling pathway
TNF-α activates the NF-κB signalling pathway, thereby 
increasing necrosis and infl ammation and inhibiting 
myogenesis
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fi bre degradation and enhanced regeneration of skeletal muscle and diaphragm, accompanied 
by an improve in muscle function, and had a positive effect on the Ca2+-homeostasis.434-436 
However PDTC can cause seizures at slightly higher doses (75-150 mg/kg) and brief periods 
of ocular discharge (excretion of fl uids from the eyes) can occur already at a concentration of 
50 mg/kg as used in the mdx experiments.437
NEMO-binding domain (NBD) peptide is a more selective inhibitor of NF-κB. It binds 
IκB-β, thereby preventing the formation of an IKK complex and inhibiting the activity of 
NF-κB. Via this pathway, NBD peptide selectively prevents infl ammation-induced NF-κB 
activation without inhibiting basal activity required for cell survival. In mdx mice it greatly 
reduces myofi bre necrosis and treatment with NBD peptide showed no dose-dependent tox-
icity.428,430
Flavocoxid, a mixed fl avonoid extract with anti-infl ammatory, anti-oxidant and NF-κB 
inhibiting properties, showed a reduced activity of NF-κB signalling pathways and so 
reduced muscle necrosis and enhanced regeneration in mdx mice.438 A clinical trial to deter-
mine its safety in DMD patients after oral administration has been terminated for unknown 
reasons (NCT01335295).
Green tea extract is rich in anti-oxidants (polyphenols), the major one being epigallocat-
echin gallate (EGCG; a fl avan-3-ol). EGCG can inhibit NF-κB activation by blocking IKK 
activity. Treatment of mdx or mdx5cv mice with green tea extract or EGCG resulted in improve-
ment anti-oxidant capacity, thereby decreasing muscle pathology and improving functions.439 
Treatment with green tea extract reduced fi brosis and improved muscle function in mdx 
mice.440 Oral administration via a diet supplemented with EGCG seemed the most effective 
route of administration compared to subcutaneous EGCG injection.441 A double-blinded, pla-
cebo-controlled, randomized pilot clinical trial to investigate the safety and possible effects 
on pathology of EGCG in DMD patients is currently ongoing (NCT01183767) and a pilot 
study with (-)-epicatechin (another fl avan-3-ol) in BMD-patients (NCT01856868).
Another dietary derived NF-κB-inhibitor is curcumin, obtained from the spice turmeric. 
In mdx mice mixed results were observed with curcumin. Intraperitoneal injections with cur-
cumin caused reductions in NF-κB and TNF-α levels, followed by enhancement in muscle 
strength.442 In contrast, in another study, dietary supplementation with curcumin had no effect 
on NF-κB activity.443 These discrepancies might be due to the different routes of administra-
tion. Studies in rats have shown the limited bioavailability of curcumin after oral compared 
to intravenous administration.444
Several other dietary derived anti-oxidant supplements (e.g. beta-carotene, vitamin A, 
vitamin C, vitamin E, and selenium) have been tested in clinical trials in DMD and other 
diseases. However mostly no, limited or even detrimental effects were observed.416,445 This 
is probably due to lack of specifi c targeting. A recent study suggests increased protein thiol 
oxidation in dystrophic muscles plays an important role in oxidative stress mediated dam-
age.446 The thiol reducing anti-oxidant N-acetylcysteine that naturally occurs in vegetables 
reduces TNF-α and thereby NF-κB activation. After systemic treatment lower TNF-α levels 
were observed in mdx mice as well as protection against myonecrosis.447,448 N-acetylcysteine 
treatment also resulted in a reduction of ROS in muscle and a decrease in centrally located 




2.6 Nutritional intervention and dietary-derived compounds
Malnutrition is commonly observed in end stages of DMD, due to eating diffi culties and 
weight loss as a consequence of muscle wasting. Approaches to manage this are food texture 
modifi cation and supplementary feeding. Importantly, daily calcium and vitamin D supple-
mentation is recommended in combination with corticosteroid therapy, since corticosteroids 
can enhance osteoporosis.450 In addition, other nutritional supplements might be benefi cial 
against muscle wasting as well. Some dietary-derived compounds, used for their anti-oxidant 
properties, have been described above (see paragraph 2.4). Next to these, amino acid supple-
mentation (taurine, creatine, arginine and glutamine) is tested in DMD patients and mdx mice.
Taurine is a free amino acid abundant in skeletal muscle having anti-oxidant and anti-in-
fl ammatory effects and modulating Ca2+-homeostasis. Taurine defi ciency has been observed 
in dystrophic mdx muscle.451 In mdx mice taurine supplementation in the food prevented 
exercise-induced damage in hind limb muscle and ameliorated measurements of degenera-
tion/regeneration cycles. However no change in degeneration/regeneration was seen in the 
diaphragm.452 In combination with prednisolone a synergistic effect was seen in the improve-
ment of muscle strength and Ca2+-homeostasis.453
Creatine monohydrate is a nutritional supplement used as an ergogenic aid by ath-
letes. After cellular uptake CK phosphorylates creatine to phosphocreatine using ATP. 
Phosphocreatine serves as an energy buffer and transport vehicle. Upon energy demand, i.e. 
muscle contraction, CK reverses this phosphorylation by converting phosphocreatine to ADP 
to regenerate ATP. Ingestion of creatine can increase creatine and phosphocreatine levels 
inside muscles, thereby enhancing mainly short, intense exercise performance.454 In vitro 
the provision of creatine to mdx myotube cell cultures, resulted in higher phosphocreatine 
concentrations, improved survival, and less Ca2+-accumulation by stimulating sarcoplasmic 
reticulum Ca2+-ATPase.455 Total creatine levels are lower in mdx muscles compared to wild 
type. In mdx mice a creatine-enriched diet from birth reduced the fi rst necrosis wave nor-
mally seen after four weeks in fast-twitch, but not in slow-twitch muscle fi bres. It restored 
the mitochondrial respiration capacity to wild type levels.456 Less effectiveness was observed 
when supplementation was started after this fi rst wave (at three month of age), suggesting 
necrosis was already too advanced. Only a lowering of muscle mass towards wild type lev-
els, but no signifi cant increase in tetanic force, was observed. As expected it did not change 
other pathological features, such as centrally nucleated fi bres and increased Ca2+-content.457 
Several clinical trials with creatine supplementation in DMD, BMD or other muscular dys-
trophy patients have been conducted with moderate results.458 Small improvements in muscle 
strength and daily-life activities were observed in patients with several types of muscular 
dystrophies.459 However in myotonic dystrophy type 1 patients, an inherited muscle disorder 
in adults, no improvement was observed.460 Three months administration to DMD and BMD 
patients increased voluntary muscle contractions, decreased muscle fatigue and lowered uri-
nary collagen excretion.461 A more extensive double-blinded, placebo-controlled, cross-over 
study in which DMD patients, of which half was using corticosteroids, received creatine or 
placebo for four months followed by a cross-over after a six week washout period, showed 
an improvement in motor function and improvement of body composition (an increase in fat 
free mass) during creatine treatment irrespective of corticosteroid use. However no improve-
ment of daily activities was found.462 Another trial determined phosphorus metabolite ratio 
(PCr/Pi), which is lowered in skeletal muscle of DMD patients and associated with impaired 
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muscle function. In the placebo group a reduction in PCr/Pi ratio was observed, whereas an 
increase was seen in creatine-treated patients. Furthermore therapeutic variability was seen 
with age. Before treatment, PCr/Pi ratios were lower in young patients (under seven years) 
compared to older patients (above seven years). Whereas young creatine-treated patients 
showed an increase in PCr/Pi ratio after supplementation, no difference was observed in 
older creatine-treated patients. Some improvement/preservation of muscle strength was 
observed by creatine treatment.463
Glutamine is the most abundant free amino acid in body and muscle protein synthesis. 
Studies on the mechanisms behind possible anti-oxidative effects of L-glutamine have been 
performed in mdx mice, which show an increase in muscle free glutamine and glutamate, 
probably due to increased muscle glutamine production during catabolic stress. Exogenous 
administration of L-glutamine reduced the glutamine levels and decreased the ratio of oxi-
dized glutathione versus total, which is an inducer of oxidative stress via activation of ERK1/2 
that was also decreased.464 Oral administration of L-glutamine in DMD patients for two or 
ten days resulted in a decrease in whole body protein degradation.465,466 However in a longer 
double-blinded, randomized, cross-over trial four months of L-glutamine administration did 
not result in improved muscle mass or function.467 Furthermore, although acute L-glutamine 
transiently stimulates insulin secretion, no effect on glucose metabolism or insulin resistance 
was observed.468
In a randomized, placebo-controlled trial comparing six month treatment with either cre-
atine or L-glutamine versus placebo in steroid-naïve DMD patients did not improve muscle 
strength or function. Only in younger patients a small improvement of both compounds 
and in older patients of creatine might have been observed, although the difference was not 
signifi cant.469
The activation of satellite cells (muscle precursor cells) upon damage to initiate muscle 
regeneration is mediated by NO-production by NOS, normally present at the sarcolemma, 
but mislocalised in DMD due to disruption of the DGC. L-Arginine is a substrate for NOS. 
Short term studies showed benefi cial effects of L-arginine supplementation in mdx mice. 
After three weeks treatment of adult mice an increase in utrophin at the sarcolemma was 
observed.470 This was also seen after two weeks treatment of young mice. L-Arginine led to 
a decrease in pro-infl ammatory cytokines (IL-6 and TNF-α) which led to a decreased activa-
tion of the NF-κB pathway and its downstream targets (e.g. MMP-2 and MMP-9). L-Arginine 
treatment led to a decrease in MMP-2/MMP-9-mediated β-dystroglycan cleavage, thereby 
increasing its level. It stabilised the utrophin/β-dystroglycan interaction and led to targeting 
of nNOS towards the sarcolemma via syntrophins.471 Also here applies that the upregulation 
of utrophin cannot solely be responsible for nNOS restoration,353 but that other mechanisms 
must also be involved. Combinational treatment with defl azacort, which increases nNOS 
expression, suggested an additional benefi t of L-arginine since three weeks treatment resulted 
in a decrease of contraction-induced injury in the limb muscle.472 However, long term treat-
ment with L-arginine in six months old mdx mice for 15 months did not affect cardiac fi brosis, 
although a decrease in infl ammatory cell density was observed.473 Long term studies even 
raised concerns of detrimental effects. Seventeen months of treatment in mdx mice resulted 
in an increase in skeletal and cardiac fi brosis. The short term effects of a decrease in MMP-2 
or MMP-9 and increase in utrophin were not observed.474 The mechanism behind this is 
probably a shift in macrophage type. In four weeks old mdx mice, at the peak of necrosis, 
high levels of M1 (pro-infl ammatory) and M2 (alternatively-activated) macrophages were 
observed in quadriceps with prominent fi brosis. M1 macrophages have been shown to lyse 
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muscle by an NO-mediated mechanism. M2 macrophages express arginase, an enzyme that 
catalyses arginine into L-proline, a precursor molecule for collagen synthesis. M2a mac-
rophages reduce lysis by M1 cells via competition of arginase with iNOS in M1 cells for its 
substrate arginine. At twelve weeks of age, at the peak of regeneration, an increase in IL-4 and 
IL-10 was observed, which deactivates M1 cells and promotes CD136+ M2c macrophages 
that can increase tissue repair.363 The deactivation of M1 cells by M2c cells can increase the 
substrate availability for arginase, thereby shifting the arginine metabolism from iNOS to 
arginase, resulting in an increase in arginase-derived metabolites, which create a more pro-fi -
brotic environment. Therefore L-arginine supplementation might increase arginase activity, 
resulting in more fi brosis on the long term. Indeed arginase-2 null mutant mdx mice showed 
reduced skeletal fi brosis; although cardiac fi brosis and function was unaltered.474 A clinical 
trial assessing the safety and effi cacy of L-arginine administration for 30 days on muscles, 
assessed by MRI, in boys with DMD or BMD, has been completed, but no results have been 
published yet (NCT01388764).
Long term (six months) treatment of three months old mdx mice with arginine butyrate 
did result in increased grip strength and reduced fi brosis. However no effect on skeletal mus-
cle or cardiac histology, cardiac function and behaviour of the mice was observed.379 Another 
study administering arginine butyrate for only six weeks to eight weeks old mdx mice also 
revealed an improvement in histology of the diaphragm and hind limb muscles. In addition 
an increase in utrophin was observed.475 The benefi cial effects might be due to the butyrate 
moiety that has HDAC-inhibitory activity. In the arginine butyrate-treated mice changes 
in HDAC-related gene expression were seen: an increase in growth promoting pathways, 
e.g. IGF-1, and a decrease in genes associated with fi brotic pathways.379
Payne et al. tested several compounds alone or as a cocktail in exercised mdx mice: cre-
atine monohydrate, conjugated linoleic acid, α-lipoic acid and β-hydroxy-β-methylbutyrate. 
Conjugated linoleic acid consists of a number of different isomers of the essential fatty 
acid linoleic acid conjugated by double bonds. It can decrease body fat accretion, improve 
immune function and act as a free radical scavenger. A-lipoic acid is a disulfi de mitochon-
drial coenzyme and a potent anti-oxidant that can improve mitochondrial function and 
enhance creatine monohydrate uptake. B-hydroxy-β-methylbutyrate is a leucine metabolite 
that is used by athletes to enhance strength and muscle mass gain by strength exercise and 
reduce exercise-related damage and muscle protein breakdown. Each compound separately 
showed some benefi t and the combination of all four components showed the most promi-
nent effect. Especially in combination with prednisolone treatment therapeutic effects were 
seen by increasing grip strength performance and improving muscle histology, as refl ected 
by a decrease in centrally located nuclei and retroperitoneal fat pad stores.476 B-hydroxy-β-
methylbutyrate has also shown in an in vitro screen to improve tetanic force in dystrophic 
myoblasts.477
2.7 The TGF-β superfamily
The transforming growth factor-β (TGF-β) superfamily consists of proteins (myostatin, 
TGF-β, activin and BMP) involved in the regulation of many cellular processes, like cell 
growth, differentiation and maintenance of homeostasis. Most members are synthesized as 
propeptides, which become activated by proteolytic cleavage and form functional dimers. 
They signal by inducing and binding to receptor complexes consisting of a type II and a type I 
65
TARGETING THE SECONDARY DEFECTS IN DMD
receptor, leading to activation of downstream, intracellular signalling pathways. The affi nity 
for type I and/or type II receptors in different cell types is affected by the presence or absence 
of coreceptors.478 These ligands can signal both via a canonical Smad-dependent pathway 
and via non-canonical Smad-independent pathways. The Smad-dependent pathway involves 
the phosphorylation of Smad-proteins, which are transported to the nucleus where they reg-
ulate transcription. Myostatin, TGF-β and activin commonly use pSmad2/3 and BMP uses 
pSmad1/5/8.479 Non-canonical pathways are, among others, the PI3K/Akt/mTOR, Raf/MEK/
ERK and p38/MAPK pathways.480
Myostatin (growth and differentiation factor 8) negatively regulates muscle growth. It is 
present in skeletal muscle cells and in adult animals myostatin has an inhibitory effect on 
satellite cells. It is encoded by the MSTN gene located on chromosome 2q32.2 and consists of 
three exons. It is transcribed as a precursor protein and acquires its active form of 12.5 kDa 
after several posttranscriptional modifi cations, among which proteolytic cleavage from its 
propeptide.481 Myostatin inhibits myogenesis and increases fi brosis via several pathways 
(fi g. 2.3a). It binds mainly to the activin receptor type IIb (Acvr2b) and to a lesser extent to 
Acvr2a. Thereafter this complex combines with activin type I receptors Acvr1b (ALK4) or 





































Fig. 2.3: Simplifi ed scheme of signalling by members of the TGF-β superfamily
All members bind to type II-type I receptor combinations, leading to activation or inhibition of several intracellu-
lar pathways. They signal both via canonical pSmad-dependent and non-canonical pSmad-indepedent pathways. 
Myostatin (a) by signalling via pSmad2/3 and several non-canonical pathways mainly inhibits muscle growth. 
TGF-β (b) also signals via pSmad2/3 and various non-canonical pathways and is a potent inducer of fi brosis. Activin 
(c) is involved in the regulation of muscle mass via the canonical pSmad2/3 pathway and uses, amongst others, 
PI3K for non-canonical signalling. BMP (d) uses the pSmad1/5/8 and p38/MAPK pathway to inhibit myogenesis.
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Tgfbr1 (ALK5) to activate downstream targets. Myostatin shows cell-type specifi c utilization 
of type I receptors: in myoblasts mainly the Acvr1b receptor is used, whereas in fi broblasts 
mainly the Tgfbr1. This is due to the presence of the coreceptor Cripto in myogenic cells, 
which is absent in non-myogenic cells. Cripto inhibits activin activity, which also uses the 
Acvr1b receptor. In non-myogenic cells myostatin uses betaglycan as a coreceptor.482 Via the 
canonical pSmad2/3 pathway myostatin signalling leads to a downregulation of myogenesis 
transcription factors, decreasing muscle progenitor cells proliferation and differentiation. It 
also acts on non-canonical p38 MAPK and ERK1/2 signalling to inhibit expression of factors, 
e.g. Pax7, which leads to a decrease in satellite cell self-renewal, thereby reducing regener-
ation. In addition, myostatin inhibits the PI3K/Akt/mTOR pathway, both directly and via 
pSmad2/3, thereby reducing protein synthesis.481,483,484 Finally, via among others pSmad2/3 
and p38 MAPK it increases fi broblast proliferation.485
TGF-βs are another subfamily, which consists of three mammalian isoforms: TGF-β1, 
TGF-β2 and TGF-β3. Their expression is induced in damaged and regenerating skeletal mus-
cle and TGF-β1 is capable of inducing fi brosis. TGF-βs bind to the type II receptor Tgfbr2, 
which then combines with a type I receptor, mainly Tgfbr1 or otherwise Acvrl1 (ALK1), and 
play a role in regulation of muscle growth, regulation and can stimulate fi brogenesis.478,486,487 
Signalling occurs both via canonical Smad2/3-dependent signalling pathways and non-canon-
ical Smad-independent pathways (fi g. 2.3b). Non-canonical TGF-β1 signalling is mediated 
via pathways such as PI3K/Akt/mTOR and Raf/MEK/ERK, which all have, amongst others, 
pro-fi brotic effects upon activation.480
Activins are homo- or heterodimers of two subunits, A (inhibin-βA), B (inhibin-βB), 
C (inhibin-βC) or E (inhibin–βE).487,488 They initiate signalling by binding to Acvr2a or 
Acvr2b, in combination with type I receptor Acvr1b or Acvr1c (ALK7) and also use pSmad2/3 
for downstream signalling via the canonical pathway (fi g. 2.3c). Activin A is also involved 
in regulation of muscle mass, since a mouse model carrying targeted deletion of inhibin-βA 
subunits, the constituents of activin A, displays increased muscle mass.488 Inhibins are dimers 
of an inhibin-α subunit with an inhibin-βA subunit (inhibin A) or an inhibin-βB subunit 
(inhibin B). They inhibit activin signalling by binding to its receptors.488
Bone morphogenic proteins (BMPs) are known to inhibit myogenic differentiation via 
activating pSmad1/5/8 and p38 MAPK signalling pathways, which in turn decrease the 
expression of myogenic regulators like MyoD and Myog (fi g. 2.3d).489 Interestingly, expres-
sion of several BMPs was found to be increased in mdx muscle.490 In DMD patient cells 
BMP4 was increased, which showed to inhibit myogenic differentiation.491 The implica-
tion of induced BMP signalling and involvement in DMD pathology is currently unknown. 
However, recent studies showed the importance of BMPs in the regulation of myogenic 
differentiation. BMP type I receptor BMPR1A (ALK3) is expressed in activated satellite 
cells, which enhances proliferation by inhibiting genes associated with differentiation. 
Knockdown of the BMP antagonist Noggin enhanced proliferation, while overexpression 
induced premature differentiation.492 Also in foetal muscle Noggin overexpression caused 
a reduced number of satellite cells and smaller muscle size.493 After muscle injury BMP is 
activated and Noggin overexpression perturbed the regeneration process, leading to smaller 
regenerated fi bres.492,493 Recently two papers were published, which highlighted the impor-
tance of BMP signalling in stimulating muscle growth and maintaining muscle mass and the 
effects of interfering with BMP signalling in models for denervation-induced atrophy.494,495 
Winbanks et al. showed that by increasing BMP ligands or using a constantly active receptor 
skeletal muscle hypertrophy was promoted via Smad1/5/8-mediated activation of mTOR 
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signalling. Furthermore increasing BMP signalling protects muscle from atrophy during den-
ervation, while inhibition worsens atrophy.495 The same was shown by Sartori et al., who 
also saw muscle atrophy after BMP inhibition. In addition BMP inhibition neutralizes the 
hypertrophic phenotype in mice lacking myostatin, suggesting that increased BMP signal-
ling is responsible for the increase in muscle mass in myostatin knockout mice.494 Therefore, 
BMPs are likely important regulators of myogenic differentiation, regeneration and muscle 
fi bre growth, although the role of individual BMP ligands and receptors and their potential 
involvement in DMD pathology remains unknown.
Since various members of the TGF-β family and/or their receptors have shown to be dif-
ferentially expressed in DMD and are involved in regulation of muscle growth and fi brosis, 
they serve as a target for several therapeutic approaches.
2.7.1 Myostatin inhibition
Mutations that lead to complete loss of myostatin are viable and have been described for 
several animals (e.g. Belgium Blue cattle, Texel sheep and dogs) and one human boy.496-503 
In each case lack of myostatin results in a vast increase in muscle mass. In whippet dogs that 
are heterozygous for a MSTN mutation (i.e. have only one functional copy) a lesser degree of 
muscle hypertrophy is observed, but they are more muscular and faster than wild type whip-
pet dogs, indicating the mutation is quantitative and loss of one allele can improve skeletal 
muscle performance.504 Mdx mice that also lack myostatin (mdx/Mstn-/-) are more muscular 
and stronger than normal mdx mice. The muscle hypertrophy is due to an increase in muscle 
fi bre number (hyperplasia) and in cytoplasmic volume (hypertrophy) rather than a change in 
the total number of myonuclei per fi bre.481 The fi brosis in the diaphragm, which increases 
with age, is reduced in these mice as well.505 Furthermore, the effect of myostatin is only seen 
in skeletal muscle; the heart of myostatin knockout mice (Mstn-/-) is similar to that of wild 
type mice. As anticipated, the absence of myostatin has no benefi cial effects on cardiac mus-
cle mass or cardiac fi brosis in the double knockout mdx/Mstn-/- mice.506 Furthermore studies 
on Mstn-/- mice revealed that the increase in muscle mass and fi bre size does not result in an 
increase in specifi c force, but even impairs it.507 To study the effect of Mstn knockout after 
muscle maturation, Mstn[f/f] mice with a tamoxifen-inducible transgene have been generated 
to achieve muscle specifi c knockout in adult stages. This also leads to an increase in muscle 
mass, although to a lesser extent than in Mstn-/- mice.502 So, prenatally myostatin acts pre-
dominantly on muscle progenitors and postnatally on differentiated muscle.481 The increased 
muscle mass observed in all myostatin null animals served as the rationale to try to inhibit 
myostatin and thereby improve muscle mass in order to compensate for the loss of muscle 
tissue in DMD.
Treatment of C2C12-cells with pharmacological antibodies that block myostatin caused a 
decrease in the phosphorylation of Smad2/3, which in turn affects the formation of Smad-
complexes, involved in the transcriptional regulation of genes associated with muscle cell 
progenitors. In vivo systemic (intraperitoneal) treatment of mdx mice with these myostatin 
blocking antibodies induced an increase in muscle mass and strength.509 Importantly, a sub-
sequent study observed improvement in diaphragm pathology by anti-myostatin antibodies 
in young mdx mice, but not in adult mdx mice, which already show marked disease progres-
sion.510 Intravenous anti-myostatin antibody (MYO-029) treatment in adult neuromuscular 
disorder patients (including BMD patients) did not lead to a signifi cant increase in muscle 
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mass in a fi rst clinical trial. It should be noted that this was mainly meant as a safety trial: 
patients were treated for only one month and due to a lack of power of the study, no reliable 
conclusions could be drawn of the therapeutic effects. Overall the antibody was well toler-
ated and safe. Only at higher concentrations of ten and 30 mg/kg it caused hypersensitivity of 
the skin, but it had no adverse side effects on muscles. However, the hypersensitivity might 
limit the dose that can be used and therefore limit the therapeutic effi cacy.511
Meanwhile, a new fusion protein joining a human antibody Fc-receptor and the ligand 
binding domain of type II receptor Acvr2b has been generated (sAcvr2b-Fc; ACE-031). This 
receptor can bind myostatin, but also its family member activin, also involved in the reg-
ulation of muscle mass and implicated in fi brosis formation in many diseases, including 
DMD. Thus, ACE-031 may act through separate mechanisms simultaneously, both increas-
ing muscle mass and inhibiting fi brosis. In wild type mice it caused an increase in muscle 
mass, without altering the fi bre type profi le of the muscle, which is changed in e.g. myostatin 
defi ciency.512 In mdx mice similar compounds (a soluble form of Acvr2b linked to a murine 
Fc-receptors; RAP-031 or sAcvr2b) resulted in a normalisation of muscle force.513,508 In a 
phase I clinical trial in healthy volunteers (postmenopausal women) treatment was well 
tolerated for both single and multiple doses and resulted in a dose-dependent increase 
in muscle mass at the cost of fatty tissue. Recently, a dose-escalation safety trial and its 
extension study in DMD patients have been terminated due to unexplained nose and gum 
bleeding and dilated small blood vessels observed in some treated patients (NCT01099761/ 
NCT01239758). The mechanisms behind these unexpected side effects are currently under 
investigation.515 Combination of this sAcvr2b-Fc with AAV-U7-mediated dystrophin exon 
skipping resulted in increased muscle growth in mdx mice, as was also seen by sAcvr2b-Fc 
alone, and improved specifi c force and resistance to contraction induced injury, also seen by 
AAV-U7 treatment alone. No clear synergistic effect of the combination was observed.516 In 
an earlier study in which the Acvr2b was knocked down by using shRNA, this knockdown 
strongly enhanced the force increase by AAV-U7-mediated dystrophin exon skipping. On the 
other hand no increase in muscle growth was observed.517 This discrepancy might be due to 
the different ways of Acvr2b blockade.
As mentioned above, myostatin is synthesized as a precursor protein that is cleaved by 
BMP-1/tolloid metalloproteinases to generate the active C-terminal part and an N-terminal 
myostatin propeptide. This propeptide can inhibit myostatin activity by preventing its binding 
to its receptor. Myostatin propeptide fused to IgG-Fc to prevent cleavage by BMP-1/tolloid 
proteases resulted in increased body and muscle mass and improved function in mdx mice.518 
For long term expression, this fusion propeptide was delivered with an AAV8 vector, result-
ing in improved muscle histology, decreased CK levels and improvement of muscle force 
(grip strength); however it reduced exercise endurance (treadmill running).519 To get stable 
transgene expression, which may not be feasible with skeletal muscle delivery, Morine et al. 
used a AAV-mediated expression of a dominant negative myostatin propeptide paired with 
a liver-specifi c promoter, thereby getting long term secretion by the liver resulting in body-
wide expression. In mdx mice this approach resulted in increased skeletal muscle mass and 
function; however in 11 months old mice no improvement in diaphragm pathology was 
seen.520Administration of this same liver-targeting myostatin inhibiting compound in GRMD 
dogs resulted in increased muscle mass over a period of 13 months and a reduction of CK 
levels and fi brosis. Cardiac morphology was not assessed.521
Follistatin is a myostatin-ligand binding protein that can inhibit its activity. Transgenic 
overexpression of follistatin in mice results in a massive increase in muscle mass and increases 
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muscle regeneration.522,523 Conversely, mice heterozygous for follistatin (follistatin+/-) show a 
reduced muscle mass and regeneration.488 An additional effect of follistatin knockout is seen 
in Mstn-/- mice and the effect of heterozygosity for follistatin is maintained by crossing with 
Mstn-/- mice, indicating that also other factors play a role in the control of muscle growth 
in parallel with myostatin and that follistatin also affects other ligands apart from myosta-
tin.488,524 Indeed, follistatin can also antagonise activin. Mice mutated for activin A also show 
a (more moderate) increase in muscle mass, suggesting both myostatin and activin A are 
involved in muscle mass regulation.488 Administration of follistatin overexpressing muscle 
progenitor cells to immunodefi cient mdx mice resulted in enhanced muscle regeneration.522 
A single injection with an AAV vector carrying a follistatin isoform that mainly affects skel-
etal muscle (FS-334) resulted in improvement of muscle mass and strength up to over two 
years in both young and aged mdx mice.525 Yet, it is not selective for myostatin, but also 
binds to activins and inhibits their activity. Since activins have numerous functions in other 
tissues than skeletal muscle, increasing myostatin by using follistatin is likely to have many 
side effects. In mdx mice a transgenic follistatin-derived myostatin inhibitor FS I-I, which is 
much more selective for myostatin, increased skeletal muscle size and strength and reduced 
the infi ltration of immune cells, without affecting activin activity.526 The safety and effi cacy 
of the FS-334 isoform expressed by AAV1 has been tested in nonhuman primates (cynomo-
lgus macaque monkeys), resulting in increased muscle mass and strength, without immune 
response or toxic side effects on other organs in the long run (over one year).527 A clinical 
trial where the follistatin gene (FS-334) in an AAV is injected in quadriceps muscles of 
BMD and sporadic inclusion body myositis (an infl ammatory, progressive muscle wasting 
disease) patients is currently ongoing for testing safety and assessing its effect on muscle 
mass and function (NCT01519349). Recently combinational treatment with this FS-334 iso-
form and microdystrophin (∆R4-23/∆CT) delivery by AAV vectors was tested in aged mdx 
mice. Whereas both treatments by itself were not capable of fully protecting muscle against 
contraction-induced injury in this advanced disease state, the combination improved this to 
near normal levels as seen in wild type mice.528
Myostatin knockdown has also been achieved by exon skipping. 2OMePS against exon two, 
resulting in a premature stop codon, resulted in good exon skipping in vitro and lowering of 
myostatin expression and its downstream targets Myf5 and Myog. Also in mdx mice exon 
skipping was observed after intramuscular injection, albeit at low levels. Furthermore, in 
contrast to DMD exon skipping, which was homogenous throughout the muscle, variation 
in skipping levels throughout the muscle was observed. In vitro the feasibility of com-
bined exon skipping of dystrophin and myostatin was shown in DMD patient-derived cells. 
However this has not been tested in vivo.529 High levels of exon skipping were observed with 
PMO AONs against exon two of myostatin. Systemic injection of vivo-morpholinos induced 
myostatin exon skipping resulting in an increase in muscle mass and myofi bre size in wild 
type mice.530 Also pPMOs showed high effi ciency and intramuscular treatment of mdx mice 
resulted in an increase of tibialis anterior muscle weight. When combined with a pPMO 
against dystrophin exon 23, both this increase in muscle mass and dystrophin exon skip-
ping was observed, showing no detrimental effects of combining both AONs. Interestingly 
the increase in muscle mass after myostatin skipping only or after combined treatment was 
observed only in female mice, not in male mice, showing gender-specifi c results.531
Next to downregulation of myostatin signalling by exon skipping of myostatin itself, 
AON-mediated exon skipping has been tested for its type I receptors (Acvr1b/Tgfbr1), which 
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also infl uences other members of the TGF-β family (activin and TGF-β). Acvr1b is a receptor 
for myostatin and activin, and Tgfbr1 is a receptor for myostatin and TGF-β. They commonly 
use the pSmad2/3 pathway as one of their downstream signalling pathways. Upregulation 
of some of these receptors has been found in DMD patients and animal models. The mRNA 
coding structure of these receptors is similar. Exon two encodes the ligand binding domain 
and exon six part of the kinase domain; skipping of exon two will result in a non-func-
tional receptor, while skipping of exon 6 will lead to an out-of-frame transcript. Attempts 
to develop AONs to skip these exons resulted in effective AONs, both in vitro and in vivo, 
against exon six of Acvr1b and exon two of Tgfbr1, which showed specifi c skipping in 
the targeted receptor. 2OMePS AONs against Acvr1b, but not against Tgfbr1, showed in 
vitro downregulation of myostatin induced pSmad3 levels only in myogenic cells and not 
in non-myogenic cells; whereas in non-myogenic cells this was only observed after Tgfbr1 
skipping. This is in line with previous results showing cell-type specifi c utilization of type I 
receptors by myostatin.482 As expected, TGF-β signalling was only affected by Tgfbr1 skip-
ping. Enhanced myoblast and delayed fi broblast differentiation was observed after skipping 
with either AON. Intramuscular injection in mdx mice of 2OMePS AONs confi rmed target 
specifi city and showed no interference with DMD exon 23 skipping after co-injection. Gene 
expression and protein analysis also showed the different roles of Acvr1b and Tgfbr1 in 
disease pathology. Skipping in either receptor resulted in an increase in Myog expression, 
indicative of enhanced muscle differentiation. In contrast, Tgfbr1 skipping resulted in a 
decrease in all fi brotic markers (Collagen1a1, Serpine1 and CTGF); whereas Acvr1b skip-
ping resulted in a decrease in Collagen1a1, but an increase in Serpine1 and CTGF. In general 
a reduction in pSmad2 levels was seen, suggesting an overall reduction of myostatin/activin/
TGF-β signalling [Kemaladewi et al., unpublished results].
A potential risk for using myostatin signalling inhibition strategies is to induce/increase DMD 
cardiomyopathy. Several studies have been performed on the effect of myostatin knockout/
inhibition on the heart showing inconsistent results. Results in Mstn-/- mice suggest it might 
induce cardiac hypertrophy and thereby be benefi cial for the repair of damaged cardiac mus-
cle, although others found no cardiac phenotype.506,532 In mdx mice also variable results were 
seen: whereas no cardiac changes were observed in mdx/Mstn-/- mice and mice treated with 
soluble Acvr2b treatment for four months, cardiac hypertrophy resulting in reduced cardiac 
function was observed by liver-targeted myostatin propeptide administration after eleven 
months.506,519,520
2.7.2 Targeting TGF-β signalling
Treatment of mdx mice with a TGF-β1 neutralizing antibody for six weeks resulted in a 
decrease in TGF-β1 expression and reduced fi brosis in the diaphragm; however no effect on 
muscle degeneration/regeneration was observed. Furthermore, an increase in infl ammatory 
CD4+ lymphocytes was detected. It is known that TGF-β1 also plays a role in infl ammation 
and immunomodulation. The overall effect of TGF-β1-inhibition on fi brosis and infl amma-
tion could have implications for long term treatment with TGF-β1-inhibitors and therefore 
combination with immunosuppressive agents might be a good strategy.533
Halofuginone (7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-
quinazolinone) has anti-fi brotic activity by inhibiting Smad3 phosphorylation downstream of 
TGF-β signalling, thereby attenuating collagen type I gene expression by fi broblasts. In mdx 
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mice it could prevent an age-dependent increase in fi brosis in young mice as well as induce 
a decrease in fi brosis in older mice (eight to nine months old). Thereby it improved prolifer-
ation of muscle cells and skeletal muscle, diaphragm and, importantly, cardiac function.534,535 
More specifi cally, in mdx mice and muscle biopsies of DMD patients the expression of the 
gene collagen triple helix repeat containing 1 (CTHCRI) was shown to be elevated, correlat-
ing with disease severity. Large infi ltrates of myofi broblasts were the source of Cthcr1 and 
halofuginone inhibited both these infi ltrates and lowered Ctchr1 expression in skeletal and 
cardiac muscle of mdx mice.536 A fi rst, open-label clinical trial assessing the safety and phar-
macokinetics of HT-100 (halofuginone hydrobromide delayed-release tablet) by comparing 
several single and multiple doses is currently ongoing (NCT018475730).
Decorin, a small leucine-rich proteoglycan, is a component of the ECM of all colla-
gen-containing tissues. It can bind TGF-β, thereby blocking its activity. It is present in the 
ECM surrounding muscle fi bres. Studies on DMD biopsies and cultured dystrophic myotubes 
found a decrease in decorin mRNA expression, mainly localised in fi broblasts, accompanied 
by an increase in TGF-β1 expression.
537,538 Puzzling, another study found contradictory results, 
whereby decorin expression was increased in DMD biopsies, hypothesizing an attempt of the 
muscles to combat fi brosis.539 Patients of the studies were in the same age range; however 
the last study only looked at two patients. Intraperitoneal treatment of mdx mice with decorin 
resulted in a 40% decrease of collagen I mRNA expression in the diaphragm.540 In injured 
skeletal muscle decorin could prevent TGF-β1-induced differentiation of myogenic cells into 
fi brotic cells.541 Further studies on overexpression of decorin by gene transfer in vitro in 
cultured murine muscle cells showed an accelerated differentiation into myotubes and an 
increased expression of myogenic genes together with a decrease in TGF-β1 and myosta-
tin expression. In vivo an enhanced regeneration and healing of muscle after injury was 
observed by decorin gene transfer. The mechanisms behind this effect of decorin on muscle 
healing are not exactly known. This study suggest that it acts on various pathways, both by 
inhibiting fi brosis by lowering TGF-β1 and myostatin expression and it may also upregulate 
regeneration, as they showed an increase in regeneration-stimulating genes like follistatin 
and MyoD.542
Suramin, a polysulfonated naphthylurea, is a TGF-β1 blocker that was able to attenu-
ate exercise-induced fi brosis and elevation of CK in six months old mdx mice after seven 
weeks of treatment. Only in cardiac muscle no improvement was observed.543 This was also 
observed in another study treating eight month old mdx mice for three months. Hereby solely 
the heart was analysed by electrocardiogram and histology.544 To protect the mdx diaphragm 
against muscle fatigue, it acted by decreasing MMP-9, involved in degradation of the ECM, 
activity and increasing β-dystroglycan, thereby having positive effects on the maintenance 
of the DGC.545 Suramin is used for the treatment of other disorders (e.g. prostate cancer) 
however it may have side effects like polyneuropathy.546
Fibrinogen is a soluble acute phase protein, which is released from infl ammatory sites and 
converted to fi brin, playing a role in fi brogenesis. In mdx mice it was shown that fi brinogen 
can bind the αMβ2-(MAC-1) receptor on macrophages, thereby inducing IL-1β expression, 
which in turn increases TGF-β expression and signalling. Fibrinogen can also induce col-
lagen synthesis directly by binding to the αVβ3-integrin receptor on fi broblasts. In fi brotic 
areas in DMD patients and mdx mice fi brinogen expression is increased, indicating it as a 
possible therapeutic target. Indeed genetic loss of fi brinogen in mdx mice (mdx/Fibrinogen-/-) 
resulted in a reduction in fi brosis and slowed down disease progression. The same could be 
achieved by pharmacological inhibition of fi brinogen in mdx mice with ancrod, a defi brino-
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genating agent. A reduction in TGF-β, pSmad2 and collagen I expression was observed, as 
well as a decrease in pro-infl ammatory cytokines (e.g. TNF-α).547 Fibrinogen also plays an 
important role in blood clotting.548 Interference with this function could increase the chance 
of bleeding. Since different domains of the protein are involved in the different functions, 
mutants could be made in which a single domain is disabled. In Fibγ390-396A mice expressing a 
mutant form of fi brinogen with normal clotting function, but lacking the αMβ2 binding motif, 
or blocking αMβ2-binding by administration of a fi brinogen/αMβ2-binding peptide, an amelio-
ration of dystrophic pathology was observed, which was reversed in the Fibγ390-396A mice by 
injecting fi brinogen. These results underline the specifi c interaction of fi brinogen with the 
αMβ2-integrin receptor on macrophages. Indeed, also in DMD patient biopsies a co-localiza-
tion of fi brinogen and macrophages (αMβ2-integrin) was observed in degenerating areas. Next 
to a decrease in αMβ2-mediated signalling, ancrod treatment resulted in a decreased inhibition 
of satellite cells, thereby enhancing regeneration.549
Another compound that has an effect on amongst others TGF-β signalling is imatinib 
mesylate, a 2-phenylaminopyrimidine derivative, which is already approved for the treatment 
of leukaemia. Imatinib selectively and competitively blocks the ATP binding sites of several 
tyrosine kinases, including c-Abl, c-Kit, and PDGF-receptors. The PI3K/c-Abl signalling 
route is also a non-Smad pathway mediating the TGF-β effects stimulating fi broblast prolif-
eration. c-Abl can be activated by both TGF-β and PDGF. Two studies in mdx mice showed 
a decrease in fi brosis/necrosis and infl ammation, thereby improving hind limb strength, after 
imatinib treatment. This was mediated by an inhibition of both fi brotic signalling mediators 
as c-Abl and PDGF and infl ammatory markers TNF-α and IL-1β.550,551 It also attenuated dys-
trophy in a more severe mdx model, the DBA/2-mdx mouse, by decreasing fi brosis.552
Bowman-Birk Inhibitor concentrate is a soy-derived serine protease inhibitor, which 
resulted in improvement in muscle pathology and function in mdx mice after oral admin-
istration. It did not act on proteasome activity but reduced calpain activity. A decreased 
expression of TGF-β1 and pSmad2/3 was seen and a reduced myostatin activation, resulting 
in increased muscle hypertrophy and decreased fi brosis. Bowman-Birk Inhibitor concentrate 
inhibits several proteases, but no changes in other growth signalling pathways (p38 MAPK, 
Akt or NF-κB) were seen.553
2.7.3 BMP antagonists
BMP antagonists, e.g. Noggin, can enhance muscle differentiation and regeneration. Indeed, 
inhibition of BMP signalling with Noggin resulted in increased expression of regeneration 
markers both in vitro in C2C12-cells and in vivo in mdx/Utrn+/- mice. Muscle histology was 
improved in these mice. However these are non-selective BMP antagonists.489 Furthermore, 
as described in paragraph 2.7 opposite effects were observed after denervation-induced atro-
phy. Hereby Noggin overexpression worsened pathology instead of ameliorating it.494,495 
These different observations demonstrate that BMP signalling has different effects on sat-
ellite cells/myoblasts and muscle fi bres and that the effect of inhibition or stimulation is 
context dependent. In DMD a lot of muscle fi bre damage and regeneration is observed, while 
in denervation-induced atrophy a lot of muscle mass is lost, leading to smaller and weaker 
fi bres. However it indicates the large probability of side-effects while interfering with BMP 
signalling pathways.
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Fig. 2.4: Simplifi ed scheme of the 
renin-angiotensin system
Angiotensinogen is converted by renin and 
angiotensin-converting enzyme (ACE) to 
its active form angiotensin II, which sig-
nals mainly via the AT1 receptor to increase 
infl ammation and fi brosis. It has pro-in-
fl ammatory effects by activating the NF-κB 
pathway. It increases fi brosis/inhibits myo-
genesis both directly by activating several 
pSmad-dependent and independent path-
ways and indirectly by increasing TGF-β 
expression. Signalling via AT2 is thought 
to have opposing effects and to be induced 
during AT1 blockade.
2.8 The Renin-Angiotensin System
Activation of the renin-angiotensin(-aldosterone) system (RA(A)S; fi g. 2.4) is known to 
play a role in the pathogenesis of, among others, cardiac fi brosis. This system has also 
been shown to be upregulated in muscular dystrophy. Angiotensin I is converted by ACE 
to angiotensin II, which in turn binds to its receptors angiotensin II receptor type 1 (AT1) 
and angiotensin II receptor type 2 (AT2). Via AT1 it asserts its main effects, among others 
increasing infl ammation, fi brosis and stimulating cell proliferation.554,555 It has pro-infl amma-
tory actions by increasing the production of ROS which activate the NF-κB pathway.556,557 
Next to increasing infl ammation, RAS also increases fi brosis via both TGF-β1-dependent 
and TGF-β1-independent mechanisms (fi g. 2.3b/4). Firstly, it can upregulate the expression 
of TGF-β1 directly via the NADPH oxidase/p38/MAPK pathway. Secondly, by enhancing 
downstream targets of TGF-β1 signalling.
558 The RAS system is thought to act upon both 
the Smad-dependent and Smad-independent pathways. In vitro angiotensin II induces a late 
(24 hours) TGF-β-dependent pSmad2/3 activation. In cells lacking the TGFB gene or where 
endogenous TGF-β was blocked, angiotensin II induced rapid phosphorylation of pSmad2/3 
and increased expression of the pro-fi brotic markers CTGF and collagen I. This was blocked 
by a specifi c AT1 antagonist. Furthermore, inhibition of p38 MAPK also diminished this 
phosphorylation indicating that angiotensin II activates the Smad pathway via AT1 and 
MAPK activation.559,560 AT1 signalling is thought to also stimulate the non-canonical path-
ways PI3K/Akt/mTOR and Raf/MEK/ERK TGF-β independently.561,562 Signalling via AT2 
is thought to have opposite effects to AT1 signalling, e.g. anti-fi brotic and inhibiting growth, 
and there is negative crosstalk between both receptors. Therefore activation of AT2 during 
specifi c AT1 blockade may contribute to the benefi cial effects on cardiac dysfunction.262,563
Considering the upregulation of RAS in DMD and its known pro-infl ammatory and pro-fi -
brotic effects, several therapeutic strategies try to target this system at different levels.555
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The fi rst group of compounds are ACE-inhibitors, which are already widely used in the treat-
ment of cardiomyopathies, where they have shown to reduce morbidity and mortality. They 
inhibit the conversion of angiotensin I to angiotensin II by ACE and can be divided in three 
groups based on their molecular structure. The fi rst group are sulphydril-containing agents 
(e.g. captopril (the fi rst ACE-inhibitor)), the second group are dicarboxylate-containing 
agents (e.g. enalapril, perindopril and lisinopril) and the third group (phosphonate-contain-
ing agents) only includes fosinopril.8 However the clinical relevant differences between the 
different groups and/or compounds are marginal.564 Nowadays it is recommended to start 
ACE-inhibitor treatment, possibly combined with a β-blocker, in DMD at the fi rst signs of 
cardiomyopathy.565
Several ACE-inhibitors have been tested in vitro and in vivo in animal models with mixed 
results. Cozzoli et al. treated young mdx mice systemically with enalapril and observed an 
improvement in muscle function, accompanied by a decrease in necrosis. More detailed anal-
ysis of biomarkers, showed an effect on expression of genes related to infl ammation and 
oxidation (i.e. decrease in NF-κB and ROS), but no change in fi brotic markers (TGF-β1 and 
pSmad2/3), whereupon they hypothesised that pro-infl ammatory and pro-oxidative events 
precede the pro-fi brotic events.554 On the contrary, Nelson et al. treated young mdx mice for 
a short period with enalapril and did not observe an improvement in forelimb grip strength. 
However these results are rather limited, since they did not measure anything else.263 The 
contradicting results could also be due to the fact that mice in the fi rst study underwent 
an exercise protocol to aggravate muscle infl ammation and pathology, making it easier to 
induce improvement. Furthermore the RAS potentially plays a role in impairing exercise 
performance. However, recently another group observed an improvement in muscle strength 
and decrease in CTGF-induced pro-fi brotic activity both in sedentary and exercised mdx 
mice. Again no change in TGF-β1 expression.
566
Lisinopril was identifi ed in a large in vitro drug screening assay in dystrophic muscle to 
increase tetanic force.477 When combined with an aldosterone antagonist, spironolactone, it 
was able to preserve cardiac function, refl ected by a decrease in cardiomyocyte damage and 
fi brotic markers (MMPs), in mdx/Utrn+/- mice. Therapeutic effects at 20 weeks of age were 
larger when treatment was started at four weeks of age compared to start of treatment at eight 
weeks of age, indicating the importance of early intervention.567
Captopril showed its effectiveness in vitro by partially counteracting TGF-β1-induced 
myoblast differentiation inhibition in C2C12-cells.568 In vivo captopril was able to improve 
cardiac function in older mdx mice after starting treatment at two months of age.381
Studies in patients have shown positive effects of several ACE-inhibitors on cardiac func-
tion. Enalapril showed normalization of left ventricular function in half of the patients. The 
other half of the patients did not respond to enalapril treatment, but no association with type 
of mutation or age of onset of cardiac problems was found.15 ACE-inhibitor therapy is often 
combined with β-blockers (see paragraph 2.15). Several ACE-inhibitors (often enalapril or 
lisinopril) showed to delay the progression of cardiomyopathy or even improvement of heart 
function and improvement of long term survival, when used alone or in combination with a 
β-blocker in DMD patients with heart failure.569-571 In a randomized double-blinded clinical 
trial with perindopril versus placebo no difference between left ventricular ejection fractions 
(LVEFs) was observed after 36 months of treatment. Thereafter all patients (also the placebo) 
received in an open-label extension study perindopril for an additional two years. After this 
period a higher LVEF was seen in the patients who had received perindopril for fi ve years 
compared to those who only received it during the last two years. Possible reasons for the 
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absence of an effect after the fi rst phase, could have been the low a priori risk of developing 
heart failure (patients had normal LVEF at baseline) and the small study population. Since 
a placebo group is lacking in the second phase no conclusion can be drawn for the effect 
of perindopril in the group that started treatment later.572 A ten year follow-up of the same 
patients showed a higher survival rate in the patients who received perindopril from the start 
of the trial (26 out of 28 versus 19 out of 29).573 Overall all studies indicate the importance of 
early initiation of treatment.565
A clinical trial with the anti-oxidant coenzyme Q10 (see paragraph 2.4) and lisinopril is 
currently ongoing (NCT01126697). This open-label trial will compare the safety and the 
effects on cardiac function of coenzyme Q10 alone, lisinopril alone or combined treatment 
in DMD, BMD and limb girdle muscular dystrophy (LGMD) patients.
A second group of compounds targeting the RAS system are selective AT1 antagonists, to 
which losartan belongs. Losartan is used as a vasodilator to treat hypertension and is known 
to decrease TGF-β signalling.
Cohn et al. fi rst investigated the effect of losartan in mdx mice. Long term losartan treat-
ment (from six weeks of age till six to nine months) resulted in decreased disease progression 
and fi brosis and improved muscle function. In addition, they showed that after muscle injury 
in aged mdx mice, losartan improved the regenerative capacity and reduced fi brosis by antag-
onism of TGF-β signalling, refl ected by lower levels of its downstream targets pSmad2 and 
TSP-1.260 However a few years later the same group published another study indicating the 
protective effects were not mediated via TGF-β signalling, but via the IGF-1/Akt/mTOR 
pathway.262 They showed in a mouse model for sarcopenia (loss of skeletal mass and func-
tion during ageing), that losartan improved muscle architecture and functional recovery 
after cardiotoxin injection via blocking both the canonical (i.e. pSmad2) and non-canonical 
(i.e. pERK) TGF-β signalling pathway. However, experiments in disuse atrophy during age-
ing, showed no change in either pSmad or pERK, but positive effects by activation of the 
IGF-1/Akt/mTOR pathway.561 This pathway plays a role in increasing protein synthesis and 
preventing muscle regeneration.574,575 In relation to these partly contradicting results, we did 
not see any change in mdx mice in the expression of downstream targets of TGF-β signalling 
in fi brotic pathways, after losartan treatment. In addition no effect of losartan on pSmad2 
levels after TGF-β stimulation was observed in an in vitro assay. Only a modest increase 
in pERK levels might be seen (this thesis chapter 6). In addition, in the meantime other 
groups published less convincing results on the positive of losartan in muscular dystrophy. 
Nelson et al. indeed observed improvement of forelimb grip strength in mdx mice by losartan 
treatment, but only at two months of age and not at nine months of age. At two months, a 
decrease in TGF-β activity was observed, but at nine months there was no change in fi brotic 
markers. However they did observe an improvement in respiratory function in these aged 
mice.263 In two other studies long term (six months resp. two years) losartan treatment in 
mdx mice could only preserve cardiac function, but not skeletal muscle function. Probably 
the angiotensin II pathway plays a major role in the development of cardiac fi brosis, whereas 
in skeletal muscles other fi brotic pathways dominate.261,264 This is in line with the results for 
ACE-inhibitors, whose main benefi cial effects are also observed in cardiac tissue. A clinical 
trial comparing the effi cacy of losartan to the ACE-inhibitor lisinopril in DMD patients with 




2.9 Insulin-like growth factor 1 stimulation
Other ways to infl uence myogenic regeneration and differentiation are via insulin-like growth 
factor 1 (IGF-1) signalling. IGF-1 is a growth factor that plays a role in the maintenance of 
muscle mass and muscle growth. It stimulates satellite cell proliferation and differentiation 
during muscle regeneration via activating the PI3K/Akt/mTOR pathway, which stimulates 
protein synthesis and blocks apoptosis and via the Raf/MEK/ERK pathway, which increase 
cell growth and differentiation (fi g. 2.5).574,576,577 Therefore compounds that increase IGF-1 
signalling may promote muscle hypertrophy and increase regeneration in muscle wasting 
disorders like DMD.
Various IGF-1 analogues have been tested in mdx mice. A recombinant human IGF-1 
improved contractile function of the diaphragm and fatigue resistance of hind limb mus-
cles.578,579 Whereas IGF-1 overexpression causes hypertrophy at a high dose (for example 
by transgenic overexpression in mdx/Mglf+/+ mice),580 at a low dose (1.0-1.5 mg/kg/day) it 
causes a shift of muscle fi bre type towards a more oxidative and fatigue-resistance type, 
without changing the muscle mass. Thereby it reduces functional muscle defi cits in mdx 
mice. It is known that in DMD patients fast-twitch muscles are more susceptible to dam-
age than slow-twitch muscle.581 A compound that releases IGF-1 from its binding peptides 
(IGF-1 aptamer; NBI-31772), thereby increasing the level of free IGF-1, also protected leg 
muscle and diaphragm to contraction-induced injury by shifting towards a slower muscle 
type when administered via continuous infusion (6 mg/kg/day) to mdx mice. However it 
increased muscle fatigability during repeated maximal contractions, but these are unlikely 
to be made by patients in practice.582 An improved IGF-1 variant (PEG-IGF-1) showed that 
the benefi t of treatment depended on the severity of pathology. In young (mildly affected) 
mdx mice it indeed protected skeletal and diaphragm muscles; yet these effects were less pro-
nounced in more severely affected older mdx mice and absent in very severely affected mdx/
Utrn-/- mice.583 In a randomized clinical trial in DMD and BMD patients growth hormone, 
which stimulates IGF-1 production, induced a slight improvement in systolic heart function 
after three months, but no changes in skeletal muscle function.584 A longer study to test the 












Fig. 2.5: Simplifi ed scheme of the IGF-1 
signalling pathway
Growth hormone (GH) stimulates IGF-1 production, 
which binds to the Igf1 receptor, thereby activating the 
PI3K/Akt/mTOR pathway to stimulate protein synthe-
sis/block apoptosis and the Raf/MEK/ERK pathway to 
increase cell growth/differentiation.
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2.10 Anabolic agents
In contrast to catabolic agents, like corticosteroids, which reduce muscle fi bre size, anabolic 
agents aim to increase fi bre size. The rationale behind the fi rst approach is that smaller fi bres 
might be less susceptible to contraction-induced injury, thereby reducing the degeneration/
regeneration cycles, whereas the idea behind the second approach is that increasing fi bre 
size will increase muscle strength and enhance muscle repair. However, the latter might also 
make the muscles more susceptible to injury, thereby accelerating degeneration.585
B-adrenoreceptor agonists (β-agonists) are hormone-like substances that bind to the 
β-adrenoreceptors on the cell membrane. These receptors play a regulatory role in cardio-
vascular, respiratory, metabolic and reproductive functions. Skeletal muscles contain mainly 
β2-adrenoreceptors. B-agonists bind to these receptors and activate a cAMP-protein kinase A 
signalling pathway, which is involved in protein synthesis and protein degradation. Via this 
pathway they have anabolic effects on skeletal muscles and can increase muscle growth and 
repair after injury.586
B2-agonists like clenbuterol and albuterol were shown to have anabolic properties in mdx 
mice by increasing skeletal muscle mass.587,588 Results on muscle histology and function are 
less consistent. It decreased muscle degeneration in both younger (20 weeks old) and old 
(87 weeks old) mdx mice and also prevented exercise-induced fi brosis after ten weeks of 
treatment.588 However, 20 weeks treatment of six months old mice had no impact on force 
production.587 Importantly no improvement of diaphragm muscle, either on fi brosis or force 
production, could be observed.589
Another β-agonist, albuterol, has been tested in clinical trials with DMD and BMD 
patients. In a pilot study 12 weeks of treatment with 8 mg/day showed only a small increase 
in muscle strength in DMD or BMD patients, without side effects.590 In a longer dou-
ble-blinded, placebo-control trial where patients received 12 weeks of albuterol treatment 
and 12 weeks of placebo treatment with 12 weeks in between, or the other way around, also 
mainly an increase in muscle mass was seen, which might be accompanied by an improve-
ment in functional performance, but no increase in strength of several muscle groups.591 The 
same was observed for clenbuterol in trials for facioscapulohumeral dystrophy, where mainly 
increases in muscle mass were observed, but only moderate or no improvements in muscle 
strength or function.592-594 A small study in a few adult muscular dystrophy patients, among 
which one Becker patients, suggested that clenbuterol might be benefi cial in early stages of 
disease, since it could improve better preserved muscles, but had no effect on more atrophic 
muscles.595
Clenbuterol and albuterol are older generation β-agonists. Formoterol is a new generation, 
more powerful β2-agonist, which is already used for other diseases. In ten weeks old mdx 
mice, after four weeks of daily treatment with a low dose, it increased muscle mass, diameter 
and force producing capacity in peripheral muscle, without increasing muscle fatigue. Higher 
doses have generally shown to increase muscle fatigue. However also formoterol could not 
improve diaphragm muscle function.596 A concern could be that increasing muscle size might 
increase their susceptibility to contraction-induced injury, since it has been observed that 
large, fast-twitch type II fi bres, the most affected fi bre type in DMD, are especially vulner-
able to lengthening contractions. However, on the contrary, inducing muscle hypertrophy in 
these type of fi bres by formoterol treatment in mdx mice did improve their force producing 
capacity and made them less susceptible to contraction-induced injury.597
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A problem with the use of β-agonists can be that prolonged treatment leads to a downreg-
ulation of β-receptors on the muscle cell membrane and chronic administration is toxic for 
the heart and causes muscle tremor.586 Since β1-adrenoreceptors predominate in the heart, this 
might be prevented by the use of a highly selective β2-adrenoreceptor agonists, like formo-
terol. Unfortunately these still lead to mitochondrial dysfunction, as refl ected by a decrease 
in mitochondrial protein synthesis and oxidative capacity after chronic treatment of rats or 
mice, by reducing SR Ca2+-ATPase activity in the heart and impairing cardiac relaxation.598,599
Anabolic androgenic steroids (AAS) are derivatives of testosterone. They have both anabolic 
(increasing protein synthesis and muscle growth) and androgenic (stimulating primary and 
secondary sexual development in males) effects. They are well known for their (ab)use by 
athletes because of (supposed) effects on increasing muscle mass and strength. Their anabolic 
effects occur via both direct and indirect mechanisms. Directly, they bind to the androgen 
receptor, thereby stimulating MHC protein synthesis. Indirectly, they competitively bind to 
glucocorticosteroid receptors, thereby blocking those signalling pathways and decreasing 
protein catabolism. Furthermore testosterone has shown in men to increase IGF-1 expression 
thereby increasing muscle protein synthesis.600
The AAS oxandrolone, an oral synthetic analogue of testosterone, has been tested in 
clinical trials in DMD patients. In a fi rst pilot experiment an increase in overall functional 
muscle score was seen after three months of treatment.601 Thereafter a larger randomized, 
double-blinded, placebo-controlled trial for six months was performed, with moderate 
results. Although some quantitative muscle tests showed an improvement, overall there was 
no signifi cant improvement in muscle strength compared to the controls. Only, it may be that 
the oxandrolone-treated patients did not get worse, whereas the controls showed deteriora-
tion, but this was not signifi cant.602 A subsequent study on the mechanisms behind a possible 
muscle strength increasing effect of oxandrolone, showed, after three months of treatment, 
an increase in synthesis of MHC proteins and gene expression data suggested a decrease in 
muscle regeneration.603
Although in the oxandrolone trials no negative effects on muscle were observed or pos-
sibly even positive effects, an earlier study with another AAS, nandrolone decanoate, in mdx 
mice showed worsening of pathology. Three weeks treatment of young mice resulted in an 
increase in myofi bre damage and CK levels.604 The dose used in these mice (1.5 mg/kg/day) 
was comparable to those used in the clinical trials (0.1 mg/kg/day) after applying a correction 
factor based on normalisation to body surface area when translating doses between small and 
larger animals (1.5 mg/kg in mice≡0.12 mg/kg in humans).605
A possible explanation for the varying results with AAS could be due to the effects they 
exert on non-muscle tissues. Selective androgen receptor modulators such as GLPG0492 
are non-steroidal hormones that are more selective for skeletal muscle and bone. In a com-
parative trial for four weeks in exercised mdx a high dose (30 mg/kg, 6 days/wk) resulted in 
increased fatigue resistance, diaphragm force and less fi brosis, whereas nandrolone (5 mg/
kg) and α-methylprednisolone (1 mg/kg) only had a positive effects on some of these func-
tions. No negative effects were observed with nandrolone. In a 12-weeks study the effect of 
GLPG0492 was maintained, also with lower doses (3 mg/kg or 0.3 mg/kg).606
Estrogens are mostly seen as female sex hormones, but skeletal muscles are a major source of 
estrogen production in both men and women. In muscle, estrogens can increase force output 
and protect them against injury. Tamoxifen is a selective estrogen receptor modulator with 
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anti-estrogenic effects that is used in the treatment of breast cancer. It has numerous actions, 
including scavenging of free radicals, inhibiting fi brosis and acting on Ca2+-homeostasis; all 
playing a role in DMD pathology. Oral treatment of mdx5cv mice resulted in a large amelio-
ration of dystrophic pathology, refl ected by an increase in force production and histology. 
Importantly, also diaphragm and cardiac fi brosis was decreased.607,608
2.11 HDAC-inhibitors
Histone deacetylases (HDACs) play a role in the control of signalling networks involved 
in among others muscle growth, de- and regeneration. NO signalling regulates activity of 
HDAC2, a class I HDAC, by S-nytrosylation, which inhibits HDAC2-mediated gene repres-
sion, among which the myostatin inhibitor, follistatin. NO is produced by nNOS, which 
activity is disturbed in DMD (see paragraph 1.2.2), consequently HDAC signalling is also 
likely to be deregulated. Therefore HDAC-inhibitors (small molecule drugs) may be benefi -
cial to DMD patients, since they can promote muscle hypertrophy and regeneration.609
The HDAC-inhibitors trichostatin A, valproic acid and phenyl butyrate decreased CK levels 
in 12 weeks old mdx mice. Trichostatin A was shown to be most effi cient, also in induc-
ing myotube formation and increasing regeneration marker expression in cells derived from 
treated mice. Furthermore increased mortality was seen amongst valproic acid- and phenyl 
butyrate-treated animals, whereas no side effects were observed due to trichostatin A treat-
ment. Trichostatin A treatment resulted in an improved muscle cell integrity and recovery to 
exercise performance by increasing myofi bre size, mediated by an upregulation of follistatin, 
reducing fi brosis and infl ammatory cell infi ltrates.610
Another HDAC-inhibitor, givinostat, was tested long term (3.5 months) in six weeks old 
mdx mice, leading to improvement in muscle formation, histology and function.611 Givinostat 
is currently tested in DMD patients in an open-label phase I/II study (NCT01761292). First 
the safety and tolerability of escalating doses will be assessed. If this is well tolerated, patients 
will be treated for a year to determine the effects on histology and functionality.
As described in paragraph 1.2.2, in addition to the DGC, the α7β1-integrin complex links 
laminin in the ECM to the actin cytoskeleton. After observing that transgenic overexpression 
of the α7BX2 chain extended the life span of mdx/Utrn
-/- mice by threefold and ameliorated 
the pathophysiology,612 Gurpur et al. searched for compounds that could increase α7-integrin 
levels. Hereby they also identifi ed valproic acid, an FDA-approved branched chain fatty 
acid. Next to HDAC-inhibiting activity, this is also an activator of Akt. In vitro valproic acid 
increased α7-integrin thereby increasing hypertrophy and decreasing apoptosis via activating 
the Akt/mTOR/p70S6K pathway. Five weeks treatment of three months old mdx/Utrn-/- mice 
resulted in decreased fi brosis and infl ammation and improvement of hind limb contractures. 
Detailed analysis showed an increased expression of Akt and a decreased expression of ERK. 
Here no increased mortality was reported although the used dosage (240 mg/kg twice daily) 
was higher than in the previous study by Minetti et al. (160 mg/kg/day).613 In myotubes these 
pathways work antagonistic, whereby the Raf/MEK/ERK pathway promotes differentiation, 
thereby reducing hypertrophy, and the PI3K/Akt/mTOR pathway inhibits differentiation, 
thereby inducing hypertrophy. Both pathways are affected by valproic acid. Furthermore Akt 
can inhibit the Raf/MEK/ERK pathway in differentiated myoblasts, but not in their myoblast 
precursors.614 Valproic acid was able to activate Akt by α7-integrin independently, since, in 
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contrast to the cultured muscle cells, no change in α7-integrin levels was observed in these 
mice. This discrepancy is probably due to the short serum half-life of valproic acid, therefore 
dosing was not optimal to have an effect on α7-integrin.
613
In an in vitro reporter gene assay using HEK293 cells, a cell line derived from human 
embryonic kidneys, these HDAC-inhibitors, trichostatin A and valproic acid, were shown 
to enhance exon skipping by several 2OMePS AONs. A small pilot study by us in cultured 
human control myoblasts, did not show differences in AON-induced exon skip effi ciency 
between valproic acid treated cells and control cells [Verhaart et al., unpublished results].
2.12 Improvement of calcium homeostasis
As mentioned before Ca2+-homeostasis is disturbed in DMD. Controversy exists whether this 
is a secondary, passive process due to the increased membrane permeability or a direct effect 
of defects in Ca2+-regulating mechanisms.615 Both hypotheses do not have to be mutually 
exclusive. The absence of dystrophin and thereby disruption of the DGC leads to damage 
of the sarcolemma, increasing its permeability. Hereby the infl ux of calcium is increased. 
At fi rst, compensatory mechanisms can account for this increase infl ux, but eventually this 
capacity is exhausted and Ca2+-homeostasis is lost. The high Ca2+-concentration leads to 
activation of calpains (Ca2+-dependent proteases), causing cell and membrane proteolysis, in 
turn increasing membrane damage and Ca2+-infl ux, eventually leading to cell death.616 On the 
other hand, it might also be a direct effect of a higher activity of Ca2+-channels and defects in 
proteins involved in the removal of intracellular calcium.
Stretch-activated channels for non-specifi c cations (SACNSC) allow the entry of cal-
cium and sodium into cells under normal conditions. Studies have shown that these 
channels are more active in mdx mice, where both resting and stretch-induced intracellu-
lar Ca2+-concentrations are elevated compared to wild type mice. This was prevented by 
blocking of these SACNSC, which also decreased membrane permeability, suggesting this to 
be a secondary effect of increased Ca2+-infl ux. As described above oxidative stress occurs 
in DMD and ROS are increased. Studies suggest that ROS contribute to the activation of 
kinases that open these Ca2+-channels.617 Next to SACNSC, also others channels have shown 
to be deregulated in DMD and/or mdx muscle fi bres. TRPV2, a cationic channel with mech-
anosensitivity, is present in elevated levels at the sarcolemma of dystrophin-defi cient muscle 
fi bres. Transgenic expression of a dominant-negative TRPV2 mutant in mdx mice improved 
muscle histology and performance.618 Furthermore, store-operated calcium entry (SOCE) is 
increased, which is infl uenced by the Ca2+/PLC/PKC pathway and regulated by the scaffold-
ing protein α1-syntrophin, which is associated with the DGC.619
Next to an increase in Ca2+-infl ux, an impaired removal might also contribute to the 
elevated intracellular levels. A protein involved in this process, sarcoplasmic/endoplasmic 
reticulum Ca2+-ATPase was found to be dysfunctional in mdx and mdx/Utrn-/- mice.620 In 
addition to the activation of proteases, the disturbed Ca2+-homeostasis also contributes to 
the pathophysiology by increasing mitochondrial permeability, causing swelling of the 
mitochondria and downregulation of mitochondrial genes (mitochondrial permeability tran-
sition). Over time this causes rupture of the mitochondria, resulting in a metabolic crisis 
and contributing to apoptosis/necrosis of the cells. These processes might be regulated by 
cyclophilin D, a mitochondrial matrix prolyl cis-trans isomerase, encoded by the gene Pfi f. 
The Scgd-/- mouse (lacking δ-sarcoglycan) is a model for severe dystrophy in skeletal mus-
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cle and heart. Knockout of the Pfi f gene in these mice prevents mitochondrial swelling and 
thereby myofi bre necrosis.621 In addition, Ca2+-dependent signalling transduction pathways 
are stimulated, which, through negative feedback, lead to a downregulation of these path-
ways, thereby contributing to the metabolic crisis.622
Pentoxifylline, the 1-5-oxohexyl analogue of the methylxanthine theobromine, is a com-
pound with anti-infl ammatory, anti-oxidant properties and effects on Ca2+-homeostasis. It 
inhibits human dermal fi broblast proliferation and synthesis of, among others, collagen 
by these cells by selectively blocking the induction of collagen synthesis by TNF-α.623,624 
Furthermore it increases cAMP levels by inhibiting phosphodiesterase, thereby reducing the 
activity of Ca2+-channels, which improves Ca2+-homeostasis.625 Studies of effects of pentox-
ifylline in mdx show mixed results. Pentoxifylline treatment (50-100 mg/kg) resulted in an 
improvement of muscle histology and muscle strength.401,625 Another study showed a small 
delaying effect of pentoxifylline (150 mg/kg) on necrosis and increased mechanical func-
tion and resistance to fatigue of skeletal muscle.439 However, Gosselin et al. reported that a 
lower dose of pentoxifylline (16 mg/kg) had no effect on collagen in the diaphragm muscle 
and it also did not improve its contractile function.626 Subsequent clinical trials in DMD 
patients showed disappointing results. In an open-label safety study, pentoxifylline treat-
ment for one year via an orally administered immediately release formulation was so poorly 
tolerated (65% of the patients experienced intolerable gastrointestinal side effects) that half 
of the patients withdrew from the trial and no conclusions of its effi cacy could be made.627 
To circumvent these gastrointestinal side effects a subsequent randomized, double-blinded 
trial used a slow-release formulation. Yet, mild to moderate gastrointestinal and hematologic 
adverse events were still observed. In addition, no improvement or prevention of deteri-
oration of muscle strength or function was found.628 Importantly an in vitro assay on the 
contractile function of dystrophic myoblast showed a complete inhibition by pentoxifylline 
on the positive effect seen after treatment with prednisolone and creatine, highlighting the 
risk of deleterious interactions of cocktails of medicines used by some patients.477
BGP-15 (an [O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid] amidoxime deriv-
ative), a compound that increases the expression of Hsp72, was able to preserve muscle 
strength and decrease fi brosis in both mild mdx mice and severely affected mdx/Utrn-/- mice. 
Hsp72 is a protein that inhibits pro-infl ammatory cytokines like TNF-α and the NF-κB path-
way. However the benefi cial effects of BGP-15 were likely mediated by improvement in 
Ca2+-homeostasis and not by a decrease in infl ammation, since no differences in these infl am-
matory markers between mdx mice overexpressing Hsp72 (mdxTG(+)) and normal mdx mice 
were found. Further analysis showed that sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
activity was increased in these mdxTG(+) mice and that BGP-15 also stimulated its activity. 
BGP-15 is already used in clinical trials for diabetes.620
The L-type voltage-dependent Ca2+-channel blockers verapamil and diltiazem were able 
to signifi cantly decrease the Ca2+-levels in heart muscle of mdx mice and there was a trend 
observed in the diaphragm. Degeneration of the diaphragm was decreased and thereby the 
dystrophic phenotype improved. Both drugs have a cardiovascular-targeted effect, so mainly 
act on the heart and the diaphragm. They did not decrease the Ca2+-content of the skeletal 
muscle or even increased it.629 A double-blinded clinical trial showed that, although after one 
year of treatment with diltiazem the number of Ca2+-positive fi bres was lower in the treated 
group versus placebo, after three years no obvious clinical benefi ts were observed.630 Chronic 
treatment in another double-blinded trial suggested small benefi cial effects by improving 
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some skeletal muscle functions and cardiac parameters, although all results were not sig-
nifi cant.631 Overall, several trials with these and related Ca2+-channel blockers showed no 
benefi cial effect in DMD.632
In mdx mice a structural and functional defect in RyR1, a sarcoplasmic reticulum 
Ca2+-release channel, has been found too, which leads to ‘leaky’ channels.59 NO-mediated 
hypernitrosylation of this channel has also been found in BMD patients with deletions in the 
nNOS binding region (exons 42 to 45), which resulted in increased cytosolic NO production, 
thereby causing disturbance of the RyR1/calsatabin-1 complex, important for Ca2+-signalling. 
This is probably also the case in DMD, since there also nNOS is mislocalised in and 
NO-production disturbed.633 Furthermore activation of RyRs has been shown to be able to 
evoke SOCE.619,634 S107, a compound that inhibits these RyR1 channels, prevented Ca2+-leak 
and thereby improved muscle function and exercise performance in mdx mice.59
Debio-025 is a drug that inhibits cyclophilin D, which is probably involved in mitochon-
drial dependent necrosis of myofi bres. Subcutaneous treatment of both mdx and Scgd-/- mice 
(50 mg/kg) with debio-025 reduced swelling of the mitochondria and reduced fi brosis in the 
skeletal muscle and the diaphragm. Another cyclophilin D inhibitor is cyclosporine. However, 
cyclosporine is not selective for cyclophilins, but also inhibits calcineurin. Calcineurin is 
an important signalling protein for skeletal muscle regeneration after injury and differen-
tiation of skeletal muscle cells and also increases the expression of utrophin (which can 
functionally compensate for loss of dystrophin). Thus, cyclosporine will have both a positive 
and a negative effect, which are likely to negate each other. By contrast, debio-025 has no 
inhibitory effect on calcineurin activity and is more potent in inhibiting cyclophilin D than 
cyclosporine.621
Skeletal muscle primarily expresses three isoforms of calpain called μ-calpain (calpain 1), 
m-calpain (calpain 2) and p94 (calpain 3). As calpain activity is increased in dystrophic mus-
cle, calpain inhibitors may be benefi cial. On the other hand, mutations in calpain 3 are the 
cause of LGMD type 2A (LGMD2A), indicating its important role in normal muscle func-
tioning.635 Therefore caution might also be required with this approach. Experiments with 
several calpain inhibitors showed mixed results. Calpastatin is an endogenous specifi c inhib-
itor of μ- and m-calpains. Transgenic overexpression of calpastatin in mdx mice resulted in 
decreased proteolysis by calpains. Histological benefi t was seen or not, depending on which 
promoter was used.636,637 Leupeptin (n-acetyl-L-leucyl-L-leucyl-L-argininal) is a non-specifi c 
calpain inhibitor. A short term study with intramuscular injections in mdx mice, showed 
improvement of muscle histology, refl ected by decreased muscle degeneration, less centrally 
located nuclei and increased myofi bre diameter.638 In contrast, long term systemic treatment 
(six months) showed no improvements. A novel, more specifi c compound in which the inhib-
itory portion of leupeptin is linked to carnitine to improve muscle uptake (C101), also failed 
to improve muscle function and histology in both mdx mice and GRMD dogs. This is prob-
ably due to compensatory mechanisms, whereas activation of endogenous m-calpain and 
potentially also μ-calpain is increased in the presence of an exogenous calpain inhibitor.608,639
BN 82270 is a membrane-permeable prodrug of a chimeric compound BN 82204 that 
acts dually, both as a calpain-inhibitor and anti-oxidant, thereby targeting both damage due 
to disrupted Ca2+-homeostasis and ROS-induced damage. In mdx mice it prevented cal-
pain-overactivity in the diaphragm, thereby reducing fi brosis. Longer treatment (4-6 weeks) 
resulted in improved muscle function and lowering of TGF-β1 levels in skeletal muscle and 
diaphragm. However, almost no improvement in histopathology of the gastrocnemius was 
observed.640
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2.13 Matrix metalloproteinases
MMPs are zinc-dependent endopeptidases that play an important role in ECM degradation, 
infl ammation and fi brosis in various pathologies. Differential expression of several MMPs 
has been found in DMD as well. MMP-2 and MMP-9 are downstream targets of NF-κB, 
which cleave the extracellular domain of β-dystroglycan, thereby disrupting the interaction 
with α-dystroglycan. An upregulation of MMP-2 and the natural inhibitors of MMPs, TIMP-1 
and TIMP-2, was found in DMD muscle.641 The same accounts for MMP-9, the expression of 
which has been shown to correlate with disease progression, i.e. to be higher in older DMD 
patients and to increase over time.642 In mdx mice also an upregulation of MMPs was found, 
but a downregulation of TIMPs.643 Inhibition of MMP-9 in mdx mice has shown to have a 
benefi cial effect by decreasing infl ammation and fi brosis. These effects are mediated by inhi-
bition of both the NF-κB pathway and the caveolin-3 pathway.644
Since inhibition of MMP-9 has shown to have therapeutic effects in mdx mice and other 
MMPs that play a role in among others fi brosis, are upregulated in DMD as well, they might 
also serve as a therapeutic target.
Batimastat (BB-94) is an inhibitor of a broad spectrum of MMPs, including MMP-1, MMP-2 
and MMP-9 and has reported to be effective in cancer models. Short term treatment of mdx 
mice resulted in a decrease in necrosis and infl ammation, leading to an improved muscle 
function. Furthermore an improvement in components of the DGC and nNOS levels was 
seen.643
Different MMPs often activate each other, however the exact roles of different MMPs in 
skeletal muscle are not known. Furthermore, individual MMPs have shown to play different 
roles depending on the disease stage, therefore inhibition of MMPs can both be advanta-
geous as well as disadvantageous. Although MMP-2 was shown to be upregulated in DMD, 
genetic knockout of MMP-2 in mdx mice (mdx/MMP-2-/-) worsened pathology by impairing 
the growth of regenerating muscle fi bres through reduction of VEGF-mediated angiogene-
sis.645 In addition, although MMP-inhibitors as batimastat and marimastat have been found 
to be benefi cial in several types of cancers and are used in cancer clinical trials, no successful 
results have so far been shown in these trials due to side effects. Therefore global inhibition 
of MMPs could be deleterious on the long term and targeting of specifi c MMPs during dis-
ease progression will probably be necessary to have a potential therapeutic effect.643
2.14 Autophagy
A more recently emerging target is autophagy. Autophagy is an important process for clear-
ing dysfunctional organelles, e.g. defective mitochondria, augmenting energy production 
and preventing tissue damage. Autophagy was shown to be dysfunctional in DMD patient 
biopsies and mdx muscle. A persistent activation of Akt inhibits autophagy via mTOR and 
its downstream targets, like ribosomal protein S6 and 4E-BP1 (fi g. 2.6). mTOR inhibition 
by itself has been shown to be insuffi cient to rescue autophagosome formation, indicating 
also other (pro-autophagy) pathways are involved. In DMD and mdx a decreased expression 
of its downstream targets LC3 II and increase in p62 (LC3 II reduces p62 expression) was 
observed.646 pAkt inhibits the pro-autophagy FOXO3 pathway.647 FOXO3 stimulates auto-
phagy by both increasing LC3 and inhibiting mTOR.648
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AMP-activated protein kinase (AMPK) is a major metabolic sensor of the energy status 
inside cells and can switch on the autophagy pathway. The AMPK agonist AICAR (5-ami-
noimidazole-4-carboxamide-1-β-D-ribofuranoside) was a potent trigger of autophagy in mdx 
diaphragm and caused improvement of mitochondrial function, thereby ameliorating histol-
ogy and function.649
In mdx mice a long term low-protein diet, a potent autophagy-reactivating treatment, 
resulted in a decrease in pAkt/mTOR and an increase in LC3 II expression, accompanied by 
a decrease in p62. This reduced infl ammation, fi brosis and myofi bre damage and improved 
functionality.646
2.15 Treatment of cardiomyopathy
In most DMD patients cardiomyopathy develops at latter stages of disease. Signs of cardio-
myopathy include left ventricular dilation, decreased ejection fraction and increased plasma 
levels of neuroendocrines. Neuroendocrines (e.g. atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP) and norepinephrine) are cardiac hormones thought to be secreted 
in response to increasing atrial and ventricular pressure. Cardiomyopathy is nowadays fre-
quently the cause of death, especially since the introduction of assisted ventilation. Therefore 
treatment of cardiomyopathy is becoming more and more important; however most therapies 
described above do not or only modestly improve cardiac pathology and function. Several 
treatments used in cardiomyopathies with other causes, might also be effective in DMD and 
some of these have been tested in dystrophic models or DMD patients. ACE-inhibitors have 
already been discussed (see paragraph 2.8). Many patients are nowadays treated with ACE-
inhibitors, often combined with β-blockers, when signs of cardiomyopathy start to develop.565
In the RA(A)S system (see paragraph 2.8), next to binding to and signalling via the AT recep-
tors, Angiotensin II also stimulates the synthesis of the mineral corticoid aldosterone and 
emerging data indicate that aldosterone plays an independent role in vascular toxicity and 
fi brosis. Therefore aldosterone antagonists are widely used and have shown effectiveness in 
the treatment of cardiomyopathies. Aldosterone binds to aldosterone receptors (e.g. mineral 
corticoid receptors) and sexual hormone receptors. Activation of these mineral corticoid 
receptors by aldosterone and cortisol plays a role in patients with cardiovascular disease 








Chronic activation of Akt in Duchenne muscular dystrophy inhibits autophagy by activating the S6/p4E-BP1 path-
way through mTOR, which in turn inhibits autophagy, and by blocking FOXO3-mediated LC3/Bnip3 signalling. 
AMPK can switch on the autophagic pathway by inhibiting mTOR and stimulating FOXO3.
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additional benefi t on lowering mortality.650,651 As described above the competitive antago-
nist of the aldosterone receptor spironolactone, a diuretic and antihypertensive agent, has 
been tested in mdx mice. However, since this was only in combination with lisinopril, no 
conclusions can be drawn about the effect of spironolactone itself.567 Eplerenone, a spironol-
actone derivative, is a more selective compound, with a higher affi nity for mineral corticoid 
receptors and lower for sexual hormone receptors, thereby reducing the risk of side effects. 
It has so far only been tested in DMD for treatment of muscle oedema, which is caused 
by an increase in cytoplasmic Na+-content and probably contributes to muscle degenera-
tion. In a small study, eplerenone decreased Na+-concentration in muscles of DMD patients, 
thereby decreasing oedema and improving muscle strength.652 Another pilot in one female 
DMD patient showed the same result of decreasing cytoplasmic sodium and water over-
load and increasing muscle strength and mobility.653 A clinical trial to assess the effects of 
early treatment with eplerenone on cardiomyopathy in DMD patients is currently ongoing 
(NCT01521546). Eplerenone is thought to have fewer side effects than older aldosterone 
antagonists, e.g. spironolactone and its active metabolite canrenone, due to higher specifi city 
for mineral corticoid receptors. However, a meta-analysis of randomized controlled trials 
with aldosterone antagonists in systolic heart failure concluded less reduction in mortality for 
eplerenone compared to spironolactone and canrenone. In addition, it did not have a better 
side effects profi le and is much more expensive.650
Β-blockers bind to β-adrenergic receptors to inhibit sympathetic effects of binding of 
(nor)epinephrine to these receptors, thereby reducing the work load on the heart. They are 
widely used in the treatment of cardiac dysfunction and hypertension. First generation 
β-adrenoreceptor antagonists are non-selective for β1- and β2-adrenergic receptors; whereas 
second generation β-blockers are relatively selective for β1-adrenergic receptors, the predom-
inant receptor in the heart.8 Carvedilol (racemic lipophilic aryloxypropanolamine) causes 
vasodilatation by non-selective blockage of β-adrenoreceptors and α1-adrenoreceptors. It 
has proven therapeutic value as an adjunctive therapy in combination with diuretics and/or 
ACE-inhibitors in the treatment of various types of heart failure.654 A small study with carve-
dilol for six months in four DMD patients with reduced ejection fraction, did not show an 
improvement compared to controls.655 In contrast, in a study in 22 muscular dystrophy (DMD 
or BMD) patients with dilated cardiomyopathy, carvedilol treatment was safe and resulted 
after six months in a modest improvement in systolic and diastolic functions. Another open 
trial where 41 patients received carvedilol versus 13 untreated patients, an improved survival 
rate was observed when solely looked at cardiac failure as cause of death, but not when 
looked at all-cause mortality. Furthermore no changes in LVEF or BNP plasma levels were 
observed. In addition, patients with a very low ejection fraction were also treated with an 
ACE-inhibitor or pimobendan (a PDE3-inhibitor).656 A randomized, double-blinded, place-
bo-controlled clinical trial assessing the effect of nebivolol, a β1-blocker, on the prevention 
of systolic dysfunction in DMD patients is currently ongoing (NCT01648634). Furthermore 
two phase IV clinical trials with carvedilol, one with carvedilol (NCT00606775) only and 
one (NCT00819845) comparing it with the ACE-inhibitor ramipril, should have been per-
formed; however no results are published and their status is unknown.
As described before, combinational treatment with an ACE-inhibitor and a β-blocker is 
often used for DMD-related cardiomyopathy. A study in 11 symptomatic patients suggested 
this combination might reduce left ventricular dilation, BNP and ANP levels and may reverse 
symptoms; however no control group existed.14 In a study with several types of muscular 
dystrophy patients, among whom DMD patients, carvedilol plus an ACE-inhibitor improved 
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left ventricular systolic function, whereas ACE-inhibitors alone did not.657 A larger retrospec-
tive study on DMD patients with heart failure treated with an ACE-inhibitor and β-blocker 
showed a benefi cial effect on long term (over ten years) survival, which was most effective 
in asymptomatic patients with left ventricular dysfunction.569 A recent study confi rmed this 
benefi cial effect of combinational therapy (ACE-inhibitor and β-blocker) since a signifi cant 
improvement was seen in ejection fraction compared to before the start of treatment. This 
was also seen by ACE-inhibitor treatment alone and no additional value of the β-blocker was 
observed. However, this can be due to the delayed addition of β-blocker therapy.570
2.16 Summary
In this chapter various therapeutic strategies that do not aim to restore the expression of 
the dystrophin protein itself, have been discussed. These vary from genetic approaches to 
up- or downregulate the expression of other genes to pharmaceutical compounds acting 
on signalling pathways disturbed in DMD pathogenesis. At the moment the only widely 
used treatments are corticosteroids and, if signs of cardiomyopathy become apparent, ACE-
inhibitors. Unfortunately, while corticosteroids have clear benefi cial effects, i.e. prolonging 
ambulation, they also have numerous side effects.
Next to these many compounds have been identifi ed showing positive results in animal 
models or in vitro model systems. Some of these have already been tested in clinical trials, 
but unfortunately often without very convincing results. One of the problems is that many 
compounds that seem promising in vitro in cells or in vivo in animal models often fail when 
tested in clinical trials or already when tested in (higher) animal models. Partly this is intrin-
sic to translational research. However, it is to underline the international efforts for more 
standardization of animal models and outcome measures made in the last years in the frame 
of activities of the international TREAT-NMD network.658 This in order to improve predict-
ability of data obtained at pre-clinical stage.659 In addition, re-evaluation of failed clinical 
trials is important to design more appropriate pre-clinical testing methods and improve trial 
protocols in the future. This helps in understanding each other’s results and improving model 
systems.
At the moment, one promising candidate is tadalafi l, a PDE5A-inhibitor that is already on 
the market for other disorders and targets the NO-cGMP signalling pathway to enhance vas-
odilation. Results in a trial with BMD patients and in a pilot study with DMD patients were 
promising. Another promising strategy is to target the TGF-β pathway. Hereby, inhibiting 
both TGF-β and myostatin signalling, i.e. by AON-mediated exon skipping of their receptors 
seems a better strategy than targeting myostatin alone. This has only been tested preclinically, 
but it could be combined with DMD exon skipping to restore both dystrophin expression and 
enhance muscle formation. However, a concern with myostatin inhibition is to increase the 
work load on the heart, thereby increasing cardiomyopathy. This does not only account for 
myostatin inhibition, but for every therapy that mainly improves skeletal muscle function 
without targeting cardiomyopathy.
A problem will always be that most compounds only target one or a few of the secondary 
defects, while the underlying cause (lack of dystrophin) is not addressed. Therefore these 
will only temporarily alleviate the symptoms and should, once available, be combined with 
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Antisense-mediated exon skipping is a promising therapeutic approach for Duchenne mus-
cular dystrophy. It aims to restore the dystrophin open reading frame by skipping exons 
with antisense oligonucleotides (AONs) to allow production of partly functional proteins. 
The approach is currently tested in phase III clinical trials, but dosing and maintenance 
regimens have not yet been well studied.
This study compared pharmacokinetic and pharmacodynamic effects of different 
2’-O-methyl phosphorothioate RNA AON dosing and maintenance regimens in the preclin-
ical mdx mouse model. When comparing different dosing regimens over a period of eight 
weeks, higher levels of AON, exon skipping, and protein were observed in muscle after low 
daily doses compared with weekly large doses. Secondly, after receiving a high loading 
dose (1 250 mg/kg) in the fi rst week, mice treated with maintenance injections twice weekly 
for eight weeks showed higher preservation of therapeutic effects than mice receiving less 
or no maintenance injections.
In both cases, the regimen resulting in highest AON and exon skipping levels in muscle, 
also resulted in high AON levels in liver and kidneys. These studies underline the impor-
tance of balancing optimal AON effi cacy and tolerable levels in non-target organs, which 
may be fi ne-tuned by further optimisation of AON treatment regimens.
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Introduction
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disorder 
affecting around one in 5 000 newborn boys.660 It is caused by mutations in the DMD gene, 
located on the X-chromosome, leading to a disruption of the open reading frame, thereby 
causing the complete absence of the encoded dystrophin protein. Dystrophin plays an 
important role in the stabilization of muscle fi bres during contraction, by connecting the 
intracellular actin cytoskeleton to the extracellular matrix. In the absence of dystrophin, mus-
cle fi bres will be damaged with normal exercise, eventually leading to loss of muscle tissue 
and function and premature death in the third or fourth decade of life.5
The exon skipping approach aims to partly correct the underlying genetic defect on RNA 
level by restoring the dystrophin reading frame to allow production of a slightly shorter, but 
largely functional, dystrophin protein as is found in Becker muscular dystrophy (BMD), a 
much milder form of muscular dystrophy.661 To achieve exon skipping, antisense oligonucle-
otides (AONs) are used. AONs are small pieces of RNA, reverse complementary to a specifi c 
sequence in the pre-messenger RNA (pre-mRNA). By binding to its target sequence in the 
pre-mRNA, the AON interferes with the splicing of a specifi c exon, thereby preventing its 
incorporation in the mRNA.164 AONs can have different chemistries. For exon skipping the 
development with 2’-O-methyl phosphorothioate RNA (2OMePS) and phosphorodiamidate 
morpholino oligomers (PMO) or peptide-conjugated PMOs (pPMO) is most advanced.
Proof-of-principle for exon skipping-mediated restoration of dystrophin has fi rst been 
shown in vitro, i.e. in DMD patient-derived myoblast cultures, and in vivo in dystrophic 
animal models (reviewed in Aartsma-Rus et al.269). The most widely used model for DMD 
is the mdx mouse (C57Bl/10ScSn-DMDmdx/J). These mice have a premature stopcodon in 
exon 23, leading to the complete absence of dystrophin protein. Although these mice display 
a relatively mild phenotype compared to human DMD patients,81,159 this model well facili-
tates preclinical pharmacokinetic (PK) and pharmacodynamic (PD) AON studies for DMD. 
Treatment of mdx mice with 2OMePS or PMO AONs targeting exon 23 showed dystrophin 
restoration and improved muscle function.161,182,197,199,200 Exon skipping and dystrophin pro-
tein levels in heart were lower compared with skeletal muscles. This is probably due to 
differences in the nature of the dystrophin-negative muscle fi bres and cardiomyocytes. In the 
absence of dystrophin, skeletal muscle fi bres become leaky. AONs can migrate through these 
holes into the muscle fi bers.161,218 However, the heart is built up of individual cardiomyocytes, 
which do not become leaky, thereby making the targeting of the heart more diffi cult and 
requiring higher doses.200,203
2OMePS (PRO051/GSK2402968/drisapersen) and PMO (AVI-4658/eteplirsen) targeting 
human exon 51 have been tested in clinical trials. Dystrophin restoration has been observed 
after local treatment225,226 as well as after systemic treatment.229,231 Drisapersen resulted in 
dystrophin restoration in ten out of 12 patients up to 15.6% of levels in healthy controls 
after fi ve weeks of weekly subcutaneous injections. For eteplirsen dystrophin was restored in 
seven out of nine patients. The three highest responders showed levels up to 18% of controls. 
Further dose optimisation studies are ongoing for eteplirsen. Drisapersen is currently tested 
in a large, randomized, double-blinded, placebo-controlled phase III clinical study.
It is known that 2OMePS AONs have a plasma half-life of ~4 weeks in patients229 and a 
half-life of ~2-6 weeks in mdx mouse muscle.200 Thus, due to clearance and turnover of the 
AONs, but also of the dystrophin transcript and protein, repeated, life-long AON treatment 
will be required. In the 2OMePS clinical trials currently a weekly dose of 6 mg/kg/wk is used. 
However, little is known about which dose and which dosing schedule is optimal. Dividing 
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the same dose over multiple smaller injections might give better results than applying the 
same total amount at once, as has been shown for PMOs in mdx mice.239 Furthermore, it is 
known that dystrophin transcripts and proteins have a relatively long half-life.206,660 Thus, 
after having initiated the restoration of dystrophin protein, injection with lower amounts 
might be suffi cient to maintain the same effect. Studies to optimise dosing and maintenance 
regimens are diffi cult in humans, where only limited material is available (often only a 
biopsy from a superfi cial muscle and a small amount of blood plasma). Therefore, (DMD) 
animal models are a useful tool for PK/PD modelling studies. These can be used to assess the 
ratio between AON levels and the amount of exon skipping in muscles which can be used to 
extrapolate the results to the human situation.
The aim of this study was to compare different dosing and maintenance regimens through 
assessment of PK and PD profi les for different AON treatment regimens in mdx mice.
Materials and methods
All experiments were approved by the local ethical committee for animal experiments of the 
LUMC (project code 07151). Mice were housed in individually ventilated cages in the animal 
facility of the LUMC and received food and drink ad libitum. Mdx mice (C57Bl/10ScSn-
DMDmdx/J) were obtained from our own breeding facility.
Treatment of mdx mice with different 23AON dosing regimens
Four-weeks old mdx mice (n=7 or 8 per group) were injected subcutaneously with 200 mg/kg 
body weight/week 23AON (3’-uccauucggcuccaaaccgg-5’; a 2’-O-methyl phosphorothioate 
AON described previously as M23D(+2-18)197 (Prosensa Therapeutics), divided evenly over 
1, 2, or 7 injections per week for 8 weeks (i.e. 1 weekly dose of 200 mg/kg versus 2 times 
100 mg/kg versus 7 times 28.6 mg/kg). The RNA 23AON was produced in 3 gram-scale 
batches on an ÄKTA OP-100 oligonucleotide synthesizer (GE Healthcare) using standard 
phosphoramidite chemistry protocols. After synthesis, a two-step cleavage and deprotec-
tion procedure was applied; on-resin 23AON was fi rst treated with diethylamine to remove 
phosphorothioate protecting groups and subsequently subjected to concentrated ammonia 
treatment for 16 hours at 55°C. Crude 23AON (DMT-off, i.e. without 4,4’-dimethoxytr-
ityl group) was purifi ed by IEX and transformed into its sodium salt by addition of NaCl 
and subsequent desalting by ultrafi ltration. Negative mode electrospray ionization-mass 
spectrometers analysis confi rmed the identity of 23AON (MW 6888) and purity (ultra-high 
performance liquid chromatography) of all batches was found to be acceptable (>84%). Mice 
were sacrifi ced by cervical dislocation 1 week after the last injection for their group and mus-
cles (gastrocnemius, quadriceps, tibialis anterior, triceps, diaphragm, and heart) and organs 
(liver, kidney, and spleen) were isolated. Muscles were snap frozen in liquid nitrogen-cooled 
2-methylbutane, and all tissues were stored at -80°C.
Treatment of mdx mice with different maintenance doses of 23AON
In the fi rst week 4-weeks old mdx mice were treated subcutaneously with a loading dose of 
5 times (i.e. daily for 5 days) 250 mg/kg body weight 23AON. This was followed by treat-
ment with different maintenance regimens for 8 weeks: weekly 2 times 100 mg/kg (n=6), 
weekly 100 mg/kg (n=6), 100 mg/kg biweekly (n=5), 100 mg/kg monthly (n=3), or no fur-
ther injections (n=4). Mice were sacrifi ced in week 8 by cervical dislocation, and muscles 
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(gastrocnemius, quadriceps, tibialis anterior, triceps, diaphragm, and heart) and organs 
(liver, kidney, and spleen) were isolated. Muscles were snap frozen in liquid nitrogen-cooled 
2-methylbutane and all tissues were stored at -80°C.
Plasma sampling
Blood samples were taken weekly during treatment to assess creatine kinase (CK) levels. 
Blood samples were taken via the tail vein and were centrifuged at 18 000 g for 5 minutes at 
4°C to generate plasma. This was diluted 10 times in Dulbecco’s phosphate-buffered saline 
(Invitrogen) and CK levels were measured with a Refl otron system (Roche Diagnostics) 
with CK-strips (Roche). For the dosing experiments additional blood samples were taken at 
several time points after the fi rst injection in the fi rst (week 0) and the last (week 7) week of 
treatment (0, 15 minutes, 1 hour, 5 hours, and 24 hours from 4 animals per group). Finally, 
for all mice, a larger blood sample was taken prior to sacrifi ce to determine AON levels by 
enzyme-linked immunosorbent assay.
Functional testing
Mice were functionally tested weekly by forelimb grip strength and/or rotarod analysis. A 
grip strength meter (Columbus Instruments) was used to assess the forelimb grip strength 
according to the standardized operating procedure published on the translational research in 
Europe to accelerate treatments for neuromuscular disorders website.663 Mice were tested 15 
times (5 rounds of 3 consecutive measurements with 2 minutes in between). The forelimb 
grip strength corrected for body weight was calculated by dividing the average of the 3 high-
est values (the absolute strength) by the body weight in grams. For rotarod analysis mice 
were placed on a rotarod (Ugo Basile) accelerating from 5 to 45 rotations per minute in the 
fi rst 15 seconds. The longest running time until the mouse fell off in 3 trials was notated, with 
a maximum of 500 seconds.
RNA extraction and analysis of exon skipping by reverse transcriptase polymerase chain 
reaction
Muscles were minced in TriPure isolation reagent (Roche) using MagNA Lyser green 
beads (Roche Diagnostics) and a MagNA Lyser (Roche) according to the manufactur-
er’s instructions. Total RNA was extracted and 400 ng was used for reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis, using Transcriptor reverse transcriptase pol-
ymerase (Roche) in 20 μL at 42°C for 45 minutes with random hexamer primers (20 ng/μL). 
Subsequently, 1.5 μL was amplifi ed in a 50 μL PCR-reaction with 30 cycles of 94°C for 
30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds, as previously described.663 PCR 
products were visualized on 1.5% agarose gels and quantifi ed using a DNA 1000 LabChip 
on the Agilent 2100 bioanalyzer (Agilent Technologies).
Dystrophin protein analysis
Muscles were homogenized in treatment buffer containing 75 mM Tris-HCl pH 6.8-15% (w/v) 
sodium dodecyl sulphate (SDS) using zirconium beads (1.4 mm; OPS Diagnostics) by grind-
ing in a MagNA Lyser (Roche). Protein concentrations were determined using a Pierce 
bicinchoninic acid protein assay kit (Thermo Fisher Scientifi c) according to manufactur-
er’s instructions. Samples containing 30 μg of protein were made in treatment buffer with 
20% (v/v) glycerol, 5% (w/v) β-mercaptoethanol, and 0.001% (w/v) bromophenol blue, and 
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heated for 5 minutes at 95°C. Samples were loaded on 1.0 mm thick native polyacrylamide 
gel electrophoresis Tris-acetate (polyacrylamide) gels, with a linear resolving gel gradient 
of 3-8% (BioRad) and run on the Trans-Blot Turbo system for 1 hour at 75 V (0.07 A) 
and 2 hours at 150 V (0.12 A) in running buffer (XT Tricine; Biorad) in an ice container 
(Hulsker et al., in preparation). Proteins were blotted on a nitrocellulose membrane using the 
Ready to use Trans-Blot Turbo transfer packs and the Trans-Blot Turbo transfer system from 
BioRad at 2.5 A and ~25 V for 10 minutes. Membranes were blocked in 10 mM Tris-HCl 
(pH 8) and 0.15 M NaCl (Tris-buffered saline (TBS))-5% nonfat dried milk (Elk) for 1 hour, 
washed in TBS-0.05% (v/v) Tween20 (TBST) and incubated overnight with fi rst antibod-
ies 1:125 NCL-Dys1 (Dy4; NovoCastra) and, as a loading control, alpha actinin (1:5 000; 
AB72592) in TBS. Membranes were washed in TBST, incubated 1 h with the fl uorescent sec-
ondary antibodies 1:5 000 IRDye 800CW goat α-mouse IgG (Li-Cor, Lincoln, NE, USA) and 
1:10 000 IRDye 680LT donkey -α-rabbit immunoglobuline G (IgG; Li-Cor) in TBS, washed 
in TBST and TBS, and analysed with the Odyssey system and software (Li-Cor). Dystrophin 
expression in wild type control samples containing 10%, 3.3%, 1.1%, and 0.4% of protein 
were used as reference to determine the dystrophin percentages in the tested samples.
Hybridization-ligation assay for measuring 23AON concentration
For measuring the concentration of 23AON, an assay based on a previously published hybrid-
ization-ligation assay was used.664 Tissue were homogenized in 100 mM Tris-HCl pH 8.5, 
200 mM NaCl, 0.2% SDS, 5 mM ethylene-diaminetetraacetic acid, and 2 mg/mL protK using 
zirconium beads (1.4 mm; OPS Diagnostics) in a MagNA Lyser (Roche). Samples were 
diluted 10 times in PBS (plasma), 500 and 1 000 times (muscle), or 1 000 and 5 000 (liver 
and kidney) in pooled control mdx tissue in PBS. A signal probe (containing the peptide for 
antibody recognition) and a template (complementary to 23AON and the probe) were added 
to homogenized tissue samples. The subsequent ligation step only takes place when both 
23AON and probe are bound to the template. Thereafter, unbound probe was washed away 
and enzyme-linked antibodies were used to detect the amount of probe-23AON. Calibration 
curves of the analysed 23AON prepared in 60 times pooled control mouse mdx tissue in PBS 
were included. All analyses were performed in duplicate.
Statistical analysis
Data are represented as mean ± standard deviation. 23AON levels, exon skipping levels and 
protein levels were compared between all different groups using one-way analysis of variance 
(ANOVA), followed by a Bonferroni correction for multiple testing in case of signifi cance 
(p<0.05) in SPSS 17.0.2 (SPSS). To assess a possible treatment effect on the weight of mice 
over time a longitudinal analysis was perform in R,665 using the lme4 package.666 A base-
line corrected model was used, including fi xed linear and quadratic time effects; the mouse 
effect was considered to be random. PK plasma levels in week 0 and 7 have been compared 
by non-compartmental analysis on sparse sampling data, using Phoenix® WinNonlin® 6.2 
(Pharsight). Data are expressed as mean ± standard error of the mean.
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Results
PK/PD analysis of different dosing regimens
In this study the relation between dosing regimens, exposure, and outcome (molecular and 
functional) has been investigated. Therefore mdx mice were injected for eight weeks with 
the same total dose of 23AON divided over a different number of injections (1, 2, or 7 
per week). None of the mice, including the mice injected daily for eight weeks, showed 
any sign of changes in vital parameters, including changes in weight or behaviour (data 
not shown). Serum CK levels were elevated compared to wild type mice, but did not differ 
signifi cantly from reference values in saline-treated mdx mice or between different dosage 
groups (fi g. 3.1a). In addition, both rotarod (fi g. 3.1b) and forelimb grip strength (fi g. 3.1c) 
analyses did not show differences with saline-treated mdx mice, wild type mice or between 
the various dosage groups.
The plasma profi le of the AONs was assessed after the fi rst AON injection in week 0 and 
week 7 (fi g. 3.2a/b; table 3.1) by non-compartmental PK plasma analysis. Afterward, sacrifi ce 
AON levels in plasma, muscle, liver, kidney, and spleen were assessed as well (fi g. 3.2c-e; 
supplementary table S3.1). Actual tissue exposures are the most relevant exposure param-
eters to take into account, since the process of uptake, distribution to tissue, or excretion 
into urine is relatively fast, while the stability of AONs in tissue is long (earlier publications 












































































Fig. 3.1: Plasma creatine kinase (CK) and functional assessment during treatment
a) Serum CK levels are elevated in all mdx mice compared to wild type mice. No differences between mice of the 
different dosing regimens were observed. No differences between functional performance by rotarod (b) or forelimb 
grip strength (c) were seen between mice of various dosing regimens. Note that for rotarod analysis and forelimb 
grip strength the wild type mice and/or untreated mdx mice perform equally well.
Error bars represent the standard deviation.
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been measured as a control to confi rm dosing and detect potential non-linearities. Because 
blood sampling in mice is limited, only fi ve time points have been used for the plasma PK 
profi le using a sparse sampling approach. An overview of non-compartmental PK exposure 
parameters is given in table 3.1. After subcutaneous injection, AONs are taken up rapidly 
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Fig. 3.2: Pharmacokinetic/pharmacodynamic profi les of antisense oligonucleotides (AONs) 
for the different dosing groups
a) In the fi rst week high peak levels after 100 or 200 mg/kg were seen rapidly (± 15 minutes) after injection, 
which declined within hours. For injection with a lower amount of AON (28.6 mg/kg), a lower peak concentration 
was seen. b) The same pattern was observed after seven weeks of injection. Furthermore drug accumulation after 
repeated dosing was observed, indicated by an extension of the plasma profi le and increase in area under the curve 
(AUC). c) Plasma levels at sacrifi ce were signifi cantly higher for the group which had received daily injections 
compared to both other groups. d/e) In most muscles (the target tissue) and all other organs analysed (the non-target 
tissues) higher AON levels were observed in mice receiving seven injections per week compared to mice receiving 
the same total dose all at once.
Error bars represent the standard deviation. G=gastrocnemius; TA=tibialis anterior; He=heart; Di=diaphragm; 
Li=liver. Ki=kidney; Spl=spleen. *p<0.05 **p<0.01
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of the maximum at 5 hours after injection (fi g. 3.2a/b). Upon repeated dosing, the plasma 
profi le gets extended and the area under the curve (AUC) increases, which is indicative 
of the drug accumulation in tissues (fi g. 3.2b/table 3.1). The plasma exposures increase at 
higher dosing levels, both for the maximum plasma concentration (Cmax) and the AUC. The 
increase is more than dose-proportional between 28.6 and 100 mg/kg (~10 times for Cmax 
and ~7 to 10 times for the AUC). This indicates that mechanisms responsible for distribution 
to tissue can be saturated, which can explain the decreasing tissue levels at the higher dosing 
level of injection, while the total weekly dose remains the same (fi g. 3.2c-e). The increase 
in exposure between 100 and 200 mg/kg appears somewhat less than dose-proportional in 














1 x 200 mg/kg/week 174 ± 14 381 ± 78 193 ± 70 577 ± 162 1.1 1.5
2 x 100 mg/kg/week 109 ± 11 244 ± 10 116 ± 3 407 ± 20 1.1 1.7
7 x 28.6 mg/kg/week 10 ± 1 24 ± 2 14 ± 1 56 ± 5 1.5 2.4
Table 3.1: PK analysis of plasma levels in the fi rst and last week of treatment
Non-compartmental analysis on sparse sampling data has been performed to calculate the Cmax and AUC for the 
different dosing regimens, showing a more than dose-proportional increase in plasma exposure levels for both 
parameters at higher dosing levels.
Data are expressed as mean ± standard error of the mean.
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Fig. 3.3: Exon skipping levels and dystrophin protein expression
a) Examples of RT-PCR analysis of the quadriceps and diaphragm muscles showing the unskipped wild type (334 bp) 
and exon 23 skipped (121 bp) product. b) Quantifi cation of exon skipping levels in different muscles. In skeletal 
muscle no differences between the different dosing regimens were observed. Signifi cantly higher levels were seen in 
the heart and diaphragm of daily injected mice versus mice injected once and/or twice weekly. c) No differences in 
the expression levels of the dystrophin protein levels were observed between all dosing groups in the quadriceps. In 
the diaphragm a slight, but not signifi cant, increase was found in the daily injected mice.
Error bars represent the standard deviation. M=size marker; PCR ctrls=negative PCR-controls; G=gastrocnemius; 



























Fig. 3.4: Plasma CK before initial treatment 
and after eight weeks of maintenance treat-
ment
Plasma CK is highly variable in mice, and no differences 
were observed between different maintenance regimens 
after treatment.
Error bars represent the standard deviation.
the further decrease in tissue levels, it suggests an enhanced renal excretion of free AONs 
in plasma when binding to plasma proteins gets saturated at higher plasma concentrations.
When comparing exon skipping levels between the different groups of mice, no dif-
ferences were seen between the different groups in muscle (fi g. 3.3a/b; supplementary 
table S3.1). Only in the heart and diaphragm an increase in exon skipping levels was found in 
the daily injected mice compared to the mice injected once and/or twice weekly (fi g. 3.3b). A 
direct correlation between AON and exon skipping levels was not found, except for the heart 
(fi g. 3.2d versus 3.3b). Furthermore the higher AON and/or exon skipping levels in daily 
injected mice did not result in higher protein levels (fi g. 3.3c; supplementary table S3.1). 
These were low and comparable for all groups in the quadriceps. Slightly higher dystrophin 
protein levels were observed for daily injected animals in both quadriceps and diaphragm, 
but this was not signifi cant due to the low levels in general and high interindividual differ-
ences (fi g. 3.3c). No exon skipping or dystrophin restoration was observed in non-treated 
animals (data not shown).
PK/PD analysis of different maintenance regimens
To study the effect of different maintenance 
regimens, mdx mice were subjected to dif-
ferent maintenance schemes for eight weeks. 
After an initial ‘loading’ treatment with fi ve 
times 250 mg/kg 23AON in the fi rst week 
(proven to be effective in previous exper-
iments200,259), mice were injected twice 
weekly, once weekly, twice monthly, or once 
monthly with 100 mg/kg or did not receive 
any further injections for the subsequent 
eight weeks. During this period, no differ-
ences in weight or functional performance 
by rotarod analysis were seen between all 
groups (data not shown). Furthermore, CK 
levels did not show differences at the end of 
the eight weeks treatment period (fi g. 3.4).
The amount of 23AON in several muscle 
groups and organs was assessed for the dif-
ferent regimens (fi g. 3.5a/b; supplementary 
table S3.2). The 23AON was detectable in all samples analysed, even in those that did not 
receive any further injections for eight weeks after the initial treatment in the fi rst week. 
For all muscles (fi g. 3.5a) and organs (fi g. 3.5b) levels were highest (p<0.05) in the mice 
injected twice weekly compared with other groups. Also, the mice injected once weekly, had 
signifi cantly higher levels for most muscles and organs compared with the mice, which had 
received no injections and/or only once a month during the maintenance period. Only in the 
tibialis anterior and heart differences were observed between the group that received injec-
tions twice per month and the group that received no further injections. A clear trend with the 
number of injections and tissue levels was observed for all tissues.
In contrast to the dose optimisation phase, in this maintenance phase the exon skipping 
levels followed the pattern observed for AON levels (fi g. 3.5a versus 3.5c; supplementary 
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table S3.2), that is, a decrease in exon skipping percentages with decreasing numbers of 
injections (and thus total dose). Only in heart, the differences were less clear, partly due to 
higher variations between individual mice and partly due to the fact that the exon skipping 
levels in heart were lower in mice injected twice a week compared with the skeletal mus-
cles. For the mice that received AONs twice weekly, exon skipping levels were signifi cantly 
increased compared with less frequently injected mice in all muscles, except for heart. Mice 
injected once weekly showed higher levels only in the gastrocnemius, quadriceps, and dia-
phragm and differences between the other groups were seen only for the diaphragm (fi g. 
3.5c). For dystrophin protein expression (fi g. 3.5d; supplementary table S3.2) only in the 
diaphragm signifi cantly higher protein levels were found in the twice-weekly injected mice 
versus the mice injected once monthly or not at all after the loading phase. The reason that 
no clear differences were observed in protein levels is the overall low expression levels and 
high variation between individual mice.
Detailed PK/PD analysis of dosing and maintenance regimens
The ratios between exon skipping and AON levels observed in the different muscle groups 
A B
C D
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Fig. 3.5: Biodistribution, exon skipping levels and protein expression
a/b) A dose-dependent pattern was observed for the number of maintenance injections and the AON levels in all 
analysed muscles and other organs. For all muscle groups and other organs, levels were signifi cantly higher in the 
mice which received two times 100 mg/kg/wk during the maintenance period compared to almost all other groups. 
Mice which had received one injection per week also showed higher levels compared to mice which had received 
less injection in all tissues, except for the gastrocnemius and kidney. c) The exon skipping levels also showed a 
dose-dependent pattern with the number of injections. However, levels were only signifi cantly higher for mice 
injected twice and/or once per week, and less differences were observed between mice injected with less mainte-
nance injections. d) Protein levels were only increased in the diaphragm for mice that were injected twice per week 
compared to mice injected once per month or that did not receive maintenance injections.
Error bars represent the standard deviation. G=gastrocnemius; TA=tibialis anterior; He=heart; Di=diaphragm; 
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Fig. 3.6: Ratio of exon skipping versus AON levels in different muscle groups and AON 
levels in the muscle (target tissue) versus non-target organs
a) The exon skipping/AON ratios did not reveal large differences between the different dosage regimens. Only in 
the diaphragm relatively more exon skipping for a certain amount of AON was observed for the daily injected mice. 
The ratios were markedly lower in the heart compared to other muscles. b) In gastrocnemius and tibialis anterior 
exon skipping/AON ratios were a bit higher in mice receiving less frequent maintenance injections. Here, heart 
ratios were also markedly lower. c) Ratios between the AON levels in the target organ (muscle) versus the non-target 
organs were similar for the different dosage regimens. d) More variation was observed between muscle/non-target 
organ AON level ratios for the different maintenance regimens for the kidneys and spleen.
Error bars represent the standard deviation. G=gastrocnemius; TA=tibialis anterior; He=heart; Mu=muscle; 
Di=diaphragm; Li=liver; Ki=kidney; Spl=spleen.
were assessed (fi g. 3.6a/b). The ratios were much higher, i.e. more exon skipping for a certain 
amount of AON, in skeletal muscles than in heart, suggesting that in heart the majority of 
AON is probably trapped in the interstitium and therefore ineffective. No clear pattern was 
observed for the different dosing regimens (fi g. 3.6a). In limb muscles the ratios were higher, 
albeit with large interindividual variations, for the mice injected once a week, suggesting 
that lower AON levels were able to induce the same amount of exon skipping levels or that 
more AON was taken up by the muscle fi bres. By contrast, in the diaphragm a higher ratio 
was observed for the mice injected seven times a week, suggesting that for this organ daily 
injections may lead to improved uptake of AONs. 
For the maintenance study mice, receiving less frequent injections (and thereby also a 
lower total dose) showed a higher exon skipping/AON ratio for the gastrocnemius and tib-
ialis anterior (fi g. 3.6b). This may be a refl ection of the fact the exon skipping is a stepwise 
process (AON uptake, exon skipping, dystrophin restoration) and suggests that dystrophin 
transcripts have a relatively long half-life.
The ratios of the average AON levels in skeletal muscles (gastrocnemius, tibialis anterior, 
and diaphragm) and those in non-target organs (kidney, liver, and spleen) were also calcu-
lated (fi g. 3.6c/d). For the different dosing regimens, no differences were observed (fi g. 3.6c). 
For the comparison of the different maintenance regimens the ratios, were generally similar 
(fi g. 3.6d).
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Discussion
Antisense-mediated exon skipping is currently one of the most promising therapeutic 
approaches for Duchenne muscular dystrophy. This approach has shown encouraging results 
in preclinical experiments in vitro and in vivo in animal models and in early phase clinical 
trials.667 However, to improve the therapeutic effect, optimisation of the treatment regimen is 
necessary. In mdx mice, the optimal dose is around 200 mg/kg body weight for 2OMePS.200 
This is much higher than the dosages used in clinical trials (6 mg/kg body weight). However, 
a correction factor must be applied when translating from mice to humans (see Guidance for 
Industry605). When applying this correction factor, 200 mg/kg in mice would correspond to 
16 mg/kg in humans. This is slightly higher than the dose used in humans, but this can be 
explained by differences in clearance and regeneration capacity between mice and humans, 
interexon differences, and differences in PK/PD properties of 23AONs versus 51AONs. 
Although some preclinical studies into the PK/PD profi les of AONs have been done in ani-
mal models,200,239 it is uncertain whether the currently used dosing schedule in clinical trials 
is the best. During optimisation there will always be a trade-off between the effi cacy (exon 
skipping and dystrophin restoration) due to AONs in the targeted muscles and the amount 
that ends up in other organs, like the liver and kidneys, where it potentially can have adverse 
effects. Therefore, detailed PK/PD analyses were done for different 2OMePS 23AON dosing 
and maintenance regimens in order to model the AON and exon skipping effects.
Interestingly, dividing the same total dose of 2OMePS AONs over multiple, daily injec-
tions was more effective than giving the same dose in one or two weekly injections, especially 
for heart and diaphragm. This is in concordance with a study on PMO AONs in mdx mice, 
which also reported increased effectiveness with multiple, low dose injections compared to 
a single, high dose injection.239 In the present study, a single injection with a high amount 
of AON resulted almost immediately in high plasma levels, which rapidly declined. This is 
partly due to uptake by, and potentially saturation of the tissues, but also largely due to clear-
ance by the kidneys. For 2OMePS AONs, in contrast to PMOs, this is partly prevented by 
the serum binding properties of the PS-backbone.668 However the binding capacity of serum 
proteins is limited, and at high concentrations saturation is reached, leading to urinary excre-
tion,669 explaining the higher concentrations of AONs in the muscles after multiple injections 
with low dose of AONs, which were signifi cant in tibialis anterior and heart. Due to lower 
peak levels, which do not exceed the binding capacity of the serum proteins, all AON can 
bind serum proteins, resulting in higher availability of AON, indicated by the accumulation 
over time seen in this group, as refl ected by the plasma levels at sacrifi ce. However, this 
effect is not only seen in the muscles, but also in the other organs (liver, kidney, and spleen). 
When comparing the amount of AON in the muscles and non-target organs the ratio was 
roughly similar between the different dosage regimens, indicating that the uptake of AONs 
in the different tissues increases with the same proportion with increasing numbers of smaller 
injections.
The exon skipping levels measured here were lower than those reported in our previous 
studies.161,200 This is most likely due to the fact that previously a nested PCR was used to 
detect exon skipping. It has now been shown that this gives an overestimation of exon skip-
ping.663 Therefore, to more accurately determine skipping percentages, a single PCR was 
used in our current study. Indeed the exon skipping levels reported here are more comparable 
to another report using a single PCR.259
For the different dosing regimens, no clear correlation was observed between the biodis-
tribution pattern to individual muscles and the exon skipping levels observed (fi g. 3.6a). A 
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possible explanation could be that a treatment period of eight weeks is not suffi cient to reach 
a steady state. This is confi rmed by our earlier fi ndings that upon longer treatment exon skip-
ping levels increase up to 12 weeks,219 while they do not increase further after 24 weeks.201 
In the gastrocnemius and tibialis anterior, where no increase in skipping was observed, this 
ratio was higher for mice who received the AONs all at once. Notably, in heart multiple, 
small injections did result in higher AON levels, which did correlate to higher exon skipping 
levels. This suggests that optimising the dosing regimen is possibly a way to improve heart 
targeting. This is important, since previous studies have shown that targeting heart so far has 
been challenging.200,203
No clear increase in protein levels was seen for the different dosing groups, except for 
a small increase in the diaphragm. This is mainly due to the high standard deviation and 
because levels are low in general, which is expected after such a short treatment period in 
mice. Notably, in clinical studies higher dystrophin levels were observed already after fi ve 
weeks of treatment.229 This could be due to differences in muscle fi bre permeability between 
DMD patients and mdx mice and suggests there may be dissimilarities in biodistribution 
between DMD patients and mdx mice.
Furthermore, different regimens to maintain the effect achieved by initial treatment were 
compared in this study. In contrast to the dosing regimen study, here a clear dose-dependent 
pattern was observed, where more maintenance injections resulted in higher AON, exon 
skipping and dystrophin levels. This difference can be due to the initial loading with a very 
high dose of AON, the fact that this study was longer and/or because the total dose received 
by the mice was similar in the dosing study, whereas different groups received different total 
doses in the maintenance study. Notably, the exon skipping/AON ratio was higher in the 
groups receiving the lowest number of injections. This could refl ect differences in turnover 
of AON and RNA transcripts. Animals were sacrifi ced one week after the last injection of the 
group receiving maintenance injections twice weekly. This means that the animals that did 
not receive maintenance injections had their last AON treatment nine weeks before sacrifi ce. 
For these animals it is anticipated that part of the AON is already turned over (as refl ected 
by the lower AON levels in the muscles, fi g. 3.5a). However, apparently the turnover of 
exon skipped transcript is slower, resulting in a higher exon skipping/AON ratio. Our results 
underline the long half-life of the 2OMePS AONs in muscle, as low levels of AON and exon 
skipping were still detected eight weeks after the last injection. More extensive studies are 
required to study the turnover of the different components (AON, transcript, and proteins) 
in more detail.
For the selection of an optimal dosage and maintenance regimen in humans, clinical 
studies are indispensable. However, preclinical animal studies provide important indications 
of the effects of different treatment regimens and can be used in data models to enable fur-
ther optimisation. Achieving high levels of exon skipping and dystrophin restoration are of 
course aimed for. However, as with most drugs, one also has to balance this with how much 
AON accumulates in non-target tissues, mainly liver, kidney, and spleen. 
Additional studies are needed for more extensive PK/PD modelling and to further eluci-
date the long term effects of AONs on different levels (i.e. RNA and protein).
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phragm Liver Kidney Spleen
1 x 200 mg/kg/week 0.38 ± 0.18 22.9 ± 5.1 15.4 ± 8.0 21.6 ± 5.8 21.2 ± 5.5 273 ± 41 223 ± 70 80 ± 19
2 x 100 mg/kg/week 0.54 ± 0.29 28.4 ± 9.5 21.6 ± 3.9 29.3 ± 6.8 28.1 ± 7.6 336 ± 66 273 ± 82 126 ± 20
7 x 28.6 mg/kg/week 1.03 ± 0.23 28.8 ± 4.9 26.7 ± 3.3 35.0 ± 5.8 26.7 ± 4.5 386 ± 70 352 ± 97 155 ± 42













1 x 200 mg/kg/week 15.0 ± 9.5 11.9 ± 8.0 8.9 ± 3.5 11.1 ± 7.3 1.7 ± 1.3 8.1 ± 3.6 0.7 ± 0.3 0.9 ± 0.4
2 x 100 mg/kg/week 12.6 ± 8.1 11.5 ± 7.9 8.0 ± 3.3 11.0 ± 6.1 2.2 ± 1.3 9.4 ± 4.5 0.7 ± 0.3 1.1 ± 0.3
7 x 28.6 mg/kg/week 13.2 ± 2.0 13.7 ± 2.3 11.8 ± 2.0 14.5 ± 3.7 4.1 ± 1.7 18.0 ± 2.3 0.8 ± 0.6 1.6 ± 1.0
Supplementary Table S3.1: Overview of PK/PD data of different dosing regimens
Summary of the AON, exon skipping and protein levels at sacrifi ce in week 8 of the different dosing regimens. 
23AON levels are expressed as μg/mL (for plasma) or μg/g tissue (for organs). Exon23 skipping levels are expressed 
as skipped transcript as percentage of total transcript. Dystrophin protein levels are expressed as percentage of wild 
type levels in the same muscle.







anterior Heart Diaphragm Liver Kidney Spleen
2 x 100 mg/kg/week 49.3 ± 16.5 40.1 ± 5.1 56.9 ± 5.8 47.4 ± 10.6 671 ± 113 645 ± 234 348 ± 38
1 x 100 mg/kg/week 33.6 ± 12.2 19.4 ± 2.0 31.9 ± 6.4 32.6 ± 3.3 481 ± 77 305 ± 190 178 ± 35
2 x 100 mg/kg/month 26.0 ± 12.7 14.8 ± 6.6 22.5 ± 5.0 13.9 ± 2.8 277 ± 35 119 ± 34 65 ± 16
1 x 100 mg/kg/month 11.7 ± 0.6 8.5 ± 0.0 13.1 ± 1.1 9.2 ± 0.7 224 ± 9 154 ± 32 55 ± 5
No further injections 6.2 ± 0.8 4.4 ± 1.7 9.2 ± 1.9 8.9 ± 3.1 146 ± 55 41 ± 30 41 ± 12













2 x 100 mg/kg/week 14.3 ± 1.9 12.7 ± 2.2 10.8 ± 2.8 11.4 ± 2.4 3.7 ± 1.1 11.9 ± 2.6 2.2 ± 1.5 2.1 ± 0.4
1 x 100 mg/kg/week 7.5 ± 2.1 6.8 ± 2.9 5.7 ± 1.8 4.7 ± 1.3 2.3 ± 1.4 7.0 ± 1.6 1.2 ± 0.5 1.2 ± 0.8
2 x 100 mg/kg/month 3.9 ± 1.2 3.8 ± 1.5 3.6 ± 0.5 3.7 ± 2.2 0.9 ± 1.0 3.4 ± 1.3 0.9 ± 0.4 0.7 ± 0.1
1 x 100 mg/kg/month 6.5 ± 2.2 2.6 ± 0.1 3.5 ± 1.0 4.5 ± 1.7 1.4 ± 1.3 2.9 ± 1.4 0.8 ± 0.1 0.4 ± 0.3
No further injections 2.5 ± 1.3 1.4 ± 1.1 2.2 ± 0.7 2.2 ± 1.4 1.0 ± 0.5 2.1 ± 0.7 0.5 ± 0.2 0.4 ± 0.3
Supplementary Table S3.2: Overview of PK/PD data of different maintenance regimens
Summary of the AON, exon skipping and protein levels at sacrifi ce in week 8 of the different dosing regimens.
23AON levels are expressed as μg/g tissue. Exon23 skipping levels are expressed as skipped transcript as percentage 
of total transcript. Protein levels are expressed as percentage of wild type levels in the same muscle.
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Antisense-mediated exon skipping is currently in clinical development for Duchenne muscu-
lar dystrophy (DMD) to amend the consequences of the underlying genetic defect and restore 
dystrophin expression. Due to turnover of compound, transcript and protein, chronic treat-
ment with effector molecules (antisense oligonucleotides) will be required. To investigate 
the dynamics and persistence of antisense 2’-O-methyl phosphorothioate oligonucleotides, 
exon skipping, and dystrophin expression after dosing was concluded, mdx mice were treated 
subcutaneously for eight weeks with 100 mg/kg oligonucleotides twice weekly. Thereafter, 
mice were sacrifi ced at different time points after the fi nal injection (36 hours-24 weeks). 
Oligonucleotide half-life was longer in heart (~65 days) compared with that in skeletal mus-
cle, liver and kidney (~35 days). Exon skipping half-lives varied between 33 and 53 days, 
whereas dystrophin protein showed a long half-life (>100 days). Oligonucleotide and exon 
skipping levels peaked in the fi rst week and declined thereafter. By contrast, dystrophin 
expression peaked after three to eight weeks and then slowly declined, remaining detectable 
after 24 weeks. Concordance between levels of oligonucleotides, exon skipping and proteins 
was observed, except in heart, wherein high oligonucleotide levels, but low exon skipping 
and dystrophin expression were seen. Overall these results enhance our understanding of the 
pharmacokinetics and pharmacodynamics of 2’-O-methyl phosphorothioate oligos used for 
the treatment of DMD.
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Introduction
Duchenne muscular dystrophy (DMD) is the most prevalent form of inherited muscular dys-
trophies affecting around one in 5 000 newborn boys.1,2 Patients display severe progressive 
muscular weakness due to the absence of the dystrophin protein, which functions as mechan-
ical stabiliser during muscle contraction. In the absence of dystrophin the muscle fi bres are 
easily damaged and are gradually replaced by fi brotic and adipose tissues. First symptoms 
generally become apparent at two or three years of age, after which, pathology develops 
rapidly. Patients often die before the age of 30 years due to respiratory and/or cardiac failure.5
In humans, lack of dystrophin is generally caused by out-of-frame deletions or small 
mutations that introduce premature stop codons in the DMD gene.670 Several animal models 
are available for DMD, among which, the mdx mouse (C57Bl/10ScSn-DMDmdx/J) -which 
does not express dystrophin due to a premature stop codon in exon 23- is the most widely 
used.79 However, the lack of dystrophin is less disastrous in mdx mice than in humans. These 
mice have a nearly normal life expectancy, only slightly impaired muscle function and a bet-
ter muscle quality compared with DMD patients.671 Nevertheless, this mouse model displays 
several features of the DMD pathology, i.e. muscle degeneration and leaky fi bres due to the 
absence of dystrophin, and is very useful for preclinical studies.672
During the past several years a lot of progress has been made toward the development of 
antisense oligonucleotide (AON)-mediated exon skipping as a potential therapy targeting the 
underlying genetic defect of DMD. This aims to restore the reading frame or bypass a small 
mutation by skipping one or more exons. Thereby translation can continue and a largely 
functional protein can be formed, as is found in the related, but much milder Becker muscular 
dystrophy. After obtaining proof-of-principle in vitro in cultured cells and in vivo in animal 
models, clinical trials for AONs with two different backbone chemistries, 2’-O-methyl phos-
phorothioate RNA (2OMePS) and phosphorodiamidate morpholino oligomers (PMO), are 
currently ongoing.673 Systemic (subcutaneous) treatment with drisapersen (2OMePS AON, 
targeting exon 51) for fi ve weeks induced dystrophin expression in ten of 12 patients up to 
15.6% of levels found in healthy persons.229 Treatment with eteplirsen (PMO AON, targeting 
exon 51) by intravenous infusion resulted in dystrophin restoration in seven of 19 patients at 
highly variable percentages up to 18% of control levels.231 Placebo-controlled phase 2 and 3 
trials have been conducted for drisapersen. Encouraging results were reported for the phase 2 
trials, suggesting improved walking distance in six minutes for treated patients compared 
with placebo administered after 24 and 48 weeks of treatment. However, it was recently 
reported that the primary outcome measure (distance walked in six minutes) in the phase 3 
trial,233 although slightly improved in the treated patients, did not differ signifi cantly from 
the placebo treated patients. More detailed analysis is pending. In addition to drisapersen 
(targeting exon 51), AONs targeting other exons, i.e. exon 44, 45 and 53, are under clinical 
evaluation.
Because RNA-mediated therapies are subject to clearance and turnover of AONs and the 
dystrophin transcripts and proteins, repeated, life-long injections will be required to maintain 
therapeutic effects. Therefore, insight in the pharmacokinetic (PK) and pharmacodynamic 
(PD) properties of these compounds is essential to determine how long the effects persist and 
to assess dosing frequencies and regimens. Previous studies have revealed a plasma half-life 
for 2OMePS AONs of around four weeks in patients229 and a tissue half-life of two to six 
weeks in mdx mouse muscle.200 It has previously been observed that uptake of AONs is better 
in dystrophic muscle than in healthy muscle, probably due to the dystrophic “leaky” nature 
of the muscle fi bres. Both subcutaneous and intravenous routes of administration resulted 
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in muscle uptake and exon skipping, but intravenous injections led to much higher AON 
levels in liver and kidneys, although AON levels in muscle were comparable with those adter 
subcutaneous treatment.200 Furthermore, for 2OMePS AONs, exon skipping and dystrophin 
protein levels vary among different muscle tissues. Generally exon skipping levels in heart 
are lower, whereas the levels are comparable in limb muscle and diaphragm.161,200,201,219,240,259 
Increase in exon skipping and accumulation of dystrophin protein were seen up to 12 weeks 
of treatment and long term treatment for six months has been shown to be feasible.201,219 
Comparison of various maintenance regimens revealed that eight weeks after the last dose, 
the decline in AON levels was faster than the decline in exon skipping and protein levels, 
indicating differences in turnover.240 However, the relation between clearance and turnover 
of the compound, the induced skipped transcript, and restored dystrophin protein and long 
term analysis of the persistence of different effects after subcutaneous treatment have not 
been studied. In order to expand our understanding of the PK/PD relationship of 2OMePS 
AONs, mdx mice, in which the mutation can be bypassed by skipping of exon 23, were dosed 
with 100 mg/kg twice weekly for eight weeks via the subcutaneous route, after which, tissues 
were harvested at different time points for the analysis of 23AON, exon skipping and protein 
levels.
Materials and methods
All experiments were approved by the local ethical committee for animal experiments of 
the Leiden University Medical Center. Mice were housed in individually ventilated cages in 
the animal facility of the Leiden University Medical Center and received food and drink ad 
libitum. Mdx mice (C57Bl/10ScSn-DMDmdx/J) were obtained from our own breeding facility.
Treatment of mdx mice with 23AON and sample preparation
Starting at an age of 3-4 weeks, 36 mdx mice were treated subcutaneously with 100 mg of 
23AON/kg body weight in 100 μL saline twice weekly for 8 weeks. The 23AON molecule, 
previously described as M23D(+2-18), is a 2’-O-methyl phosphorothioate RNA oligonucleo-
tide with a full-length phosphorothioate backbone, specifi cally targeting exon 23197 (Prosensa 
Therapeutics, Leiden, the Netherlands). Mice were sacrifi ced by cervical dislocation at dif-
ferent time points after the last injection: t=36 hours and 1, 3, 8, 12, and 24 weeks (6 mice 
(3 males, 3 females) per time point). Before sacrifi ce, blood samples were taken for plasma 
PK analysis (see below). Plasma was generated by centrifuging at 18 000 g for 5 min and it 
was stored at -80 ºC until analysis. After sacrifi ce, muscles (triceps, tibialis anterior, quadri-
ceps, heart and diaphragm) and liver, kidney and spleen were isolated, snap frozen in liquid 
nitrogen cooled 2-methylbutane and stored at -80 °C.
Assessment of 23AON levels with a hybridization-ligation assay
An assay based on a previously published hybridization-ligation assay was used for the deter-
mination of the 23AON level in different tissues at Prosensa Therapeutics.664 Tissues were 
homogenized in 100 mM Tris-HCl (pH 8.5), 200 mM NaCl, 0.2% sodium dodecyl sulfate, 
5 mM ethylenediaminetetraacetic, and 2 mg/mL protK using zirconium beads (1.4 mm; OPS 
Diagnostics, Lebanon, NJ) in a MagNA Lyser (Roche Diagnostics, Almere, the Netherlands) 
111
DYNAMICS OF 2OMEPS AON EFFECTS
according to manufacturer’s protocol. Plasma samples were diluted tenfold, muscle samples 
500 and 1 000 times and organs 1 000 and 5 000 in pooled control mdx tissue in phos-
phate-buffered saline. A signal probe (containing the peptide for antibody recognition) and 
a template (complementary to 23AON and the probe) were added to homogenized samples. 
Only when both 23AON and probe are bound to the template, a ligation step will take place. 
After this step and washing away of the unbound probe, enzyme-linked antibodies were used 
to detect the amount of probe-23AON. Calibration curves of the analysed 23AON prepared 
in 10% pooled plasma or in pooled control mouse mdx tissue in phosphate-buffered saline 
were used to quantify 23AON. All analyses were performed in duplicate.
RNA extraction and analysis of exon skipping by RT-PCR
Muscles were homogenized in TriPure isolation reagent (Roche Diagnostics) using zirco-
nium beads (1.4 mm; OPS Diagnostics) by grinding in a MagNA Lyser (Roche Diagnostics). 
Total RNA was extracted and 600 ng was used for reverse transcription–polymerase chain 
reaction analysis. Complementary DNA was generated by incubating at 42 °C for 45 min 
with random hexamer primers (20 ng/μL) and Transcriptor reverse transcriptase polymerase 
(Roche Diagnostics) in 20 μL. Subsequently, 2 μL of cDNA was amplifi ed in a 50 μL poly-
merase chain reaction reaction with 30 cycles of 94 °C for 30 sec, 60 °C for 30 sec, and 72 
°C for 30 sec, as previously described.663 PCR products were visualized on 1.5% agarose gels 
and quantifi ed using a DNA high sensitivity chip on the LabChip GX, in combination with 
the LabChip GX software (Caliper Life Sciences, Teralfene, Belgium).
Analysis of dystrophin protein expression by Western blot
Muscles were minced in treatment buffer containing 75 mM Tris-HCl pH 6.8-15% (w/v) 
sodium dodecyl sulphate using zirconium beads (1.4 mm; OPS Diagnostics) or MagNA Lyser 
green beads (Roche Diagnostics) in a BBY24M Bullet Blender Storm (Next Advance, Averill 
Park, NY). Protein concentrations were determined using a Pierce bicinchoninic acid protein 
assay kit (Thermo Fisher Scientifi c, Waltham, MA) according to manufacturer’s instructions. 
Samples containing 30 μg of protein were made in treatment buffer with 20% (v/v) glycerol, 
5% (v/v) β-Mercaptoethanol and 0.001% (w/v) Bromophenol blue and heated for 5 min at 95 
°C. Wild type control samples containing 10%, 3.3%, 1.1% and 0.4% of protein were used as 
reference. Samples were loaded on 1.0 mm thick native PAGE Tris-acetate (polyacrylamide) 
gels, with a linear resolving gel gradient of 3-8% (BioRad, Veenendaal, the Netherlands) and 
run on the Trans-Blot Turbo system for 1 h at 75 V (0.07 A) and 2½ hrs at 150 V (0.12 A) in 
an ice container. Proteins were blotted on a nitrocellulose membrane using the Ready to use 
Trans-Blot Turbo transfer packs in combination with the Trans-Blot Turbo transfer system 
(BioRad) at 2.5 A and ~25 V for 10 min. Membranes were blocked in 10 mM Tris-HCl (pH 8) 
and 0.15 M NaCl Tris-buffered saline (TBS)-5% non-fat dried milk (Elk, Campina Melkunie, 
Zaltbommel, the Netherlands), washed in TBS-0.05% (v/v) Tween20 (TBST). Membranes 
were incubated overnight with 1:125 NCL-Dys1 (Dy4; NovoCastra, Newcastle Upon Tyne, 
UK) and α-actinin as loading control (1:7 500; AB72592; Abcam, Cambridge, UK) in TBS. 
The next day, membranes were washed in TBST, incubated 1 h with the fl uorescent second-
ary antibodies IRDye 800CW goat-α-mouse IgG (1:5 000; Li-Cor; NE) and IRDye 680LT 
donkey-α-rabbit IgG (1:10 000; Li-Cor) in TBS, washed in TBST and TBS and analysed with 




For 23AON levels, individual data are represented for each measurement and exponential 
curves were fi tted for each tissue. For exon skipping and protein levels data are represented 
as mean ± SD for each tissue. PK plasma parameters (terminal half-lives of the molecule in 
plasma and tissue) were derived by non-compartmental analysis using Phoenix WinNonLin 
software (version 6.2; Pharsight Corporation, Mountain View, CA). For samples in which 
23AON was not detectable, values were set at 50% of limit of quantifi cation of mouse 
23AON in neat plasma (i.e. 50% of 0.011 μg/ml). For statistical testing, SPSS version 20.0 
(IBM Corporation, Armonk, NY) was used. A p value ≤0.05 was considered signifi cant.
Results
Dynamics of 23AON levels in plasma, muscle and organs
To investigate the dynamics of the effects induced by treatment with 2OMePS AONs, mice 
were treated subcutaneously with 100 mg 23AON/kg body weight twice weekly for eight 
weeks. Six mice per group were sacrifi ced at different time points after the last injection, 
ranging from 36 hours up to 24 weeks. To assess the uptake, turnover and clearance of the 
AON in plasma and different tissues, 23AON levels were determined with an AON specifi c 
hybridization-ligation assay, and average results were calculated (Fig. 4.1; Table 4.1). For 
all tissues, this revealed a decline in AON levels after the fi nal injection, and 23AON was 
still detectable in muscle, liver, and kidney after 24 weeks (on average around fi ve to ten 


































Fig. 4.1: 23AON levels in plasma, muscle and other organs over time
A hybridization-ligation assay was used to determine 23AON levels in plasma, muscle, and organs at different time 
points ranging from 36 hours up to 24 weeks after the fi nal injection. Data are represented on a logarithmic scale. 
Each dot represents an individual measurement and lines are fi tted through the averages for each tissue. AON, anti-
sense oligonucleotide.
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to 65 days in heart (Table 4.1). The half-life in heart was much longer than that in the other 
tissues. Although the terminal half-life in diaphragm was comparable to liver and kidney, it 
was slightly shorter in limb muscles (quadriceps and triceps) and comparable with that found 
in plasma. As observed previously,200 AON levels were higher in liver and kidney than in 
muscle. When comparing the different muscles with each other, 23AON levels were higher 
in diaphragm and heart than in limb muscles (p<0.05). No differences were observed in 
23AON levels when comparing liver and kidney. Oligonucleotide levels in plasma decreased 
rapidly after the fi nal dose and by 24 weeks, 23AON was barely detectable when levels in 
only two out of six mice reached the limit of detection.
Dynamics of exon skipping levels in muscle
The exon 23 skipping levels were determined in several limb muscles, diaphragm and heart 






anterior Diaphragm Heart Liver Kidney
0.2 0.462 ± 0.205 32.3 ± 9.1 33.0 ± 5.6 54.3 ± 11.4 49.1 ± 9.0 477.0 ± 49.7 655.7 ± 419.9
1 0.245 ± 0.183 33.9 ± 16.3 28.2 ± 4.6 51.1 ± 16.3 40.7 ± 10.5 456.1 ± 101.3 479.7 ± 437.9
3 0.236 ± 0.119 18.8 ± 6.1 18.3 ± 6.6 40.5 ± 12.5 40.6 ± 9.2 510.9 ± 119.6 289.6 ± 200.3
8 0.137 ± 0.092 8.9 ± 5.1 5.7 ± 1.7 18.1 ± 12.9 13.3 ± 1.6 270.1 ± 109.3 160.1 ± 155.0
12 0.052 ± 0.041 2.9 ± 1.2 2.0 ± 0.7 6.4 ± 2.5 10.2 ± 2.0 142.7 ± 29.1 70.3 ± 44.5




30 32 28 45 65 48 38
Table 4.1: Average AON levels at each time point per tissue and terminal half-life for each 
tissue
a23AON levels are expressed as μg/mL for plasma and μg/g tissue for muscle and other organs (mean ± SD).
Time (wks)
Exon skipping levelsa Protein levelsb
Quadriceps
Tibialis 
anterior Diaphragm Heart Quadriceps Diaphragm
0.2 11.3 ± 1.3 11.2 ± 2.6 11.3 ± 2.4 4.1 ± 0.5 0.61 ± 0.23 2.36 ± 0.49
1 9.7 ± 2.1 8.7 ± 1.9 11.7 ± 2.7 3.2 ± 0.7 0.95 ± 0.13 1.93 ± 0.52
3 6.9 ± 2.2 9.4 ± 1.6 10.6 ± 3.4 2.7 ± 0.5 1.31 ± 0.63 2.43 ± 0.85
8 5.7 ± 2.4 2.8 ± 1.0 8.6 ± 0.5 0.9 ± 0.7 0.91 ± 0.44 2.75 ± 1.21
12 3.1 ± 1.3 2.2 ± 1.7 3.7 ± 1.6 1.0 ± 0.3 0.56 ± 0.38 2.42 ± 0.99




53 33 49 39 103 137
Table 4.2: Average exon skipping and protein levels at each time point per muscle and 
terminal half-life for each muscle
ND, not detectable.
aExon 23 skipping levels are expressed as skipped transcript as percentage of total transcript (mean ± SD). bDystro-
phin protein levels are expressed as percentage of wild type levels in the same muscle (mean ± SD). 
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and one week after fi nal AON injection) and declined thereafter. Exon skipping levels were 
signifi cantly lower in heart compared to skeletal muscle (p<0.01). After 24 weeks skipping 
was undetectable in all samples. No large differences in rate of decline between individual 
muscles were observed, considering the interindividual variations within a tissue and the 
half-life varied between 33 and 53 days.
Dynamics of dystrophin protein expression
Restoration of dystrophin protein expression after AON treatment was detectable at each 
time point in quadriceps and diaphragm (Fig. 4.3; Table 4.2). No dystrophin was observed 
for untreated mdx mice (data not shown). In treated muscles dystrophin levels were initially 
low, peaked somewhere between three and eight weeks after the fi nal injection for both dia-
phragm and quadriceps, and then slowly declined. Levels in diaphragm were and remained 
signifi cantly (p<0.01) higher than those in quadriceps and also were slightly more stable, 
with half-lives of ~100 and 130 days, respectively. In heart no dystrophin protein levels 
>0.5% could be detected (data not shown).
Correlation among 23AON levels, exon skipping, and protein expression
For the majority of muscles analysed, a correlation among 23AON levels, exon skipping and 
protein expression was observed. The highest 23AON levels were observed in the diaphragm, 
resulting in highest exon skipping and dystrophin protein expression. Lower 23AON levels 

































Fig. 4.2: Exon skipping levels in different muscles over time
a) Representative example of an RT-PCR analysis for the quadriceps. Unskipped product consists of 334 base 
pairs and exon 23 skipping results in a 121 base pair product. PCR ctrls indicates PCR controls, M is marker. b) 
Quantifi cation of exon 23 skipping levels by RT-PCR analysis at several time points after the fi nal 23AON injection. 
Data are represented as mean ± SD. AON, antisense oligonucleotide.
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time points analysed, slightly lower than or comparable with exon skipping levels in dia-
phragm. Furthermore, the level of dystrophin protein expression in quadriceps was lower 
than the corresponding values observed in diaphragm. By contrast, this correlation was not 
observed in heart, wherein 23AON levels were relatively high (comparable with diaphragm), 
while exon skipping levels were signifi cantly lower than those in skeletal muscle; moreover 
dystrophin protein expression was very low.
When comparing patterns of the different parameters, both 23AON and exon skipping 
levels peaked shortly after treatment, within the fi rst week, and thereafter showed a similar 
decline pattern, whereas the profi le of dystrophin protein expression was shifted, peaking a 
few weeks after treatment and displaying a more prolonged effect (Fig. 4.4).
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Fig. 4.3: Dystrophin protein levels in muscle over time
a) Representative examples of Western blot analyses for the diaphragm showing low levels of dystrophin protein 
(top) at all analysed time points. As loading control, α-actinin (bottom) was used. b) Quantifi cation of dystrophin 




AON-mediated exon skipping is currently in advanced stages of clinical development as 
a potential therapy for DMD aiming to partly correct consequences of the genetic defect. 
However, due to clearance of AONs, skipped transcripts, and restored dystrophin protein, 
chronic treatment will be required. One way to try and prolong the effect is to deliver anti-
sense sequences using (viral) vectors in order to achieve a stabler expression of the AONs. 
Adeno-associated viruses (AAVs) expressing modifi ed small nuclear ribonucleoprotein 
(snRNP) particles, i.e. U1 and U7 small nuclear ribonucleoprotein particles, in which the 
small nuclear RNA is replaced by the desired AON sequence, have shown to induce long 
term dystrophin rescue in the mdx mouse.246 This approach has also been proved to result 
in long term cardiac expression of dystrophin in the GRMD dog,327 harbouring a deletion of 
exon 7, requiring exon 6 and 8 skipping to restore the reading frame.122 Drawbacks of using 
AAVs as vectors are toxicity concerns and the possibility of an immune response against the 
viral vector, resulting in the loss of transduced fi bres.300 A recent fi ve year follow-up study 
in GRMD dogs did not show immune rejection; however after fi ve years, disappearance of 
dystrophin protein expression was observed, probably due to instability of the newly formed 
protein.251 The same was observed in a study in mdx mice, wherein it was also shown that 
AAV vectors and transgene expression were lost quicker from dystrophic muscle than from 
healthy muscle.252 Therefore, repetition of treatment would still be required, which is not pos-
sible due to immunization against the AAV after the fi rst injection. This makes it unlikely this 
approach will be clinically applicable in the near future. Thus, the AON approach is more 
viable in the short term, which involves repeated injections, and knowledge about the PK 
and PD effects is, therefore, valuable. The detailed longitudinal analysis of different muscles, 
kidney and liver is ethically and practically challenging in humans but more straightforward 
in mice. In this study, the clearance/turnover of AON, transcript, and protein over time in 
mdx mice after treatment with 2OMePS AON, one of the two background chemistries mainly 
used in clinical trials, was studied.
First of all the decline in 23AON levels over time was studied in plasma, muscle, and other 
organs following subcutaneous injections. After injection, AON levels in plasma decline rap-
idly due to uptake by organs and clearance, which occurs primarily through the kidney. For 
2OMePS AONs this is partly modulated by the plasma protein binding properties of the 
phosphorothioate backbone of the AONs, but when high doses are injected exceeding the 
BA

































Fig. 4.4: Comparison of time effects at different levels
Comparison of time course of 23AON levels, exon skipping, and protein expression after the fi nal injection for 
(a) quadriceps and (b) diaphragm. Data are represented as percentages of levels observed at time point t=36 hours 
(set at 100%) for 23AON, exon skipping ,and protein levels separately. Error bars represent the standard deviation. 
AON, antisense oligonucleotide
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binding capacity, unbound AONs will be cleared rapidly.668,669 The fi rst time point analysed 
was 36 hours after the fi nal injection, the time point when previous studies indicated that the 
majority of the plasma clearance has already occurred.240 The mean half-life determined for 
23AONs in mice (30 days) was comparable with that observed for 51AON in patients (29 
days).229 When comparing different muscle types, higher 23AON levels in diaphragm and 
heart were observed, whrereas the longest terminal half-life was found in heart. This was 
probably due to reduced AON turnover because the turnover rate of cardiac muscle cells is 
much slower than that of skeletal muscle fi bres (especially dystrophic skeletal muscle fi bres). 
This is in line with previous observations of a longer half-life of AONs in heart compared 
with that in skeletal muscle. In the previous study, a markedly shorter half-life in triceps (~10 
days) was observed compared with that in quadriceps (~33 days), whereas in the current 
studies half-lives are comparable (~30 days). Furthermore, the currently calculated half-life 
in heart is longer (65 days versus 46 days).200 These discrepancies are probably due to the 
fact that in the previous study only four time points up to 14 days after the fi nal injection 
were measured, consisting of two mice per time point, making the estimations less accurate. 
Furthermore, in the previous study intravenous injections were used, which show higher lev-
els of AON uptake by the kidney and liver,200 which can also have contributed to the observed 
differences. As expected, AON levels in liver and kidney were much higher than those in 
muscle. It has been noticed before that for 2OMePS AONs levels are similar in liver and 
kidney161 and here is shown that the decline pattern is comparable too. Unfortunately, when 
comparing the terminal half-lives in the non-target organs (liver and kidney) to the targeted 
organ (muscle), half-lives were slightly shorter in limb muscles compared with those in liver 
and kidney. A longer muscle half-life would have been advantageous for planning off-treat-
ment periods, e.g. to prevent accumulation of compounds in liver and kidney. Nevertheless, 
the absolute reduction of AON levels in liver and kidney is greater than that in muscles. 
Second, exon skipping levels were determined in several skeletal muscles and the heart. 
Here, highest levels were also observed shortly after the fi nal injection (within the fi rst week), 
whereupon they declined in a similar pattern as the 23AON levels. For diaphragm, the higher 
23AON levels were also accompanied by high exon skipping levels whereas by contrast, 
this correlation was not observed in heart, wherein, although 23AON levels were relatively 
high (comparable to diaphragm), exon skipping levels were signifi cantly lower than those in 
skeletal muscle.
Third, dystrophin protein levels were determined. These showed a delayed pattern, peak-
ing a few weeks later, compared with AON and exon skipping levels. Importantly, although 
levels were low in general, dystrophin protein expression was observed up to 24 weeks. Wu 
et al. determined the half-life of the dystrophin protein in mdx mice after a single intrave-
nous injection with peptide-conjugated PMOs (pPMOs) targeting exon 23. This resulted in 
a protein half-life of ~2 months for skeletal muscles and levels had dropped to around 10% 
after fi ve months.206 The half-lives measured in our experiments were a bit longer (three to 
four months), resulting in a smaller decrease in dystrophin levels; 30-50% of initial levels 
were still observed after ~5 months (levels at 24 weeks compared with peak levels) in both 
muscles. A possible explanation is the difference in experimental set-up and backbone chem-
istry of the AONs between both studies. In the present study, 2OMePS AONs were used, 
whereas the study of Wu et al. used pPMOs. These two chemistries probably have a differ-
ent biodistribution pattern, as was also seen between 2OMePS AONs and naked PMOs.161 
Because AON PKs were not measured in the study of Wu et al., it is not known how much 
AON remained in the muscle to induce further exon skipping and dystrophin production, 
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resulting in differences over time. Furthermore Wu et al. only used a single AON injec-
tion, whereas mice were treated for a longer period in our study. A single injection is more 
likely to give variation in AON levels between mice, which infl uences the preciseness of 
the half-life estimations. Therefore, both results are not directly comparable. Unfortunately, 
dystrophin protein was barely detectable in heart. This was also seen in a study using PMO 
AONs wherein dystrophin expression could be detected in all analysed muscles, except for 
the heart, after seven weeks of treatment.202 Probably, overall higher skipping levels and/or 
longer treatment times are needed for protein restoration. This is underlined by the fact that 
after six months of weekly treatment with 200 mg/kg, dystrophin was readily detectable in 
heart.201
Overall there was a good correlation between AON effects at different levels. In dia-
phragm, the higher 23AON levels were accompanied by higher exon skipping levels and 
protein expression. Only in heart, the higher 23AON levels did not result in higher exon 
skipping and protein levels. This can be explained by inherent differences between car-
diac and skeletal muscle. As mentioned before, skeletal muscles become permeable in the 
absence of dystrophin, facilitating the uptake of AONs. The heart is built up of individual 
cardiomyocytes, which do not display this leakiness, thereby making it harder for AONs to 
get inside.200,203 The assay used for determination of 23AON levels does not discriminate 
between AON inside the heart as whole organ and AON that is actually inside the cardio-
myocytes. Therefore, the presence of higher 23AON levels, but lower exon skipping levels, 
suggest that in heart the majority of AON is probably located in the interstitium and there-
fore ineffective. This might also be the reason why, although low 23AON levels were still 
detectable after 24 weeks, no exon skipping could be observed at this time point. Other pos-
sibilities are that this is due to differences in sensitivity of the assay used for determination 
of AON levels versus those for determining exon skipping levels or that the low AON levels 
are insuffi cient to induce exon skipping. Expression percentages for dystrophin protein are 
much lower than those for exon skipping. This is usually seen for both 2OMePS201,240 and 
PMO/pPMO AONs,161,206,211,212 and this discrepancy can be explained by the fact that exon 
skipping levels are compared to the total transcript levels in the mdx mouse, whereas dystro-
phin protein levels are compared with wild type dystrophin levels. It has been reported that 
compared with wild type dystrophin transcripts, a 5’ to 3’ imbalance exists for mdx dystro-
phin transcripts. This means that not all mdx dystrophin transcripts are complete and cannot 
be translated into dystrophin protein.674
In conclusion, 23AON and exon skipping levels show a similar decline pattern over time 
after the fi nal injection. Exon skipping is not detectable anymore after six months, but its 
effects on dystrophin protein restoration remain quite stable. After treatment AONs are taken 
up by muscles and other organs, partly leading to immediate excretion without inducing 
further effects and partly leading to exon skipping inside the muscle fi bres. Thereafter, new 
dystrophin protein can be formed, which displays a long half-life. The differences in rates 
of turnover of the compound itself, RNA and protein infl uence these effects, in addition to 
differences in composition and amount of degeneration and regeneration between different 
muscle groups. Our results proved further insight in how these processes interact and are 
useful for studying the long term effects of AON treatment.
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The eff ect of 6-thioguanine on 
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mediated exon skipping treatment 
for Duchenne muscular dystrophy
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The severe muscle wasting disorder Duchenne muscular dystrophy (DMD) is caused by 
genetic defects in the DMD gene, leading to a complete absence of dystrophin protein. Of 
the therapeutic approaches addressing the underlying genetic defect, exon skipping through 
antisense oligonucleotides (AONs) is the closest to clinical application. Several strategies 
to improve the effi ciency of this approach are currently being investigated, such as the use 
of small chemical compounds that improve AON-mediated exon skipping levels. Recently, 
enhanced exon skipping in combination with a guanine analogue, 6-thioguanine (6TG) was 
reported for phosphorodiamidate morpholino oligomers (PMO). Here the effect of 6TG on 
the exon skipping effi cacy of 2’-O-methyl phosphorothioate RNA (2OMePS) and PMO 
AONs in vitro and in vivo was further evaluated, as well as the effect of 6TG by itself. Results 
confi rm an increase of exon skipping levels in vitro, however, in contrast to the previous 
report, no effect was observed in vivo. Importantly, 6TG treatment in vitro resulted in numer-
ous additional DMD exon skipping events. This, in combination with the known cytotoxic 
effects of 6TG after incorporation in DNA, warrants reconsidering of the use of 6TG as 
enhancer of AON effi ciency in DMD, were chronic treatment will be required.
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Introduction
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both 
muscle wasting disorders caused by mutations in the DMD gene. However, DMD is char-
acterized by a much more severe and progressive phenotype than BMD. In DMD, children 
generally become wheelchair-dependent around the age of ten, need assisted ventilation 
before their twenties, develop cardiac problems shortly thereafter and die before their thirties. 
By contrast, the BMD phenotype is much more variable with an average age of onset around 
12, wheelchair-dependency in their twenties and death in their forties for the most severely 
affected patients.5 However, less severely affected patients can remain asymptomatic into 
their fi fties and have nearly normal life expectancies.675 Furthermore, only around 50% of 
BMD patients develops dilated cardiomyopathy.5 The differences between both phenotypes 
are due to the different nature of the underlying genetic defects. The DMD gene, located on 
Xp21, encodes dystrophin, an important protein for muscle fi bres. Dystrophin forms a bridge 
between the actin cytoskeleton and the extracellular matrix, thereby giving mechanical sta-
bility to the fi bres during contraction.670 In DMD the reading frame is disrupted, leading to 
a premature stop of translation and thereby formation of a truncated, non-functional protein. 
Consequently, fi bres are easily damaged and die, which leads to a gradual loss of muscle 
tissue and replacement by fi brotic and adipose tissue. By contrast, in BMD mutations do 
not affect the reading frame, allowing protein translation to continue, resulting in internally 
deleted dystrophin proteins, which are partly functional. Therefore in BMD patients the dis-
ease progression is slower.49
This difference underlies the rationale of the exon skipping therapy. Hereto antisense oli-
gonucleotides (AONs) are used to hide a specifi c exon from the splicing machinery, inducing 
the skipping of this exon in order to restore the reading frame and allow the production of 
a shortened, Becker-like dystrophin protein. After demonstration of proof-of-principle and 
obtaining encouraging results in vitro in cultured patient-derived cells and in vivo in animal 
models, clinical trials are currently ongoing.673 For these trials two different backbone chem-
istries are used: 2’-O-methyl phosphorothioate RNA (2OMePS) and phosphorodiamidate 
morpholino oligomers (PMO).
There are several ways to further optimize the effi ciency of AON-mediated exon skipping. 
First, AON effi ciency can be improved following previously identifi ed guidelines that take 
into account target RNA accessibility, thermodynamic properties and the presence of known 
splicing motifs.676 Furthermore the effi ciency depends on the amount that reaches its target 
organ (muscle and heart) and organelle (cell nucleus), but also on the turnover of the com-
pound, skipped transcripts and internally deleted dystrophin proteins, and on the muscle cells. 
A second approach has been to improve AON effi cacy by conjugating PMOs to cell-pene-
trating peptides (pPMOs) or dendrimeric octaguanidine polymers (vivo-morpholinos).163,677 
These indeed lead to enhanced exon skipping and protein restoration, but also raise safety 
concerns.162 Determination of a relatively low LD50 of pPMOs indicates a high level of acute 
toxicity.206 A third strategy is to optimize administration or dosing regimens [Verhaart et al., 
manuscript submitted]. Another possibility is to enhance exon skipping levels using small 
chemical compounds. Chemical compounds that infl uence splicing have been reported, i.e. 
the cytokine kinetin to specifi cally correct the splice defect in familial dysautonomia and 
several compounds have been identifi ed to enhance exon 7 inclusion in spinal muscular atro-
phy.253,254 For DMD, TG003 has been reported to induce exon 31 skipping and dystrophin 
restoration in patient cells harbouring a point mutation in this exon.255 However this com-
pound is specifi c for this mutation, so its application is rather limited. In order to identify more 
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general exon skipping enhancing compounds, large drug screening systems have been used. 
Ideally these compounds should enhance AON-induced exon skipping rather than inducing 
skipping by themselves, as the latter involves the risk of aspecifi c exon skipping events. For 
DMD, Hu et al. identifi ed a guanine analogue, 6-thioguanine (6TG) that enhances PMO-
induced exon 23 skipping in vitro in cultured mdx cells, which carry a nonsense mutation in 
exon 23, thereby causing the absence of dystrophin protein.79 Increased exon skipping levels 
were also observed after local intramuscular injection of AONs and 6TG in mdx mice.256
6TG is widely known as an antileukemic agent due to its cytotoxic effects after incorpora-
tion in the DNA during replication.678 The mechanism by which 6TG enhances PMO-induced 
exon skipping on pre-mRNA level is not known. Hu et al. suggested that alternative splicing 
could be enhanced after alteration of the structure of the DMD gene by incorporation of 6TG. 
Alternatively, 6TG, a small nucleobase, might interact with the bases of the PMO, thereby 
improving delivery effi ciency to the nucleus and binding to the targeted sequence.256
To investigate whether the effect of 6TG on exon skipping also applies to other exons 
and AON chemistries, here the effects of 6TG treatment alone or in combination with AONs 
targeting several human exons in vitro and mouse exon 23 in vitro and in vivo were exam-
ined. In vitro 6TG indeed enhanced exon skipping levels for all targeted exons, but only at 
low AON concentrations or with suboptimal AON sequences. However, we were not able to 
detect the previously reported, enhanced exon skipping levels for 2OMePS or PMO AONs. 




An immortalized control human myoblast cell line 7304.1,679 a mouse myoblast cell line 
C2C12 and primary DMD patient-derived myoblasts cultures with a deletion in exon 51-55 
(DL589.2)177 were used in this study. Cells were cultured on a collagen layer (1:30; Pure 
Col; Nutacon BV; The Netherlands). DL589.2 cells were cultured in Nutrient Mix F-10 
(HAM) supplemented with GlutaMAX, 20% fetal bovine serum (FBS) and 1% Penicillin-
Streptomycin (P/S) (Gibco-BRL; the Netherlands). For 7304.1 cells this medium was mixed 
1:1 with Skeletal Muscle Cell Basal Medium supplemented with 10% FBS, 1.4% GlutaMAX, 
1% P/S, 5 μg hEGF, 0.5 μg hFGF, 25 mg Fetuin, 5 mg Insulin and 200 μg Dexamethasone 
(PromoCell GMbH; Germany). C2C12 cells were cultured in Dulbecco’s Modifi ed Eagle 
Medium (DMEM, without phenol red) supplemented with 10% FBS, 1% P/S, 2% GlutaMAX 
and 1% D-glucose (Gibco-BRL). Human cells were grown at 37°C, 5% CO2 and mouse 
cells at 37°C, 10% CO2. To induce differentiation into myotubes, medium was changed into 
DMEM supplemented with 2% FBS, 1% P/S, 2% GlutaMAX and 1% D-glucose (Gibco-
BRL) for C2C12 and patient-derived cells and into DMEM supplemented with 3% horse 
serum (Gibco-BRL), 1% P/S and 2% GlutaMAX for 7304.1 cells when cells were 80-90% 
confl uent. Cells were differentiated in 3 mL differentiation medium per well of a 6-wells 
plate for 5 to 10 days depending on the cell type.
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6TG treatment and AON transfection
6-Thioguanine (6TG; Cas number 154-42-7; Sigma-Aldrich; the Netherlands) was added 
48 hours before AON transfection and maintained during and after transfection at indi-
cated concentrations (30-90 μM). For 2OMePS AONs (Eurogentec; Belgium and Prosensa 
Therapeutics; the Netherlands) cells were transfected in 1 mL differentiation medium 
for 4 hours with indicated concentrations using polyethylenimine (PEI, Exgen 500; MBI 
Fermentas; Germany), according to the manufacturer’s instructions, using 2 μL of PEI per 
μg of AON for human cells and 3.5 μL of PEI per μg of AON for mouse cells. Cells were 
harvested >24 hours after transfection. For PMO AON (Gene Tools; OR, USA) experiments, 
PMOE23(+07-18) was added 72 hours before RNA analysis with or without 6TG at indi-
cated concentrations according to manufacturer’s instructions. An overview of used AONs, 
their backbone chemistries and sequences is given in table 5.1.
AON name Target species Chemistrya Sequence (5’-3’)
h45AON5 human 2OMePS gcccaaugccauccugg 
h50AON1 human 2OMePS cucagagcucagaucuu
h50AON2 human 2OMePS ggcugcuuugcccuc
h53AON1 human 2OMePS cuguugccuccgguucug
h55AON1 human 2OMePS cuguugcaguaaucuaugag
M23D mouse 2OMePS uccauucggcuccaaaccgg
PMOE23 mouse PMO ggccaaaccttcggcttacctgaaat
Table 5.1: Overview of AONs and their sequence used in this study
a2OMePS=2’-O-methyl phosphorothioate RNA; PMO=phosphorodiamidate morpholino oligomers
In vivo 23AON and 6TG treatment
All experiments were approved by and performed following the guidelines of the Dier 
Experimenten Commissie (Animal Experimental Commission) of the Leiden University 
Medical Centert (permit number: 08224). Effort was put in minimizing the amount of dis-
tress caused to the animals as much as possible. Mice were housed in individually ventilated 
cages in the animal facility of the LUMC and received food and drink ad libitum. Mdx mice 
(C57Bl/10ScSn-DMDmdx/J) were obtained from our own breeding facility.
For the fi rst experiment 5 weeks old mdx mice were anesthetized with isofl urane. Mice 
were intramuscularly injected in both gastrocnemius muscles on 2 consecutive days with 
0, 1, 10 or 50 μg 6TG with or without 20 μg (≡2.9 nmol) M23D(+2–18) 2OMePS AONs 
specifi cally targeting exon 23197 (Prosensa Therapeutics) in 40 μL saline (n=2 per condition; 
6TG dosing was kept constant within one mouse). Mice were sacrifi ced 10 days after the last 
injection by cervical dislocation and muscles were isolated.
For the second experiment 7 or 8 weeks old mdx mice were anesthetized with isofl urane 
and intramuscularly injected in both gastrocnemius muscles on 2 consecutive days with 20 
μg (≡2.9 nmol) M23D(+2–18) 2OMePS AON, or 5 μg (≡0.60 nmol) M23D(+07-18) PMO 
AON with or without 25 μg 6TG or 25 μg 6TG only (n=4 per condition; 6TG dosing was kept 
constant within one mouse). Mice were sacrifi ced 10 days after the last injection by cervical 
dislocation and muscles were isolated.
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RNA extraction and analysis of exon skipping by RT-PCR
Harvested cells were lysed with TriPure isolation reagent (Roche Diagnostics; Switzerland). 
Total RNA was extracted and 400 ng of RNA was used for RT-PCR analysis, using Transcriptor 
reverse transcriptase polymerase (Roche) in 20 μL at 55°C for 30 min with an appropriate 
primer (primer sequences on request). cDNA was amplifi ed by nested PCR. Three microlit-
ers of cDNA were amplifi ed in a 25 μL reaction for 20 cycles of 94°C (40 sec), 60°C (40 sec) 
and 72°C (80 sec), followed by 32 cycles of 94°C (40 sec), 60°C (40 sec) and 72°C (60 sec), 
with 1.5 μL of PCR product in a 50 μL reaction.
Muscles were homogenized in TriPure isolation reagent, using zirconium beads (1.4 mm; 
OPS Diagnostics; NJ, USA) by grinding in a MagNA Lyser (Roche) according to manufac-
turer’s instructions. Total RNA was extracted and 1 μg of RNA was used for RT-PCR analysis, 
using Transcriptor reverse transcriptase polymerase in 20 μL at 42°C for 45 min with random 
hexamer primers (20 ng/μL). Then, 1.5 μL of cDNA was amplifi ed in a 50 μL reaction for 
30 cycles of 94°C (30 sec), 60°C (30 sec) and 72°C (30 sec), as previously described.663 All 
PCR products were visualized on 1.5 or 2% agarose gels and exon skipping levels were quan-
tifi ed using a DNA 1000 LabChip on the Agilent 2100 bioanalyzer (Agilent Technologies; 
CA, USA) according to the manufacturer’s protocol.
Sequence analysis
RT-PCR products were isolated from agarose gels using the QIAquick Gel Extraction kit 
(Qiagen; the Netherlands) according to manufacturer’s instructions. Direct DNA sequencing 
was performed by the Leiden Genome Technology Center (Leiden, the Netherlands) using 
the BigDye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems) and 
analysed on a 3730xl DNA Analyzer (PE Applied Biosystems).
Protein extraction and Western blot analysis
Muscles were minced in treatment buffer containing 75 mM Tris-HCl pH 6.8-15% (w/v) 
sodium dodecyl sulphate (SDS) using zirconium beads (1.4 mm; OPS Diagnostics) by grind-
ing in a MagNA Lyser. Protein concentrations were determined using a Pierce bicinchoninic 
acid (BCA) protein assay kit (Thermo Fisher Scientifi c; MA, USA) according to manufac-
turer’s instructions. Samples containing 30 μg of protein were made in treatment buffer with 
20% (v/v) glycerol, 5% (w/v) β-Mercaptoethanol and 0.001% (w/v) Bromophenol blue and 
heated for 5 min at 95°C. As reference, wild type (C57Bl/10ScSnJ) control samples con-
taining 33%, 11%, 3.7%, 1.2% and 0.4% of protein were used. Samples were loaded on 
1.0 mm thick native PAGE Tris-acetate (polyacrylamide) gels, with a linear resolving gel 
gradient of 3-8% (Bio-Rad; the Netherlands) and run on the Trans-Blot Turbo system for 
1 h at 75 V (~0.07 A) and 2 hrs at 150 V (~0.12 A) in XT Tricine running buffer (Bio-Rad) 
in an ice container [Hulsker et al., manuscript in preparation]. Ready to use Trans-Blot 
Turbo transfer packs in combination with the Trans-Blot Turbo transfer system (BioRad) at 
2.5 A and ~25 V for 10 minutes were used to blot the proteins on a nitrocellulose membrane, 
which were blocked in 10 mM Tris-HCl (pH 8) and 0.15 M NaCl (TBS)-5% non-fat dried 
milk (Elk, Campina Melkunie; the Netherlands) and washed in TBS-0.05% (v/v) Tween20 
(TBST). Membranes were incubated overnight with primary antibodies 1:125 NCL-Dys1 
(1:125; Dy4; NovoCastra,; UK) and α-actinin (loading control; 1:5 000; AB72592; Abcam; 
UK) in TBS. Membranes were washed in TBST, incubated 1 h with the fl uorescent secondary 
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antibodies IRDye 800CW goatαmouse IgG (1:5 000; Li-Cor; NE, USA) and IRDye 680LT 
donkeyαrabbit IgG (1:10 000; Li-Cor) in TBS, washed in TBST and TBS and analysed with 
the Odyssey system and software (Li-Cor).
Results
6TG induces exon skipping by itself and enhances exon skipping by 2OMePS 
AONs in human muscle cells in vitro
The effect of 6TG on exon skipping by 2OMePS AONs was fi rst tested in vitro in cultured 
human muscle cells derived from a healthy control. Without 6TG exon 50 skipping was 
observed in decreasing levels till 50 nM of h50AON1. When 6TG was added, exon skipping 
was also observed for lower levels (25 and 5 nM) of h50AON1 and without AON. 6TG 
enhanced exon skipping levels for 50 nM of AON, but not for higher AON concentrations 
(100 and 200 nM) (fi g. 5.1a). For a less effi cient AON (h50AON2) again low exon skip-
ping levels in combination with 6TG were observed for 0-25 nM of AON. However, for 
higher AON concentrations (50-200 nM) a clear enhancement was observed in combination 
with 6TG compared to h50AON2 only (fi g. 5.1b). The same effect was seen for the AONs 
h45AON5, h53AON1 and h55AON, where low levels of exon skipping were detected with-
out or with doses ≤25nM of AONs and an improvement in skipping levels was seen for 
50-200 nM (data not shown).
Thereafter, the effect on DMD patient cells with a deletion of exon 51-55 was investi-
gated. For this deletion, the reading frame can be restored by exon 50 skipping. As has been 
reported previously, there is some very low level of exon 50 skipping detectable in untreated 
cells.177 Treatment with increasing concentrations of h50AON1 (fi g. 5.1c) or h50AON2 (data 
not shown) resulted in a dose-dependent increase of exon 50 skipping. Exon skipping levels 
were further increased by co-treatment with 6TG. However, 6TG treatment by itself also 
resulted in similar levels of exon skipping (fi g. 5.1c, most right black bar).
Because exon skipping was observed after 6TG addition in the absence of AONs, other 
regions of the dystrophin transcript were investigated to assess exon skipping events. The 
exon 70-75 region is known to be subjected to alternative splicing events in a tissue and dif-
ferentiation-specifi c manner. In untreated human control cells exon 71 and 71 to 74 skipping 
was observed (fi g. 5.1d/e, left lane/bars). However, after 6TG treatment the alternative exon 
skipping events were greatly enhanced and exon 71, 74, a combination of 71 and 74, and 
71-74 skipping were observed (confi rmed by sequence analysis (fi g. 5.1d/e)). Furthermore, 
exon 45, 46, 53 and 55 skipping was observed in the exon 44-55 region (data not shown), 
suggesting that splicing is disrupted throughout the transcript rather than that 6TG specifi -
cally enhances AON-mediated exon skipping.
6TG enhances mouse exon 23 skipping in cultured mouse cells in vitro, but 
not in mdx mice in vivo
The effect of 6TG was then tested in vivo by intramuscular injections of 2OMePS mouse 
exon 23AONs in the gastrocnemius muscles of mdx mice on two consecutive days. Mice 
were sacrifi ced ten days after the last injection and the injected muscles were isolated and 
analysed. Exon 23 skipping was only observed after treatment with 23AON and no enhance-
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ment was seen after co treatment with 6TG in any tested concentration (fi g. 5.2a).
Since Hu et al. reported increased exon 23 skipping levels after combinational treat-
ment with a PMO against exon 23 and 6TG compared to PMO alone,256 the experiment was 
repeated with murine exon 23AONs of the 2OMePS and the PMO backbone. First the effect 
of 6TG was explored in vitro in mouse C2C12 cells for both chemistries. Here, only a mod-
erate increase of exon 23 skipping was observed after treatment with low concentrations of 
either AON. The increase was less obvious at higher AON concentrations (fi g. 5.2b). Note 
that exon skipping levels induced by 2OMePS and PMO AON cannot directly be compared, 
since for 2OMePS AONs PEI is needed as a transfection reagent (leading to very effi cient 
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Fig. 5.1: Effect of 6TG on muscle cells in vitro.
a) In healthy control muscle cells, 6TG only enhanced exon skipping with 2OMePS AON at lower concentrations of 
AON (a) or with a less effi cient AON (b). c) In DMD patient cells harbouring a deletion 51-55, skipping of exon 50 
was observed after treatment with AONs against this exon. This was greatly enhanced by 6TG treatment. 6TG alone 
also induced high skipping of this exon (right bar). d/e) Example of greatly enhanced alternative exon skipping in 
control cells by 6TG around exon 70-75. In non-treated cells next to the wild type product (468 bp) only skipping 
of exon 71 (429 bp) and 71-74 (138 bp) was seen, whereas in 6TG-treated cells also skipping of 74 (309 bp) and 
combined skipping of exon 71+74 (270 bp) was observed.
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transfection), while PMOs were added to the medium. Hu et al. did not observe exon skip-
ping after treatment with 60 or 90 μM 6TG by itself. However, our results showed some exon 
skipping with 60 μM 6TG in the absence of AON treatment (fi g. 5.2b, left white bar).
Thereafter the in vivo experiment with local treatment was repeated now using both PMO 
and 2OMePS AONs. As has been observed previously, PMOs induced more effi cient exon 
23 skipping than 2OMePS AONs.161 Again, no increase of exon skipping levels by 6TG was 
seen for 2OMePS AONs (fi g. 5.2c). Furthermore, in contrast to the results obtained by Hu 
et al., exon skipping levels by PMO AONs were also not increased (fi g. 5.2c). No induction 
of exon 23 skipping was observed after treatment with 6TG alone. Finally, the effect of 
6TG on dystrophin protein expression was investigated (fi g. 5.2d/e). Untreated mdx mice or 
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Fig. 5.2: Effect of 6TG on exon 23 skipping and dystrophin protein expression.
a) In vivo in mdx mice no enhancement by 6TG of exon skipping by 2OMePS AON targeting exon 23 was observed. 
No skipping of exon 23 was observed after injection with 6TG alone. b) In vitro in a mouse control cell line, 6TG 
enhanced exon skipping by both 2OMePS and PMO AONs only moderately at low AON concentrations. Without 
AON treatment no exon 23 skipping was observed. However 6TG alone induced a small percentage of exon 23 skip-
ping by itself (left white bar). c) After local injection in vivo, no enhancement of exon skipping by 2OMePS or PMO 
AON against exon 23 was observed. No skipping of exon 23 was observed after injection with 6TG alone. d/e) No 
effect of 6TG on dystrophin protein expression was observed by itself or after combinational treatment with AON.
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mice treated with 6TG alone did not have any dystrophin expression. Treatment with PMO 
and 2OMePS AONs induced dystrophin expression, but combinational treatment with 6TG 
did not increase the dystrophin levels. In accordance with the higher exon skipping levels, 
dystrophin levels were higher after PMO than 2OMePS treatment. However, the differences 
between individual mice were larger as well after PMO treatment.
In summary, 6TG by itself induced numerous exon skipping events in vitro at low concen-
trations and only showed enhancement of exon skipping levels at low AON concentrations 
and/or of suboptimal AONs. In vivo no effect of 6TG on exon skipping levels was observed.
Discussion
At present only palliative therapies are available for DMD. Exon skipping induced by AONs 
is the most promising therapeutic strategy that targets the underlying genetic effect and is 
currently tested in phase III clinical trials.673 Since higher exon skipping levels will probably 
lead to enhanced therapeutic effects, several ways to improve effi ciency are under investi-
gation. One of the strategies is to combine AON treatment with chemical compounds. 6TG 
was identifi ed as a compound that could enhance PMO mouse exon 23 skipping in vitro and 
locally in vivo.256 To further explore whether the effects of 6TG on exon skipping also apply 
to other exons and AON chemistries, here additional experiments were performed.
In vitro results showed that 6TG indeed had the potential to enhance exon skipping for 
2OMePS AONs as well, but only when combined with suboptimal AONs or at suboptimal 
concentrations. Furthermore, various additional exon skipping events were observed after 
treatment with 6TG alone in different regions of the dystrophin transcript. By contrast, in 
vivo after local, intramuscular injections no enhancement of AON-induced exon skipping 
levels or exon skipping events by 6TG alone were observed. This in contrast to previous 
published results where increased exon skipping was observed after intramuscular PMO 
and 6TG injections and no exon skipping events were detected after 6TG treatment alone.256 
Our fi rst explanation for this discrepancy was that the enhancing effect of 6TG might be 
dependent on the backbone chemistry of the AON, which infl uences the biophysical, bio-
chemical and biological properties (for more information see Chan et al. Clin Exp Pharmacol 
Physiol 2006150 and Amantana et al. Curr Opin Pharmacol 2005680), but this was ruled out by 
repeating the experiment with AONs of both chemistries. We could still not reproduce the 
reported effects for PMOs, despite the fact that the conditions for the experiments were very 
similar: identical PMOs were used, the same route of administration was used, mdx mice 
were of comparable age (6-8 wks old) and time of analysis after injection (2 weeks/10 days) 
was almost identical. The only difference was the specifi c muscle that was injected (tibialis 
anterior versus gastrocnemius), but we feel it is unlikely this causes the observed discrepancy, 
since a correction factor (2.5 times) was used to account for the difference in size of the mus-
cle. Absolute exon skipping percentages cannot be compared between both studies, since no 
values are reported in the published study and skipping percentages are known to vary with 
different methods of quantifi cation.663
The exon skipping events we observed after 6TG treatment throughout the dystro-
phin transcript, suggest splicing may have been disrupted for other genes as well. As such, 
unintended effects of 6TG treatment cannot be ruled out. Furthermore, 6TG is known 
for its antileukemic effects due to cytotoxicity via several mechanisms after being incor-
porated in the DNA during replication. This causes miscoding, leading to recognition by 
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the post-replicative mismatch repair system, which cuts at the miscoded base pair.681,682 
Furthermore, the 6TG modifi ed-DNA duplex modifi es the structure very locally, which alters 
specifi c DNA-processing enzyme activities and recognition by proteins.683,684 In addition, the 
presence of 6TG blocks the formation of quadruplex DNA by telomeres and other DNAs, 
which causes blockage of replication and thereby cytotoxicity after one round of replica-
tion.685 All these effects explain the delayed onset of cytotoxicity by 6TG. These mutagenic 
effects mainly affects rapidly proliferating cells like leukemic cells,686 but will also affect 
other dividing cells. Since 6TG in leukaemia is always used in treatment regimens combin-
ing several chemotherapeutic agents, it is diffi cult to interpret the contribution of 6TG itself 
to the toxicity observed after chemotherapy in most studies.687,688 Long term treatment with 
6TG alone in humans or animals has not been reported. However, there are reports about 
6-mercaptopurine (6MP, a guanine analogue related to 6TG). Although there is no evidence 
for secondary malignancies after chronic maintenance chemotherapy with 6MP,689 repeated 
treatment of mice with a low dose of 6MP resulted in lethal mutations.690 Therefore, it is not 
unlikely 6TG by itself could have similar side effects. This combined with our own obser-
vations of disturbed splicing, makes us doubt whether 6TG would be a good candidate to 
improve the therapeutic effi ciency of AON therapy.
However there are other candidates to improve exon skipping levels with more specifi c 
effects, like the aforementioned TG003 for exon 31 skipping.255 Hopefully further research 
will identify a compound that can improve AON-mediated exon skipping more specifi cally.
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In Duchenne muscular dystrophy (DMD), dystrophin defi ciency leading to progressive 
muscular degeneration is caused by frame-shifting mutations in the DMD gene. Antisense 
oligonucleotides (AONs) aim to restore the reading frame by skipping of a specifi c exon(s), 
thereby allowing the production of a shorter, but semifunctional protein, as is found in the 
mostly more mildly affected Becker muscular dystrophy (BMD) patients. AONs are cur-
rently investigated in phase III placebo-controlled clinical trials. Most of the participating 
patients are treated symptomatically with corticosteroids (mainly predniso(lo)ne) to stabilize 
the muscle fi bres, which might affect the uptake and/or effi ciency of AONs. Therefore the 
effect of prednisolone on 2’-O-methyl phosphorothioate AON effi cacy in patient-derived 
cultured muscle cells and the mdx mouse model (after local and systemic AON treatment) 
was assessed in this study. Both in vitro and in vivo skip effi ciency and biomarker expression 
were comparable between saline- and prednisolone-cotreated cells and mice. After systemic 
23AON treatment for eight weeks, dystrophin was detectable in all treated mice. Western 
blot analyses indicated slightly higher dystrophin levels in prednisolone-treated mice, which 
might be explained by a better muscle condition and consequently more target dystrophin 
pre-mRNA. In addition, fi brotic and regeneration biomarkers were normalized to some 
extent in prednisolone- and/or 23AON-treated mice. Overall these results show that the use 
of prednisone forms no barrier to participation in clinical trials with AONs.
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Introduction
Duchenne muscular dystrophy (DMD) is a severe, muscle-wasting disease, affecting around 
1 in 3 500 newborn boys. First symptoms generally become visible before the age of fi ve 
years, followed by wheelchair dependency around the age of ten. Most patients die at about 
30 years of age, predominantly due to heart and respiratory failure.5
DMD is caused by mutations in the DMD gene, located on the short arm of the X chro-
mosome (Xp21), leading to the complete loss of the dystrophin protein it encodes.39,691 
Dystrophin stabilizes muscle fi bres by connecting intracellular actin to the extracellular 
matrix,692 through a long repeat domain that intersperses the two essential binding domains. 
In the absence of dystrophin, muscle fi bres will be continuously damaged during contrac-
tion, which leads to an infl ux of infl ammatory cells and secretion of cytokines, in particular 
tumour necrosis factor (TNF)-α.358,426,427 TNF-α activates the IκB kinase (IKK)/NF-κB sig-
nalling pathway in macrophages, which in turn increases necrosis and infl ammation and 
reduces regeneration in muscle fi bres.428,429 Fibrotic tissue is formed by fi broblasts and even 
by satellite cells, which, once fi brotic tissue has been formed, start to produce collagen type I 
and no longer take part in regeneration.693 Fibroblasts from dystrophin-negative mdx mice, a 
naturally occurring mouse model for DMD,79 remain activated even when activating factors 
from immune cells have dissipated.694 These processes further increase fi brosis which gradu-
ally replaces the damaged muscle fi bres. Especially fi brosis in the endomysium is negatively 
correlated with functional performance in patients.695 Last, muscle regeneration is reduced 
through induction of the transforming growth factor (TGF)-β pathway by the fi brotic tis-
sue.696
At present there is no cure for DMD. However, there are pharmacological approaches that 
try to combat the symptoms caused by the underlying genetic defect. The main treatment is 
the use of the corticosteroids prednisone, prednisolone (the active form of prednisone), or 
defl azacort (an oxazoladine derivative of prednisone).368 Their exact mechanism of action is 
unknown, but studies have shown that corticosteroid-treated patients have increased muscle 
strength and remain ambulant for about three years longer than untreated patients.10,13 In mdx 
mice a positive effect of prednisolone on muscle strength and histology (decrease of centrally 
located nuclei) was seen.371 This benefi cial effect is probably through the anti-infl ammatory 
effects and the reduction of muscle necrosis.10,369 In a dystrophin-defi cient Caenorhabditis 
elegans, the amount of degenerating cells is decreased after treatment with prednisone.369 
Because C. elegans only has a very simple immune system, this indicates other mechanisms 
are involved as well. One study suggests that defl azacort activates the calcineurin/NF-AT 
(nuclear factor of activated T cell) pathway and thereby increases the expression of NF-AT 
target genes, among which the dystrophin homologue utrophin, which can partly take over 
the function of dystrophin, thereby decreasing the dystrophic muscle fi bre pathology.374 An 
alternative possibility is that the anabolic effect of corticosteroids in patients increases mus-
cle regeneration and growth by enhancing proliferation of myogenic precursor stem cells 
or myoblasts.10 Furthermore, corticosteroids have a positive effect on calcium homeosta-
sis, which is deregulated in patients with DMD.368 Unfortunately, corticosteroids also have 
deleterious side effects375 such as osteoporosis,377 weight gain, growth inhibition,13 delayed 
puberty, and cataracts.376 They have a catabolic effect on muscle in unaffected individuals,378 
but in DMD this is generally abrogated by the positive effects. In mdx mice it has even been 
shown that prednisolone induced fi brosis in the heart,381 but this is not observed in patients 
with DMD, in whom corticosteroid use prevents/delays ventricular dysfunction.382,383
Approaches aiming to restore the underlying genetic defect of DMD are currently under 
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investigation. At the moment, the most promising strategy is exon skipping, using antisense 
oligonucleotides (AONs) to restore the disrupted reading frame. These AONs target a specifi c 
region in the pre-mRNA involved in appropriate exon inclusion. In this way they prevent the 
exon to be recognized by the spliceosome and, consequently, it will not be incorporated in 
the mRNA.164 The resulting in-frame mRNA transcript allows translation of a protein that is 
internally deleted, but contains the essential actin and extracellular matrix binding domains, 
and therefore it will be partially to largely functional.697 These dystrophins will resemble 
the internally deleted proteins found in patients with Becker muscular dystrophy (BMD), 
who have a much milder phenotype and longer life expectancy.42,43 Proof of principle has 
been obtained in vitro with both healthy and patient-derived cultured primary human myo-
blasts176,177,188 and in in vivo studies in mdx mice.161,205,207,209 Exon skipping can be performed 
using AONs with various backbone chemistries.161 For in vivo studies, mainly 2’-O-methyl 
phosphorothioate (2OMePS) and morpholino phosphorodiamidate (PMO) AONs are used. 
These have also been used in two exploratory clinical trials with local injections which have 
shown positive results.225,226 A phase I-IIa systemic clinical trial with 2OMePS AONs has 
been completed and a dose-dependent effect was seen after subcutaneous injections with 
AONs against exon 51. Treatment resulted in exon skipping and dystrophin expression up to 
~15% of normal expression levels. In an open label extension study, three months of weekly 
injections with the highest dose resulted in an increase in functional performance, with-
out serious adverse events.229 The fi rst systemic clinical trial with PMOs showed promising 
results as well: seven out of 19 patients, mainly in the higher dose groups, showed dystrophin 
restoration after treatment, albeit with a lot of variability between patients.231
Larger multicenter placebo-controlled trials with 2OMePS AONs have now been initi-
ated. The majority of the patients involved in these trials will use corticosteroids, primarily 
predniso(lo)ne. Thus far the effect of corticosteroid treatment on AON biodistribution and 
skipping effi ciency has not been studied. Corticosteroids are thought to stabilize the dam-
aged muscle fi bre membrane, whereas the exon skipping approach actually makes use of the 
fact that in patients with DMD the membrane is leaky, allowing higher uptake of AONs.200 
Thus, corticosteroid treatment could result in decreased uptake of AONs and lower levels 
of exon skipping and dystrophin restoration. On the other hand, the exon skipping approach 
requires a suffi cient amount of pre-mRNA to be effective, which is expressed only by muscle 
tissue and not by fi brotic tissue. Therefore, more dystrophin pre-mRNA might be available 
when the muscle is better preserved due to corticosteroid treatment. To elucidate this, the 
effect of co-treatment with 2OMePS AONs and prednisolone on patient-derived muscle cell 
cultures and in dystrophic mdx mice was assessed.
The results suggest that prednisolone treatment does not interfere with 2OMePS AON 
uptake and exon skipping levels in patient-derived muscle cells in vitro and mdx mice in vivo. 
Prednisolone might even enhance the dystrophin expression induced by exon 23-specifi c 
AONs (23AONs) in mdx mice.
Materials and methods
Cell cultures and AON transfection
Two patient cell cultures, DL589.2 (deletion exon 51-55) and 53914.1 (deletion exon 
52) (previously described177,188) were grown to 80% confl uency on high-serum medium. 
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Differentiation was induced by switching to low-serum medium. Prednisolone in saline 
(Leiden University Medical Center (LUMC) pharmacy, Leiden, The Netherlands) was added 
in doses ranging from 0.2 to 2.25 μg/mL to determine optimal concentration. For AON 
transfection experiments prednisolone was added at 0.75 μg/ml to the medium. When dif-
ferentiation was deemed suffi cient (generally after approximately ten days), h50AON1 and 
PRO051176 were transfected in the respective patient cell cultures and the control cells using 
polyethylenimine (PEI, Exgen 500; MBI Fermentas, Sank Leon-Rot, Germany), according 
to the manufacturer’s instructions and using 2.5 μL PEI per μg AON (n=12 per condition per 
cell line). All AONs were 2’-O-methyl RNA oligonucleotides with a full-length phospho-
rothioate backbone (Eurogentec, Seraing, Belgium and Prosensa Therapeutics, Leiden, The 
Netherlands). Cells were harvested two days after transfection.
In vivo 23AON and prednisolone treatment
All experiments were approved by the local animal ethical experimental committees. Mice 
were housed in individually ventilated cages in the animal facility of the LUMC (Leiden, The 
Netherlands) or Laboratory of Pharmacology and Toxicology (LPT; Hamburg, Germany) 
and received food and drink ad libitum. Intramuscular experiments were performed at the 
LUMC and mdx mice (C57Bl/10ScSn-DMDmdx/J) with one or two copies of the utrophin 
gene (mdx/Utrn+/- or mdx/Utrn+/+) were obtained from our own breading facilities. The sys-
temic experiments were performed at the LPT and mdx mice from Charles River Laboratories 
(Sulzfeld, Germany) were used.
For the intramuscular 23AON treatment, mice were subcutaneously698 injected with pred-
nisolone (1 mg/kg; LUMC pharmacy) (n=4) or saline (n=4) on weekdays from the age of 
four weeks until the end of the experiment. At the age of eight weeks, the mice were anaes-
thetized with isofl urane and intramuscularly injected via both gastrocnemius muscles on two 
consecutive days with 2.9 nmol (~20 μg) M23D(+2-18), 2’-O-methyl phosphorothioate RNA 
oligonucleotides with a full-length phosphorothioate backbone, specifi cally targeting exon 
23197 (produced by Prosensa Therapeutics) in 40 μL saline. Ten days after the second injec-
tion the mice were sacrifi ced by cervical dislocation and muscles were isolated.
For the systemic 23AON treatment male mdx mice (n=8-10 per group) at the age of fi ve 
weeks (day 1) were anaesthetized with ether and underwent surgery to implant a predniso-
lone pellet (1 mg/kg/day in a 60-day slow-release subcutaneous pellet379) under the dorsal 
skin (groups 2 and 4) or underwent mock surgery (groups 1 and 3) at the start of the experi-
ment. Mice were injected subcutaneously with 250 mg M23D(+2-18)/kg body weight once 
daily for fi ve days in test week 1 and 100 mg M23D(+2-18)/kg body weight twice a week 
in test weeks 2 to 8 (groups 3 and 4), or saline (groups 1 and 2). Mice were sacrifi ced ten 
days after the last injections and muscles (gastrocnemius, tibialis anterior, quadriceps, heart, 
and diaphragm) and organs (liver and kidney) were isolated, snap frozen in liquid nitro-
gen-cooled 2-methylbutane, and stored at -80°C.
Measurement of creatine kinase levels
Blood samples were taken weekly via the tail vein. Samples were centrifuged at 1 700 g 
for 10 min at 4°C. Serum was stored at 4°C and creatine kinase (CK) levels were measured 
after diluting them 10 times in Dulbecco’s phosphate-buffered saline (D-PBS; Invitrogen, 
Carlsbad, CA) and were measured with a Refl otron system (Roche Diagnostics, Basel, 
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Switzerland) with CK-strips (Roche).
RNA extraction and analysis of exon skipping by RT-PCR
Harvested cells were lysed with RNA-Bee (Campro Scientifi c, Veenendaal, The Netherlands). 
Total RNA was extracted and 400 ng of RNA was used for RT-PCR analysis, using Transcriptor 
reverse transcriptase polymerase (Roche) in 20 μL at 55°C for 30 min with an appropriate 
primer (primer sequences on request). cDNA was amplifi ed with a nested PCR. Three micro-
liter cDNA was amplifi ed in a 25-μL reaction for 20 cycles of 94°C (40 sec), 60°C (40 sec), 
and 72°C (80 sec), followed by 32 cycles of 94°C (40 sec), 60°C (40 sec), and 72°C (60 sec), 
with 1.5 μL PCR product in a 50-μL reaction.
Muscles were minced in TriPure Isolation Reagent (Roche) using MagNA Lyser green 
beads (Roche) or zirconium beads (1.4 mm; OPS Diagnostics, Lebanon, NJ) according 
to the manufacturer’s instructions. Total RNA was extracted and 1 μg RNA was used for 
RT-PCR analysis, using Transcriptor reverse transcriptase polymerase (Roche) in 20 μL at 
42°C for 45 min using random hexamer primers (20 ng/μL). Then, 1.5 μL cDNA was ampli-
fi ed in a 50-μL reaction for 30 cycles of 94°C (30 sec), 60°C (30 sec), and 72°C (30 sec), 
as previously described.663 All PCR products were visualized on 1.5 or 2% agarose gels 
and quantifi ed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). 
PCR products were quantifi ed using DNA 1000 LabChip on the Agilent 2100 Bioanalyzer 
(Agilent Technologies) according to the manufacturer’s protocol. Bioanalyzer analysis has 
been shown to be an accurate method for exon skipping quantifi cation in mdx muscle.663
Hybridization-ligation assay
The assay for measuring the concentration of the 23AON in tissue samples is based on a 
previously published hybridization ligation assay.664 Briefl y, a signal probe (containing a 
peptide for antibody recognition) and a template (complementary to 23AON and the probe) 
were added to homogenized tissue samples. This was followed by a ligation step that only 
takes place when both AON and probe are bound to the template. Unbound probe was then 
washed away and the amount of probe-AON was detected using enzyme-linked antibodies 
against the probe. Muscles/organs were homogenized in proteinase K buffer (0.1 M Tris-HCl 
(pH 8.5), 0.2 M NaCl, 0.2% sodium dodecyl sulphate (SDS), and 5 mM EDTA) containing 
proteinase K (2 mg/mL; Invitrogen), using MagNA Lyser green beads (Roche) or zirconium 
beads (1.4 mm; OPS Diagnostics) by grinding in a MagNA Lyser (Roche) and incubating 
overnight at 55°C with gentle agitation. Calibration curves of the analysed 23AON prepared 
in 60 times pooled control mouse mdx tissue in PBS were included. All tissues were diluted 
in pooled control mdx mouse tissue. The muscle samples were diluted 500 and 1000 times, 
and liver and kidney tissue 1000 and 5000 times. All analyses were performed in duplicate.
Protein extraction and Western Blot analysis
Western blotting was performed as described.161,177,699 Briefl y, muscles were homogenized in 
75 mM Tris-HCl (pH 6.8)- 15% SDS, using MagNA Lyser green beads (Roche), by grinding 
in a MagNA Lyser (Roche). Protein concentrations were determined with Pierce bicin-
choninic acid (BCA) protein assay kit (Thermo Fisher Scientifi c, Waltham, MA) according 
to the manufacturer’s instructions. Samples containing 75 μg of protein were made in 75 mM 
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Tris-HCl (pH 6.8), 15% SDS, 5% 2-mercaptoethanol, 2% glycerol, and 0.001% bromophe-
nol blue, boiled for 5 min, loaded on a 4-7% gradient polyacrylamide gel, and run overnight 
at 4°C. Control samples containing 3.75 (5%), 1.5 (2%), 0.75 (1%), and 0.075 (0.1%) μg pro-
tein was used as a reference. Gels were blotted to nitrocellulose BA83 (Whatman/Schleicher 
& Schuell, Dassel, Germany) for 6 hr at 600 mA at 4°C. Blots were blocked with 5% nonfat 
dried milk (Campina Melkunie, Zaltbommel, The Netherlands) in (Tris-buffered saline (TBS) 
followed by an overnight incubation at 4°C with NCL-DYS1 (dilution 1:125, NovaCastra, 
Newcastle-upon-tyne, UK) in TBS plus 0.05% Tween20 to detect dystrophin. As second-
ary antibody the fl uorescent IRDye 800CW goat anti-mouse IgG (dilution 1:5 000, Li-Cor, 
Lincoln, NE) was used. Blots were visualized and quantifi ed with the Odyssey system and 
software (Li-Cor).
Immuno-histochemistry and dystrophin quantifi cation
Sections (thickness, 8 μm) were cut with a Shandon cryotome (Thermo Fisher Scientifi c) on 
Superfrost Plus slides (Thermo Fisher Scientifi c) along the entire length of the gastrocnemius 
with a minimum interval of 240 μm between the sections. Slides were fi xed for 5 min in ice-
cold acetone and blocked with PBS-0.05% Tween-5% horse serum. Slides were incubated 
overnight with dystrophin diluted 1:50 (dystrophin (C-20) sc-7461; Santa Cruz Biotechnology, 
Heidelberg, Germany) and spectrin diluted 1:200 (anti-spectrin β-3 polyclonal antibody PA1-
46007; Thermo Fisher Scientifi c) as primary antibodies. As secondary antibodies Alexa Fluor 
488-conjugated donkey anti-goat IgG diluted 1:1000 (A11055; Invitrogen) for dystrophin and 
Alexa Fluor 594-conjugated donkey anti-rabbit IgG diluted 1:1000 (A21207; Invitrogen) for 
spectrin were used. Slides were mounted with VECTASHIELD HardSet mounting medium 
with 4’,6-diamidino-2-phenylindole (DAPI) (H-1550, Vector Laboratories, Burlingame, CA). 
Images were made with a fl uorescence microscope (Leica DM5500; Leica Microsystems, 
Rijswijk, The Netherlands) at 20x magnifi cation. Dystrophin levels were assessed with Leica 
MM Basic Offl ine software (Leica Microsystems) by calculating the average maximum 
intensity of ten randomly placed rounds at the membranes minus the average of the average 
of ten randomly placed rounds in the cytoplasm.
Biomarker analysis
Total RNA was purifi ed with a NucleoSpin RNA II kit according to the manufacturer’s 
instructions including a DNase digestion (Macherey-Nagel, Düren, Germany). The integ-
rity of purifi ed RNA was checked with an RNA 6000 Nano LabChip on the Agilent 2100 
Bioanalyzer (Agilent Technologies) according to the manufacturer’s protocol.
One microgram of RNA was used for cDNA synthesis, using BioScript (GC biotech, 
Alphen aan den Rijn, The Netherlands) in 20 μL at 70°C for 10 min and 42°C for 1 hr, with 
random hexamer primers (20 ng/μL). Gene expression levels were determined for Cd68, 
Lgals3 (lectin, galactoside binding, soluble, 3), biglycan, Lox, MyoD, myogenin, Mrf4, and 
Gapdh (Glyceraldehyde-3-phosphate dehydrogenase) by real time qPCR using SensiMix 
SYBR (GC biotech) and the Roche LightCycler 480 (Roche) (primer sequences on request), 
with a program consisting of 45 cycles of 95°C (10 sec), 60°C (30 sec), and 72°C (20 sec).
For microRNA (miRNA) analysis 1 μg of unpurifi ed RNA was used. Input RNA 
was reverse transcribed using an miScript reverse transcription kit (Qiagen, Venlo, The 
Netherlands) according to the manufacturer’s protocol. Two microliters of ten times diluted 
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cDNA was used as input for the real-time qPCR, using SensiMixTM SYBR (GC biotech) 
on the Roche LightCycler 480 (Roche), using a program consisting of 55 cycles of 95°C 
(10 sec), 57°C (30 sec), and 72°C (20 sec). Specifi c forward primers for miR-31 and 5S 
were used in combination with an universal reverse primer complementary to the adapter 
sequence of the RT-primer (primer sequences on request).
Calculations of relative expression were done with the LinRegPCR quantitative PCR data 
analysis software, version 11.3.700 Gapdh, stably expressed across all conditions, was used 
to correct for differences in cDNA input for protein-coding transcripts and 5S was used to 
correct for differences in starting concentrations for miR-31.
Statistical analysis
Data are represented as mean ± SD. Exon skipping percentages, 23AON concentrations, and 
protein levels between AON and prednisolone plus AON groups were compared using an 
independent samples, two-tailed, Student’s t test in Excel 2003 (Microsoft Offi ce Professional 
Edition 2003; Microsoft, Redmond, WA). Values of p less than 0.05 after correcting for mul-
tiple testing were considered signifi cant.
Statistical signifi cance between all four groups for dystrophin staining, plasma creatine 
kinase levels at the end of the experiment (day 64), and biomarker expression was assessed 
by one-way analysis of variance (ANOVA), followed by a Bonferroni correction for multiple 
testing in case of signifi cance (p<0.05) in SPSS 17.0.2 (SPSS, Inc., Chicago, IL).
To asses a possible treatment effect on the weight of mice over time a longitudinal anal-
ysis was perform in R,665 using the lme4 package.666 A baseline corrected model was used, 
including fi xed linear and quadratic time effects; the mouse effect was considered to be 
random.
Results
Prednisolone does not interfere with exon skipping in cultured cells and 
intramuscular 23AON injection
The effect of prednisolone on exon skipping effi ciency was fi rst determined on cell cultures. 
Various doses of prednisolone were added to culture medium (0.2–2.25 μg/ml) The highest 
dose did not induce cell death, but impaired differentiation was observed (data not shown), a 
known effect of corticosteroids.378 The dose of 0.75 μg/ml was selected for further study, as 
it did not induce cell death, did not affect differentiation, and is comparable to the dose that 
is used in most patients (recommended dose, 0.75 mg/kg/day10,368,384,701).
Patient-derived cell cultures were pretreated for ten days with 0.75 μg/mL prednisolone, 
or with saline as a control. Subsequently, cells were transfected with 400 nM concentrations 
of the appropriate AON. Skipping of the targeted exon was seen in all cells (fi g. 6.1) and 
no difference was seen between prednisolone- and saline-treated cells. Exon 51 skipping 
in cells with a deletion of exon 52 (53914.1) averaged at 40% for both saline- and predni-
solone-treated cells. For exon 50 skipping in cells with a deletion of exon 51-55 (DL589.2) 
percentages were ~70%, with relatively small variation (fi g. 6.1a). Similar exon skipping 
levels were also found for other AON concentrations in the presence or absence of predniso-
lone (data not shown).
141
PREDNISOLONE EFFECTS ON AON TREATMENT
In vivo, the effect of systemic prednisolone treatment was fi rst tested by local, intra-
muscular, injections with 23AON, a 2’-O-methyl phosphorothioate AON inducing exon 23 
skipping (M23D(+2-18)).197 Mdx mice were pretreated subcutaneously with saline or 1 mg/
kg prednisolone for four weeks, starting at the age of four weeks.698 This age was chosen 
because the major regeneration and degeneration cycles in mdx mice have been shown to 
take place at about this age.702 The prednisolone dose is comparable to doses used by patients 
with DMD.368 At the age of eight weeks, mice received two consecutive injections with 
2.9 nmol 23AON locally in the gastrocnemius muscles. Exon skipping percentages were 
determined by primary PCR and bioanalyzer analysis.661 No signifi cant differences in exon 
skipping levels were observed (fi g. 6.1b). Nested PCR analysis, the most commonly used 
method for determining exon skipping at present,161,199,210,243,677,703 resulted in higher skipping 
levels of around 20% (data not shown). However, it has been shown that nested PCR gives 
an overestimation of the absolute exon skipping percentages.663
Prednisolone does not affect exon skipping effi ciency systemically in mdx 
mice
To investigate the effect of prednisolone on systemic treatment with 23AON, fi ve-week-old 
male mdx mice were treated for eight weeks simultaneously with prednisolone (1 mg/kg/day 
via a subcutaneous slow-release pellet, shown to be an effective mode of delivering379,704) or 
saline and 23AON (250 mg/kg, fi ve times in week 1; and 100 mg/kg, two times in week 2 to 8, 
subcutaneously) or saline. During the treatment the weight of the mice was monitored. In 
contrast to the weight increase seen in humans, prednisolone-treated mice (both prednisolone 
alone and prednisolone and 23AON) weighed signifi cantly less compared with saline- or 
23AON alone-treated mice (fi g. 6.2a). This is in line with results described in the literature.705 
In the absence of prednisolone, no difference in weight between 23AON- and saline-treated 
mice was observed. Plasma creatine kinase (CK) levels (a measure of muscle damage) did 
not differ signifi cantly for the various groups after treatment (data not shown). Notably, lev-
els were generally much lower than expected (up to 2000 U/L in all mice, whereas, in general 
levels up to 8000 U/L are found in untreated mdx mice). This may have been due to the time 








































Fig. 6.1: Effect of prednisolone on antisense oligonucleotide mediated exon skipping in 
vitro and intramuscularly in the mdx mouse
Means are shown for each group. Error bars represent the standard deviation.
a) In two patient cell lines no effect on skipping percentages of addition of prednisolone was seen (n=12 per con-
dition). For 53914.1 cells (deletion exon 52) AONs against exon 51 were used, and for 589.2 cells (deletion exon 
51-55) AONs against exon 50. b) Prednisolone did not affect exon skipping after intramuscularly injection of 
























-5 5 15 25 35 45 55 65
15
PCR ctrlsP + AON




























































Fig. 6.2: Systemic treatment with prednisolone and/or 23AONs
Effect on body weight of all treatments and antisense oligonucleotide mediated exon skipping and 23AON biodis-
tribution after co-treatment with prednisolone or saline. Per group, eight mice were analysed. Means are shown for 
each group. Error bars represent the standard deviation.
a) Body weight was decreased in both prednisolone treated groups compared to both saline and 23AON alone-
treated mice (p<0.01). b) RT-PCR analysis for the tibialis anterior. Wild type product consists of 334 base pairs and 
exon 23 skipping results in a 122 base pair product. S=saline, P=prednisolone. c) No difference in exon skip percent-
ages between saline and prednisolone co-treatment with 23AONs was seen. Exon skip percentages were determined 
by DNA 1000 lab-on-a-chip analysis on the Agilent 2100 Bioanalyzer. d) Biodistribution analysis showed a small 
decrease in 23AON uptake in the quadriceps and diaphragm, but not in the heart. **p<0.01 compared to 23AON 
alone-treated mice
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Average skipping levels were comparable for skeletal muscles and diaphragm and skip-
ping levels did not differ between saline- and prednisolone-treated animals (fi g. 6.2b/c). In 
heart, exon skipping levels were much lower, as described previously,161 but detectable in all 
samples. No skipping was observed without 23AON treatment for any of the muscles (data 
not shown).
Assessment of the concentrations of 23AON in the various tissues showed in predniso-
lone-treated mice a small, but signifi cant decrease in 23AON concentration in the quadriceps 
and diaphragm (fi g. 6.2d). In the heart the levels were almost comparable to those found 
in skeletal muscle, without real difference between both treatment groups. The majority of 
the 23AON ends up in the liver and kidneys. Levels were similar in the liver for predni-
solone-treated animals versus control animals, whereas an almost signifi cant decrease in 
23AON concentration was seen in the kidneys. Overall, 23AON levels in muscle and organs 
were slightly lower in the prednisolone-treated mice.
23AON-mediated expression of dystrophin protein is slightly increased in 
prednisolone treated animals
Dystrophin protein expression was determined in two ways: by Western blot analysis and by 
immunofl uorescent staining of cross-sections. Assessment of protein levels by Western blot 
(fi g. 6.3a/b) revealed restoration of expression in all 23AON-treated mice, albeit at low levels 
(<5% of wild type control). Quantifi cation indicated slightly elevated protein levels for mice 
Prednisolone




















































B C Immunofluorescent stainingWestern Blot analysis
Fig. 6.3: Dystrophin expression detected by immunofl uorescent staining and Western blot 
analysis
Per group, eight mice were analysed. Means are shown for each group. Error bars represent the standard deviation.
a) Representative example of western blot analysis (gastrocnemius muscle), showing low levels of dystrophin pro-
tein (top) in all 23AON-treated mice. No band was detected in control mice. Myosin (bottom) was used as loading 
control. b) Quantifi cation of dystrophin protein expression by Western blot showed a slight increase in protein levels 
in 23AON-treated mice, which was signifi cant for the gastrocnemius muscle, but not for the diaphragm. *p<0.05 
compared to 23AON alone treated mice. c) Immunofl uorescent staining with dystrophin antibody in the gastrocne-
mius muscle showed dystrophin expression above background levels in both 23AON-treated groups, but no differ-
ence between prednisolone-and saline-treated mice. **p<0.01 compared with saline-treated mice.
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treated with both prednisolone and 23AON compared with mice treated with 23AON alone; 
the difference was signifi cant for the gastrocnemius. In the diaphragm the same trend was 
seen, but this increase was not signifi cant (fi g. 6.3a/b). However, with these low dystrophin 
expression levels, differences may be more diffi cult to observe. Immunofl uorescent staining 
showed dystrophin expression above background levels (saline/prednisolone alone treated- 
mice) for both 23AON-treated groups, but no difference was observed between saline- and 
prednisolone-treated animals (fi g. 6.3c). Untreated mdx mice did not express dystrophin.
Biomarkers
The expression levels of multiple mRNA transcripts have been shown to be changed in the 
mdx mouse. These can be used as biomarkers to assess the effect of therapeutic interven-
tions.706 Expression levels for several immunological, fi brosis, and early and late regeneration 
markers for the tibialis anterior and diaphragm were assessed by quantitative PCR. The main 
changes in expression levels were seen in the tibialis anterior of 23AON- and/or predniso-
lone-treated mice (fi g. 6.4; supplementary table S6.1). In the diaphragm the differences were 
relatively smaller. The immunological markers Cd68 and Lgals3 are elevated in mdx mice 
and have been shown to fall after high levels of AAV-induced exon skipping.704 In our study, a 
signifi cant decrease for both Cd68 and Lgals3 was observed in the tibialis anterior of 23AON-
treated mice (fi g. 6.4a/b). Prednisolone treatment did not induce a signifi cant decrease for 
these immunological markers, although a trend was observed for both. Interestingly, for mice 
treated with both 23AONs and prednisolone, levels were higher than those in mice treated 
with either compound. The fi brotic markers biglycan and Lox, known to be elevated in mdx 
mice,706,707 were lower in the tibialis anterior of prednisolone-treated mice (only for Lox), 
23AON-treated mice, as well as in mice receiving both treatments (fi g. 6.4c/d). Because of 
interindividual variations this difference was signifi cant only for the group receiving both 
treatments compared with saline-treated mice for biglycan. To examine the effect of pred-
nisolone and 23AON on regeneration, levels of the early regeneration markers MyoD and 
myogenin, which are elevated in mdx mice,708 were measured. Both markers fell signifi cantly 
after prednisolone and/or AON treatment (fi g. 6.4e/f). Furthermore, the late regeneration 
marker Mrf4 has been shown to be inhibited by glucocorticoid treatment.378,709 Levels were 
highly variable in the tibialis anterior, but in the diaphragm a signifi cant decrease compared 
with saline-treated mice was seen for 23AON-treated mice with and without prednisolone 
(fi g. 6.4g). Another regeneration marker, the microRNA miR-31, showed a small decrease 
after both prednisolone and 23AON treatment, and a nearly signifi cant decrease compared 
with control mice was seen after combinational treatment in the diaphragm (fi g. 6.4h). In 
conclusion, treatment with either prednisolone, 23AON, or a combination seems to normal-
ize the levels of fi brotic and regenerative biomarkers to some extent in the tibialis anterior, 
while a smaller effect was observed in the more severely affected diaphragm.
Discussion
AON-mediated exon skipping as a potential therapy for DMD is being tested in placebo-con-
trolled clinical trials and is likely to become clinically applicable in the near future. Most 
patients currently use corticosteroids, mainly prednisone, to slow down disease progression. 
Prednisolone has been shown to have a positive effect on muscle maintenance and quality. 
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Fig. 6.4: Expression of biomarker levels measured by quantitative PCR
Per group, eight mice were analysed. Means are shown for each group, corrected for Gapdh or 5S expression. Values 
are expressed relatively to tibialis anterior levels of saline-treated mice. Error bars represent the standard deviation. 
Immunological markers Cd68 (a) and Lgals3 (b), fi brotic markers biglycan (c) and Lox (d), early regeneration mark-
ers MyoD (e) and myogenin (f), late regeneration marker Mrf4 (g) and miR-31 (h) were measured. miR-31 was only 
determined in the diaphragm (values expressed relatively to saline-treated mice)
*p<0.05 **p<0.01 compared to saline-treated mice
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This could affect exon skipping effi ciency either positively or negatively. It has been noticed 
previously that uptake of AONs and exon skipping effi ciency are higher in dystrophic muscle 
than in wild type muscle.200 This is thought to be caused by the leakiness of the dystrophic 
muscle membranes, which facilitates the entry of AONs in the muscle cells.200,217 In fact, 
in mice containing only one utrophin allele in the absence of dystrophin (mdx/Utrn+/-), 
which are more severely affected, exon skipping levels are higher than in the mdx mouse 
[Tanganyika-de Winter, C.L. et al., unpublished observations]. Therefore stabilization of the 
muscle fi bres by prednisolone could have a negative effect on AON uptake and thereby 
decrease its effi ciency. Conversely, improving the quality of the muscle could lead to more 
muscle fi bres, increasing the total amount of dystrophin pre-mRNA, the target of AONs, and 
thereby increase the therapeutic potential of AONs. In this study the effect of prednisolone 
on AON uptake and biodistribution, exon skipping levels, and dystrophin restoration was 
examined.
In two patient cell cultures and one healthy control cell culture no differences were seen 
in 2OMePS AON-induced exon skipping between prednisolone and saline cotreatment. Thus, 
the effect prednisolone has on muscle cells does not seem to infl uence skipping effi ciency in 
vitro. The same appears to be true in vivo, where muscle cells are in their natural environment. 
After local injections of 23AON, skipping effi ciency was the same between salin-e and pred-
nisolone-treated mice. The same holds for systemic 23AON treatment, where exon skipping 
percentages were similar between both treatment groups for skeletal muscle, diaphragm, and 
heart.
The 2OMePS dose used in this study is much higher than that used in clinical trials using 
the same chemistry229 (200 versus 6 mg/kg/week). However, for most drugs a correction fac-
tor applies when translating doses between small and larger animals based on normalization 
to body surface area (See Guidance for Industry605). When applying this correction factor, a 
dose of 16 mg/kg would be predicted for humans, which is in the same order of magnitude as 
the 6 mg/kg used in the trials. The slightly higher corrected dose for mice might be explained 
by a higher clearance rate for 2OMePS AONs in mice and potential differences between 
pharmacokinetic and pharmacodynamic properties between exon 23- and exon 51-targeting 
AONs.
The exon skipping levels in vivo after 2OMePS AON treatment (both locally and system-
ically) are relatively low. Vivo-morpholinos (i.e., modifi ed morpholinos, conjugated with a 
dendrimeric octaguanidine) have been shown to lead to much higher skip levels.221,229 This 
may partly be due to differences in analysis method, primary versus nested PCR.663 In either 
case, at the moment the clinical relevance of these high levels is limited, as exon skipping 
levels in the currently ongoing systemic trials are low.229,231 Higher exon skip effi ciency 
would obviously be desired, but for now only nonconjugated AONs are being tested in clini-
cal trials. Nevertheless, low levels of dystrophin protein have already lead to histological and 
functional improvement in mice,710 and the low exon skipping levels in our study did result 
in dystrophin restoration, which was slightly increased in prednisolone-treated mice.
As seen in previous studies161,200 the majority of the 23AON ends up in the liver and the 
kidneys after systemic treatment. A small decrease in 23AON concentration was seen in the 
quadriceps and diaphragm in prednisolone-treated mice compared with saline-treated mice, 
but this did not lead to a decrease in exon skipping percentages. This might be explained by 
the localization of the AON within the tissue. The 23AON concentration is measured in the 
whole muscle and therefore refl ects both AONs present in the fi bres (where exon skipping 
can be induced) and in the extracellular matrix and interstitial spaces (where no exon skip-
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ping can be induced). The lower levels observed in muscle may be due to less sequestration 
in the extracellular matrix caused by an improvement in muscle quality. Therefore, the higher 
levels in the AON-treated animals do not necessarily have to result in higher exon skipping 
levels, because part may be sequestered in the extracellular matrix and interstitial spaces. 
This is supported by the fi nding that more dystrophin was expressed in prednisolone-treated 
mice, which might be another indication of a positive effect on muscle quality (more dys-
trophin pre-mRNA) by prednisolone, because the same percentage of skipping in more 
transcripts leads to higher protein production. In this study an AON with the 2’-O-methyl 
phosphorothioate chemistry was used; however, it is anticipated that the results also hold for 
the other chemistry that is approaching use in large clinical trials (morpholino phosphorodi-
amidate AONs).
The best known effect of prednisolone is its suppressive effect on the immune system. 
However, no clear decrease in the immunological markers Cd68 and Lgals3 was seen in 
prednisolone-treated mice. By contrast, the levels of myogenic transcription factors MyoD 
and myogenin (regeneration markers) were decreased, although not signifi cantly everywhere, 
for all treated groups, suggesting that prednisolone treatment did have an effect on muscle. 
This concurs with previous fi ndings that prednisolone treatment leads to a general reduction 
in proliferation, and MyoD and myogenin are downregulated in methylprednisolone-treated 
adrenalectomized rats.711 Because AONs interact only with their target sequence, a general 
effect as observed for prednisolone is unlikely. In this case regeneration might be reduced 
because of reduction in muscle damage, infl ammation, and fi brosis as a consequence of the 
dystrophin restoration. The less pronounced reduction in Mrf4 levels might be explained 
by the timing. MyoD and myogenin are elevated early in regeneration,712 peaking at 72 hr 
after induction of regeneration,708 whereas Mrf4 is increased in maturing myofi bres.7102 The 
combination of prednisolone and 23AON showed mixed effects. The absence of a decrease 
in immunological markers, as seen in 23AON-treated mice, is probably due to confl icting 
results in one or two mice, which abolish the small differences observed. Fibrotic and regen-
eration markers followed roughly the same pattern as prednisolone and/or 23AON treatment 
alone. miR-31 is a microRNA that, amongst others, targets the 3’ untranslated region of the 
dystrophin mRNA, thereby repressing its translation and expression. It has been shown to 
be localized in regenerating myoblasts and is almost absent in wild type muscle fi bres, but 
is upregulated in mdx mice. Furthermore, repression of miR-31 led to an increase in dystro-
phin expression in AON-treated human DMD myoblasts.713 In all treated mice a trend was 
observed toward normalisation, which seemed to be more pronounced after combinational 
treatment. The downregulation of miR-31 might be another explanation for the improved 
dystrophin levels after prednisolone treatment.
It is surprising that even the limited levels of dystrophin found in this short-term study 
resulted in improved muscle quality to some extent. However, long term presence of low 
amounts of dystrophin has been reported to result in benefi cial effects before. The mdx3cv 
mouse model, which has approximately 5% of dystrophin since birth, performs signifi cantly 
better in the grip strength test compared with mdx mice.102 Our own results in mice with 
low levels of dystrophin (mdx-XistΔhs) confi rm these results; here, low levels of dystrophin 
(<15%) were suffi cient to improve histology and muscle function and to normalize biomark-
ers [van Putten, M. et al., manuscript submitted]. Notably, in clinical trials low dystrophin 
levels after AON treatment appear to result in functional improvement.229
In conclusion, this work shows that there is no negative effect of prednisolone and 23AON 
on each other’s therapeutic outcome in any of the tests, suggesting that patients can continue 
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using prednisone during exon skipping trials. Prednisolone might even have a positive effect 
on AON treatment.
Acknowledgments
We are grateful to Rick Vermue and Ruurd Verheul (Prosensa Therapeutics) for assistance 
with the hybridisation-ligation assay, and to Maarten van Iterson (LUMC) for assistance 
with the statistical analysis. This work made use of the infrastructure of the Center for 
Medical System Biology (CMSB) and the Center for Biomedical Genetics (CBG) in which 
the LUMC participates. LUMC is a partner in the FP6 TREAT-NMD network of excellence 
(LSHM-CT-2006–036825). This work is supported by grants from the Prinses Beatrix Fonds, 
The Netherlands (grant W-OR09-12) and the Dutch Duchenne Parent Project.
Author Disclosure Statement
Tatyana G. Karnaoukh, Ingrid G.M. Kolfschoten, Anne Vroon, and Judith C.T. van Deutekom 
report being employed by Prosensa Therapeutics. LUMC has patents on the exon skipping 
applications. Hans Heemskerk, Gertjan B. van Ommen, Judith C.T. van Deutekom, and 
Annemieke Aartsma-Rus report being coinventors on some of these patents, and as such are 
entitled to a share of royalties.
149










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The eff ect of losartan in vitro and 
in vivo on muscle signalling and 




LOSARTAN EFFECTS ON MUSCLE SIGNALLING AND AON TREATMENT
Introduction
The renin-angiotensin system (RAS) plays a role in the maintenance of blood pressure and 
fl uid balances and is, amongst others, involved in the development of cardiomyopathy. Upon 
activation, renin is secreted by the kidneys, which converts angiotensinogen, an α-glyco-
protein released by the liver, into angiotensin I. Angiotensin I in turn is converted in its 
active form angiotensin II by the membrane-bound metalloproteinase angiotensin converting 
enzyme (ACE), which has numerous effects, amongst others on vascular smooth muscle 
cells to induce vasoconstriction. It exerts its main effects by binding to the angiotensin II type 
1 (AT1) receptor, but also binds to angiotensin II receptor type 2 (AT2).714 This system has 
shown to be upregulated in DMD and increases fi brosis by both transforming growth factor-β 
(TGF-β)-dependent and independent mechanisms.554,555
TGF-β is a member of the TGF-β superfamily, proteins that are involved in the control 
of many cellular processes such as growth and differentiation. TGF-β mainly signals via 
the type II receptor Tgfbr2 in combination with the type I receptor Tgfbr1 (ALK5). TGF-β1, 
one of the three mammalian isoforms, is known to be induced in regenerating muscle and 
is a potent inducer of fi brosis. Downstream signalling occurs via the canonical Smad2/3-
dependent pathway and non-canonical Smad-independent pathways.478 TGF-β1 is upregulated 
in patients and mice lacking dystrophin, a protein that is crucial to maintain muscle fi bre sta-
bility during contraction and lack of which leads to severe muscle damage and replacement 
of muscle tissue by fi brotic and adipose tissue. The level of TGF-β1 expression has shown 
to be correlated with disease severity in dystrophin negative Duchenne muscular dystrophy 
(DMD) patients and mdx mice.715,716
AT1 stimulates TGF-β via the NADPH oxidase/P38/MAPK pathway, thereby enhancing 
downstream signalling.558 TGF-β-independently AT1 activation works directly on the PI3K/
Akt/mTOR and Raf/MEK/ERK pathways, which also induce fi brosis.561,562
Losartan is a selective AT1 receptor antagonist, thereby anticipated to have an antagonis-
tic effect on TGF-β. In mdx mice it improved regeneration and reduced fi brosis after acute 
injury. Six to nine months of treatment ameliorated the disease progression evidenced by a 
decrease in fi brosis and improving muscle strength.260
Antisense oligonucleotide (AON)-mediated exon skipping, described in more detail in 
previous chapters, targets DMD transcripts, which are only expressed in muscle fi bres and 
not in fi brotic/adipose tissue that gradually replaces the muscle fi bres when the disease pro-
gresses. Indeed the fi rst clinical trial in DMD patients using local intramuscular injection of 
AONs targeting exon 51 already showed that patients with better muscle quality were able to 
produce more dystrophin.225 Therefore combining AON-treatment with a muscle preserving 
agent might increase the therapeutic effects of AON-mediated exon skipping. In light of the 
described effects of losartan for preserving muscle quality, in this chapter the effects of losar-
tan itself and in combination with AONs were examined.
Materials and methods
Cell culture
A mouse myoblast cell line (C2C12) and primary human myoblasts derived from a healthy 
control (KM109)697 and a DMD patient with a deletion of exon 51-55 (DL589.2)177 were used 
in this study.
Mouse C2C12 myoblasts were cultured on a collagen layer (1:30; Pure Col; Nutacon 
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BV; the Netherlands)at 37ºC 10% CO2 in Dulbecco’s Modifi ed Eagle Medium (DMEM, 
without phenol red; Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS), 
1% penicillin streptomycin (P/S), 2% GlutaMAX and 1% D-glucose (all from Gibco-BRL, 
Life Technologies; the Netherlands).
Human myoblast were cultured on a collagen layer (1:30; Pure Col; Nutacon BV) in 
Nutrient Mix F-10 (HAM) supplemented with GlutaMAX (Gibco-BRL), 20% FBS and 
1% P/S at 37ºC 5% CO2. To induce differentiation into myotubes medium was switched 
into DMEM without phenol red supplemented with 2% FBS, 1% P/S, 2% GlutaMAX and 
1% D-glucose (Gibco-BRL) when cells reached 80-90% confl uence.
Smad phosphorylation assay
For the Smad phosphorylation assay C2C12 cells were seeded in a 6-well plate at a density 
of 3·105 cells/well. After overnight serum starvation, cells were treated for 1 hour with 0, 
0.5 or 50 μg/mL losartan potassium (Cozaar®; Merck Sharp & Dohme BV; the Netherlands) 
or 10 μM Transforming Growth Factor-β type I receptor kinase inhibitor (LY-364947; 
Sigma-Aldrich; the Netherlands) dissolved in serum-free medium. Cells were stimulated 
with 1 ng/ml of TGF-β1 (kindly provided by Ken Iwata, OSI Pharmaceuticals, Melville, NY, 
USA) for 45 min. Cells were lysed with sample buffer containing 100 mM Tris-HCl (pH 6.8), 
4% (w/v) SDS, 0.1% (w/v) bromophenol blue, 20% (v/v) glycerol, and 8% (v/v) β-mercap-
toethanol and stored at -20ºC for protein analysis.
Losartan treatment and AON transfection
Losartan potassium (Merck Sharp & Dohme BV) was dissolved in differentiation medium. 
KM109/DL589.2 cells were differentiated in 6-wells plates for 7-10 days before transfec-
tion. Losartan was added at concentrations ranging from 0 to 50 μg/mL and maintained 
during and after transfection. Cells were transfected with 500 pmol h49AON1 targeting exon 
49 or h50AON1 targeting exon 50 (2’-O-methyl RNA oligonucleotides with a full-length 
phosphorothioate backbone (2OMePS) previously described176; Prosensa Therapeutics; 
the Netherlands) in 1 mL differentiation medium for 4 hours using 2 μL polyethylenimine 
(PEI, Exgen 500; MBI Fermentas; Germany) per μg AON, according to the manufacturer’s 
instructions. Cells were harvested >24 hours after transfection.
In vivo losartan and 23AON treatment
All experiments were approved by and performed following the guidelines of the local ani-
mal ethics experimental committee of the Leiden University Medical Center (permit number: 
08224). Mice were housed in individually ventilated cages in the animal facility of the 
LUMC and received food and drink ad libitum. Mdx mice (C57Bl/10ScSn-DMDmdx/J) with 
one or two copies of the utrophin gene (mdx/Utrn+/– or mdx/Utrn+/+) were obtained from our 
own breeding facilities.
Four weeks old mice were treated orally (via the drinking water) with 0.6 g/L losartan 
potassium (Sigma-Aldrich) till the end of the experiments. Control mice received normal 
drinking water.
For intramuscular 23AON experiments, mdx mice (M/F) were, after 6 weeks of losartan/
control treatment, anesthetized with isofl urane and intramuscularly injected in both 
gastrocnemius muscles on two consecutive days with 2.9 nmol (≡20 μg) of M23D(+2–18), a 
2OMePS RNA oligonucleotide specifi cally targeting exon 23,197 in 40 μL saline (n=2-3 per 
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condition). Mice were sacrifi ced 10 days after the last injection by cervical dislocation and 
muscles were isolated.
For systemic 23AON experiments, mdx/Utrn+/- mice (M/F) were treated for 8 weeks 
with subcutaneous injections of saline, losartan in drinking water, subcutaneous injections 
of 23AON or losartan in drinking water and subcutaneous injections of 23AON (n=3-4 per 
group). 200 mg/kg body weight/week M23D(+2–18) divided over 4 injections was injected 
subcutaneously. During treatment functional performance was tested weekly by rotarod and 
two limb hanging wire testing and in the last week by grip strength testing.717 Blood samples 
were taken weekly via the tail vein for creatine kinase (CK) level measurements. Mice were 
sacrifi ced 10 days after the last 23AON injection and muscles were isolated, snap frozen in 
liquid nitrogen-cooled 2-methylbutane, and stored at -80ºC.
Creatine kinase level measurements
Blood samples were centrifuged at 18 000 g for 5 min at 4ºC to generate plasma. CK lev-
els were measured after diluting the samples 10 times in Dulbecco’s phosphate-buffered 
saline (D-PBS; Invitrogen; CA, USA) and were measured with a Refl otron system (Roche 
Diagnostics; Switzerland) with CK-strips (Roche).
RNA isolation and exon skipping analysis by RT-PCR
For RNA isolation harvested cells were lysed with RNA-Bee (Campro Scientifi c; the 
Netherlands) and total RNA was extracted. RT-PCR analysis was performed using 
Transcriptor reverse transcriptase polymerase (Roche) in a 20 μL volume at 55ºC for 30 min 
with an appropriate primer. cDNA was amplifi ed by nested PCR. Three microliters of cDNA 
was amplifi ed in a 25 μL reaction for 20 cycles of 94ºC (40 sec), 60ºC (40 sec) and 72ºC 
(80 sec), followed by 32 cycles of 94ºC (40 sec), 60ºC (40 sec) and 72ºC (60 sec), with 1.5 μl 
of PCR product in a 50 μL reaction.
Muscles were minced in RNA-Bee (Campro Scientifi c) using MagNA lyser green beads 
(Roche) according to manufacturer’s instructions. Total RNA was extracted and 1 μg of RNA 
was used for RT-PCR analysis, using Transcriptor reverse transcriptase polymerase (Roche) 
in 20 μl at 42ºC for 45 min with random hexamer primers (20 ng/μl). Then, 1.5 μl of cDNA 
was amplifi ed in a 50 μL reaction for 30 cycles of 94ºC (30 sec), 60ºC (30 sec) and 72ºC 
(30 sec), as previously described.663 All PCR products were visualized on 1.5% agarose gels 
and exon skipping levels were quantifi ed using a DNA 1000 LabChip on the Agilent 2100 
bioanalyzer (Agilent Technologies; CA, USA) according to the manufacturer’s instructions.
Protein extraction and Western blot analysis
Cells were lysed with sample buffer containing 100 mM Tris-HCl (pH 6.8), 4% w/v sodium 
dodecyl sulphate (SDS), 0.1% w/v bromophenol blue, 20% v/v glycerol and 8% v/v β-mer-
captoethanol. Muscles were homogenized in lysis buffer containing 50 mM Tris-HCl 
(pH 7.5). 50 mM NaCl, 1 mM EDTA, 1% Triton X100, 0.1% SDS, cOmplete EDTA-free 
protease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor cocktail (Roche) 
using MagNA lyser green beads (Roche) according to manufacturer’s instructions. Protein 
concentrations were determined using a Pierce bicinchoninic acid protein assay kit (Thermo 
Fisher Scientifi c; IL, USA) according to manufacturer’s instructions, samples containing 
equal amount of protein were made and mixed 1:1 with sample buffer. Protein lysates 
were separated on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose mem-
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branes (Amersham; Belgium). Membranes were blocked in TBST-5% milk for 45 min at 
4°C and incubated in primary antibody overnight at 4°C, followed by incubation with IgG-
horseradish peroxidase-conjugated secondary antibody for 1 h. The detection was performed 
using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientifi c). As 
primary antibodies rabbit polyclonal anti-phosphorylated Smad2 (1:1000; Ludwig Institute 
for Cancer Research; Sweden); rabbit polyclonal anti-phosphorylated ERK1/2 (1:1 000; 
Cell Signaling Technology, Inc.), mouse monoclonal anti-α-actin (Sigma-Aldrich) and 
rabbit monoclonal anti-ERK1/2 (1:1 000; Cell Signaling Technology Inc.) were used. As 
secondary antibodies goat-anti-rabbit and goat-anti-mouse IgG-HRP (1:2 500; SantaCruz 
Biotechnology; Germany) were used.
Biomarker analysis
For biomarker analysis total RNA was purifi ed with a NucleoSpin RNA II kit according to 
the manufacturer’s instructions, including a DNase digestion (Macherey-Nagel; Germany). 
One microgram of RNA was used for cDNA synthesis using random hexamer primers 
(20 ng/μl) and BioScript (GC biotech; the Netherlands) in 20 μl at 70ºC for 10 min and 42ºC 
for 1 h. Gene expression levels were determined for Gapdh (glyceraldehyde-3-phosphate 
dehydrogenase), AT1 (angiotensin II type 1) receptor, Ctgf (connective tissue growth fac-
tor), Collagen1a1 (collagen type I α1), PAI1 (plasminogen activator inhibitor 1)/Serpine1, 
Myogenin and TGF-β1 (transforming growth factor β1) by real-time qPCR using 2 μL of 10x 
diluted cDNA, 1 μL of forward primer (0.8 pmol/μL), 1 μL of reverse primer (0.8 pmol/μL)
and 4 μL SensiMix SYBR (GC biotech) per sample and the Roche LightCycler 480 (Roche) 
with a program consisting of 45 cycles of 95ºC (10 sec), 60ºC (30 sec) and 72ºC (20 sec). 
Relative expression was calculated with Lin-RegPCR quantitative PCR data analysis soft-
ware, version 11.3.700 Gapdh, stably expressed across all conditions, was used to correct for 
differences in cDNA input.
Histology
Sections of 8 μm were cut from the gastrocnemius muscle with a Shandon cryotome (Thermo 
Fisher Scientifi c Co.; PA, USA) on Superfrost Plus slides (Thermo Fisher Scientifi c, Menzel- 
Gläser; Germany) with a minimum interval of 240 μm between the sections. Slides were 
fi xed for 5 min in ice-cold acetone and stained with Harris haematoxylin and eosin (H&E) 
(Sigma–Aldrich) according to conventional histological procedures. Pictures were taken at 
5x magnifi cations with a Leica DC500 camera and Leica IM50 software connected to a Leica 
DM LB light microscope (Leica Microsystems; The Netherlands). For blending and back-
ground correction Adobe Photoshop CS3 version 10.0.1 was used. Freely available ImageJ 
software with the haematoxylin/eosin (H&E) colour deconvolution plugin (Rasband, W.S., 
ImageJ, US National Institutes of Health; MD, USA) was used to determine the fi brotic/
necrotic percentage of the entire cross section.717
Results and Discussion
Since losartan has been shown to act by antagonising TGF-β signalling as indicated by atten-
uating its downstream targets, including phosphorylation of Smad2,260 the effect of losartan 
on TGF-β-induced pSmad2 was analysed in vitro. Differentiated mouse myocytes (C2C12 
cells), were serum starved overnight and incubated for one hour with different concentrations 
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Fig. 7.1: Losartan does not infl uence Smad2 phosphorylation upon TGF-β1 stimulation
A large increase in pSmad2 (60 kDa) is observed in stimulated muscle cells, which was not attenuated by pre-treat-
ment with losartan. LY-364947, a TGF-β1 receptor kinase inhibitor, was used as a positive control for TGF-β1 inhi-
bition. B-actin (42 kDa) was used as loading control.
of losartan before stimulation with TGF-β. pSmad2 analysis showed a potent induction of 
Smad2 phosphorylation upon TGF-β stimulation, which was not observed in non-TGF-β 
stimulated cells (fi g. 7.1). Losartan did not attenuate this effect, which might be explained by 
the fact that no AT1 receptor expression could be detected in C2C12 cells (data not shown).
Healthy and DMD-derived muscle cells were treated with AONs targeting exon 49 and 
50 in the absence and presence of varying concentrations of losartan. Losartan treatment did 
not infl uence exon skipping effi ciencies (data not shown). Then the effect of losartan on local 
23AON injection was studied. Four weeks old mdx mice were treated orally with losartan for 
six weeks after which they received two intramuscular injections with AONs against exon 
23 in their gastrocnemius muscles. RNA analysis did not show differences in exon skipping 
levels between losartan-treated and control mice (fi g. 7.2).
To determine if there was any effect of losartan itself on signalling and muscle quality 
pSmad2 protein analysis and biomarker expression were performed after eight weeks of 
losartan treatment. pSmad2 protein might be reduced in losartan treated mice (fi g. 7.3a), 
however group sizes were too small to draw conclusions. Expression pattern of most bio-
markers did not differ between both groups in several skeletal muscles. Only a moderate 
reduction of some fi brotic markers (i.e. PAI1/Serpine1) was observed, while no change in 



















Fig. 7.2: Losartan has no effect on exon 
skipping levels after intramuscular injec-
tion of 23AONs in mdx mice
Quantifi cation of exon 23 skipping levels after two 
intramuscular injections of 23AON in the gastrocne-
mius muscle. Six weeks pre-treatment with losartan 
did not change exon 23 skipping levels.



































































































































Fig. 7.3: pSmad2 protein levels and biomarker expression in losartan-treated mdx mice
a) After eight weeks of losartan treatment some reduction in pSmad2 protein expression (60 kDa; lower band) might 
be observed in the gastrocnemius and diaphragm of losartan-treated mice compared to control mice. However group 
sizes are small. b-g) Biomarker expression analysis showed no changes in several skeletal muscle in expression of 
the Angiotension type I receptor itself (b), several fi brotic markers (c-e), a regeneration marker (f) and TGF-β1 (g), 
known to be differentially expressed in mdx mice. The housekeeping gene Gapdh was used to correct for differences 
in cDNA input and average expression is plotted relatively to control mice.
Error bars represent the SD. G=gastrocnemius; TA=tibialis anterior; Di=diaphragm; AT1=angiotensin II type 1 
receptor; Ctgf=connective tissue growth factor; PAI1=plasminogen activator inhibitor 1; TGF=transforming growth 
factor
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Thereafter the effect of losartan treatment on systemic 23AON treatment was analysed. 
Four weeks old mdx/Utrn+/- mice were treated for eight weeks with losartan, 23AON, a com-
bination of both or control. Mdx/Utrn+/- mice were used, since pathology has shown to be 
aggravated compared to mdx mice, which display a relatively mild phenotype.88 When we 
had included several animals in this experiment, additional reports on losartan in dystrophic 
mice were published that were much less promising than the initial publication. The fi rst 
report showed only preservation of cardiac function after two years of treatment, but no effect 
on skeletal muscle.261 Long term treatment did improve respiratory function, but increase of 
fore limb strength was only observed at two months of age and not at nine months.263 Another 
group also did not observe improvement of skeletal muscle function, although a decrease 
in fi brosis was observed. They did see improvement of cardiac function, combined with 
decreased fi brosis in the heart.264 Given these controversial results, we decided to perform 
an interim analysis to determine the effects of losartan itself. During treatment no changes 
in creatine kinase levels, a measure of muscle damage, and functional performance were 
observed between groups (data not shown). Histological analysis of the gastrocnemius by 
haematoxylin-eosin staining did not show attenuation of fi brosis by either losartan or 23AON 
treatment (fi g. 7.4a/b).
Notably, the new literature also described that the positive effects observed in the fi rst 
experiments were not mediated via blocking of TGF-β signalling via the AT1 receptor, but 

























Losartan AON Losartan + AON
Fig. 7.4: Histological analysis of losartan and/or AON treated mdx/Utrn+/- mice.
No changes in fi brotic/necrotic area as measured by haematoxylin-eosin staining of the gastrocnemius muscle in 
mice treated with losartan and/or 23AON were observed.
a) Representative example for each group. Fibrotic/necrotic area is stained by haematoxylin (blue/purple), whereas 
eosin (pink) represents healthy tissue. b) Quantifi cation of fi brotic/necrotic area.
Data are represented as mean±SD.
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by stimulating the signalling via the AT2 receptor after AT1 receptor blockage, which has 
anti-fi brotic effects by blocking pERK.262 Therefore, the effect of losartan on pERK1/2 was 
examined. Indeed in losartan treated cells a decrease in pERK1/2 (p44/p42 mitogen activated 
protein kinase or MAPK) was observed, independently of TGF-β stimulation (fi g. 7.5a), 
however in mice results showed large variation between different mice, independently of 
treatment (fi g. 7.5b). Furthermore in studies in animal models for other diseases, e.g. disuse 
atrophy, no changes were observed in either pSmad2 or pERK1/2 expression.561
In conclusion no effect of losartan on pSmad2 phosphorylation in vitro was observed. In 
vivo no signs of improved muscle quality, e.g. by histology or biomarker expression, were 
seen. These results and the building evidence in literature that the main, if any, benefi cial 
effects of losartan are at cardiac function after long term treatment, made us decide to dis-
continue further treatment in combination with AONs. Hopefully in the future more effective 



























Fig. 7.5: Effect of losartan on ERK1/2 phosphorylation
a) In mouse myotubes a decrease in ERK1/2 phosphorylation (44/42 kDa) was observed, independently of TGF-β 
stimulation. This was not observed with a specifi c, a TGF-β1 receptor kinase inhibitor (LY-364947). B-actin (42 kDa) 
was used as loading control. b) A large variation in pERK1/2 levels was observed between individual mice, showing 












During the past years major steps forward have been made in developing antisense-medi-
ated exon skipping, a potential therapy for DMD, which hopefully can turn the very severe 
progressive disease in a milder disease course and improve the quality of life. In addition, 
the knowledge about disease pathology and AONs is increasing. The antisense compounds 
are continuously developed further. However, there is still a lot to discover and hurdles to 
overcome to make the therapy successful. There are several strategies to try to improve its 
effi cacy. One way is to improve the AONs itself or their administration. Another way is to 
enhance the therapeutic outcome by improving the amount/quality of their target, i.e. muscle.
Towards the fi rst approach in chapter 3 and 4 more detailed studies into the pharmacoki-
netic and pharmacodynamic properties of AONs in mdx mice are described. In chapter 3 
the effect of different dosage schemes in mdx mice at several levels was tested. Compared 
to single weekly injections, dividing the same total amount of AON over multiple injections 
showed to enhance its effects. Furthermore this chapter covered the infl uence of the fre-
quency of repetition of injections on the maintenance of these effects after initial treatment. 
In both cases it revealed that increasing the desired effects, i.e. exon skipping and dystrophin 
restoration also increases the AON load on non-target organs, i.e. the liver, kidney and spleen, 
thereby increasing the risk of side effects on the long term. Therefore a balance between both 
effects has to be found. Towards this aim, in chapter 4 a more detailed analysis of the phar-
macokinetic and pharmacodynamic profi le of AONs in mdx mice was performed by studying 
the turnover of the compound, skipped transcripts and newly formed dystrophin protein. This 
highlighted in particular the long half-life of the dystrophin protein. These studies may have 
implications for optimising AON administration schemes.
In the second part of this thesis several compounds were tested to directly or indirectly 
infl uence antisense-mediated exon skipping effects. In chapter 5 an agent described in the 
literature to directly enhance AON-mediated exon skipping, 6-thioguanine (6TG), was tested 
in cultured cells and locally in the mdx mouse. In vitro a large number of undesired skipping 
events were observed, underlining that caution must be taken when using such compounds, 
since the chance of side effects is high. In vitro enhancement was only observed with subop-
timally designed AONs or at suboptimal AON-concentrations, while in vivo no differences 
were observed. Here only 6TG has been tested, but other small molecules, like the recently 
described dantrolene, could be more effective and specifi c.
In chapter 6 and 7 pharmaceutical compounds, which could potentially improve muscle 
quality, were tested in combination with AONs. In chapter 6 prednisolone was used. At 
the moment, since a therapy targeting the underlying genetic defect is lacking, corticos-
teroids (predniso(lo)ne or defl azacort) are the main (pharmacological) treatment for DMD 
patients. Therefore most participants in clinical trials are using these compounds, which 
might infl uence the uptake and/or effi ciency of AONs. Results showed that both therapies 
did not negatively infl uence each other and that prednisolone might even slightly enhance 
the therapeutic outcome of AON treatment. In chapter 7 another pharmaceutical compound 
that showed promising results in literature on preserving muscle quality and functionality in 
mdx mice, losartan, was tested in combination with AONs to see if it could enhance effi cacy. 
However these experiments were stopped prematurely, since interim analyses did not show 
any benefi cial effects of losartan itself or on the working of AONs. This was supported by 
new literature. The results of these losartan experiments are an example of how sometimes 
published results can be diffi cult to reproduce, but at the same time underline the value of 
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trying to reproduce other (or your own) results and the importance of publishing negative 
outcomes, to avoid unnecessary repetition or clinical development of suboptimal drugs. In 
addition to the compounds described in these chapters, several compounds have been tested 
in cell models for their effect on exon skipping or in vivo for their effect on muscle quality 
in the mdx mouse, but unfortunately no compound has been found so far that can enhance 
exon skipping itself or improve the therapeutic outcome in vivo by improving muscle quality.
The hypothesis behind combining AONs with muscle quality improving agents was that 
AONs can only be effective if their target, dystrophin RNA, is present, which is only produced 
by muscle cells. First clinical trials had shown that the amount of dystrophin production and 
functional outcome depended on the amount of muscle tissue left, i.e. the muscle quality. 
However, improving muscle quality could also have a negative effect on AON effi ciency. 
It is known from studies comparing the uptake of AONs between wild type and mdx mice 
that the uptake is much lower in wild type mice, since the AON uptake is facilitated by the 
leakiness of the dystrophic muscle fi bres. If this permeability decreases by improving muscle 
quality, the uptake might be hampered. Therefore the reason no enhancement of AON effects 
could be found, can either be that there is no effect or that the positive and negative effects 
are neutralizing each other. Furthermore large interindividual variation causes that only large 
improvements will be picked up and longer treatment time might be needed, before differ-
ences will be found. This also raises the question how meaningful very small differences 
would be in the clinic at the end.
Probably larger improvements can be made by improving the effectiveness of the AON 
therapy itself. One strategy is to use viral vectors to get a higher and longer lasting expression 
of AONs. However, this approach has many drawbacks as viral vectors can evoke immune 
responses, as a result of which repetition of treatment is not possible. At the moment, a 
better strategy seems to be to modify the AONs themselves. Preclinical studies in vitro 
and in vivo have shown that large improvements can be made by for example conjugating 
muscle-targeting peptides to them. Although also here prudence is called for, since some of 
these peptides have shown to be toxic in higher animals, like primates.
An issue that appears in every study is the diffi culty of targeting the heart, where observed 
exon skipping levels and restored dystrophin protein are much lower compared to skeletal 
muscle. This will become more and more important once the therapy becomes more effective, 
since higher activity levels will result in a higher workload on the heart. Also here conjuga-
tion of the AON with a specifi c heart-targeting peptide might be an option.
Nevertheless results from recent clinical trials have shown the importance of muscle 
quality. It indicates that starting treatment as early as possible would be recommended. The 
therapy can only put a hold on or slow down muscle degeneration, not bring back muscle that 
is already lost. Reaching a level of dystrophin restoration high enough to do so, is needed. 
Therefore more detailed studies on the effect of different levels of dystrophin restoration on 
muscle overall muscle functioning, but also on differences between individual muscles are 
very helpful.
All these matters require further investigation and optimisation of the AON-mediated 
exon skipping therapy. Especially the clinical trials will give more insights on the translation 
from animal models to humans and on the problems that have to be tackled in order to make 
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Duchenne muscular dystrophy (DMD) is a severe, progressive neuromuscular disorder, 
nowadays affecting around 1 in 5 000 newborn boys worldwide. First symptoms of muscle 
weakness appear around the age of two or three years, refl ected by diffi culties with running, 
standing upright and climbing stairs. Progressive loss of muscle function leads to wheel-
chair-dependency around the age of ten to fi fteen. Involvement of respiratory and cardiac 
muscles will lead to premature death, often before the age of thirty. Becker muscular dystro-
phy (BMD) is a related disease, but symptoms are often much milder and life expectancies 
are nearly normal.
DMD is caused by the absence of the dystrophin protein, encoded by the DMD gene. 
Dystrophin forms a bridge between the actin cytoskeleton inside the muscle fi bres and the 
extracellular matrix surrounding the fi bres. Hereby it provides mechanical stability to the 
muscle fi bres during contractions. In the absence of dystrophin, fi bres easily get damaged 
during use. Normally, muscles are capable of repairing this damage. When this becomes 
chronic, the repair system gets exhausted and eventually muscle tissue will be replaced by fat 
and fi brotic tissue, leading to a loss of muscle function.
Three base pairs of a gene encode one amino acid of a protein (genetic code). Translation 
occurs by fi rst transcribing the DNA-code in an RNA-code and thereafter translating the 
RNA into protein. Translation starts at the ‘start signal’ and ends at the ‘stop signal’ of the 
transcript. The genetic code is dispersed over exons, divided by introns (non-coding parts), 
which are removed at RNA-level during splicing. In DMD patients mutations in the DMD 
gene cause a disruption of the genetic code, i.e. by insertion or deletion of (an) exon(s) con-
sisting of a number of base pairs not divisible by three, or by introduction of a premature 
stop signal. This leads to premature termination of protein synthesis and complete absence 
of a functional protein, since one of the anchoring parts is missing. BMD is also caused by 
mutations in the DMD gene, but the reading frame stays intact, i.e. the number of base pairs 
inserted or deleted is divisible by three. This allows the production of a largely functional 
protein, containing both anchoring parts, which only is shorter or longer in the middle.
At the moment no treatments addressing the underlying genetic cause are available for 
DMD. A limited number of therapies targets one or a few of the symptoms, delaying disease 
progression, but not preventing it. Corticosteroid treatment has shown to be effective and 
ACE-inhibitors can delay the onset of cardiomyopathy. Many more compounds are tested 
pre-clinically, some showing positive effects on some of the mechanisms deregulated by the 
disease.
Antisense oligonucleotide (AON)-mediated exon skipping aims to restore the disrupted 
open reading frame in DMD patients, by removing (‘skipping’) an exon, thereby allowing 
the production of shorter, but largely functional Becker-like dystrophin proteins. The exon is 
hidden during splicing by covering it with an AON specifi c for the targeted exon. Proof-of-
principle for this approach has been shown in cell cultures and animal models for DMD and 
is currently tested in clinical trials.
The effi ciency of AON-mediated exon skipping relies on several aspects. First of all the 
presence of the target tissue. Dystrophin is only expressed by muscle tissue and not by adi-
pose and fi brotic tissue, which replaces the muscle tissue during disease progression. Better 
preservation and improvement of quality of muscle tissue would increase the amount of 
target for AON-mediated exon skipping. Secondly it depends on the amount of AON that 
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reaches this target. One way to infl uence this is optimisation of dosing regimen. In this thesis 
both aspects have been studied in (DMD) cell cultures and the mdx mouse model (a mouse 
model with a mutation in the DMD gene leading to the absence of a functional dystrophin 
protein).
 
In chapter 3 different dosage treatment regimens were compared in mdx mice. This revealed 
that if the same total amount of AON compound is given in multiple smaller portions, it leads 
to more uptake of the compound by the muscles, where it is needed for therapeutic effects. 
This in turn led to higher exon skipping percentages and restoration of dystrophin production. 
On the other hand, a higher uptake of AONs by other organs such as the liver and the kidney 
was also observed.
AONs do not lead to a permanent change in exon skipping or dystrophin restoration. Due 
to turn-over of the compound, chronic treatment will be required. Comparison of different 
maintenance schemes, after initial treatment, showed that more frequent repetition of treat-
ment led to higher maintenance of the effects in muscle, but again also increased the AON 
level in the other organs (chapter 3). To search for a balance between these effects, the turn-
over of effects at AON, RNA and protein levels were studied in more detailed (chapter 4). 
This showed, unfortunately, that for AONs this was comparable between muscle and other 
organs. However the dystrophin protein was still detectable six months after treatment, long 
after the exon skipping or AONs could be detected. These results indicate that the use of an 
intermittent dosing schedule might be useful to maintain treatment effects, but reduce side 
effects.
Small molecules could be used to enhance exon skipping effi ciency. We tested one of these 
compounds (called 6TG), described by others to enhance skipping effi ciency (chapter 5). 
However, we discovered that, although it indeed enhanced exon skipping mainly in DMD 
cell cultures, also various other skipping events were observed next to the skipping of the 
targeted exon. This increases the chance of off-target effects and therefore we do not consider 
6TG as a suitable candidate for further use.
As mentioned, dystrophin is only expressed by muscle tissue and not by adipose and fi brotic 
tissue. Therefore less targets remain when disease progresses. Improving muscle quality with 
pharmaceutical compounds is another way to enhance treatment outcomes. Nowadays most 
patients are already treated with corticosteroids. Prednisolone (the most used corticosteroid) 
did not negatively infl uence the AON treatment itself or its functional outcomes in mdx mice 
(chapter 6). For prednisolone this is important to know, since patients in clinical trials are 
often treated with corticosteroids.
While searching for muscle quality improving compounds, losartan was tested (chap-
ter 7), as literature described it as a promising candidate. However, no positive effects on 
muscle quality of losartan itself or on AON treatment were observed. Furthermore, during 
experiments more literature became available doubting its positive effects. Therefore these 
experiments were stopped. Unfortunately no other candidate could be found that enhanced 




Duchenne spierdystrofi e (DMD) is een ernstige, X-gebonden spierziekte, die voorkomt bij 
ongeveer 1 op de 5 000 pasgeboren jongetjes. De ziekte wordt gekenmerkt door progressieve 
spierzwakte. Bij deze patiënten worden de eerste symptomen zichtbaar rond hun tweede 
of derde levensjaar: ze hebben moeite met rennen, opstaan en traplopen. Toename van spi-
erzwakte zorgt ervoor dat ze meestal tussen hun tiende en vijftiende in een rolstoel belanden 
en uiteindelijk door ademhalings- en tegenwoordig met name hartproblemen sterven voor 
het dertigste levensjaar. Becker spierdystrofi e (BMD) is een verwante ziekte. In BMD zijn 
de symptomen echter over het algemeen een stuk milder en de levensverwachting is vrijwel 
normaal.
Duchenne wordt veroorzaakt door mutaties in het DMD-gen dat codeert voor het dystrofi ne 
eiwit. Dit eiwit vormt een brug tussen het actine cytoskelet in spiervezels en de extracellu-
laire matrix rondom de spiervezels, noodzakelijk voor de stabiliteit. Door de afwezigheid 
van dystrofi ne raken de spiervezels gemakkelijk beschadigd tijdens bewegingen. Normaal 
gesproken kunnen de spieren deze schade herstellen, maar als de beschadiging chronisch 
wordt, raakt het herstelsysteem uitgeput en wordt steeds meer spierweefsel vervangen door 
bind- en vetweefsel. Dit leidt uiteindelijk tot een verlies van spierfunctie.
Genen (DNA) bevatten de genetische code voor eiwitten. Hierbij coderen drie baseparen 
in een gen voor één aminozuur van een eiwit. Vertaling van de genetische code vindt plaats 
door eerst de DNA-code over te schrijven naar een RNA-code en vervolgens deze te vertalen 
in een eiwit. De vertaling begint bij een ‘start signaal’ en eindigt bij een ‘stop signaal’ van een 
transcript. De genetische code is verdeeld over exonen, waartussen zich intronen (niet-coder-
ende delen) bevinden. Deze intronen worden er op RNA-niveau uitgeknipt tijdens een proces 
genaamd ‘splicing’. Bij Duchenne patiënten zorgen mutaties in het DMD-gen voor ver-
storingen in de genetische code; bijvoorbeeld door de insertie of deletie van één of meerdere 
exonen waarvan het aantal baseparen niet deelbaar is door drie, of door de introductie van 
een vroegtijdig stop signaal. Dit zorgt ervoor dat de aanmaak van eiwit vroegtijdig gestopt 
wordt. Een functioneel eiwit ontbreekt dan, aangezien het één van de verbindingsdelen mist. 
Becker wordt ook veroorzaakt door mutaties in het DMD-gen. In dit geval blijft echter het 
leesraam behouden, d.w.z. het aantal toegevoegde of verwijderde baseparen is deelbaar door 
drie. Hierdoor kan een grotendeels functioneel eiwit gevormd worden dat beide verbindings-
delen bevat en alleen in het midden een stukje korter of langer is.
Op dit moment zijn er voor Duchenne geen therapieën beschikbaar die de onderliggende 
genetische oorzaak aanpakken. Er bestaan slechts een klein aantal therapieën gericht op één 
of een paar symptomen van de ziekte. Deze kunnen hooguit de progressie van de ziekte 
vertragen, maar niet voorkomen. Corticosteroïden zijn één van de weinige middelen die 
bewezen hebben effectief te zijn (hierdoor belanden patiënten gemiddeld drie jaar later in 
een rolstoel) Deze worden dan ook door de meeste patiënten gebruikt. Verder kunnen ACE-
inhibitoren de eerste symptomen van hartfalen vertragen. Verder worden momenteel veel 
middelen preklinisch getest, waarvan enkele positieve effecten laten zien op sommige mech-
anismen die door de ziekte verstoord zijn.
Exon skippen door middel van antisense oligonucleotides (AONs) probeert het ver-
stoorde leesraam te herstellen door een extra exon te verwijderen (‘skippen’), waardoor een 
korter, maar grotendeels functioneel Becker-achtig dystrofi ne eiwit gevormd kan worden. 
Het wordt gedaan met behulp van AONs die binden aan een specifi ek exon waardoor dit 
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tijdens het splicen niet meer herkend wordt als exon. Het eerste bewijs dat dit daadwerkelijk 
mogelijk was, is aangetoond in celkweken en diermodellen voor Duchenne. De aanpak wordt 
momenteel getest in klinische trials.
Verschillende aspecten beïnvloeden de effectiviteit van het exon skippen m.b.v. AONs. 
Allereerst de aanwezigheid van spierweefsel waarin de skip plaats moet vinden. Dystrofi ne 
wordt namelijk alleen tot expressie gebracht in spierweefsel en niet in het bind- en vetweef-
sel, dat het spierweefsel in latere stadia van de ziekte vervangt. Als het spierweefsel beter 
behouden zou blijven en van betere kwaliteit zou zijn, zou er meer beschikbaar zijn voor 
de AONs. Een andere manier om de effectiviteit te verbeteren, is door het verhogen van de 
hoeveelheid AON die daadwerkelijk in de spiercellen terecht komt. Dit kan onder andere 
beïnvloed worden door de toediening te optimaliseren. In dit proefschrift is naar beide 
aspecten onderzoek gedaan in (patiënten) cellen en in de mdx muis (een muismodel met 
een mutatie in het DMD-gen waardoor geen functioneel dystrofi ne eiwit aanwezig is). Er is 
onderzocht of het kon leiden tot een verhoogde effectiviteit van de AON therapie.
In hoofdstuk 3 zijn verschillende doseringsschema’s vergeleken in de mdx muis. Dit liet zien 
dat als dezelfde totale hoeveelheid AON toegediend werd in meerdere, kleinere porties, meer 
AON opgenomen werd door de spieren (de plek waar het nodig is voor de therapeutische 
effecten). Dit leidde tot hogere exon skip percentages en meer herstel van dystrofi ne pro-
ductie. Het leidde echter ook tot een hoger opname van AONs door andere organen zoals de 
lever en de nieren.
Het exon skippen en het herstel van dystrofi ne eiwit productie door AONs is niet per-
manent. Omdat de AONs afgebroken en/of uitgescheiden worden door het lichaam, zal 
chronische behandeling nodig zijn. Vergelijking van verschillende onderhoudsdoseringen 
na initiële behandeling, liet zien dat vaker herhalen van de injecties ervoor zorgde dat de 
effecten in de spier beter behouden bleven, maar dat eveneens dit leidde tot hogere AON 
niveaus in andere organen (hoofdstuk 3). Om hier een evenwicht tussen te vinden, is het ver-
loop van de effecten op AON, RNA en eiwit niveau in meer detail bestudeerd in hoofdstuk 4. 
Hieruit bleek, helaas, dat het verloop van de niveaus van de AONs vergelijkbaar was voor 
spieren en andere organen. Dystrofi ne eiwit was echter zes maanden na de behandeling nog 
steeds detecteerbaar. Dit is lang nadat exon skippen en AONs gedetecteerd konden worden. 
Deze resultaten geven aan dat een doseringsschema met onderbrekingen mogelijk gebruik 
zou kunnen worden om de therapeutische effecten te behouden, maar de bijwerkingen te 
verminderen.
Kleine moleculen kunnen gebruikt worden om de effectiviteit van het exon skippen te 
verhogen. Wij hebben één van deze moleculen (6TG genaamd) getest. In de literatuur is 
beschreven dat dit de exon skip effectiviteit verhoogt (hoofdstuk 5). Uit ons onderzoek, dat 
hoofdzakelijk in celkweken werd uitgevoerd, bleek echter dat, hoewel de exon skip percent-
ages inderdaad hoger werden, ook verschillende andere exonen onbedoeld geskipt werden. 
Dit verhoogt de kans op bijwerkingen en daardoor is 6TG naar onze mening geen goede 
kandidaat voor verdere experimenten.
Zoals eerder genoemd wordt dystrofi ne alleen tot expressie gebracht in spierweefsel en niet 
in bind- en vetweefsel, waardoor minder aangrijpingspunten voor de therapie overblijven 
naarmate de ziekte vordert. Daarom is het verbeteren van de spierkwaliteit met farmaceutica 
een andere manier om therapeutische effecten te verhogen. Tegenwoordig worden de meeste 
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patiënten behandeld met corticosteroïden, voornamelijk prednisolone. Prednisolone had 
geen negatieve effecten op de AON behandeling of de functionele effecten daarvan in mdx 
muizen (hoofdstuk 6). Dit is van belang voor klinische trials, aangezien de meeste patiënten 
die daaraan deel nemen, behandeld zullen worden met corticosteroïden.
Van de verschillende middelen die volgens beschrijvingen in de literatuur de spierkwal-
iteit verhogen, was losartan één van de meest belovende. Daarom hebben wij losartan ook 
getest, alleen en in combinatie met AONs (hoofdstuk 7). Hierbij werden echter geen pos-
itieve effecten van losartan op de spierkwaliteit of op de effectiviteit van de AONs gezien. 
Daar kwam bij dat tijdens de experimenten, meer literatuur naar buiten kwam die de eerder 
beschreven resultaten in twijfel trokken. Dit heeft ons doen besluiten de experimenten te 
stoppen. Helaas hebben we tot op heden geen andere kandidaat kunnen vinden die tot ver-








AAS  Anabolic androgenic steroids
AAV  Adeno-associated virus
ABD  Actin-binding domain
ACE  Angiotensin-converting enzyme
Acvr  Activin receptor
AMPK  AMP-activated protein kinase
ANP  Atrial natriuretic peptide
AON  Antisense oligonucleotide
ASC  Adipose-derived stromal cell
AT  Angiotensin II receptor 
BMD  Becker muscular dystrophy
BMP  Bone morphogenic protein
BNP  Brain natriuretic peptide
CK  Creatine kinase
CMV  Cytomegalo virus
CNS  Central nervous system
CXMD  Canine X-linked muscular dystrophy
DGC  Dystrophin-associated glycoprotein complex
DMD  Duchenne muscular dystrophy
ECM  Extracellular matrix
EGCG  Epigallocatechin gallate 
EIS  Exon inclusion sequence
ENA  Ethylene bridged nucleic acid
ESC  Embryonic stem cell
ESE  Exonic splicing enhancer
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
GRMD  Golden retriever muscular dystrophy
HDAC  Histone deacetylase
HFMD  Hypertrophic feline muscular dystrophy
IGF  Insulin-like growth factor
IFN  Interferon
IKK  IκB kinase
Lgals3  Lectin, galactoside binding, soluble, 3
LGMD  Limb girdle muscular dystrophy
LNA  Locked nucleic acid
LVEF  Left ventricular ejection fraction
MDSC  Muscle-derived stem cell
MHC  Major histocompatibility complex
MMP  Matrix metalloproteinase
MNF  Myocyte nuclear factor
MRI  Magnetic resonance imaging 
MSP  Muscle-targeting heptapeptide
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NBD  NEMO-binding domain 
NF-AT  Nuclear transcription factor of activated T-cell
NMD  Nonsense-mediated decay
nNOS  Neuronal nitric oxide synthase
NP  Nanoparticle
NSAID  Non-steroidal anti-infl ammatory drug
PD  Pharmacodynamic
PDE  Phosphodiesterase
PDGF  Platelet-derived growth factor
PDTC  Pyrrolidine dithiocarbamate
Pip  PMO or PNA internalisation peptide
PK  Pharmacokinetic
PMMA  Polymethylmethacrylate
PMO  Phosphorodiamidate morpholino oligomer
PNA  Peptide nucleic acid
PO  Phosphodiester
pPMO  Peptide-conjugated phosphorodiamidate morpholino oligomer
PS  Phosphorothioate
PTM  Pre-trans-splicing molecule
PV  Parvalbumin
RA(A)S  Renin-anigiotensin(-aldosterone) system
ROS  Reactive oxygen species
RyR  Ryanodine receptor
SACNSC Stretch-activated channels for non-specifi c cations
snRNP  Small nuclear ribonucleoprotein
SOCE  Store-operated calcium entry
SR  Serine-and arginine-rich
TALEN  Transcription activator-like effector nuclease
TGF  Tranforming growth factor
TNF  Tumour necrosis factor
Utrn  Utrophin
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